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Abstract  
A Systems approach to understanding Dupuytren’s Disease, March 2011 
Samrina Rehman, PhD, The University of Manchester  
  
Introduction: Dupuytren’s disease (DD) is an ill-defined fibroproliferative disorder affecting the palms 
of the hands of certain patient groups. Whether changes in DD fibroblasts are due to genetic 
alterations alone or related to metabolic dysregulation has not yet been investigated.  
Hypotheses: 1. DD is a disease of several networks rather than of a single gene. 2. DD may be 
investigated more effectively by employing systems biology.  3. Strict definition of cell passage number 
is important for the revelation of any DD phenotype.  4. Some of the differences between DD and 
healthy tissues reside in a difference in their respiratory metabolism. 5. Any such differences are akin 
the Warburg effect noted for tumour cells in the literature.  
Methods:  We induced hypoxia in healthy and disease cells to test whether the difference in disease 
cell types and healthy is the same as the difference in control fibroblasts cultured in normoxia and 
hypoxia. We investigated both at the metabolic level (intracellular and extracellular) and at the 
transcript level. This study also employed Fourier transform infrared spectroscopy to permit profiling of 
cells: (1) DD cords and nodules against the unaffected transverse palmar fascia (internal control), (2) 
those (1) with carpal ligamentous fascia (external controls) (3) those in (1) against DD fat surrounding 
the nodule, and skin overlying the nodule. We then compared metabolic profiles of the above to 
determine the effect of serial passaging by assessment of reproducibility. Subsequently, a novel 
protocol was employed in carefully controlled culture conditions for the parallel extraction of the 
metabolome and transcriptome of DD-derived fibroblasts and control at normoxic and hypoxic 
conditions to investigate this hypothesis. Gas chromatography-mass spectrometry combined with 
microarrays was employed to identify metabolites and transcript characteristic for DD tissue 
phenotypes. The extracellular metabolome was also studied for a selected subset. The metabolic and 
transcriptional changes were then integrated employing a network approach. 
Results: Carefully controlled culture conditions combined with multivariate statistical analyses 
demonstrated metabolic differences in DD and unaffected transverse palmar fascia, in addition to the 
external control. Differences between profiles of the four DD tissue phenotypes were also 
demonstrated. In addition early passage (0-3) metabolic differences were observed where a clear 
separation pattern in clusters was observed. Subsequent passages (4-6) displayed asynchrony, losing 
distinction between diseased and non-diseased sample phenotypes. A substantial number of 
dysregulated metabolites involved in amino acid metabolism, carbohydrate metabolism and also 
metabolism of cofactors and vitamins including downregulated cysteine and aspartic acid have been 
identified from the integrative analyses. Metabolic and transcriptional differences were revealed 
between fibroblast cell samples (passage number 3) cultured in 1% and 21% oxygen. The hypothesis 
that the difference in disease and healthy cells maybe akin to the differences in healthy cells in 
normoxia and hypoxia was rejected as only a very small number of significant molecules from these 
studies coincided in perturbed fascia and disease samples. No lactic acid was observed and little 
difference in the pyruvate concentrations. Yet, upon perturbation several of these transcripts and 
metabolites involved in the afore-mentioned pathways were significantly dysregulated.   
Conclusion: Early, but not late, passage numbers of primary cells provide representative metabolic 
and transcript fingerprinting for investigating DD. A unique parallel analysis of transcript and metabolic 
profiles of DD fibroblasts and control, enabled a robust characterization of DD and correlation of 
parameters across the various levels of systemic description. The tools that should facilitate our 
understanding of these complex systems are immature, but the pleiotropy of the difference between 
health and DD tissue suggest the aetiology of a network-based disease. 
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 Chapter 1 
Introduction 
This Chapter provides an introduction to the thesis and the motivation to do this research. 
The study focuses on bringing together two disparate fields; Dupuytren‟s disease (DD) and 
Systems Biology (SB). Approximately 180 years have elapsed, since the first literature 
reference on DD. Conventional research methods have continued to investigate the causes 
underlying DD formation and progression yet has not identified the precise 
aetiopathogenesis of this disease. Single gene approaches have not delivered for DD, and 
DD is a complex disease requiring network analysis. With SB approaches becoming 
increasingly popular in cancer research, it is timely to implement a novel approach where the 
two fields may now cross-fertilise. We first review (1.2; Appendix A) how DD may be a 
network disease, such that a SB approach may help understanding the former. In the latter 
part of this Chapter research objectives of this study (1.3) and the workflow (1.4) to 
implement the strategy used to test the hypotheses which follow in later chapters is outlined. 
Project aims are listed in 1.5. 
 
1.1 About this work 
1.1.1 Motivation 
Dupuytren‟s disease (DD) is a benign fibroproliferative tumour of unknown 
aetiopathogenesis affecting the palm of the hand, which often causes progressive, permanent 
contracture of the digits [1]. Surgical treatment of DD is symptomatic and associated with a 
high rate of recurrence which in some cases leads to amputation of the involved digits [2]. 
Advanced understanding of the mechanisms involved could lead to more-effective and 
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perhaps less invasive therapies. The principal clinical deformity of DD is characterised by a 
slowly progressive and irreversible flexion of the fingers as a result of decreased distance 
between the origin and insertion of the palmar fascia. The slowly progressive shortening of 
the affected digits is termed a contracture [3]. Pathogenesis of DD is characterised by the 
varying proliferative potential of myofibroblasts, (specialised fibroblasts expressing α-
smooth muscle actin (α-SMA)).   
The DD process is described by macroscopical investigations of the affected area that 
demonstrate phenotypic differences between two structurally distinct fibrotic elements (i.e. 
the nodule and the cord).  The nodule is thought to be involved in the most biologically 
active phase of the disease, characterised by soft-tissue masses containing a dense population 
of fibroblasts, which are largely myofibroblasts.  On the contrary, the cord is relatively 
avascular and acellular exhibiting a collagen-rich structure that contains a smaller population 
of myofibroblasts. These abnormal fibroblasts are considered to be responsible for causing 
the disease [4, 5]. In addition, previous hypotheses yet few, have hinted towards pathological 
relevance of adipose tissues (the fat cushioning the nodules) [6] and observations from post-
dermofasciectomy resulting in lower recurrence rates may indicate a relation to the skin 
overlying the nodule (SON) [7]. Furthermore, whether any significant changes in DD are 
due to genetic alterations alone or the consequence of metabolic dysregulation has not to 
date been demonstrated. 
 The analysis of transcription has been pivotal in recent analyses aimed at deciphering 
the control and mechanisms underpinning progression towards a diseased state. In this 
respect, major advancements have been made. Molecular studies from harvested tissue 
biopsies and in-vitro cultivation of fibroblasts derived from DD tissue have demonstrated 
presence and dysregulation (over and under expression) of several candidate genes [8-10]. 
Previous microarray and linkage studies have demonstrated key genes of interest that may 
potentially be involved in DD pathology. A recent study has investigated the differential 
gene expression analysis of subcutaneous fat, fascia, and skin overlying the DD nodule in 
comparison to control tissue [11]. 
However there still exist huge technical and knowledge limitations that hinder the 
accumulation of transcriptional data alone to synthesis of information. Further validation is 
necessary with more sensitive experimental approaches that can be systematically and 
iteratively investigated and validated with modeling approaches to predict responses with 
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certainty to identify and classify the levels of complexity in disease state of individual DD 
phenotypes.  
SB approaches promise to assist by bridging this deficit, making available novel 
analytical tools to unravel transcriptional data through the building of models and 
mathematical predications based on observations. Omics strategies within the framework of 
a SB context offer platforms such as Fourier Transform-Infrared (FT-IR) spectroscopy 
(metabolic fingerprints or non-invasive footprint screening) as a potential diagnostic and 
screening tool, and quantitative real-time polymerase chain reaction (qRT-PCR) for 
quantifying the transcript levels or making use of microarrays as exploratory tools. Such 
methods allow cost-effective and rapid methods of detection. SB is one of the most widely 
discussed fields among the emerging fields of post-genomic disciplines. It applies 
quantitative, mechanistic modeling to the study of genetic networks, signal transduction 
pathways and metabolic networks [12-16]; to understand the complexity of biological 
phenomena at all functional levels in a given cell, organism or tissue. Systems-level 
approaches are making a definitive pace towards scientific understanding and 
biotechnological applications [17]. 
SB for the present largely relates to unicellular organisms, and this study/thesis is one 
of the first to utilise SB to explore the metabolic characteristics and to advance the 
understanding of transcript data in a higher organism (i.e. primary cultures from DD 
(human) biopsies) in the field of medical SB. The data presented in this thesis shall 
constitute to highly systematic studies for a SB case related to DD.   
The purpose of this study is to develop and test our hypothesis that DD is a network 
disease.  This hypothesis has two parts: 
(i) The DD and corresponding healthy tissue differ in function through differences 
between their molecular (and perhaps intercellular) networks, rather than 
differences in a single molecule, in a plethora of unrelated molecules.    
(ii) DD can be caused by any of a variety of perturbations in regulatory networks that 
lead to the above network differences 
Working towards this purpose, I endeavored to develop and engage in a data-driven top-
down SB approach, towards the identification of transcriptome and metabolome differences 
between DD and healthy cells.  The aim is to identify some of the mRNAs and some of the 
metabolites that are different. By projecting the identified molecules onto the existing 
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genome-wide maps, or into functional categories, the objective is to identify pathways that 
account for differences seen with metabolites and transcripts, separately and in conjunction. 
In a bottom-up approach, I shall test an additional hypothesis that some of the differences 
between DD and healthy tissues reside in a difference in their respiratory metabolism.  In 
addition, I shall also examine the hypothesis that any such differences are akin the Warburg 
effects noted for tumour cells in the literature. Overall the aim is to delineate the above as a 
SB approach that may also be of use for the analysis of other ill-understood human diseases. 
 
1.1.2 Strategy of the study and its structure in text 
This study works towards the above aims in seven more or less sequential steps.  Each of 
these corresponds to a chapter of this thesis.  Most steps involve a targeted search for data 
generating a hypothesis.    
The latter part of this Chapter (1.2) reviews how the scientific literature addresses the 
above aims and to what extent SB approaches have already been implemented.  It also 
develops a perspective on how SB may help DD research and ends in outlining the strategy 
followed in this study. The philosophy behind this approach and the plan of action is 
discussed (1.3). Finally, the specific objectives sought in each chapter are outlined followed 
by a summary of the workflow (1.4). Section 1.2 has been submitted to Arthritis Research & 
Therapy and is currently under review. The background concerning the experimental 
techniques, design, patient recruitment, sample size and protocols for all materials and 
methods for Chapters 3-6 are given in Chapter 2. 
 Because SB attempts to analyse and understand in terms of all the networks and 
molecules that may affect a system (organism), its approaches tend to be more 
comprehensive than those of molecular and cell biology in the sense that it accounts for 
dynamic interactions taking place within a system i.e. the subject in question and its 
environment.  In addition the data generated by SB approaches are likely to be utilised by 
other groups, either for modeling approaches, or for connecting them to additional 
experimental data sets (e.g. transcriptome data to proteome data).  This makes it important 
for SB to come to well defined and reproducible experimental (and computational) systems.  
SB is also more sensitive than molecular biology to differences between the in vivo 
physiological state and experimental in vitro states; one is almost forced to work with freshly 
isolated tissues.  However such human tissues are barely accessible, and by virtue of the 
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randomness by which they become available do not lend themselves much to well prepared 
and reproducible experimentation. An alternative could be the use of cell lines derived from 
such primary tissues.   However, the establishment and maintenance of cell lines inevitably 
has consequences for the network functioning of the cells. In the case of DD cells and their 
healthy counterparts for instance, the DD cells may lose their DD characteristics when 
cultured, or develop differences with normal cell that have little to do with the differences 
between the diseased and the healthy tissue in the patient and represent positive selection for 
cells able to survive in-vitro culture conditions.  In Chapter 3, we examine how DD cells 
change when taken from tissue and cultured.  This will enable definition of which passage of 
cell culturing would be best to use in systems approaches to DD, as a compromise between 
retaining in situ DD character and having sufficient cell numbers for analysis.  We shall 
investigate this by implementing the concept of a systems signature defined through FT-IR 
spectroscopy.  Using this methodology we shall assess the reproducibility in vitro of DD 
subsets (i.e. nodule, cord, fat & SON) as compared with internal control (transverse palmar 
fascia) and external controls (carpal ligamentous fascia). To highlight the optimal conditions 
to further investigate the DD system is the objective of Chapter 3.  
SB also tries to integrate possibly all relevant literature data and pre-existing 
knowledge with new experimental data, all in its attempts to understand network 
functioning.  To this aim, systematic text mining of the literature is important.  In Appendix 
E3(2)(manuscript in preparation) we discuss the rationale to develop a novel text mining 
tool, which may help to depict accurate relationships in bio-networks by using natural 
language processing approaches.  Time constraints have kept us from further implementing 
this methodology in the present study. 
The conclusions from the fingerprint screening study in Chapter 3 are focused upon 
to investigate whether there are significant differences in functional genomics between DD 
and healthy cells, and whether a Warburg effect exists in the DD cell.  High-throughput 
studies are used to examine the response to hypoxia at the level of the metabolome and 
transcriptome. These will be shown to provide a useful - albeit noisy and incomplete - sketch 
of the cellular network response to hypoxia (or hypoxia reoxygenation) stimulus. Chapters 4 
and 5 discuss in detail how this was investigated with the use of omics technologies. In 
Chapter 4 a metabolomics approach (using gas chromatography-mass spectrometry (GC-
MS)) identifies dysregulated metabolites, as well as the pathways in which they occur. A 
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first question we shall address is whether the difference in disease cell types (nodule, cord 
and SON) and control cell type is the same as the difference in control fibroblasts cultured in 
normoxia and hypoxia. Second, we shall ask in which specific disease cell type (nodule, 
cord, and/or SON) is the difference with normal cells in intracellular metabolome the 
largest? In addition, the extent of the Warburg effect is also tested when hypoxia is induced 
in the disease cell types. We surmise that not only may DD cells have a Warburg phenotype; 
they may also have a different propensity to assume such phenotype when exposed to 
hypoxia.  In addition, the external stimuli may induce pathway inhibitors - clues can be used 
to investigate and demonstrate maximal differential response in a number of DD cell 
cultures.  
In Chapter 5 the disease cell types (nodule) which demonstrated the most significant 
differences compared with normal and perturbed fascia, were then selected to investigate the 
Warburg effect in the DD transcriptome. Candidate genes were identified and the question 
addressed here is whether the identified transcripts/genes and metabolites show congruence 
across the various levels of systemic description in the context of pathways i.e. the DD 
metabolome and transcriptome. Integration of these complex data sets is a key challenge and 
is the objective of the small Chapter 6, which also involves the mapping onto known genome 
wide pathway maps.    
For accurate interpretation of the intracellular dynamics within the DD cell 
metabolome and transcriptome it is essential to harvest these molecules in identical 
conditions. Current SOP‟s do not permit the harvesting and extraction of these moieties 
simultaneously. This necessitated developing a novel protocol to meet this requirement. The 
aim here was the simultaneous collections at one time point of the three moieties from all 
samples i.e. the extracellular metabolome, the intracellular metabolome and RNA. A robust 
standard operating protocol for three simultaneous sample extractions is given and applied 
for the first time. This novel protocol is discussed in Chapter 2.3.2 - 2.3.3.  
The ultimate goal of this work would be the initiation of a system-wide, data-driven 
model that includes all genes, enzymes, metabolites, and regulatory proteins that are 
involved in hypoxia defenses in DD. It is advantageous to decide a priori the necessary level 
of detail and the corresponding modeling strategy. This would then be extended to model 
metabolism at the level of enzyme fluxes, within the constraint-based framework. The 
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signaling network that modulates these enzymes could then be represented as a map of 
bidirectional links derived from interaction databases.  
 Although it is quite a task to build complete representations of these networks from 
the parts list, factors that define the problem of interest, such as cell type (cord, nodule and 
control fascia), time window (acute, passage number, metabolome and transcript extraction) 
and the specific context (hypoxia) help to narrow the number of players. After iterations of 
experimental validation and refinement, this network model may help to find modulators and 
targets on which to apply more detailed modeling strategies. 
The project encompasses integration of large data-sets from metabolomics and 
transcriptomics collected from suitable test subjects and matched controls. These data are 
used as a basis for the construction of probabilistic and statistical models. In each of the 
studies, the data sets generated have large diversities of characteristics and also have 
different research objectives including automated high-throughput data analysis, 
classification and prediction, as well as multivariate pattern comparison. Hence various 
signal processing and pattern recognition techniques are required to analyse these data sets to 
reveal their patterns and achieve the objective of research. Several models of the same data 
are explored including unsupervised methods principal component analysis (PCA), and 
supervised methods; principal component-discriminant function analyses (PC-DFA) and 
Analysis of Variance-principal component analyses (ANOVA-PCA). These are described in 
their respective chapters and background is given is Chapter 2.2. The prediction of each of 
these models to the same training data set is compared and further experiments conducted on 
new disease & control cell cultures to predict the response of these cells from their system 
signatures. Appropriate computational techniques have been used to elucidate models of 
relationships between gene, protein and metabolite signals and cell functional responses to 
extracellular cues. Elucidated network relationships from candidate subset of metabolites 
and candidate transcripts resulting from experiments are given in Chapter 6.  
The development of a mathematical model can now be initiated to address clinical 
implications. This type of approach will ultimately provide a model and rationale for the 
development of new, dynamic and dual therapeutic strategies and is likely to influence drug 
design. The implications of the findings of this project are not only important for DD but 
also for other fibrotic systems onto which these interactions can be projected. A discussion 
and conclusion of this thesis is given in Chapter 7 followed by references and appendices. 
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The directions for possible future work are chosen here towards further improvement of 
fingerprint screening and validating with text mining approaches, increase on accuracy, 
mapping and integrating pathways and reduction of anomalous results with targeted 
approaches. This work was supported by the BBSRC and EPSRC via the Doctoral Training 
Centre at Manchester Centre for Integrative Systems Biology.  
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1.2 Dupuytren’s – A Systems Biology disease? 
The following is an extensive review of the scientific literature that addresses the above aims 
and to what extent SB approaches have already been implemented.  It also develops a 
perspective on how SB may help DD research and ends in outlining the strategy followed in 
this study. Because Section 1.2 is a manuscript and has been submitted to a peer-reviewed 
journal, it consists of its own abstract, introduction, results, discussion and references. Please 
refer to Appendix A.  
 
1.3 Philosophy of Approach  
The rest of this chapter summarises the concepts and methods applied in this research thesis 
from metabolomics and transcriptomics technologies. The practical problems associated 
with DD research and the rationale behind this approach and statistical data analysis relevant 
for this thesis are given.  
 
1.3.1 Establishing an optimum cell system to investigate Dupuytren’s disease 
Life is structured on many levels of biological organisation. Only in the current post-
genomic era, after sequencing of many genomes (http://genomesonline.org/), we are now 
starting to appreciate the complexity of biological organisation at the cellular level. To 
understand the function and dysfunction of such complex systems requires integrated, 
systems-level approaches. To understand complex disease systems this rationale is even 
more significant. 
The differentiation of DD subsets (nodule, cord and uninvolved transverse palmar 
fascia) has classically been performed on the basis of clinical presentation, histopathology 
and morphological features and more recently with high density microarrays. However, 
phenotypic variations within the DD tissue have led to plausible questioning with regards to 
the classification of this disease. The high degree of macroscopical un-relatedness between 
fibroblasts from the nodule and cord illustrates this. Within the framework of SB, functional 
analyses of the cell should be investigated at all „omics levels in order to determine the 
underlying causes of DD formation. Previous studies have focused on biochemical factors in 
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isolation; whilst mostly concentrating on tissue biopsies harvested from DD subjects, there 
has been no work to date on the cascades involved in cellular dysfunctioning within a 
systems context. More recently few studies have focused on the DD myofibroblasts with the 
use of high throughput technologies.  
 It is envisaged the fibroblast is the key cell implicated in cell signaling events leading 
to DD pathogenesis. One study investigated differences in nodule or cord-derived fibroblasts 
focusing on their cellular metabolic activity [18]. Controls were obtained from carpal 
ligaments. The fibroblasts derived from cords presented higher metabolic activity compared 
with fibroblasts derived from nodules or controls (fascial retinaculum) using an XTT assay. 
Nodular fibroblasts presented lower activity than those of control fascial fibroblast assays.  
Despite accumulating evidence that in vitro conditions have an impact on gene 
expression patterns, there are limited studies that have investigated differential gene 
expression in both tissue culture and biopsies. To address these questions, Shih et al 2009 
investigated the gene expression levels of candidate genes differentially expressed in DD 
tissue phenotypes including not only the cords, nodule and fascia but also the fat and SON to 
determine whether the observed results from tissue biopsies were comparable to those from 
cell cultures, in order  to identify potential biomarkers [19]. 
A number of studies have implicated involvement with the TGF-β pathways when 
compared with tissues from the DD palmar fascia [20]. These distant sites are thought to be 
uninvolved in the disease process and may serve as internal controls in addition to tissue 
biopsies harvested from the palmar fascia of patients having Carpal Tunnel Decompression 
(CTD). While the transverse palmar fascia (from the DD patient) would be thought a more 
appropriate control and preferred site for study accounting for a homogeneous study set, 
correlating to the adjacent diseased sites respectively (if excised/harvested on same day), the 
CTD fascial tissue from individuals unaffected by DD has been documented in many studies 
as the common choice for control however this attributes to heterogeneity.  Cellular profiles 
in the Dupuytren tissues (nodules and cords) ultrastructural studies display confirmed 
differences from the transverse palmar fascia, and although it is not completely understood 
nor proven that these tissue from the Dupuytren patient are confirmed as 100% normal, 
macroscopical evidence suggests these may be suitable as internal controls for comparison. 
For this reason, not only is it acceptable but also intriguing in this study to compare the DD 
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tissue (nodule and cords) with those where the site is confirmed to be uninvolved in the 
diseased palm.  
 
1.3.1.1 Passage Number Effect on Metabolic Fingerprint 
Cell line quality is crucial to successful experimentation and an important step to ensure 
reliable and reproducible results. Continuous cell lines are increasingly being used and may 
serve as valuable research tools in medicine and biotechnology [21, 22].  However, the 
ability of continuous cell lines to exist almost indefinitely has opened the possibility of 
questionable sub-culturing practices [23, 24] and hence, scientific data produced as a result 
of experiments performed. The issue has been raised in some recent literature that over-sub-
culturing may have a profound impact that can lead to changes in cell lines properties over 
time. Such changes may occur at high passage numbers where cells may experience 
alterations in cell morphology, response to stimuli, growth rates, protein expression and 
signaling, compared to lower passage cells. In addition, the in vitro culturing conditions may 
affect gene expression profiles and/or ultimately cell phenotypes [25, 26].  
Altered phenotypes in late passage cultures of the DD nodule have been reported, 
where the authors suggest late passage cultures of DD nodule fibroblasts display phenotypes 
similar to those of cord-derived fibroblast [26]. It is difficult to make comparisons from 
previous studies as the reported results are often based on different cellular passages which 
could have a dramatic effect on their gene expressions.  Previous studies on fibroblasts 
derived from DD tissues have looked at cellular passages without considering factors that 
may affect not only morphological changes but gene expression and metabolic differences 
too. Few studies state the passage number used but do not question nor address why those 
cellular passages were selected. It is possible that a higher or an inconsistent passage number 
may lead to production of an adequate biomass, but this has not been investigated or 
reasoned to date.  
 Moreover, normal cells undergo a finite number of divisions and then cease dividing 
after some passages (a process known as replicative senescence), whereas tumour cells are 
able to proliferate indefinitely [27, 28]. The acquisition of an unlimited proliferative 
potential has been proposed as one of the critical steps in cancer (neoplastic diseases), which 
arises as a consequence of the accumulation of multiple independent mutations in genes that 
regulate cell proliferation and survival. Although differing numbers of passages have been 
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reported in the studies investigating the dupuytren tissue, any change in the proliferative 
potential of the fibroblast has not been stated. DD fibroblasts may possess a higher potential 
for matrix and collagen production through passages than control fascia cells because the 
DD nodules and cords result from an uncontrolled proliferative cellular state. Differences in 
collagen, fibronectin proteins, matrix expression proteins and even proteoglycans could be 
affected by passaging because it is thought that at earlier passages all cells would mostly be 
proliferating while at later passages they would tend to become senescent [29].  
 
1.3.1.2 Whole cell fingerprinting to obtain a system signature 
Careful consideration should be given to factors which could affect the reproducibility of 
data or produce instrument drift including sample preparation, instrument contamination and 
data processing. Time and order of sample analysis could provide significant sources of 
variability, potentially obscuring the biological variation which we seek to characterise. 
FT-IR spectroscopy is a well-established tool for the identification of transition 
phenomena in systems passing through different phases. Within the biosciences, the 
applications of FT-IR have been numerous and diverse. FT-IR spectroscopy can detect and 
identify endogenous (fingerprint) and secreted (footprint) metabolites. It has proven to 
rapidly and accurately identify bacteria to the sub-species level [30], differentiate between 
clinically relevant species [31], and has provided a metabolic footprint of tryptophan-
metabolism mutants [32] as well definitively discriminating between a range of bacterial 
genera. It‟s use as a rapid, yet non-invasive method for embryonic secretome determination 
from preliminary results has demonstrated its powerful potential  as a diagnostic tool [33].  
This approach is based on the principle that when a sample is interrogated with an 
infrared (IR) beam, the functional groups within the sample will absorb the infrared radiation 
and vibrate in one of a number of ways, either stretching, bending, deformation or 
combination vibrations [34]. These absorptions/vibrations can then be correlated directly to 
(bio)chemical species and the resultant infrared absorption spectrum can be described as an 
infrared „fingerprint‟ characteristic of any chemical or biochemical substance. 
 In this study FT-IR spectroscopy is employed as a metabolic fingerprinting screen 
with multivariate statistical techniques for cluster analysis to assess reproducibility of cells. 
In this respect, FT-IR is used to determine the presence of metabolites and their unique 
fingerprints using a metabolomic analysis of fibroblast cultures derived from different DD 
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tissue phenotypes (nodule, cord, subcutaneous fat and SON) to compare early (primary) 
cultures to late passages in order to identify the most representative passage for the disease. 
Controls are both internal (transverse palmar fascia) and external (CTD palmar fascia or 
transverse carpal ligamentous fascia) fibroblasts grown in the same culture medium and 
conditions. It is hypothesised that the culturing conditions may have a profound impact on 
gene expression and metabolic activities as the cells adapt to a new artificial environment 
and the most suitable passage representative of the disease remains unknown. Such 
physicochemical spectroscopic methods are increasingly discussed to have a huge potential 
in disease diagnostics as these platforms offer/facilitate “whole-organism fingerprinting.”   
The fingerprint study in this project forms the basis and starting point of the 
subsequent omics approaches investigated in the concept of a systems signature 
determination. In addition, the fibroblast cultures grown in same culture media are analysed 
for any change in cellular properties due to the passage effect. Details of materials and 
methods are given in Chapter 2.3.1. 
  
1.3.2 Metabolism and Warburg effect 
Metabolism is a constitutive process within a cell. There is still much to learn about how cell 
metabolism is regulated during proliferation. In multicellular organisms, most cells are 
exposed to a constant supply of nutrients. Survival of the organism requires control systems 
that prevent aberrant individual cell proliferation when nutrient availability exceeds the 
levels needed to support cell division. Uncontrolled proliferation is prevented because 
mammalian cells do not normally take up nutrients from their environment unless stimulated 
to do so by growth factors. Many cancer cells overcome this growth factor dependence by 
acquiring genetic mutations that functionally alter receptor-initiated signaling pathways [35]. 
There is growing evidence that some of these pathways constitutively activate the uptake and 
metabolism of nutrients that both promote cell survival and fuel cell growth [36]. 
It is known that tumours alter the metabolic profiles of the cells, which display a 
higher rate of glucose uptake and glycolytic activity when compared to their benign/normal 
counterparts [37]. These metabolic changes might confer a common advantage on many 
different types of cancers, which allows the cells to survive and invade. Another important 
characteristic in many cancer cells is the increase in utilisation of the anaerobic glycolytic 
pathway, converting pyruvate to lactate. This fermentation phenotype was initially thought 
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to raise as an adaptive response to the hypoxic microenvironment that tumour cells were 
forced through an inefficient, disordered and commonly insufficient vascular system [38]. 
However, not all the tumour cells are under hypoxic stress, and the anaerobic glycolytic 
pathway is used even if the tumour cells are in presence of oxygen [39], displaying a 
constitutive alteration in carbon metabolism. This phenomenon is termed as the „Warburg 
effect‟ named after Otto Heinrich Warburg [38].  
Warburg found that unlike most normal tissues, cancer cells tend to “ferment” 
glucose into lactate even in the presence of sufficient oxygen to support mitochondrial 
oxidative phosphorylation and hence their metabolism is often referred to as “aerobic 
glycolysis [40].”  The excess generation of lactate accompanies the Warburg effect. For most 
proliferating cells, nutrients are not limiting so there is no selective pressure to optimise 
metabolism for ATP yield. In contrast, a selective pressure for rate of metabolism does exist. 
For example, immune responses and wound repair depend on the speed of the proliferative 
expansion of effector cells. To survive, the organism must signal the responding cells to 
maximize their rate of anabolic growth. Cells that convert glucose and glutamine into 
biomass most efficiently will proliferate fastest [40]. In addition, there is emerging evidence 
that cellular metabolism within a tumour can be heterogeneous, with some cells using the 
excess lactate generated as a fuel for mitochondrial oxidative phosphorylation; a major 
cellular source of reactive oxygen species (ROS) production [41]. 
Cells with excess nutrient uptake that have not converted to aerobic glycolysis would 
be predicted to have increased oxidative phosphorylation and ROS production. Cellular 
energy supply and demand under hypoxic conditions is regulated by many interacting 
signaling and transcriptional networks, which complicates studies on individual proteins and 
pathways. Ambient air has oxygen partial pressure (pO2) = 158 mmHg, tracheal air in the 
human is pO2 = 149 mmHg, alveolar air; pO2 =100 mmHg; and arterial blood; a pO2 = 95 
mmHg [42, 43]. 
One proposed explanation for Warburg‟s observation is that tumour hypoxia selects 
for cells dependent on anaerobic metabolism [44]. However, cancer cells appear to use 
glycolytic metabolism before exposure to hypoxic conditions. For example, leukemic cells 
are highly glycolytic [45], yet these cells reside within the bloodstream at higher oxygen 
tensions than cells in most normal tissues. Similarly, lung tumours arising in the airways 
exhibit aerobic glycolysis even though these tumour cells are exposed to oxygen during 
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tumorigenesis [46]. Thus, although tumour hypoxia is clearly important for other aspects of 
cancer biology, the available evidence suggests that it is a late-occurring event that may not 
be a major contributor in the switch to aerobic glycolysis by cancer cells. Hypoxia is also 
known as the major cause of necrotic cell death in many diseases. 
 
1.3.2.1 Metabolomics:  A component of systems biology  
Recent development in „omics technologies provide an opportunity to study the effects of 
oxidative stress systematically. Metabolites are potentially a good indication of the state of 
our health. Therefore measurement and analysis of metabolites can be a precise and 
potentially valuable source for identifying biomarkers for diagnostics and drug therapy[47]. 
Metabolomics technologies act as components of systems biology that allow high-
throughput analysis of metabolites, allowing determination of their concentrations, in 
biological samples [48].  
While the genome, transcriptome and proteome are estimated to be quite large, by 
contrast the metabolome is relatively small. It is estimated that there are approximately 7,900 
metabolites in humans as has been proposed by the human metabolomics project [49]. This 
number represents the naturally synthesised biochemicals in humans and now includes some 
complex oligosaccharides, peptides, etc. The total number of synthesised biochemicals is 
much smaller; however, the technology to measure all of those small compounds in a single 
sample is complex and challenging. A major advantage to this smaller number of 
metabolites is the decreased chance of a random false discovery measurement which often 
results when large numbers of measurements are made on a small number of samples, such 
as the small group sizes typically available for most clinical studies – ours is typically one 
such case. 
The primary goal of any metabolomics effort is to extract, identify, and quantify as 
many as possible small molecular compounds (e.g. metabolites) in a biological sample under 
set conditions and to correlate the changes observed to changes in environmental condition 
or perturbation. Yet the size and chemical complexity of the metabolomes itself represent an 
analytical challenge since metabolites differ significantly in their physical and chemical 
properties (volatility, solubility); molecules vary from being polar to non-polar. Moreover, 
these small molecules have a wide range of structures; their molecular weights range from 
50Da to over 1500Da and differ in concentrations. As diverse as these compounds may be, 
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the task for metabolomics is to extract, identify and quantify all of the metabolites in a 
biological sample. To produce an accurate/informative profile of these molecules, not only 
samples themselves, but every compound present in a sample must be reproducibly extracted 
and measured, even when the identity is not known or its presence predicted. Sample 
reproducibly of DD and control cells has been shown and is the objective of Chapter 3.  
This complexity necessitates the use of analytical tools and methodologies of high 
sensitivity, high separation efficiency (specificity) and with the ability to detect metabolites 
over a wide range of concentrations (typically, mM to sub-pM). Global analysis of the 
metabolome is achieved with more than one analytical technique and most commonly is 
achieved using chromatographic separation to fractionate complex samples into simpler 
components according to their physico-chemical properties and linearly introduced into a 
mass-spectrometer (MS) or nuclear magnetic resonance (NMR) spectrometer for detection. 
Gas-chromatography (GC) [50, 51], liquid chromatography (LC) [52, 53] or capillary 
electrophoresis (CE) are most commonly utilised analytical methods to separate metabolites 
based on selectivity and specificity.  
 
1.3.2.2 Metabolic profiling of Dupuytren’s disease phenotypes in oxidative stress 
At present, little is known regarding DD pathogenesis, and even less regarding its cellular 
functions, i.e. metabolic functions and regulation of intermediates involved in glycolysis, 
TCA cycle, pentose phosphate shunt and amino acid metabolism. Knowledge of what 
proliferating cells need in healthy cells and how these cells adapt in hypoxia in terms of 
energy to generate biomass will help to establish hypotheses if not a direct connection 
between disease and a healthy cells. This will illuminate signaling pathways that drive cell 
growth and the regulation of DD cell metabolism.  
Here, we test our hypothesis whether DD cells are also under this Warburg effect. 
This is achieved by inducing a perturbation in healthy cells (fascial cells) cultured in pO2 = 
158 mmHg  corresponding to a concentration of 21% atmospheric oxygen and compare their 
metabolic profiles with healthy cells exposed to hypoxia i.e. in pO2 of 8 mm Hg 
corresponding to concentration of 1% oxygen. Then we examine our hypothesis that any 
such differences are akin the Warburg effects noted for tumour cells in the literature by 
comparing the extracts from intracellular (endo-) and extracellular (exo-) metabolomes 
acquired from DD nodule, cord and SON cultures against those acquired from healthy cells 
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and under hypoxia-induced fascia. The aim here is to identify potential biomarkers of DD by 
comparing the metabolic profiles obtained from disease and healthy cells. In addition, 
response to hypoxia is also examined in the intracellular metabolome of disease cells; this 
may aid in biomarker identification by imposing stress on disease cells. Furthermore the 
question is; if a Warburg effect exists, in which DD phenotype is this effect greatest? What 
are these key players (metabolites) and which pathways are these mapped onto? For 
convenience, fibroblasts from fascia, nodule, cord and SON cultured in pO2 = 158 mmHg 
(21% oxygen, normoxia) are designated as „F21‟, „N21‟, „C21‟, „S21‟ and those cultured in 
concentrations of 1% oxygen (hypoxia)  designated as „F1‟, „N1‟, „C1‟ and „S1‟ 
respectively.  
A point to note here, although pO2 =158 mmHg is not physiologically relevant for 
tissue, the palmar fascia pO2 is expected to be approx 40 mmHg; well above hypoxic 
conditions. Previous studies reported no culturing conditions other than O2 at 21% (ambient 
conditions/setting in standard cell culturing facilities). To make a fair comparison, main 
consistency with previous reported finding and due to technical limitations we were unable 
to provide sufficient culture biomass in all three O2 conditions i.e. 6%, 1% and 21% 
simultaneously. A comparison between 21% (termed normoxic) and 1% (termed hypoxic) is 
made to determine the effects of hypoxia upon the respiratory metabolism of all cultures. 
Metabolic profiling of samples employed GC-MS. Metabolic identification and the effect of 
perturbation is the objective of Chapter 4. Details of materials and methods used in this 
study are explained in Chapter 2.3.2. 
These biomarkers could open up the possibility of developing new, early or 
presymptomatic treatments to improve outcomes or even prevent pathology. Furthermore, 
the validation of biomarkers that can detect early changes specifically correlated to reversal 
or progression of DD is crucial for intervention. Used as predictors, these biomarkers could 
help to identify high-risk individuals and disease subgroups potentially useful as targets for 
chemointervention trials, whilst as surrogate endpoints, biomarkers may be useful for 
assessing the efficacy and cost effectiveness of preventative interventions at a speed that is 
not possible when the incidence of manifest DD is used as the endpoint.  
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1.3.3 Transcriptomics: a component of systems biology 
The transcriptome is the complete set of RNA transcripts produced by the genome at any one 
time. Transcriptomics, the study of the transcriptome involves large-scale analysis of 
messenger RNAs transcribed from active genes to follow when, where, and under what 
conditions genes are expressed. Unlike the genome, the transcriptome is extremely dynamic 
[54]. Our cells contain the same genome regardless of the type of cell, stage of development 
or environmental conditions. Conversely, the transcriptome varies considerably in these 
differing circumstances due to different patterns of gene expression. Transcriptomics is 
therefore a global way of looking at gene expression patterns and in this respect is one such 
component of systems biology that can aid in discovery experiments.  
Microarray technologies allow the examination of gene expression on the scale of a 
genome when an organism or cells experience a changing status thus providing a practical 
method for measuring the expression level of thousands of genes simultaneously. 
Measurement of gene expression with high accuracy and precision is possible with real time 
PCR [55, 56]. This technique can measure and quantify gene expression one at a time and is 
used as a standard for validation and measurement of a few selected genes [56]. However, 
using microarrays it is possible to measure the expression of thousands of genes or more so 
‘transcripts‟ simultaneously [57].  
 Microarray analysis is a very active area of research now. The fields of systems 
biology and microarray analysis are both growing exponentially with > 40,000 hits in 
PubMed using the term „systems biology‟ and > 47,000 hits for „DNA microarray analysis.‟ 
In just over a period of six months (July, 2010 to January 2011) 6000+ papers with terms 
„microarray‟ were added to the database. By contrast, only ~2100 publications on DD have 
appeared since the original publication by Guillaume Dupuytren in 1831, only 56 hits with 
„gene expression + dupuytren‟ and only 11 hits with „microarray + dupuytren.‟ 
 
1.3.3.1 Exploring dynamical changes in DD and control transcriptome  
In addition to dynamic property changes recurring in DD metabolomes and healthy fascia in 
response to hypoxia, simultaneous changes in the transcriptome will also inevitably be in 
progress. A number of key metabolites and pathways that may contribute to DD progression 
or have been invoked as a consequence of hypoxic stress highlighted from results in Chapter 
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4 also demand explanation at the transcriptome level. Intermediates involved in amino acid 
and carbohydrate metabolism have shown significant differences from this analysis. In 
Chapter 5 Affymetrix microarrays were employed extending this approach to investigate the 
perturbation effect in their transcriptome. This study examines whether gene expression 
analysis of such cells could provide a more representative picture of the dynamics involved 
in DD. It is surmised these transcripts will produce a specific signature for DD 
complementing the metabolomics study and allow us to look for cell signaling pathways / 
targets in a controlled systematic manner. The emerging data will form the basis for 
selecting appropriate models for pathway studies.  
In this study, we use 12 x Human Genome U133 Plus 2.0 Arrays (HG U133 Plus 
2.0).  Each chip contains 54,675 probe sets allowing analysis for relative expression levels of 
more than 47,000 transcripts and variants, including more than 38,500 well characterised 
genes and UniGenes [58]. The probe sets represented on these are selected from sequences 
in GenBank®, dbEST and RefSeq [59]. In addition these chips include a set of constitutively 
expressed human maintenance genes to facilitate the normalisation of array experiments. 
This set of normalisation genes has demonstrated consistent levels of expression over a 
diverse set of tissues and serves as a tool to normalise data prior to performing data analysis. 
Details of materials and methods used in this study are explained in Chapter 2.3.3. 
 
1.3.4 Discovery of pathway biomarkers through network analysis  
The qualitative systematic studies from Chapters 3-6 provide us with robust and 
reproducible data sets or at least the parts list that can now facilitate the initiation of model 
construction to study the interplay between theory, experiment and technology and now 
hypothesis testing by modeling the cellular systems. Key parameters and variables of the DD 
and control system can be assigned. The parameters of this dynamical system are those 
properties that are either inherent to the system or whose values can be controlled e.g. to 
study metabolic networks, these would be delineated as the initial concentrations of enzymes 
and metabolites, enzyme kinetic properties such as Km, kcat and Ki. The variables by 
contrast would be those that change during the time evolution of the system e.g. 
concentrations of metabolites and metabolic fluxes. Since it is the parameters that control the 
variables, it is more common to measure the variables than the parameters. Methods which 
start with variables and seek to infer the topology and parameters of the system that 
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generated them are known as „inverse methods‟ or „system identification‟ methods - 
considerably more demanding computationally.  
 At present, knowledge is largely dispersed across various databases ranging from 
proteome-proteome interaction databases [60], human metabolome database (HMDB) [49], 
gene ontology (GO)[61] etc. To facilitate in bridging or integrating some of these databases, 
systems such as Gaggle [62] incorporating geese such as KEGG [63] , Cytoscape [64], 
STRING [65] and more, Taverna [66] and Ingenuity Pathway Analysis (IPA) [67] are found 
to be of considerable utility. Such tools consider both the significance of gene expression 
changes and their topological characteristics in order to better evaluate their impact on the 
pathways of interest [68]. 
 Functional links between molecules e.g. proteins can often be inferred from genomic 
associations between the genes that encode them. However some interactions such as 
protein–protein interactions are not limited to direct physical binding and may also interact 
indirectly e.g. by sharing a substrate in a metabolic pathway or by regulating each other 
transcriptionally. For predicting such functional associations (including direct binding), the 
current growth in completed genomes offers unique opportunities through so-called 
„genomic context‟ or „non-homology-based‟ inference methods [69, 70]. The graphical 
representations of the networks of inferred, weighted entity–entity (e.g. protein-protein, 
gene-protein or enzyme-substrate) interactions provide a high-level view of functional 
linkage, facilitating the analysis of modularity in biological processes.  
Visualisation of networks is highly important, and for this reason, IPA [67] is 
employed for topological network analysis. Combining statistically significant filtered gene 
lists and metabolite lists from the studies in Chapters 4 & 5 to find specific key pathways 
may be indispensable for understanding the regulation of metabolism in DD. Chapter 6 
involves detailed analysis of metabolomic and transcriptomic data using integrative pathway 
analysis which illuminates molecules some which may be of potential importance in the 
pathophysiology of DD and may prove to be important as biomarkers. In this experimental 
model of hypoxia induced in DD cultures and healthy cells, we seek to visualise factors 
affecting the metabolic profiles resulting from the response to hypoxia which induced 
discriminating changes in the metabolic pathways. The aim here is to infer metabolic and 
signaling pathways involved in DD and healthy systems employing both separately and in 
conjunction the statistically relevant small molecules and transcripts by mapping the 
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molecules identified in key transcriptional pathways (and networks) onto the metabolic 
pathways (and networks). The molecules highlighted from metabolite mapping and gene 
mapping will highlight key variables that can then enable construction of model building 
(e.g. constraint-models, kinetic models or Boolean models). 
 In addition the highest scoring networks in the analyses both with and without the 
gene expression data are explored with the aim of illustrating the effects of hypoxia an on 
inflammation, oxidative stress (production of reactive oxygen species), and metabolism. The 
networks identify a number of pathways, key molecules which could play a focal role in DD. 
MetPA (Metabolomics Pathway Analysis) [71]; is also employed for the visualisation and 
analysis of metabolomic data within the biological context of metabolic pathways. In both 
these algorithms, topological connections are inferred from fisher‟s exact ratio. False 
Discovery Rate (FDR) multiple testing correction (Benjamini and Hochberg analysis) [72] is 
possible in IPA. Additionally IPA includes modeled relationships between proteins, genes, 
complexes, cells, tissues, drugs, pathways, and diseases (direct and indirect relationships). It 
includes information from a broad range of published biomedical literature, internally 
curated knowledge, and a wide variety of trusted 3rd party sources and databases, so 
integration from a wide variety of information in one place is possible. All of the content in 
the Ingenuity Knowledge Base is structured, timely (updates occur weekly), and quality 
controlled to ensure quality.  
 
1.3.5 Summary 
The studies in this thesis form a starting point for metabolic and/or signaling network 
analyses.  There are several benefits to modeling for example testing whether the model can 
be made to reflect known experimental facts in DD fascia compared to healthy palmar fascia 
or analysis of the model to understand which parts of the cell system (properties, 
components) contribute to a certain factor e.g. perturbation effect or so-called sensitivity 
analysis. Furthermore, hypothesis generation and testing out rapidly the effects of a change 
or manipulation in the system computationally would be preferred than to perform costly 
future experiments to determine more „what if‟ experiments. Due to cost and time 
constraints, an integrative metabolomics and transcriptomics approach is applied to detect 
and identify variables from endogenous (fingerprint) and secreted (footprint) metabolites 
present in case and controls subjects. Affymetrix microarrays were used to profile a selected 
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subset of samples to both identify and integrate with metabolites data and examine the 
networks using IPA [67] and MetPA [71] to infer metabolic and transcriptional networks 
within cell systems (DD, control and perturbed). 
1.4 Workflow of the Study  
A view of the systems approach (Figure 1), in the framework described involves the 
following sequence of steps: 
 
1. Gather high-throughput molecular fingerprint data from vibrational spectroscopy 
using FT-IR to define all the potential components thought to be involved in DD 
formation and internal & external control. 
2. Assess reproducibility of cultures over time (passage number) by determining the 
hyper spectral signature of each sample with chemometrics & cluster analysis to 
determine the most suitable in vitro representatives for metabolic and transcript level 
profiling and induction of perturbation effects. 
3. Identify key regions of activity from the vibrational bands (i.e. lipids, proteins, 
sugars, nucleic acids). 
4. Examine the extra cellular metabolome with vibrational spectroscopy.  
5. Establish a cell culture system to isolate three biomarkers from the same population 
of cells to enable isolation and measurement of: metabolic footprint and fingerprint, 
and transcriptome.  
6. Simultaneously culture samples in same growth condition and conditioned media in 
normoxic and hypoxic conditions to examine and monitor the perturbed components. 
7. Harvest three cellular components from the same populations of cells in each culture 
condition 21% and 1% oxygen: metabolic footprint, intracellular metabolites and 
mRNA. 
8. Examine metabolic content harvested from the intracellular and extracellular 
metabolome using GC-MS.  
9. Identify key metabolites in disease and control system. 
10. Investigate the effect of hypoxia in the perturbed fascia and compare these resultant 
molecules with those in disease. 
11. Construct key metabolic pathways from this data. 
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12. Investigate this Warburg effect in the transcriptome with high through-put 
Affymetrix oligonucleotide microarrays. 
13. Identify key dysregulated transcripts/genes 
14. Construct key pathways from this data. 
15. Map these genes upon metabolic pathways previously identified in step 11 and vice 
versa. 
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Figure 1 Research pipeline to show the steps involved in this highly exploratory systems biology approach to 
understanding Dupuytren‟s disease. 
 
Chapter 1                                                                                              Dupuytren’s – a Systems Biology disease? 
44 
 
1.5 Aims of this project 
1. To test the hypothesis that metabolic profiles acquired from DD fibroblast cultures 
derived from different DD and control tissue phenotypes are unique to their tissue of 
origin using FT-IR spectroscopy. 
2. To compare the metabolic profiles of DD fibroblast cultures derived from different DD 
and control tissue phenotypes. 
3. To determine effect of serial passaging by comparison of early (primary) cultures to late 
passages in order to identify the most representative passage for the disease using FT-IR 
spectroscopy by assessment of reproducibility on the metabolic fingerprint/profile). The 
passage determined shall be used for subsequent studies once established the hypothesis.  
4. To identify the metabolites that are different in healthy and DD. This will be investigated 
using fibroblast cultures selected from the most suitable representative passage number 
for the disease as determined in steps 1-3. Using a non-targeted approach and a more 
sensitive analytical technique; GC-MS is employed to profile the pool of metabolites 
present within the disease and control fibroblasts. 
5. To determine whether altered oxygen tension (i.e. hypoxic condition) affects the 
composition of intracellular and extracellular metabolomes and the transcriptomes (gene 
expression) of early DD and control fibroblast cultures using GC-MS and Affymetrix 
microarrays for high throughput profiling respectively. This is to test the hypothesis 
whether the difference in disease cell types (nodule, cord and SON) and control cell type 
is the same as the difference in control fibroblasts cultured in normoxia and hypoxia.  
6. To test in which specific disease cell type (nodule, cord, and/or SON) is the difference 
with normal cells in intracellular metabolome the largest?  
7. To examine the extent of the Warburg effect when hypoxia is induced within the disease 
cell types.  
8. To integrate transcript and metabolite profiling data through a SB approach in order to 
determine congruence between the levels of certain metabolites, gene transcripts and 
their protein product(s) using SB tools to identify metabolic pathways, signaling 
pathways and key networks (connections and intercellular dynamics) that may attribute 
to formation of DD. 
 Chapter 2 
Materials and Methods 
2.1 Background to Experimental Techniques 
This chapter provides the background and theory to the experimental techniques applied in 
this thesis (2.1). Data analysis methodologies (2.2) and the complete protocols for each of 
the experiments in Chapters 3-6 (2.3) are provided.  
 
2.1.1 Fourier transform Infra-red Spectroscopy as a metabolic fingerprinting 
screen 
Infrared (IR) spectroscopy is one of the most common spectroscopic techniques used by 
organic, inorganic chemists and medicinal chemists for the detection of different chemical 
functional groups in the sample [73, 74]. In addition to its ability to provide information 
about the structure of a compound it is also used as an analytical tool to assess the purity of a 
compound [74].  
In IR spectroscopy, IR radiation is passed through a sample. Some of the IR radiation 
is absorbed by the sample and some is transmitted. Different functional groups present in the 
sample absorb characteristic frequencies of IR radiation [75]. This is recorded in the form of 
a spectrum which is a plot of intensity vs. frequency with wavelength or wavenumber as the 
x-axis and absorption intensity or percent transmittance as the y-axis. The resulting spectrum 
represents the molecular absorption and transmission, creating a molecular fingerprint of the 
sample. Like a fingerprint no two unique molecular structures produce the same infrared 
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spectrum [76]. In simple terms, IR spectroscopy is the absorption measurement of different 
IR frequencies by a sample positioned in the path of an IR beam.  
The IR region lies between the visible and microwave regions having wavenumbers 
from approximately 12,500 cm
-1
 to 10 cm
-1
, or wavelengths from 0.78 to 1000 μm. 
Frequency ν (nu) is the number of wave cycles that pass through a point in one second. It is 
measured in Hz, where 1 Hz = 1 cycle/sec. Wavelength, λ (lambda), is the length of one 
complete wave cycle and is often measured in centimeters (cm). 
 
Wavelength and frequency are inversely related: 
      ν  =  c/ λ        where λ= Wavelength (µm), c = Speed of Light. 
and Energy is related to frequency by: 
E =  h ν          where, ν= Frequency (Hz), h = Planck’s constant 
 
The IR region is divided into three regions: the near, mid, and far IR (Figure 2). In 
wavenumbers, the mid IR range is 4000 - 400 cm
–1
. An increase in wavenumber corresponds 
to an increase in energy. This study is performed in the most frequently used mid IR region, 
between 4000 - 400 cm
–1
. 
 
Transmittance, T, is the ratio of radiant power transmitted by the sample (I) to the radiant 
power incident on the sample (I0). Absorbance (A) is the logarithm to the base 10 of the 
reciprocal of the transmittance (T).  
A log10 = (1 / T) = –log10T = –log10I / I0 
The transmittance spectra provide better contrast between intensities of strong and weak 
bands because transmittance ranges from 0 to 100% T whereas absorbance ranges from 
infinity to zero. Often the same sample will give quite different profiles for the IR spectrum, 
which is linear in wavenumber, and the IR plot, which is linear in wavelength. This may 
appear as though some IR bands have been contracted or expanded. 
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Figure 2  The diagram shows the whole electromagnetic spectrum and the position of IR region divided into 
three regions; the near, mid, and far IR.  
 
 
2.1.1.2 Theory of Infrared Absorption 
All atoms in a molecule above absolute zero temperature (0 K) are in continuous vibration 
with respect to each other. A molecule absorbs radiation when the frequency of a specific 
vibration is equal to the frequency of the IR radiation directed on the molecule. Each atom 
within the molecule has three degrees of freedom, which corresponds to motions along any 
of the three Cartesian coordinate axes (x, y, z). A polyatomic molecule of n atoms has 3n 
total degrees of freedom. Of these, 3 degrees of freedom are translational, describing the 
motion of the entire molecule through space. Additionally, there are 3 rotational degrees of 
freedom for a non-linear molecule and 2 rotational degrees of freedom for a linear molecule 
which correspond to the rotations of the entire molecule. Therefore, the remaining 3n – 6 
degrees of freedom are true, fundamental vibrations for nonlinear molecules and for linear 
molecules 3n – 5 fundamental vibrational modes because only 2 degrees of freedom are 
sufficient to describe rotation [77].  
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 Among the 3n – 6 or 3n – 5 fundamental vibrations, those that produce a net change 
in the dipole moment may result in an IR activity and those that give polarisability changes 
may give rise to Raman activity (complementary technique to FT-IR). Some vibrations can 
be both IR- and Raman-active. The total number of observed absorption bands can be 
different and are often reduced from the total number of fundamental vibrations. This is 
because some modes are not IR active and a single frequency can cause more than one mode 
of motion to occur. Conversely, additional bands are generated by the appearance of 
overtones (integral multiples of the fundamental absorption frequencies), combinations of 
fundamental frequencies, differences of fundamental frequencies, coupling interactions of 
two fundamental absorption frequencies, and coupling interactions between fundamental 
vibrations and overtones or combination bands (Fermi resonance). The intensities of 
overtone, combination, and difference bands are less than those of the fundamental bands. 
The combination of all factors creates a unique IR spectrum for each compound [78].   
 
Table 1 An example of atoms as point objects with corresponding degrees of freedom. 
 
 
molecule translational rotational bond length bond angle 
C 3 0 0 0 
O 2 3 2 1 0 
H 2 O 3 3 2 1 
 
 Vibrations can be in the form of bonding vibrations (the number of chemical bonds), 
bending vibrations (change of bonding angles), torsional vibrations, out-of-plane vibrations, 
wagging scissoring etc. Infrared radiation is absorbed and the associated energy is converted 
into these types of motions. Table 1 gives an example of atoms, as point objects that have no 
dimension and hence no moment of inertia and therefore, cannot have rotational degrees of 
freedom. Besides three translational and one vibrational degrees of freedom, a diatomic 
molecule can only rotate rigidly about its center of mass, since it has no cross sectional 
dimension (a bond is idealized as having no thickness). For larger molecules, such as water, 
there can be an oscillation of the bond angle [78]. 
Excitations of the vibrational modes of molecular bonds occur when the molecular 
orbitals absorb photons with infrared wavelengths. A group of these wavelengths are listed 
in Appendix B; Table 22. For example, carbon dioxide CO2 is a linear three atomic molecule 
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that has 4 vibrational degrees of freedom. H2O is non-linear also having three atoms and has 
3 degrees of freedom. These degrees of vibrational freedom occur when each bond acts like 
a spring and carries with it potential and kinetic energy (obeys Hookes law) [79]. Each 
normal mode has its own quantum number and is independent of the other modes.  
 
2.1.1.3 The interpretation of infrared spectra  
Interpretation of vibrations of a polyatomic molecule is complex. The determination of the 
reduced mass of a specific normal mode for larger molecules is increasingly complex. 
However, partitioning and identifying functional groups within a molecule gives valuable 
information and a good approximation about its composition.  
 The interpretation of infrared spectra can be achieved by correlation of absorption 
bands in the spectrum of an unknown compound with the known absorption frequencies 
characteristics for particular types of bonds and functional groups. The most important 
factors sought for elucidation of structure are Intensity (weak, medium or strong), shape 
(broad or sharp), and spectral position (cm
-1
) in the spectrum. For example, X-H stretching 
vibrations due to the light hydrogen atom are in good approximation independent of any 
other vibrations and are found in the region of 3400cm
-1
, and if an O-H bond is present, a 
broad peak is observed in this region. A C=O group with two sharp intensity peaks (one 
longer than the other) would be absorbed around 1715± 100cm
-1
 due to asymmetric and 
symmetric stretching. The four important regions of the IR spectrum are shown Appendix B; 
Table 23, Figure 69. 
 For complexed biological systems little can be understood by simply looking at the 
spectra alone as all spectra will show broad contours in a similar shape due to the typical 
composition of a biological cell (e.g. cells, nuclei, proteins and nucleic acids are present in 
all organisms). It is more practical to incorporate multivariate statistical analyses (MVA) 
methods to help seek trends in the data and to aid interpretation; one such technique is 
principal component analysis (PCA).  
Spectral fingerprints, regardless of the means of acquisition, are highly complex, 
representing the sum of all compound present in a sample. In general, it is very difficult to 
identify, let alone quantify, individual compounds. The introduction of group frequencies 
allows the identification of structural elements of a molecule and makes IR spectroscopy an 
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important tool for the identification of molecular structure and for quantitative analysis 
http://www.rwc.uc.edu/koehler. 
 An IR spectrum represents a fingerprint of a sample with absorption peaks which 
correspond to the frequencies of vibrations between the bonds of the atoms making up the 
material. However, each different material is a unique combination of atoms and no two 
compounds produce an identical spectrum. Therefore, IR spectroscopy can result in a 
positive identification (qualitative analysis) of every different kind of material. In addition, 
the amplitude of the peaks in the spectrum is a direct indication of the amount of material 
present. With modern software and signal processing algorithms, IR spectroscopy is an 
excellent tool for rapid high throughput quantitative chemical analysis [80]. FT-IR 
Spectroscopy is widely employed in metabolomics for initial finger and footprinting 
analysis.  
 
 
2.1.2 Gas chromatography – mass spectrometry in metabolomics 
Gas chromatography mass spectrometry (GC/MS) is a hyphenated analytical platform 
widely employed in the field of analytical science and metabolomic studies for the analysis 
of volatile organic compounds [81]. The GC is employed as front end separation source 
where complex chemical samples are fractioned into simpler components via interactions 
with both the stationary (analytical column) and mobile phases (carrier gas). The type of 
stationary phase employed is dictated by the chemical nature of the compounds (i.e. polarity, 
this is different for fat, proteins etc) and its sample matrix. A small volume of liquid sample 
(1-5 μL) is injected into a high temperature, pressurised injection port assembly causing it to 
immediately vaporise. The sample is then deposited onto the top of the analytical column 
under the influence by the carrier gas, it then migrates through the column as it does 
individual components within the sample will interact with the stationary phase at varying 
degrees. The separation of each individual component within the sample mixture will be 
more pronounced and eventually separates into individual discrete bands. These are then 
eluted from the analytical column. Each band/peak represents an individually resolved 
component within the sample mixture. The eluents are then ionised using an electron impact 
source generating a molecular ion and is then introduced into the mass spectrometer. 
Molecular ions generated are usually unstable and therefore can undergo self fragmentation 
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into smaller sub units. The resulting ion fragments are then detected based on their mass to 
charge ratio (m/z) within the MS producing a mass spectrum of the eluent peak. A 
fragmentation profile is generated for each eluted peak within the sample; the profile is 
highly characteristic and indicative of the original parent molecule. Further examination of 
the isotopic ratios, distribution and composition of these ion fragments, can yield detailed 
significant chemical information regarding the chemical structure and functional groups 
present. The fragmentation profiles are then matched against a known mass spectral library 
such as NIST08 [82] using AMDIS (http://www.amdis.net/) to aid in the identification of the 
unknown compounds.  
 
2.1.2.1 Chemical derivatisation   
Most biofluids and tissue are involatile and this necessitates additional sample processing 
steps to convert the sample, amenable to GC-MS analysis chemical derivatisation is 
employed to achieve this. This method transforms molecules to give them a volatile 
characteristic thus reducing polarity allowing analysis by GC-MS [83]. In smaller molecules 
low volatility may be the result of strong intermolecular attraction between the polar groups 
present [84]. Polar groups such N-H, O-H and S-H groups undergo hydrogen bonding and 
have a significant contribution towards the intermolecular attraction. By replacing the active 
hydrogen in those groups through alkylation, acylation or silylation will dramatically 
increase its chemical volatility particularly in compounds with multiple polar groups. Bulky, 
nonpolar silyl groups such as CH3 are often used for this purpose. This method also serves to 
increase the quality of analysis by improving the chromatographic profiles of the chemical 
compound and overall resolution of the analysis [83].  
 
2.1.3 Microarray: a source of high-throughput biological datasets 
Deoxyribonucleic acid (DNA) is the hereditary molecule of all cellular life forms. Found 
inside the nucleus of a cell, it stores and transmits genetic information. The concept of 
“gene” is simply a piece of this DNA, yet encoded in so many different ways can depict a 
phenotype that distinguishes one from another. The complete set of DNA in any cell of an 
organism is called its genome. However, the genome is only a source of information. In 
order to function, it must be expressed. Gene expression occurs in two stages. First, DNA 
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(gene sequence) is transcribed to produce an RNA sequence through a process called 
transcription. Next, this messenger RNA, or mRNA travels from the nucleus to the 
cytoplasm. Each gene sequence in DNA that codes for a protein is expressed as a sequence 
in mRNA. The phrase “gene expression” in quantitative terms means the amount/abundance 
of mRNA present inside the cell. The mRNA sequence is then converted to proteins through 
a process called translation.   
Microarray technologies allow the examination of gene expression (or study of the 
transcriptome) on the scale of a genome when an organism or cells experience a changing 
status thus providing a practical method for measuring the expression level of thousands of 
genes simultaneously. A microarray is typically a glass slide on to which DNA molecules 
are fixed in an orderly manner at specific locations called „features’ or ‘probes’. There are 
two types of microarrays; oligonucleotide microarrays based on Affymetrix technology 
(single-channel) that uses photolithography-directed combinatorial chemical
 
synthesis to 
manufacture its GeneChips, the other type is a spotted microarray which is based on cDNA 
microarray technology [85]. Both these microarrays are based on the mechanisms of DNA 
hybridisation; a process of combining complementary single stranded nucleic acids into a 
single molecule. Two perfectly complementary sequences of nucleotides bind to each other 
under normal condition - a process known as annealing. The microarray contains an array 
series of thousands of microscopic probes of DNA oligonucleotides attached to a glass or a 
silicon chip. Each probe contains picoMoles of a specific DNA sequence [86]. This can be a 
short section of a gene that is expressed in the cell. The oligonucleotide microarrays based 
on Affymetrix technology synthesize small 20-25mer sequences on the probe. A set of 5-15 
probes target a 100 to 200 base pair segments from a known mRNA. These are called „probe 
sets.‟ Affymetrix GeneChip arrays have multiple probes associated with each target. The 
probe set can be used to measure the target concentration and this measurement is then used 
in the downstream analysis to achieve the biological aims of the experiment, e.g. to detect 
significant differential expression between conditions, or for the visualisation and/or 
clustering of data. 
 In single-channel microarrays, the arrays are designed to give estimations of the 
absolute levels of gene expression. A strength of the single-dye system lies in the fact that an 
aberrant sample cannot affect the raw data derived from other samples, because each array 
chip is exposed to only one sample. Another benefit is that data can be compared to arrays 
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from different experiments; the absolute values of gene expression may be compared 
between studies conducted months or years apart or labs apart around the world.  
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2.2 Data analysis 
2.2.1 An essential tool for Metabolomics Data analysis: Chemometrics  
Modern analytical instruments can generate a large amount of data in a short time. 
Metabolomics techniques enable high-throughput application to separate complex mixtures 
with several hundreds of chemical compounds, and can provide spectra of the compounds 
for structure elucidation. These analytical techniques provide as powerful tools to analyse 
various types of samples and give a very detailed insight into the nature of the sample. 
However, efficient data analysis methods to extract useful and interpretable information 
from the huge amount of data are a challenge. Chemometrics is the subject of using 
statistics, mathematics methods to solve chemical and biological problems [87]. In addition 
to classical statistical approaches that can be applied to the data sets such as student's t-test, 
ANOVA chemometrics also employed various multivariate methods for analysing complex 
data sets which has more advantages in terms of sensitiveness, robustness and wider 
application prospect. Nevertheless the goal of these statistical or machine learning methods 
is to identify the biochemicals that best represent the most significant changes between the 
groups in the study. 
The basic principle of chemometrics: given the data under consideration, utilise the 
methods of mathematics and statistics to help with the aim of extracting and interpreting 
information for modeling and prediction [87]. Chemometrics deals with experimental 
design; signal processing; pattern recognition; calibration and evolutionary signal processing 
and curve resolution [88]. This is a huge field and certain sections are beyond the scope of 
this study. Experimental design, signal processing and pattern recognition techniques are 
discussed in this thesis. 
 
2.2.2 Pattern recognition in complex data sets 
Pattern recognition techniques can be categorised into two types: unsupervised pattern 
recognition and supervised pattern recognition [89]. Unsupervised pattern recognition plays 
the most important role in exploratory data analysis since it does not require much prior 
information. The information provided by unsupervised pattern recognition is “data driven”, 
i.e. the pattern revealed by unsupervised techniques purely depends on the data used for 
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modeling/clustering and prediction is often not of concern. There are two main tasks for 
unsupervised pattern recognition: (1) data visualisation and (2) cluster analysis; allowing 
examination of the dominated underlying trends within the data set. Therefore, it can be 
considered as a discovery data analysis tool. 
 
2.2.2.1 Unsupervised pattern recognition:  Data visualisation & cluster analysis 
Perception of patterns within data can best be captured by visualisation of data points 
directly through a 2-D or 3-D scatter (score) plot. Since the human eye can only perceive at 
most in 3 dimensions, it is not easy to directly visualise data with more than 3 dimensions. It 
is often desirable to summarise such complexity by projecting the data points into a lower 
dimensional subspaces defined by a few “latent variables”. Such process is under the name 
of  “component analysis” [89]. The most popular component analysis method, is principal 
component analysis (PCA) [90, 91]. This has become the most commonly used data 
visualisation and modeling method in Chemometrics. PCA projects the original multivariate 
data points into a lower dimension space defined by a subset of mutually orthogonal axis 
(principal components, PC) while still preserving the major variations of the data set. In 
PCA, the data matrix is decomposed into the product of 2 matrices named scores matrix and 
loadings matrix[91]. The scores matrix records the relative position of the samples while the 
loadings matrix records the contribution of each variable to the pattern shown in the scores 
matrix. The modeling importance of each principal component (PC) is measured by the 
percentage of total explained variance (TEV) by the PC. If, for example, the sum of TEV of 
the first two PC is high (e.g. 90% of the total variance) then the scatter plot of PC1 vs. PC2 
is a good two-dimensional representation of the original data structure. PCA can also be 
used for predictive modeling.  
Another important area of unsupervised pattern recognition is „cluster analysis.‟ The 
objective of cluster analysis is to partition a given data set into a small number of groups 
(clusters) in terms of similarity as such that data points in the same cluster are more similar 
to each other relative to than the other data points in different clusters further away. One well 
known cluster analysis algorithm is Hierarchical Cluster Analysis (HCA) [92]. The clusters 
identified by such cluster analysis can be further validated by supervised pattern recognition.  
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2.2.2.2 Supervised pattern recognition  
Supervised pattern recognition is used for the purpose of predictive discrimination and 
calibration purposes, where it aims to correctly associate a known response to the correct 
output with minimal error [92]. Given a finite number of classes to be separated, a decision 
rule (classifier) is derived based on a predefined group of samples with known class 
members (training set) and such a rule has capability to predict the class membership of 
unknown samples (test set). The accuracy of the prediction model/classifier is assessed by its 
„generalisation performance‟ of the classifier. To successfully solve a supervised pattern 
recognition problem, two types of problems need to be considered: underfitting and 
overfitting. Underfitting refers to the predictive model not having sufficient complexity to 
fully detect the entire systematic trend in the data set and therefore not being able to give an 
accurate prediction. In contrast, the problem of overfitting refers to an over-complex 
predictive model. Not only the systematic trend but also noise has been modelled. 
Overfitting is particular dangerous in practical applications because it can give a perfect 
prediction on the training set while giving very high prediction errors on the unknown test 
set. Linear Discriminant Analysis (LDA) and its variants, Discriminant Function Analysis 
(DFA) [92, 93]; regression models such as Partial Least Squares for discriminant analysis 
(PLS-DA) [94] and Artificial Neural Networks (ANNs) [95] are some widely used 
supervised pattern recognition methods. 
 
2.2.2.2.1 Principal component-discriminate function analysis (PC-DFA) 
DFA, also known as canonical variate analysis (CVA) was used in Chapter 3 and 4. Since 
DFA cannot handle the problem of colinearity well which is common to almost all 
metabolomics data, it is necessary to "clean" the data beforehand by using PCA. Thus in 
practical use, PCA and DFA is usually applied in a consecutive manner and such 
methodology is under the name of PC-DFA. PC-DFA/CVA is a form of supervised pattern 
recognition as it is applied with a priori knowledge of the class membership of each sample. 
PC-DFA algorithm is based on the Manly principles [96] and it aims to minimise the within 
group variance while maximising the between group variance (by maximising its Fisher ratio 
[97, 98]. The Fisher ratio is defined as the class to class ratio variation divided by the sum of 
the within class variation:  
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((M1-M2)
2
)/(V1+V2),  
where M1 and M2 are mean of Class 1 and Class 2 and V1 and V2 are the variances of the 
Class 1 and Class 2. This method has been extensively applied in metabolomics for the 
analysis of spectroscopic data (Raman and FT-IR) [31, 99, 100]. Discrimination of salt stress 
in tomatoes [101], identification of urinary tract infection bacteria [31] and recently applied 
to the understanding of plant-pathogen interactions [102].  
A PC-DFA/CVA model is generated by using a portion of the data as a training set to 
initially construct the PC-DFA model, its generalisation performance is then assessed by the 
use of a test set, not previously used in the generation of PC-DFA model, this test set is then 
projected onto the cluster space, by examining the Euclidean distance of projected data point 
of the test to that of the training test within cluster space it accuracy can be evaluated, 
typically a third validation set (data points not previously used in either the training and test 
set)  is used to further check the robustness and validity of the PC-DFA model and guard 
against over fitting of the data set.  The PC-DFA model can be optimised by adjusting the 
number of PC used to increase its generalisation performance. The trends or difference 
identified in the model are through the loading of DFs and this is followed by validation 
using other methods or normally confirmed using univariate statistics.  
The Euclidean distance between a priori group centers in DFA space using the first 
two functions (DF1 and DF2), was used to construct a similarity measure, and these distance 
measures were then processed by an agglomerative clustering algorithm to construct a 
dendrogram. 
 
2.2.2.2.2 ANOVA-PCA, a semi-supervised approach 
ANOVA-PCA can be considered as a method somewhere in the middle between 
unsupervised and supervised methodologies. A main drawback of PCA is that it is 
completely variance driven and in this respect, PCA can be disturbed by the variance caused 
by the variables/metabolites which are not affected by the biological experiment. It is 
possible that the most significant PCs obtained from PCA are not related to the aim of the 
study simply because that there are other factors which cause more variances than the factors 
which the experiment was designed to investigate did. Analysis of variance-principal 
components analysis (ANOVA-PCA) is developed to cope with such problem by actively 
incorporating the experimental design into the PCA. 
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ANOVA-PCA creates a series of matrices which contain the means of the different 
levels of the factors under investigation and interactions of these factors according to the 
experimental design, to which are added the residual errors [103]. PCA is then applied to 
each of these mean plus error matrices in order to evaluate the significance of the effects 
caused by each factor against the residual error. Construction of submatrices of the data for 
each factor can be more easily interpreted, visually and statistically, by PCA. Similar to 
PCA, scores and loadings are obtained, which can be used to study the existence of 
groupings of individuals and to evaluate the importance of the initial variables in the 
definition of the effects and the sources of residual variation and to compare it to the 
different factors in the experimental design. This procedure is not related to the ANOVA-
based method that is often used to detect significant variables prior to a multivariate analysis 
such as PCA. Although this method also uses the labeling information, the key difference 
between ANOVA-PCA and supervised methods is that ANOVA-PCA "encourages" the 
PCA to discover the variation of interest by use an ANOVA like data-preprocessing and thus 
increase the chance of discover the variation of interest in the first or first a few PCs while 
supervised methods seek an optimal separation boundary between known classes. As a 
result, the risk of over-fitting of ANOVA-PCA is lower than that of supervised methods 
because it makes no attempt to separate the samples according to their membership 
information. 
The reason ANOVA-PCA is used in this study (2.3.2) is that there are many different 
types of variations in the data and in many cases only a small subset of variation are of 
interest. The variance that PCA considered to be important (i.e. the trends shown in the first 
a few PCs) are not necessarily the ones what we want to see and ANOVA-PCA appeared to 
be much more effective than PCA in revealing the difference between different groups of 
samples. 
 
2.2.3 Microarray data analysis 
The vast numbers of publications that have reported methods for microarray data analysis 
follow differing analytical strategies. Microarray data analysis is a complicated process as 
this technology is associated with many significant sources of experimental uncertainty, 
which must be considered in order to make confident inferences from the data. However, 
there is no standardised microarray data analysis pipeline but what is available are 
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opinionated analysis pipelines based on experience, nature of biological question in the 
study, suitability of method to the experimental design. Following image processing, and 
transformation using the proprietary Affymetrix image analysis software to generate CEL 
files (and other files e.g. CHP, DAT), discovery of relationships between genes can be 
pursued in many ways.  
Affymetrix microarrays are designed to give estimations of the absolute levels of 
gene expression. Relative intensities of each probeset can be used in ratio-based analysis to 
identify up-regulated and down-regulated genes. Expression ratios are the primary form of 
comparison. Background correction and quantile normalisation using Robust Multi Array 
(RMA) [104] and GeneChip Robust Multi Array (GC-RMA) are popular methods used. 
Exclusion of MM data in RMA reduces noise, but loses information. Inclusion of adjusted 
MM data in GC-RMA reduces noise, but retains MM data.  
Like metabolomics data, analysis of gene expression data can be classified into two 
different types; unsupervised and supervised learning. In the case of unsupervised learning 
(exploratory data analysis), the expression data is analysed to identify patterns that can group 
genes or samples into clusters without the use of any form of a priori knowledge. While in 
supervised learning the use of annotation is incorporated to create genes or sample clusters 
in order to identify patterns that would be characteristic of respective clusters. Pattern 
recognition methods have been discussed in 2.2.2.  
Among the most common and important analysis tools is data visualisation using 
heatmaps. Gene expression data is converted to a colour code for visualisation. Common 
practice uses red for up-regulated genes, green for down-regulated genes, and black for no 
change. For simultaneous analysis of a set of microarrays, the data is clustered in terms of 
genes or arrays using different clustering algorithms and the output is visualised by a 
heatmap. Agglomerative hierarchical clustering is commonly used for the analysis of gene 
expression data [92]. The representation of this hierarchy is a dendrogram. This can help 
separate and identify locations of different clusters. Other popular clusters algorithm such as 
Partitioning Around Medoids (PAM) algorithm [105] and k-means [106] are also widely 
used in gene expression data analysis..  
 Arbitrary thresholds such as > 2 fold change (FC) have been used to rank/identify 
genes of interest. Other common methods performed are Pearson‟s correlation coefficient; 
distance metric used in various clustering algorithms including HCA and rank correlation 
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coefficient. Univariate tests can also be applied. Significance analysis of microarray (SAM) 
performs thousands of T-tests efficiently [107]. 
 A number of methods for finding pairs of co-expressed genes, based on correlation or 
measures of mutual information have been used to understand gene regulation [108-112]. 
There are also model based approaches such as Bayesian models which have been very 
successful and are now used extensively [113-118]. Such models explicitly represent and 
reason about biological entities in a modular way, as well as capture the mechanistic details 
of the underlying biological systems. Puma: Propagating Uncertainty in Microarray Analysis 
[119], one such package incorporated the Gamma Model of Signal [120]. These packages 
are freely available via the R-Bioconductor software suite [121]. Bioconductor is an open 
source and open development software project for the analysis and comprehension of 
genomic data. It is based primarily on the statistical R programming language. Other, 
emerging new methodologies for gene expression analysis are making use of Boolean logic 
[122]. Despite this each method has its pros and cons for analysing noisy data.  
Due to experiment errors and noise, there will always be some difference in 
expression between groups. However, it is the size of this difference in comparison to the 
variance (i.e. the range over which expression values fall) that will tell us if this expression 
difference is significant or not. Thus, if the difference is large but the variance is also large, 
then the difference may not be significant. However, a small difference with a very small 
variance could be significant. For example, T-test and ANOVA test return a p-value that 
takes into account the mean difference, the variance and the sample size. The p-value is a 
measure of how likely a particular gene will return if no real difference existed. This is 
called formulating a null hypothesis. A p-value < 0.05 indicates that the chance of this gene 
being different is due to random occurrence and there was in fact no real difference is small 
and therefore the gene could be considered significantly different in the group expression 
data. However, the p-value itself is only valid to a single test. When the statistics test has 
been performed on multiple targets, the chance of having false positive discovery increases 
along with the number of the tests been performed. For example, choosing a threshold of 
0.05 means there is a 5% chance (1 in 20) the returned result is false positive in a single test, 
However, if one perform such test on 2 different genes (assuming the two genes are 
independent to each other) using the same p-value threshold, the chance of at least one of 
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these 2 being false positive becomes 1-0.95×0.95=0.0975. This issue is known as the 
multiple testing problem [123]. 
A number of approaches to overcoming this multiple testing have been suggested. 
These include, assigning an adjusted p-value to each test, or choosing a lower p-value 
threshold e.g. 0.01 or 0.001. The Bonferroni correction [124] is also a popular method, but 
often too conservative. While the method reduces the number of false positives, number of 
true discoveries is also axed. The False Discovery Rate (FDR) approach determines adjusted 
p-values for each test. However, this method controls the number of false discoveries in only 
the significant values, hence it is less conservative than Bonferroni approach and is a 
preferred method to truly identify significant results. An FDR adjusted p-value is now 
termed the q-value. 
When doing lots of tests, as in a microarray experiment, it is more intuitive to 
interpret p and q values by looking at the entire list of values rather that looking at each one 
independently. In this way, a threshold of q < 0.05 has meaning across the entire experiment 
indicating how many false positives can be expected by using this cut-off. 
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2.3 Materials and Methods 
 
2.3.1 Whole-cell fingerprinting using FT-IR (Chapter 3) 
2.3.1.1 Experimental design  
Patient Recruitment – Study 1 
All cases involved in the study were diagnosed to have advanced stage of DD, which was 
determined by the presence of nodule and cord causing contracture of the 
metacarpophalangeal joint and the proximal interphalangeal joint in the involved hand. The 
mean age of the patients participated in Study 1 was 67 ± 10 years. The exact age and 
demographics for all patients can be seen in Appendix B, Table 24. All patients were male 
(except DD13; female) caucasians who had not undergone any previous surgical or non-
surgical treatments.  
 
Patient Recruitment – Study 2 
Four DD cases and five controls subjects (CTD) were included in the study. All recruited 
DD cases were diagnosed with advanced stage of DD, which was determined clinically by 
an experienced hand surgeon. All patients presented flexion contracture of the 
metacarpophalangeal joint and proximal interphalangeal joint as well as presence of nodules. 
All DD patients in this study were male Caucasians and only one (DD2) had undergone 
previous surgical treatment. The mean age was 60 ± 12 years. Four of the five control 
subjects included in the study were Caucasians, and one being Asian Indian. Three of the 
control subjects were male and two were female. The average age of the control subjects was 
57 ± 19 years. The study was approved by the institutional review board for human subjects‟ 
research. 
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Table 2 Demographic details from Dupuytren cases in Study 1 and 2. 
Patient ID Age Sex
DD8 77 M Nodule Cord Fascia
DD9 58 M Nodule Cord Fascia Fat Skin
DD10 76 M Nodule Cord Fascia
DD11 67 M Nodule Cord Fascia Fat Skin
DD12 52 M Nodule Cord Fascia Fat Skin
DD13 74 F Nodule Cord Fascia Fat Skin
Patient ID Age Sex
DD16 46 M Cord Fascia
DD17 67 M Nodule Cord Fascia Fat Skin
DD2-R Nodule Cord Fascia Fat Skin
DD18 68 M Nodule Cord Fat
CT4 67 M Fascia* Fat* Skin*
CT5 78 M Fascia* Fat* Skin*
CT6 62 F Fascia* Fat* Skin*
CT7 50 F Fascia* Fat* Skin*
CT8 28 M Fascia* Fat* Skin*
*CTD patient, external control
Study 1
Anatomical location
Anatomical location
Study 2
 
 
Samples Collections 
DD tissue phenotypes (nodule, cord, unaffected transverse palmar fascia, subcutaneous fat 
superficial to nodule and SON) were carefully dissected using magnifying loupes from each 
patient at the time of surgery (Figure 3(a), Table 2). Three tissue biopsies, including the skin, 
subcutaneous fat and palmar fascia (transverse carpal ligament), were obtained from 
individuals undergoing carpal tunnel release (Figure 3(b). Each biopsy was bisected for 
either 1) cell culture processing or total ribonucleic acid (RNA) extraction or 2) for cell 
culture processing and histology tissue processing. The biopsies used for establishing tissue 
cultures were thoroughly washed for 15 min in 1× Dulbecco‟s phosphate buffered saline 
(Lonza, Belgium) and 1% penicillin/streptomycin (Lonza, Belgium), at room temperature. 
For histological analyses to determine tissue and cell morphology, the biopsies were stored 
in formalin at 3
o
C, and processed within 48 hrs. The harvested biopsy samples for total 
ribonucleic acid (RNA) extraction were kept in RNAlater (Ambion, UK) at 4
o
C overnight 
and stored at -80
o
C until required for subsequent gene expression analysis. 
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Skin
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a)
b)
 
Figure 3 (a) The five sites from the diseased hand. The Dupuytren‟s disease-associated tissues that are 
subjected to analysis in this study. Five different Dupuytren‟s disease-associated tissues in each patient‟s hand 
are collected, the normal fascia (unaffected transverse fascia), palmar nodule and cord, skin overlying nodule, 
and fat. 3 (b) The palm of an unaffected individual used as control. The palm of the hand of a control 
subject, where the overlying skin has been removed to demonstrate the position of the palmar fascia harvested. 
Skin, palmar fascia (transverse carpal ligament) and fat were obtained from control subjects, individuals 
undergoing carpal tunnel release. 
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2.3.1.2 Specimen Processing & Tissue/Cell Culture 
To establish the tissue cultures, the biopsies were further dissected into small pieces, roughly 
1mm
3
 in size, with sterile scalpels. The tissue pieces were incubated in 0.25-5% collagenase 
A solution (Roche Diagnostics, GmBh, Germany) at 37
o
C for 2.5 to 3 hours. The 
collagenase activity was inhibited using fibroblast culturing media (Dulbecco‟s Modified 
Eagle‟s Medium 3 (Lonza, Belgium) supplemented with 10% heat-inactivated fetal bovine 
serum (Lonza, Belgium), 1% penicillin/streptomycin (Lonza, Belgium) and 1% non-
essential amino acids (Lonza, Belgium)). The digested samples were centrifuged at 1,500 
rpm (approximately 400 ×g) for 5 minutes. Each pellet was re-suspended in 5mL fibroblast 
culturing media, seeded to 25cm
2
 culturing flask (Corning, UK) and incubated at 37
o
C in 5% 
CO2. The culturing media was replaced every 48 hours and cell passages were carried out at 
approximately 80-90% confluency using trypsin-ethylene diamine tetraacetic acid (200mg/L 
ethylene diamine tetraacetic acid, 500mg/L trypsin; Lonza, Belgium). The first sub-culturing 
(passage) was performed on cultures that were grown directly from the biopsies. These were 
called passage 0 (P0). Following the first centrifugation of cells, ½ of the pellet obtained was 
seeded onto 1 x 75cm
2
 in study 2 (now called P1 cells) and the ½ pellet was frozen down in 
DMSO containing freezing media. (In Study 1, all cells from the pellet were passaged onto 
new flasks for the first time (4 x 25cm
2 
in equal amounts) and no sample from the previous 
passage (P0) was retained. From here on further passaging was performed on ¼ of the cells 
grown from the current passage (called P1) and ¾ was kept in freezing media containing 
DMSO into 3 separate nunc tubes equally and transferred into Mr Frostie at room 
temperature. These were then stored at -80ºC until required for FT-IR analysis. During the 
incubation period the fibroblasts purity was assessed by morphological observation under an 
inverted phase contrast microscope. The spent culture medium containing all excreted 
metabolites (footprint) were kept in 15 mL falcon tubes and stored at –80°C until analysis. 
The approximate % confluency (85-90%) and days each sample was passaged was recorded. 
All passages of the cell cultures were used in this study. The steps involved in sample 
preparation to sample interrogation are illustrated in Figure 4. All work was conducted using 
a single production batch of serum. 
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Figure 4 A diagram to show the steps undertaken from tissue processing to sample interrogation by FT-IR. 
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Morphological Assessment and Haemocytometer Counting 
Morphological changes of DD and CTD fibroblasts in all groups were monitored under an 
inverted phase contrast microscope during the tissue culture experiments. At the end of each 
passage, cells were washed with phosphate buffered saline (PBS), and detached from the 
culture dish by 0.25% trypsin. Cell number was then counted through direct visualisation 
using a haemocytometer. Prior to sub-culturing, 20 μL of cell suspension was then mixed 
with 20 μL Trypan Blue (Nacalai Tesque, Inc.), a dye exclusion that leaks into cells with 
damaged plasma membranes. In this way, the dead cells were stained blue, allowing the 
living and the dead cells to be distinguished. A 10 μL amount of this solution was then 
placed in a haemocytometer and the number of living cells counted, while being viewed with 
a light microscope. Figure 70 (i) and (ii) in Appendix B show confluent monolayer images 
for nodules and cords fibroblast samples. Average no. of cells per T25 cm
2
 flask were 600-
650,000 for nodules, 400-500,000 for cords, 350-400,000 for the internal control fascia, 400-
500,000 for the subcutaneous fat and 600-670,000 for the skin overlying the nodules. The 
average number of cells per flask and the number of days between each passage for each 
sample was recorded.  
 
2.3.1.3 FT-IR-Fingerprint Sample Preparation 
15µL aliquots of the sample cells dissolved in 50µL DPBS suspensions were evenly applied 
onto a polished silicon (Bruker, Coventry) microplate containing 96 wells. Each sample was 
spotted in triplicates in a random arrangement. Prior to analysis the samples were oven dried 
at 50°C for 30 min. Samples were run in triplicate. The FT-IR instrument used was the 
Bruker IFS28 FT-IR spectrometer (Bruker Spectrospin Ltd., Coventry, United Kingdom) 
equipped with a mercurycadmium-telluride detector cooled with liquid nitrogen. The silicon 
plate was then loaded onto the motorised stage of the FT-IR.  
 The IBM-compatible personal computer used to control the IFS28 spectrometer was 
programmed (using Opus, version 2.1, software running under IBM O/S2 Warp provided by 
the manufacturers) to collect spectra over the wavenumber range of 4,000 cm
–1
 to 600 cm
–1
 
at a rate of 20 s
–1
. A spectral resolution of 4 cm
–1
 was used. To improve the signal-to-noise 
ratio, the spectra were co-added and averaged (Study 1; 468 and Study 2; 927). Each sample 
was thus represented by a spectrum containing 1764 points and spectra were displayed in 
terms of absorbance calculated from the reflectance-absorbance spectra using the Opus 
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software. The combination of both biological and analytical replicates was employed in the 
FT-IR analysis to measure the biological variance in the data. The employment of „analytical 
or machine replicates‟ may be averaged to reduce the heterogeneity of the biological 
replicates in the analysis of the data. An empty well was used to take a reference background 
measurement.  
 
2.3.1.4 FT-IR-Footprint Sample Preparation 
20uL of the secreted metabolites collected in spent media were spotted directly onto the 
Silicon microplates, oven dried and subjected to FT-IR as above.  
 
2.3.1.5 FT-IR data pre-processing and multivariate statistical analysis 
Preprocessing  
All statistical analyses were performed using Matlab R2010a (MathWorks, Inc., MA). The 
ASCII data were imported into Matlab. To minimise problems arising from baseline shifts, 
empirical pre-processing techniques to reduce/eliminate light scattering effects were applied. 
The following procedures in Matlab (methods 1 & 2) were implemented. Method 1 The 
spectra were first scaled / normalised so that the smallest absorbance was set to 0 and the 
highest absorbance was set to +1 for each spectrum. These normalised spectra were then 
detrended by subtracting a linearly increasing baseline from 4,000 to 600 cm
-1
; and finally, 
the smoothed first derivatives of these normalised and detrended spectra were calculated by 
using the Savitzky-Golay algorithm [125]. Method 2 – (yielded best separation between 
tissue phenotypes) To reduce/eliminate light scattering effects an empirical pre-processing 
technique (extended multiplicative scatter correction (EMSC) [126], order 4) was applied to 
the spectra. These normalised spectra were then detrended by subtracting a linearly 
increasing baseline from 4,000 to 600 cm
-1 
where necessary. This method was also tested 
using PyChem 3.05a [127]. 
 
Cluster analyses  
Data were grouped into four categories (the samples included are listed in Tables 25-30 in 
Appendix B)) listed in combinations in Table 3 for comparisons using MVA. The pipeline 
used for MVA on the hyperspectral FT-IR data is detailed in Figure 5. To reduce the 
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dimensionality of the multivariate data whilst preserving most of the variance, Matlab (and 
PyChem (3.05a)) [127] was used to perform PCA according to the NIPALS algorithm [91, 
94].  For each PCA performed on the chosen combination of samples, of the original 1764 
spectral points in the respective study, the maximum percentage of the total variance 
retained in the first 20 principal components (PCs) was recorded for supervised discriminant 
function analysis (DFA). 
DFA was employed for samples where PCA was insufficient for clear pattern 
recognition from the scores plot or where the sample and group size was greater than PCA 
could withstand. DFA; also known as canonical variate analysis [96]  then discriminated 
between groups on the basis of the retained PCs that were used as inputs to the DFA 
algorithm with the a priori knowledge of which spectra were replicates.  DFA was 
programmed to minimise „within-group‟ variance and maximise „between-group‟ variance, 
and as this process uses information based on the biological replicates from each sample, it 
does not bias the analysis, allowing any natural trends or time-dependent trajectories to be 
observed.  
 Using PyChem, the Euclidean distance between a priori group centers in DFA space 
using the first two functions (DF1 and DF2), was used to construct a similarity measure, and 
these distance measures were then processed by an agglomerative clustering algorithm to 
construct a dendrogram. 
 
2.3.1.6 Haematoxylin and Eosin Staining 
Histological examination of palmar aponeurosis tissue specimens stained with haematoxylin 
eosin (H&E) to confirm macroscopical differences in DD phenotypes and control were 
performed. The H&E slides from disease and control tissues are shown in Appendix C; 
Figures 71 (i-viii).   
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Table 3: List of categories and the sample set chosen for principle component analyses. 
 
CATEGORY STUDY SAMPLE SET
1 1A, 2A
Differentiation of diseased subsets (nodule, cord) 
and fascia (internal  control) wrt passage number
2 2C
Differentiation of diseased subsets (nodule, cord) 
with fascia (internal  control) and CTD fascia 
(external control) wrt passage number
3 2B
Differentiation of diseased subsets (nodule, cord) 
with fascia (internal  control), fat and SON wrt 
passage number
4 1A, 2A, 2B
Differentiation of individual sites, from all 
passages wrt to individual patient
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Figure 5 A workflow representing the procedure implemented to analyse the samples from Dupuytren‟s 
disease and control fibroblast cell cultures. 
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2.3.2 Metabolic profiling of fibroblasts under oxidative stress using GC-MS 
(Chapter 4) 
 
2.3.2.1 Experimental design 
Patient Recruitment – Study 3 (GC-MS and Microarray Chapter 4 & 5) 
DD patients (n = 8 men) were used in this study. The age range was between 55 and 70 years 
with a mean age of 67 years (SD ±7). Patient recruitment procedure was followed as 
previously stated in Section 2.3.1.1 and demographic information is given in Appendix D. 
Figure 6 illustrates the experimental design for this study and for part of Chapter 5.  
 
Source of Biopsy Tissue Specimens 
Tissue biopsies were obtained from 8 male DD patient having dermofasciectomy: nodules 
from the palm (n = 7), cords from the palm (n = 7); of which 6 nodules and cords were 
obtained from the same individuals. Transverse palmar ligament (internal control; n = 3) and 
SON (n = 4) were also obtained where possible. Biopsies were harvested at the time of 
surgery. Tissue was carefully excised to include merely the diseased or the normal fascia 
without the adjacent adipose/connective tissue. The tissue was then placed immediately into 
DPBS and transported to the laboratory within an hour to establish cell cultures.  
 
2.3.2.2 Experimental Protocol 
Overview 
This protocol describes methodology for quantifying the concentrations of endogenous and 
secreted metabolites in cultured cells using GC-MS. Cell cultures were established for each 
sample in 21% and 1% oxygen concentrations. In this way, each sample acts as its own 
biological control with 3 biological replicates. Many metabolites turn over very rapidly; 
thus, correctly measuring intracellular metabolite concentrations requires the ability to 
sample cells quickly. If not, the measured levels will reflect the metabolic state induced by 
the handling steps leading up to quenching of metabolism, rather than normal cellular 
physiology. As previously described in Section 2.3.1 DD fibroblast are adherent cells. 
Metabolism was quenched with minimal perturbation of the culture via quick aspiration of 
medium, one wash step (4°C) and addition of cold (-75°C) 70% methanol. The solvent 
addition stopped metabolism (initially due to the temperature drop and subsequently by 
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denaturing enzymes) and simultaneously initiated the extraction process by disrupting the 
cell membrane. Sample preparation for GC-MS analysis followed as described below. 
 
DD fibroblasts are cultured ~ 85-90% confluency in T150ml culture 
flasks in  1) 21% O2 and 2) 1% O2
Each sample acts as its own biological  control with 3 biological 
replicates
GC-MS  GC-MS AFFYMETRIX PLUS 2.0 
1. Aspirate Footprinting media 
2. Retain aliquot per flask
3. Syringe filter into centrifuge tubes
4. Snap freeze in liquid N2
5. Store at -80C until analysed
6. Wash with PBS (4oC X 1)
7. Add 70% MeOH (-75C) to quench cell metabolism
8. Harvest cells by scraping
9. Remove cellular biomass by pipette aspiration and collect 
into falcon tubes
10. Extract metabolites through 3 freeze-thaw cycles. Snap 
freeze in liquid N2 and thaw on dry ice
11. Centrifuge to pellet cell debris and collect supernatant into 
pre-weighed falcon tubes
12. Store at -80 C until analysed (All in one go -1 month)
13. Resuspend cell debris iin 1ml HPLC graded water and 
transfer to pre-weighed eppedorfs
14. RNA extraction
15. RNA QC check –Agilent
16. Microarrays - Metabolomics work 
indicates which samples to do arrays on 
(pre & post-hypoxia)
Nodule (N=7) Cord (N=7) Fascia (N=3)     SON (N=4) 
P3,  Controls - 21% O2
Nodule (N=7) Cord (N=7) Fascia (N=3)     SON (N=4) 
P3,  Hypoxic stress 1% O2
1. Footprint 2. Intracellular metabolome 3. RNA
Experimental Design
Parallel metabolomics and transcriptomics exp 
 
Figure 6 Experimental protocol illustrating steps involved in combined extraction method for metabolomics 
and transcriptomic level investigation to extract 1. metabolic footprint 2. intracellular metabolome and 3. RNA 
from same population of cells 
 
Cell culture 
A total of 126 samples were processed and stored. Samples from (passage 1) DD nodules (n 
= 7), cords (n = 7), fascia (n = 3) and (SON (n = 4)) were seeded into T25 cm
2
 culture flasks. 
Upon 90% confluency, samples were passaged into 2 x T75cm
2
 culture flasks. Approx 1-1.5 
million cells were obtained from each T75cm
2
 flask. Upon 85-9% confluent, these were 
subcultured into 6 x 150cm
2
 flasks; (3 x 150cm
2
 in normoxic O2, 3 x 150cm
2
 in 1% O2, 3 
replicates for each sample. DD fibroblasts were grown until 85-90% confluent in a) 21% O2, 
5 % CO2 and b) 1% O2, 5% CO2. A total of 63 flasks were in normoxic culture and 63 in 
hypoxia. Culture medium for conditions (a) and (b) had same formulation i.e. DMEM 
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(500mL) supplemented with L-glutamine (1%), NEAA (1%) and FBS Gold (10%) and 
Pen/strep (1%). Preparation of the 1% oxygen media (termed hypoxic media) is given below. 
For the purposes of these experiments, 21% O2 was regarded as normoxic and 1% O2 as 
hypoxic conditions for the term DD cultures. After 48-72 h, culture medium was replaced 
with fresh equilibrated medium, All work reported was conducted using a single production 
batch of serum.  
 
Preparation of 1 % oxygen (hypoxic) media 
Data: 1 mol of gas = 22.4 L at 25
o
C, hence 23.0 L at 37
o
C.  Therefore the concentration of 
oxygen (O2) in pure oxygen is:  1000/22.4 mM at 25
o
C, 1000/23 at 37
o
C.  Air contains 
approximately 20.8 % oxygen, hence the oxygen concentration in air is:  at 25
 o
C: [O2]air = 
0.208*1000/22.4 mM= 208/22.4=9.3 mM and at 37
o
C: [O2]air = 0.208*1000/23.0 mM= 
208/23.0=9.0 Mm. Oxygen concentration in water at 25
o
C:-  „Water solubility of oxygen at 
25
o
C and pressure = 1 bar is at 40 mg/L water [128]. In air with a normal composition the 
oxygen partial pressure is 0.2 atm. This results in dissolution of 40
 
x 0.2 = 8 mg O2/L in 
water that comes in contact with air. A formula that calculates for 760 Torr pressure and 25 
°C : 8.3 mg O2/L is given in [129-131].  In terms of molarity this gives: [O2] = 8.3/32=0.26 
Mm. We need higher temperature however: For 37°C the formula gives: [O2]= 6.9/32=0.22 
Mm (760 mmHg (Torr), 29.92 in Hg, 14.696 PSI, 1013.25 millibars, hence 1 atmosphere is 
approximately 760 Torr). The ratio in oxygen molarities in gas to water is: At 25°C : 36 and 
at 37 °C : 41. In what follows we assume that this ratio is 40 at all temperatures.  
 
Making use of the head space 
Measure the total volume of the bottle including all the head space.  Let us call this volume 
Vml. 
Make the empty bottle anaerobic with N2 gas.  Add a volume of X = x.V ml to the bottle.  
Make sure that the head space is anaerobic by using N2 gas.  Close the bottle with an oxygen 
impermeable cap. We assume that this is done with medium at 37°C.  Now we calculate X:  
 
The total amount of oxygen in the bottle before equilibration is: 
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Two-thirds of the bottle was filled with aerobic medium and the headspace made anaerobic 
with N2. 
 
Metabolite quenching & extraction and obtaining RNA for microarrays 
Isolation of the exometabolome, intracellular endometabolites and total RNA from the 
samples was achieved using a novel combined extraction method developed recently and 
tested on neuroblastoma cell lines [132]. This method permits the isolation of three samples 
from the same population of cells: metabolic footprint, intracellular metabolites and RNA. 
Appropriate changes to this protocol were made for optimal extraction of glycolysis 
intermediates without compromising on RNA integrity or quality. 
 
Isolation of the Metabolic Footprint and Intracellular Metabolites 
Cells were grown from each biological sample until 85-90% confluent. Metabolic footprint 
samples containing exometabolome (secreted metabolites) were obtained from 1mL of used 
growth media. The media was aspirated from cultures, sampled directly from the flask and 
passed through a 0.2µm filter to remove any cells and collected in 2mL pre-labeled 
Eppendorf tubes. The media was immediately snap-frozen in liquid nitrogen, placed in dry 
ice and then stored at -80
o
C until ready for GC-TOF-MS analysis.  
 Following the collection of footprint, the remaining medium was aspirated and the 
cells were washed once with 4
o
C PBS (12mL) and quickly aspirated any traces. Immediate 
addition of 70% methanol (8mL pre-chilled to -75
o
C) was added to quench metabolic 
activity. The selection of cold methanol: water 70:30 as an extraction solvent was based on 
previous systematic studies for extraction of glycolysis intermediates. A large cell scraper 
was used to harvest cells quickly over ice as addition of the quenching solution increases the 
temperature. The cellular biomass was removed by pipette aspiration and collected in 15mL 
centrifuge tubes. Metabolites were immediately snap frozen in liquid nitrogen. Metabolites 
were then extracted through 3 freeze-thaw cycles (vortexed for 30-40 s each time and 
thawed on dry ice) in order to permeabilise the cells, resulting in the leakage of the 
metabolites from the cells. The supernatant (containing the metabolite) was collected by 
centrifugation (15000 × g for 7 min) and transferred into pre-weighed falcon tubes and 
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placed in dry ice. The extracts were stored at -80
o
C until ready for MS preparation. To one 
of the three replicates pellets containing the cell debris and the RNA, trizol (1mL) was added 
and stored at -80
o
C until ready for RNA extraction post metabolomics data analysis. Two of 
the three replicates pellets containing cell debris and RNA were dried to remove residual 
solution and then weighed to determine the mass of dried biomass after extractions to 
determine volume of metabolites needed for analysis. 
 
Derivatization of metabolites for GC-TOF-MS analysis 
Samples were prepared for MS immediately before the analysis was carried out by 
determining the accurate volume of extracts to dry down. These volumes were then 
lyophilized for 16 h in a vacuum concentrator (HETO VR MAXI with RVT 4104 
refrigerated vapor trap; Thermo Life Sciences, Basingstoke, U.K). For MS analysis 
endometabolome samples (200 μL) were spiked with 4 μL internal standard solution and 
lyophilised. Dried extracts were then derivatized as follows; 50 μL of 20 mg mL-1 O-
methoxylamine hydrochloride in pyridine was added, vortexed, and incubated at 80 °C for 
15 min in a dri-block heater. A volume of 50 μL of MSTFA was then added and the extracts 
incubated at 80°C for a further 15 min. On completion, 20 μL of retention index marker 
solution was added (0.3 mg mL
-1
 docosane, nonadecane, decane, dodecane, and pentadecane 
in pyridine) prior to centrifugation at 15 800 × g for 15 min. The resulting supernatant (90 
μL) was transferred to GC-MS vials for analysis.  
 
2.3.2.3 Gas chromatography/Time-of-Flight mass spectrometry analysis 
The samples were analyzed in a random order by employing a GC-TOF-MS (Agilent 6890 
GC coupled to a LECO Pegasus III TOF mass spectrometer) using a previously described 
method in [133].  
 
2.3.2.4 Footprint sample analysis 
To allow normalisation of response variability, conditioned culture medium was prepared 
GC-TOF-MS analysis by spiking 200 ml aliquots of cell-free supernatant with 100 ml 
internal standard solution (0.17 mg/ml succinic d4 acid). 
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2.3.2.5 Metabolite identification 
The GC-MS data was deconvoluted producing a peak table of the metabolites identified, a 
three dimensional matrix of information: scan number (related to the time since injection), 
mass and signal intensity. Raw data were processed using LECO ChromaTof v2.12 and its 
associated chromatographic deconvolution algorithm, with the baseline set at 1.0, data point 
averaging of 3 and average peak width of 2.5. A reference database was prepared, 
incorporating the mass spectrum and retention index of all metabolite peaks detected in a 
random selection of samples so to allow detection of all metabolites present, whether or not 
expected from the study of bibliographic data. Each metabolite peak in the reference 
database was searched for in each sample and if matched (retention index deviation <+/- 10; 
mass spectral match > 750) the peak area was reported and the response ratio relative to the 
internal standard (peak area-metabolite/peak area-succinic-d4 acid internal standard) 
calculated. These data (matrix of N samples × P metabolite peaks) representing normalised 
peak lists were exported in ASCII format for further analysis. Metabolites were definitively 
identified by matching the mass spectrum and retention index of detected peaks to those 
present in a mass spectral library constructed at the University of Manchester [134]. A match 
is defined as a match factor greater than 750 and a retention index +/- 10. 
Processed data are described by individual metabolite features (chromatographic 
peaks described by an accurate mass, retention time and peak area). Multiple features can 
represent a single metabolite. Therefore, raw data are represented by metabolite features and 
not metabolites. Metabolite features described in the raw dataset were putatively or 
definitively identified as metabolites in the processed dataset. Putative identification 
involved the matching of the measured accurate mass to accurate mass(es) present in the 
Manchester Metabolomics Database (MMD) and as previously described in [134]. Definitive 
identification involved the matching of accurate mass and retention time of the metabolite to 
that of authentic chemical standards analysed under identical conditions. The reporting of 
multiple metabolites for a single feature is a result of several metabolites having the same 
accurate mass (isomers) which have not been analysed as authentic standards and have 
identical retention times. Also a metabolite can be detected as different ion types (for 
example, a protonated species in positive ion mode and a deprotonated ion species in 
negative ion mode). Only chromatographic peaks assigned a chemical identity as a 
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metabolite are reported, chromatographic peaks not assigned a chemical identity were not 
reported. 
 
2.3.2.6 Metabolomics Data Analysis - Chemometrics 
Analysis of GC-MS raw data and metabolite levels 
Univariate and multivariate analysis were performed on the ion ratio data sets. All statistical 
analyses were performed using Matlab R2010a (MathWorks, Inc., MA). Within a GC-MS-
based data matrix composed of response ratios (peak area-metabolite/peak area - internal 
standard), it is possible to obtain zero (or not detected) values for any given metabolite peak 
caused by either of the following reasons: the metabolite is not present or is present at a 
concentration below the limit of detection; or the metabolite cannot be resolved from others 
in the chromatograph by the deconvolution software. In these cases, the following procedure 
was used to improve data structure for statistical analysis techniques. For univariate analysis, 
two approaches were applied: 1) All data was accounted and the zero values were replaced 
with „NaN‟ (not a number) 2) only the median value of the three replicates was accounted. In 
any case, all peaks with more than 20% missing values were removed from the analysis. 
Outliers were suppressed using 95% Winsorisation – eyeballing data from raw PCA scores 
plots. For multivariate analysis, if two of three replicates were zero values and the third 
replicate was a non-zero value, the third (non-zero) replicate was replaced with zero. If two 
of three replicates were non-zero values and the third replicate was a zero value, the zero 
value for the third replicate was replaced with the mean of the other two replicates. 
Prior to multivariate statistical analyses, data was normalised to zero mean, unit 
variance, (also known as auto-scaling) so that results were not dominated by a small number 
of high intensity peaks but gave equal weighting to peaks of low intensity. A number of 
normalisation methods were investigated including taking the log10, square root, cube root 
and quad root to reduce the dominating effect of higher intensity peaks. MVA were then 
performed using unsupervised (PCA) and supervised clustering methods using principal 
components-discriminant function analysis (PC-DFA). Analysis of variance - principal 
component analysis (ANOVA-PCA) was also used to quantify the relative variance arising 
from site, oxygen tension, analytical uncertainty and to test the significance of differences in 
the chemical composition. 
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The PC-DFA models constructed were cross-validated by iteratively removing one-
third of the available data from the training set and using it as a test set, where these data 
points were projected into the PC space and subsequently the discriminant function space 
and ANOVA-PCA scores space built by the training data. 
 Univariate statistical analysis was performed, using the non-parametric Wilcoxon 
sign rank test and Friedman test to identify metabolites which showed significant difference 
between two types of samples. The critical p-value for rejecting the null hypothesis in a 
single test is 0.05. However, where many metabolites are tested in parallel, the p-value for 
rejecting the individual hypothesis is typically reduced to lower the probability of type 1 
errors (false positives). Therefore, a p-value of 0.01 was also used in these experiments and 
false discovery rate (FDR) controlling test applied. This however, was found too stringent on 
the data sets returning no metabolites. Boxplots were drawn to show relative concentration 
distributions for all samples with respect to a given peak. Figure 7 shows the flowchart of 
steps involved in this experiment, from experimental to data analysis. 
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Figure 7 Flowchart of metabolomics experiment – from experimental design through to data analysis. 
My Workflow
126 samples (63 hypoxic, 63 normoxic)
42 (21 hypoxia and 21 normoxia) – class
129-variables (metabolite peak ID)
Experimental – GC-MS
Analysis of intracellular metabolome 
Metabolite profiling by GC/TOF-MS 
(3 biological reps, 1 technical rep)
(Agilent 6890 coupled to Leco Pegasus III 
GC-TOF-MS courtesy of  Warwick Dunn 
MCISB)
Data pre-processing 
Deconvolution
Extract pure spectra from chromatograph 
Peak table
Raw and normalised data 
Scaling methods
Logs, sqrt,, (sqrt)3
auto scale
Multivariate Data Analysis 
Remove weak peaks and/or weak 
samples
PCA, DFA, Anova-PCA
Account for presence of multiple trends 
within experimental design 
1% vs 21%, site vs. site
Identify significant variables from 
loadings plot
Experimental Design
Sample collection 
Meta Data
Patients 
(N=8)
Age
Gender
Health
Univariate Data Analysis 
Wilcoxon Signrank and Friedman test
Results
Correlate results from multivariate 
and univariate analyses for significant 
metabolites detected  
Cell culture
Harvesting and extraction
lyophilization and 
derivatisation
Pathway analysis
metabolite ID and concentration
Account for sparseness , missing value 
amputation
Column 
and/or
Row normalisation
Peak Library matching
Remove weak peaks and/or weak 
samples
both raw data median
Select signifiant and interesting 
metabolites/peaks
Box-whisker plot
Results and interpretation of 
candidate subset of peaks
Results and interpretation and 
combine with transcriptome
candidate genes  
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2.3.3 Dynamic changes in Dupuytren’s Disease and control transcriptome in 
hypoxia (Chapter 5) 
 
2.3.3.1 Experimental design  
DD patients 44, 60 & 61 (n = 3, men) were entered into the study. These are patients 4, 7 and 
8 from the metabolomics study. The 12 samples are listed in Table 4. The following samples 
were used to perform this study: F1, F21, N1 and N21. Demographic and meta data of these 
patients can be found in Appendix D. 
 
Table 4 The twelve samples included for transcriptional level analysis. 
 
Sample No. Patient No. Patient ID Site in Hand Oxygen %
1 4 DD44 Fascia 1
2 4 DD44 Fascia 21
3 4 DD44 Nodule 1
4 4 DD44 Nodule 21
5 7 DD60 Fascia 1
6 7 DD60 Fascia 21
7 7 DD60 Nodule 1
8 7 DD60 Nodule 21
9 8 DD61 Fascia 1
10 8 DD61 Fascia 21
11 8 DD61 Nodule 1
12 8 DD61 Nodule 21
 
2.3.3.2 Experimental Protocol  
RNA extraction 
Samples in trizol (collected in Section 2.3.2) were removed from -80°C freezer and allowed 
to thaw quickly on ice. The contents were transferred to a sterile 1.5mL Eppendorf tube and 
centrifuged at 13,000 rpm for 10 min at 4°C. The supernatant was then recovered into a new 
pre-labeled tube and 0.2mL chloroform (Sigma Aldrich) (per mL of trizol used) was added. 
These were left at room temp for 2 min and then centrifuged at 13,000 rpm for 15 min. The 
upper aqueous layer was pipetted into a fresh Eppendorf tube and an equal volume of 70% 
ethanol was added to this and mixed by pipetting up and down. Following this 700μL of the 
sample, including any precipitate that may have formed was transferred to an RNeasy mini 
column placed in a 2 mL collection tube. This was centrifuge for 15 sec at 13,000 rpm and 
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the flow through discarded. 700μL buffer RW1 to the RNeasy column was added and then 
centrifuge for 15 sec at 13,000rpm. The flow through and collection tubes were discarded. 
The RNeasy column was placed into a new 2 mL collection tube and 500 μL buffer RPE was 
added (RPE buffer is supplied as a concentrate and 4 vols of 96 – 100% EtOH is added 
before using). The tubes were centrifuged for 15 sec at 13,000 rpm to wash the column and 
the flow through was discarded. Another 500 μL buffer RPE was added, centrifuged and the 
flow through discarded. The RNeasy column was centrifuged for 1 min at 13,000 rpm to dry 
the RNeasy silica-gel membrane and then placed into a new 1.5mL collection tube, washed 
with 30 – 50 μL RNase - free water directly on to the RNeasy silica-gel membrane. Tubes 
were closed and left at room temperature for 1 min and then centrifuged at 10,000 rpm for 1 
min. This was followed by sample quantification.  
 
RNA quantification and quality analysis 
RNA was quantified and quality checked using a NanoDrop ND-1000 UV-visible 
spectrophotometer (Labtech International, Ringmer, UK). RNA integrity was assessed using 
the Agilent 2100 Bioanalyzer (Agilent Technologies UK Limited, Stockport, Cheshire, UK). 
Only RNA samples that were of sufficient concentration and showed no degradation as 
evidenced by distinct ribosomal bands at 18S and 28S were used for microarray 
experiments. Ethanol precipitation was also performed on a fractional amount of these 
samples and these were quantified, quality checked and their integrity assessed as 
previously. Non- EtOH precipitated samples were used for the cDNA synthesis. 
 
Affymetrix microarray procedure 
For each sample, RNA (3µg) was reverse transcribed into cDNA using the 3' IVT Express 
Kit (Affymetrix) according to the manufacturer‟s guidelines [135]. Amplified cDNA was 
then purified using magnetic beads. Aliquots of labeled cRNA (20 µg) were fragmented and 
then hybridised to a Human Genome U133 Plus 2.0 GeneChip oligonucleotide array for 16 
hours, rotating at 60 rpm at 45°C in a GeneChip Hybridization Oven 640 (Affymetrix). Each 
chip was washed and stained on a GeneChip Fluidics Station 450 (Affymetrix) and scanned 
on a GeneChip Scanner 450 (Affymetrix) using manufacturer‟s protocol [135].  
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2.3.3.3 Microarray data analysis 
The Affymetrix array data analysis was performed using three methods. The Affymetrix 
CEL files were uploaded and analysed with the R-Bioconductor tools suite [121] using 1) 
Limma and 2) puma methods and 3) GeneSifter microarray analysis tool (geopiza, Seattle, 
WA). The individual methods are described below and Figure 8 illustrates these steps. 
 
Limma: linear models for microarray data 
Background correction and quantile normalisation were performed using (1) RMA and (2) 
GC-RMA in R-Bioconductor. PCA on normalised data was performed to test the quality of 
the array data in R and MATLAB to confirm correlation between clusters in related gene 
array chips. Differential expression analysis was performed with Limma using the functions 
lmFit and eBayes. The analysis was done by creating design and contrast matrices for the 
following sample replicates: F1vs.F21, N21vs.F21 and N1vs.N21. Gene lists of differentially 
expressed (DE) genes were created by filtering for probesets with a p-value <0.055 and FC 
>1.5. These gene expression profiles (gene lists) in terms of p-value and fold change from 
the mean were compared using the FDR Benjamini and Hochberg multiple test correction 
[72]. Results with a p-value 0.05 at the 95% confidence level were considered significant. 
Individual thresholds were further applied (p-value 0.01 to 0.05) to obtain a filtered set of 
statistically significant genes. Gene ontology (GO) over-representation analysis was 
performed using the functional annotation tool of the Database for Annotation, Visualization 
and Integrated Discovery (DAVID) 2.1 program. 
   
PUMA: Propagating Uncertainty in Microarray Analysis 
Normalisation and expression analysis was done using multi-mgMOS [136]. Differential 
expression between the sample groups (F1, F21, N21 & N1) was assessed with puma, a 
Bayesian method which includes probe-level measurement error when assessing statistical 
significance. Analysis was performed with the PUMA [119] package in R. Gross differences 
between arrays were determined using the puma variant of PCA; pumaPCA which can make 
use of the uncertainty in the expression levels determined by multi-mgMOS. Unlike many 
other methods, multi-mgMOS provides information about the expected uncertainty in the 
expression level, as well as a point estimate of the expression level. Standard PCA was 
applied to multi-mgMOS normalised data on filtered dataset by applying a threshold ≥ 1.5 
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by comparing variance of the mean expression to mean of standard error for each probe. 
Differential expression (DE) analysis was performed with the pumaDE function. The results 
of these commands were ranked gene lists in order of probability of positive log-ratio 
(PPLR) values, and the FC values. All possible combinations of pair-wise comparisons 
among experiments were taken to create sets of ratios. A gene list of differentially expressed 
genes was created by filtering for probe sets with a PPLR values ≤ 0.1 and  ≥ 0.9) and 
further filtered to reduce FDR by increasing to ≤ 0.01 and ≥ 0.99  in any of the comparisons 
for each patients between F1 vs. F2, N2 vs. F21 and N1 vs. N21 samples.  
HCA was applied on the normalised and filtered datasets using Euclidean distance 
(average linkage). Heatmap was generated based on similarity of expression profiles across 
the dataset. Pathway analysis of top 1000 and lowest 1000 genes and then on a filtered set of 
selected genes was carried out with KEGG [63]. Venn diagrams were generated to show the 
distribution of the probe set for the filtered probesets. Functional and ontology enrichment 
analysis was performed using the DAVID web-based tool version 2 [137] and the expression 
analysis systematic explorer (EASE) [138]. 
 
GeneSifter microarray analysis tool 
Relative changes in gene expression were evaluated by the expression ratio and (FC), as 
determined from the GC-RMA normalized data reported by GeneSifter. A transcript 
displaying expression ≥ 1.5 FC from the mean in at least 1 array was used as a cut-off level. 
The gene expression profile in terms of FC from the mean was compared using the 
Benjamini and Hochberg multiple test correction. Results with a p-value (adjusted p-value) ≤ 
0.05 at the 95% confidence level were considered significant. Individual thresholds were 
further applied (p-value ≤0.01 to 0.05) to obtain a filtered set of statistically significant 
genes. Two-way ANOVA test was also applied with above cut off points. Genes and arrays 
were clustered according to their expression patterns using cluster software, and heat maps 
were produced. As previously, the subset of filtered genelists were used to study for 
biological relevance using Gene Ontology, [61] and DAVID.  
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Raw data CEL files x 12
Fascia 21%, Fascia 1%, Nodule 21%, Nodule 1%
Identify significant variables from loadings  >=0.03 
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Anova
Pairwise analyses 
on mean exprs: 
N21 v F21, F1 v 
F21, N21 v N1
Threshold = 1.5, T-test, p ≤ 
0.05, Tukey, Benjamini & 
Hochberg correction , 
Volcano plots, Venn Diagrams 
Kegg Pathways LocusLink, Chromosome
Limma
multi-mgMOS
IPPLR
Distribution of summarisation method - Boxplots
Thres=2, T-test, Benjamini & 
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PAM Clustering – up/dwn
regulated
GCRMA & RMA 
PCA, Anova-PCA
Threshold 
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flasks in 1) 21% O2 and 2) 1% O2. Each sample acts as its own
biological control with 3 biological replicates
Nodule (N=3) (Disease) Fascia (N=3) (Control)     
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Experimental Design
Transcriptomics experiment 
Nodule (N=3) (Disease) Fascia (N=3) (Control)     
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Meta Data
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Microarray experiment
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std(eset)./mean(se)
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Candidate subset  of 
genes
 
 
Figure 8 Flowchart illustrating steps involved in microarray study, from experimental design to data analyses. 
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2.3.4 Inferring the metabolic and transcriptional networks specific to 
Dupuytren’s disease tumours (Chapter 6) 
 
2.3.4.1 Integrated pathway mapping with Ingenuity Pathway Analysis 
Data were first analysed using stringent chemometrics and microarray data analysis methods 
as to generate a list of significantly differentially expressed molecules as described in 
Section 2.3.3 and 2.3.4. The final set identifiers were combined for each comparison i.e. the 
HMDB ID‟s [49] / CAS registry identifiers (for definitive metabolites) and Affymetrix 
accession Probe ID‟s were combined into a single data set for each of the pairwise analyses 
F1 vs. F21, N21 vs. F21 and N1 vs. N21.  
 
IPA: Network generation  
A data set containing gene/metabolite identifiers and corresponding expression/mean fold 
change values was uploaded into the application. Each gene/metabolite identifier was 
mapped to its corresponding gene/metabolite object in the Ingenuity Pathways knowledge 
base. Those molecules previously identified as being statistically significant, called focus 
molecules, were overlaid onto a global molecular network developed from information 
contained in the Ingenuity Pathways Knowledge Base. Networks of these focus molecules 
were then algorithmically generated based on their connectivity. The network is a graphical 
representation of the molecular relationships between the molecules (genes/endogenous 
chemicals). The molecules are represented as nodes, and the biological relationship between 
two nodes is represented as an edge (line). All edges are supported by at least one reference 
from the literature (http://www.ncbi.nlm.nih.gov/pubmed), from a textbook, or from 
canonical information stored in the Ingenuity Pathways knowledge base. Top scoring 
networks generated from metabolite data sets alone were mapped onto top scoring transcript 
data networks and vice versa. 
 
Global functional analysis  
The functional analysis identified the biological functions and/or diseases that were most 
significant to the data set. Molecules from the dataset uploaded that were associated with 
biological functions and/or diseases in the Ingenuity Pathways Knowledge Base were 
considered for the analysis. Fisher‟s exact test was used to calculate a p-value determining 
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the probability that each biological function and/ or disease assigned to that data set is due to 
chance alone. 
 
Global canonical pathways analysis.  
Canonical pathways analysis identified the pathways from the IPA library of canonical 
pathways that were most significant to the data set. Candidates from the data set that were 
associated with a canonical pathway in the Ingenuity Pathways Knowledge Base were 
considered for the analysis. The significance of the association between the data set and the 
canonical pathway was measured in 3 ways: (1) A ratio of the number of genes from the data 
set that map to the pathway divided by the total number of genes that map to the canonical 
pathway is displayed. (2) Fischer‟s exact test was used to calculate a p-value determining the 
probability that the association between the genes in the data set and the canonical pathway 
is explained by chance alone. (3) Benjamini-Hochberg testing corrected p-values were used.  
 
2.3.4.2 Metabolomic pathway analysis with MetPA:  
Data Input and Processing 
Filtered metabolite lists and their HMDB IDs for each of the three pairwise analyses were 
uploaded in MetPA [71]. The first step involved standardisation of the compound labels 
which were subsequently compared with compounds contained in the pathway library. 1 
indicated exact match, 2 indicated approximate match, and 0 indicated no match.  
 
Pathway and Over Representation Analysis 
The pathway library „Homo sapiens (human)‟ containing 80 pathways from KEGG library 
was selected. The one-tailed Fisher's exact test for pathway enrichment analysis and pathway 
topology analysis were specified for over-representation analysis. This is to test if a 
particular group of compounds is represented more than expected by chance within the 
uploaded compound list. In the context of pathway analysis, we are testing if compounds 
involved in a particular pathway is enriched compared by random hits.  
 
Pathway Topology Analysis 
MetPA [71] uses two well-established node centrality measures to estimate node importance 
– degree centrality and betweenness centrality. As metabolic networks are directed graphs 
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the relative betweenness centrality algorithm for pathway topology analysis was selected for 
metabolite importance measure. The betweenness centrality measures focus on global 
network topology [139].  
 Chapter 3 
Metabolic Fingerprint and Footprint 
Analysis of Passaged Dupuytren’s Disease 
Cultured Fibroblasts 
 
3.1 Introduction 
Previous studies provide compelling evidence that genetic dysregulation plays an important 
role in DD formation. Macroscopic phenotypic differences between fibrotic elements in DD 
(i.e. nodule and cord), plus the fat and skin overlying the nodule (SON) also show 
microscopic differences with variable cellular density. Abnormal fibroblasts are considered 
to be responsible for causing DD.  A recent study investigated phenotypic descriptors of DD 
tissue (i.e. nodule, cord) and compared with the transverse palmar fascia (internal control) 
and transverse carpal ligamentous fascia (external control) using the Affymetrix HGU133A 
GeneChip array reporting several differentially expressed genes thought be involved in the 
pathogenesis of DD ([10] and Appendix E2(1)). In contrast to our previous study, here, the 
systemic properties of fibroblast cultures derived from different DD tissue phenotypes 
including the fat and the SON are investigated. Comparisons across previous studies are 
impeded because the reported results are often based on different cellular passages which 
could have a dramatic effect not only for morphological properties but also gene expression 
and metabolic differences too. Whether any significant changes are due to genetic alterations 
alone or the consequence of metabolic dysregulation has not to date been demonstrated. In 
this study, a systemic analysis of Dupuytren fibroblast profiles derived from different DD 
tissue phenotypes in order to identify the best time to look at the disease pattern is discussed. 
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The aim of this study is to delineate the morphological components of DD and 
control by looking at differences in cultures derived from disease tissue phenotypes and 
comparing different anatomical locations within the DD tissue using an alternative technique 
to histology. The main advantage is to simultaneously image the quantity and quality of 
multiple components in DD in relation to normal transverse palmar fascia using a technique 
with high molecular sensitivity combined with a spatial resolution down to a few 
micrometres.  
A metabolomic analysis of fibroblast cultures derived from different DD tissue 
phenotypes to compare early (primary) cultures to late passages was employed to identify 
the most representative passages for the disease. Using FT-IR spectroscopy, a comparison of 
metabolic profiles of endogenous and secreted metabolites from (1) DD cords and nodules 
against the unaffected transverse palmar fascia (internal control), (2) DD cords and nodules 
with fat surrounding the nodule, and SON. Following this metabolic profiles of those in (1) 
and (2) between different DD patients and (3) those in (1) and were compared between 
different DD patients and with external controls. 
 Carefully controlled conditions using multivariate statistical analyses (PCA and 
DFA) demonstrated early passage (0-3) metabolic differences where a synchronous 
separation pattern was observed in the PCA scores plots in DD and control fibroblasts. 
However, higher passages (4-6) demonstrated random asynchronous and overlapping 
patterns from which it was unclear how to identify and separate the diseased from non-
diseased sample phenotypes. The cord and control fibroblast clusters were in closer 
proximity in the scores plot of PC1 and PC2 across passages 0-3, while the nodule 
fibroblasts were clearly separable in all PCA plots. The analyses of the PCA scores plots 
between the five sample types from DD subsets (nodule, cord, fascia, fat and SON) 
demonstrated overlapping between the clusters in samples across passages 0-3. In the early 
passages however, the clusters of nodules and SON were in close proximity to each other, 
while the clusters representing the fibroblasts of cords, fascias and fat were often closer than 
those of the nodule. The results from FT-IR metabolic fingerprinting combined with 
chemometrics has demonstrated early passage metabolic differences showing clear 
separation between the different tissue phenotypes in DD and control fibroblasts, whereas 
higher passages demonstrated random asynchronous patterns.  
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3.2 Results 
3.2.1 Histological findings 
The DD nodule, cord, fat, and the skin overlying the nodule and the internal control – the 
transverse palmar fascia (n = 6) and the carpal ligamentous fascia – the external control from 
healthy individuals were identified and confirmed by a senior histopathologist. The nodules 
displayed regions of high cellularity and lots of nuclei were stained/visible, while the cords 
displayed a tendon like collagen rich structure. Cross sections from the fat and the skin 
overlying the nodule were also examined and compared with those from normal CTD skin 
and fat from unaffected patients.  All Histological findings can be found in Appendix C.  
 
 
3.2.2 The raw and preprocessed spectra 
Analysis of the metabolic fingerprints  
Variations in the passage numbers from cultures were investigated by FT-IR metabolic 
fingerprinting, using cell samples which had been washed thoroughly to remove any 
extracellular metabolites medium components. The total number of samples and their 
combinations selected for MVA can be seen across Tables 25-30 in Appendix B. The results 
from typical data analysis, preprocessing and MVA techniques are discussed below. The 
results of the FT-IR spectral data and MVA are presented in the form of PCA, and/or PC-
DFA scores plots as discussed under the corresponding headings for each study respectively. 
Typical raw and normalised absorbance FT-IR spectra for DD and control fibroblasts 
are shown in Figures 9 (& Figure 10) and 11 respectively. These are typical vibrational 
spectra from all samples included in Study 1 and 2. These spectra are the metabolic 
fingerprints of each sample analysed (metabolic footprint in the case of spent media) on the 
Si plate respectively; all showing broad and complex contours with relatively little 
qualitative difference between the spectra visible to the naked eye. Such spectra readily 
illustrate the need to use multivariate statistical techniques in the analysis of data. The 
spectra contain information on functional group vibrations resulting in the absorbance of 
infrared light at specific wavenumbers (1/λ). Some prominent regions (Figure 11) are 
identified to be arising from vibrational modes of  water (O-H stretch centered at 3400cm
-1
), 
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fatty acids (methyl, methylene and CHx stretches at 2956-2850 cm
-1
) proteins (amide I, C=O 
at 1652-1648 cm
-1
; amide II N-H, C-N at 1550-1548 cm
-1
), a mixed region from 1460-110 
cm
-1
 which contains information from fatty acids, polysaccharides, nucleic acids, proteins 
and polysaccharide rings and C-O vibrations at 1085-1052 cm
-1
). Note here, that large 
molecules such as proteins as well as small constituents including nucleic acids are detected 
because the sample preparation used simply DPBS to dissolve the cells and was analysed 
directly without any interference to the intact cells. FT-IR spectra for various DD phenotype 
fibroblasts (from all 5 sites), fibroblast growth media and freezing media were also recorded 
electronically. Again, all spectra showed broad and complex contours, in which there was 
relatively little qualitative difference between the spectra. 
 
 
5001000150020002500300035004000
0.05
0.1
0.15
0.2
0.25
0.3
0.35
Wavenumber (cm
-1
)
A
b
so
rb
an
ce
 (
ar
b
it
ra
ry
)
5001000150020002500300035004000
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
Wavenumber (cm
-1
)
A
b
so
rb
an
ce
 (
ar
b
it
ra
ry
)
celltest160608
 
Figure 9 Typical raw FT-IR spectra from metabolic fingerprints of cultured cells. Each sample is represented 
by an absorbance vs. wavenumber spectrum. 
Chapter 3                          Metabolic Fingerprint Analysis of Passaged Dupuytren’s Disease Cultured Fibroblasts 
93 
 
 
Figure 10 A 3-D raw FT-IR spectra from metabolic fingerprints of cultured cells. Each sample is represented 
by an absorbance vs. wavenumber spectrum. 
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Figure 11 Processed FT-IR spectra of cultured cells with band assignments.  Samples are 
normalised using the EMSC preprocessing method and baseline correction. These spectra have 
been offset to see the features more readily. Key to vibrational bands: A = fatty acid, B = 
amide, C = mixed, D = polysaccharide. 
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3.2.3 Multivariate statistical analyses to determine variability of samples 
The next stage was to perform cluster analysis on all preprocessed spectral data. This was 
done separately for all metabolic fingerprint and footprint data. A total of 309 samples were 
analysed three times (927) in Study 2 (234 samples analysed twice (468) in Study 1) and 
PCA was performed in various combinations on the data sets.  
 Firstly, the relevant passages (e.g. passage 0, 1, 2 etc) from all sites to undergo 
analysis were grouped by selecting samples from each case and control set. (e.g. all passage 
(P0) samples from DD nodules, cords and internal fascia, then from another data set all P0 
samples from DD nodules, cords and internal fascia and also the external fascia from CTD 
patient, another data set selecting for P0 cultured cells in all five DD subsets including the 
fat and SON). This was carried out across all samples selecting on the basis of passage 
number to determine any similarities and differences across the metabolic profiles 
(fingerprints in this case) to determine whether the passage had any effect on the individual 
samples when sub-cultured overtime in same culture medium and conditions. In addition, 
comparisons of both control fibroblasts were made; i.e. whether internal control 
demonstrated any similarity to fibroblast from external control and whether the choice of 
internal control being used for future studies is in fact a more appropriate or suitable 
representative. The trends sought after were those in which a gradation, similarity and 
differences within the sample clusters were evident.  
 Second, PCA was performed across all passages and all samples within the class of 
dataset in various combinations comparing the sites in individual patients across all passages 
(e.g. (i) for patient DD2; all passages across nodules, cords, fascias, and then (ii) all passages 
across (i) plus the fat and SON). 
 For each study, the two matrices produced from the transformation of the original 
data matrix, X, in the PCA model, (score and a loading matrix and residual matrix; where the 
score matrix contains information on how samples are related to each other and the loading 
matrix shows relationships between variables) were linearly combined with the original data. 
The determination of the number of significant PCs was solved in three ways. First, the scree 
plot of eigenvalues, presented in Figure 12 was examined (this is just for demonstration). Its 
shape suggested selecting between two and three PCs; majority of the variance within the 
data set are captured by the first few PCs with little importance on the later PCs. Second, the 
score plots for PC1 & PC2, PC1 & PC3, PC2 & PC3, and subsequent PCs were analysed. 
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Third, the % cumulative variance plot was examined. It was found that for PCs > 3 the plots 
became random. From these facts it was decided that 3 PCs would be the best choice. The 
selection means that most of the variance in absorption of the examined spectra will be 
further interpreted in terms of the above three factors that will be related to (i) passage 
number vs. sample type and (ii) individual patients vs. sample type including all passages. 
Figures 13 and 14 represent the PCA plots from PC1 and PC2 from Study 1 and Figures 16 
represent PCA scores plot from DD nodule, cord and internal fascia primary cultures from 
Study 2 showing the relationships between the three different phenotypes confirming their 
metabolic differences. Boundaries round the clusters were drawn manually. Each numeric 
code represents a single biological sample. Observations were made in the relationships 
between cluster spaces; the closer the samples cluster together the more biochemical 
similarity they possess. 
 
 
Figure 12 : Eigenvalues scree plot for the 
FT-IR spectra of passaged cultured 
fibroblasts subjected to PCA. 
 
 
 
 
 
 
3.2.4 Study 1A - DD Nodule and Cord vs. Transverse palmar fascia 
In the scores plots, different sites are presented as different colours. The patients are labeled 
by their numbers e.g. for each patients where three cell types were analysed (e.g. DD nodule, 
cord and fascia), there are 3 different coloured circles to represent them. For example, in the 
first plot in Figure 13, patient DD8 has 12 circles, because there were 12 samples from this 
patient. Among them, 6 are green (nodule), 3 blue (fascia) and 3 red (cord). 
PCA on EMSC normalised data was performed to test the quality of spectral data 
using the NIPALS option in MATLAB to determine covariance between clusters spectra of 
fibroblast samples. There is a clear separation of control samples and disease tissue. In 
contrast with normal samples, DD fibroblasts (nodule and cords) also show an additional 
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level of heterogeneity. There were two distinct clusters identified among the DD samples 
separating it into cord and nodule (circled in green and red) from the transverse palmar 
fascia (circled in blue) in passage 1. However, as the number of passages increase the 
samples become increasingly random and show overlapping between those derived from 
other tissue phenotypes. In Study 1, the separation is minimal between the clusters of 
individual phenotypes (nodule, cord, fascia) for samples where passage number = 2 and 
samples from cultures where passage number ≥ 3 do not demonstrate clarity in separation 
and are overlapping within the boundary of others.  
 The Fisher‟s ratio was calculated for each patient vs. passage number to determine 
separation/variability within class. The relation between Fisher‟s ratio and passage number is 
plotted in Figure 15. A linearly decreasing value for ratio as the passage numbers increase is 
observed. The trend suggests that the larger the ratio, the better the separation between 
classes (i.e. well separated classes and tight clusters for each class). The decrease in the 
ratios becoming smaller and smaller when the cells are subcultivated (as passage number 
increase) correlates with the findings from those of the PCA scores plots that show clear 
separation between the cultures of different DD phenotypes (nodule, cord and transverse 
palmar fascia) in the early passages (1 and 2) but as the passage number increases, 
asynchrony and overlapping in samples are observed. The ratio becoming smaller and 
smaller as the number of passages increase suggest a similarity (dysregulation) in metabolic 
profiles of the phenotypes consistent with the findings from the PCA indicating an overlap in 
the metabolic profiles in higher passage numbers and resembling little differences in their 
metabolic fingerprint.   
 
3.2.5 Study 1C Patient vs. Passage (Category 4) 
The samples in the PCA plots defined by PC1 and PC2 in this study were not clearly 
separable on the basis of passage number. Though some samples were far apart, the passages 
were not superimposable on cultures derived from the same phenotype. PCA scores plots 
from Patients 8-13 are shown below. Patient 9 demonstrating similar trends observed as in 
Study 1A for the three sites, here, the lower passage number 1, shows clusters from nodule, 
cord and fascia far apart, as passage number increases, the clusters between classes are now 
closer and within classes are no longer clustered as tightly. As there is biological variance 
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between patients, this difference is not so greatly observed through PCA scores plot alone, 
and so PC-DFA is used in Study 2. 
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Figure 13 Projection of the FT-IR spectra of DD fibroblasts derived from the nodule, cord and fascia (control) 
with respect to their passage number onto the plane defined by PC1 and PC2. Patients are labeled by their 
numbers e.g. for each patients where the three cell types were analysed (e.g. DD nodule, cord and fascia), there 
are three different coloured circle for it. Red circle=cords, green circle=nodules, blue circle=fascia (internal 
control).  
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Figure 14 Projection of the FT-IR spectra of DD fibroblasts derived from the nodule, cord and fascia (control) 
with respect to their passage number onto the plane defined by PC1 and PC2. Samples from variable passage 
numbers are coloured and DD nodule, cord and fascia are labeled in lower case letters n,c,f respectively.  
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3.2.6 Study 1B - DD Nodule, Cord vs. Transverse Palmar Fascia, Fat, Skin 
overlying nodule  
 
The cultures from the fat and SON were subjected to FT-IR irradiation at a different time 
course and not on two consecutive days. This was due to a technical failure that had occurred 
with the stage of the FT-IR on to which the Si plate is loaded. Therefore, the results of 1B 
were not analysed with respect to the differentiation between the five DD phenotypes, but 
only on the basis of the fat and SON passaged cultures. The PCA scores plot defined by PC1 
and PC2 showed clear differences between the clusters of two different sites (fat and SON) 
across all passages. However due to a flaw in the sample arrangement on two plates, 
(samples not sufficiently randomised); in each passage, all samples from one site were 
located on one plate while all samples from another site were located on the other plate) one 
cannot determine whether such separation was caused by biological difference or merely the 
difference caused by two different plates analysed on two different days or both. 
 
3.2.7 Study 2A - DD Nodule, Cord vs. Transverse Palmar Fascia (Category 1) 
The results from Study 1 implied that performing serial passages >3 did not demonstrate 
clear separation of the metabolic profiles obtained from spectral data of the three sites 
(nodule, cord and fascia). In Study 2A a rather inconsistent sample size was analysed. This 
inconsistency in sample no. was due to several factors ranging from a smaller number of DD 
biopsies, cells that did not grow or survive the tissue processing step, samples arriving on 
Figure 15 Fisher ratio plot vs. passage number 
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separate occasions; with up to 2-4 weeks gap, due to flaws in cell culture management 
leading to contamination of some samples, shared incubators, and also cultures grown in two 
separate buildings.  
 However, by contrast, cultures from passage 0 were also included in this study. 
Although there was very little biomass (¾ of the initial monolayer grown from primary 
fibroblast was subjected to FT-IR spectroscopy), clear separations of the three sample types 
were observed. For this study cultures from passage 0, 1, 2 and 3 were analysed. As in Study 
1A, PCA on EMSC normalised data was performed to test the quality of the spectra using 
the NIPAL option in MATLAB and results were corroborated with those in PyChem to 
confirm the covariance between clusters in spectra of fibroblasts samples. Again, there was 
clear separation of control samples and DD disease tissue. In contrast to normal samples 
(blue circles), DD fibroblasts (nodule and cords) also show an additional level of 
heterogeneity. There were 3 distinct clusters between the samples in passage 0, 1, 2 and 
again little randomisation started to occur in samples of cultures from passage 3. Study 2A 
confirmed that early passages demonstrated metabolic differences in DD and control 
fibroblasts, whereas higher passages demonstrated random asynchronous patterns. This 
study also confirms that early passage numbers are the most suitable representatives for 
investigating DD.  
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Figure 16 Projection of the FT-IR spectra of DD fibroblasts derived from the  nodule, cord and fascia (internal 
control) with respect to the passage number onto the plane defined by t[1] (PC1) and t[2] (PC2). The samples 
are labeled by numbers and shapes; 1 blue circle = transverse palmar fascia, 2 red square = nodule, 3 green 
cross = cord.  
. 
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Figure 16 Projection of the FT-IR spectra of DD fibroblasts derived from the  nodule, cord and fascia 
(internal control) with respect to the passage number onto the plane defined by t[1] (PC1) and t[2] (PC2). 
The samples are labeled by numbers and shapes; 1 blue circle = transverse palmar fascia, 2 red square = 
nodule, 3 green cross = cord.  
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3.2.8 Study 2B - DD Nodule, Cord vs., Transverse Palmar Fascia, Fat and Skin over 
Nodule 
 
The PCA scores plot did not show clear separation between clusters from sample sets from 
multiple patients combined. Mostly samples from the same phenotype showed asynchronous 
patterns regardless of the passage number. However, nodule and SON derived fibroblasts 
were in closer proximity than those cultures derived from cords, fascias and fat. In addition, 
the samples from the latter three phenotypes demonstrated overlapping in clusters across all 
passages.  
 However, clear separation of DD fascial cells nodule, cord and fascia can be 
observed from fat and SON in Patient 2, passage 0 across PC2, while some fascia can also 
be separated from all other sample clusters, Separation of  fat clusters and SON is observed 
in PC3 (Figure 17 and 18). Figures 19-21 represent the supervised scores plot from PC-DFA 
for Patient 2 passage 0-3. 
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Figure 17 PCA scores plot of the five different sites from a single patient, distinct clusters are observed, the 
spectral profile of SON and fat are highly similar to each other with the cord and fascia showing a similar 
relationship, the nodules cluster within its own space and can be separated from the rest using PC1 and PC2. 
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Figure 18 PCA score plot of PC2 vs. PC3 from patient DD2. The Fat and SON displays greater separation 
compare to PC1 vs. PC2. The overlap between Cord and Fascia is still observed.  
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Figure 19 DFA score plot of all site and passage (0-3) from patient DD2. The profile for each site with respect 
to increasing passage number is observed, where discriminate from the same site is possible based upon 
passage number. 
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Figure 20 DFA score of patient DD2 for DF1 vs. DF3, the effect of different passage number within each 
respective site is still observed.  
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Figure 21 DFA score plot of DF2 vs. DF3 for patient DD2. The trends are less clear compared to previous two 
plots.  
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3.2.9 Study 2C - DD Nodule, Cord vs. Transverse Palmar Fascia and Unaffected 
(CTD) normal palmar fascia 
 
Figure 22 shows the DF1 vs. DF2 score plot from the DD subsets compared to internal and 
external control fascia. Its analysis along the DF1 axis shows that this component divides the 
whole set of spectra into four groups; a cluster of red circles (nodules), majority of blue 
circles, (DD fascia-internal control) on the right half of the plot, majority of turquoise/cyan 
circles (CTD fascia-external control) on the left half of the plot, and green circles (cords) 
closer to the centre (zero on x-axis). 
There was clear separation between the DD fascia, nodule, cord and also external 
CTD control. Clusters of samples from DD cells always clustered apart (while showing 
separation between the individual samples) from those of CTD. This separation suggests that 
internal fascia is an appropriate control and can be distinguished from diseased fibroblasts 
using chemometrics techniques. The use of internal fascia as the control will attribute to 
homogeneity in future studies. 
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Figure 22 Projection of the FT-IR spectra of DD fibroblasts derived from the nodule, cord, fascia (internal 
control) and CTD fascia (external control) from passage 0 onto the plane defined by DF1 and DF2. Patients are 
labeled by their numbers e.g. for each patient where the four cell types were analysed (e.g. DD nodule, cord, 
fascia and CT external fascia), there are four different colours to represent them; blue circle = fascia (internal 
control); red circle = nodules; green circle = cords; and turquoise circles = CTD fascia (external control). 
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3.2.10 Study 2D- CTD Fascia, Fat, Skin 
Clear separation was observed in the fibroblasts derived from CTD fat, fascia and skin. 
3.2.11 PCA of Footprint Spectra 
No separation was observed using PCA on footprint data as the culture medium they were 
collected in was nutrient rich and undefined.  An example of the processed FT-IR spectra 
from DD footprint and the PCA plot from this data are shown in Appendix C; Figures 72 
and 73.  
 
3.3 Discussion 
3.3.1 Principal Findings  
The goal of the present work was the analysis of Dupuytren fibroblast cultures derived from 
different DD tissue phenotypes & control (CTD) fibroblast cultures comparing early 
(primary) cultures to late passages in order to identify the most representative passage for the 
disease. 
 Using FT-IR spectroscopy, the metabolic profiles of endogenous and secreted 
metabolites were acquired from (1) DD cords and nodules from the palm against the 
unaffected transverse palmar fascia (internal control), (2) DD cords and nodules with the 
cushioning fat surrounding the nodule, and with the skin overlying the nodule and (3) those 
in (1) and were compared between different DD patients and with external controls.  
 Observational changes in cell growth were recorded to determine whether cultures 
derived from DD tissue phenotypes and control changed with cell passage. The 
haemocytometer cell counts were constantly high for fibroblasts derived from DD nodule, 
cord, fat and SON across passage 1 to passage 6, while the growth of fascial cells considered 
as normal (the internal and external fascia controls) slowed down at higher passage numbers. 
The difference in the cell numbers through variable passages suggest that cell senescence 
may have been achieved by some of the control fibroblasts whereas the proliferative 
potential displayed by fibroblasts derived from the diseased nodule, cord, fat and SON 
consistently provided a high cell count. The evaluation of growth in cultivated fibroblasts 
from different samples has not only shown significant differences in their morphological 
appearance but also differences in generating the number of myofibroblasts. These numbers 
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can be correlated with tissue type as well as their unique metabolic profiles which may be of 
relevance to disease stage in some cases. 
 The FT-IR spectra showed broad and complex contours, in which there was 
relatively little visible qualitative difference between the spectra. In lesser complicated 
molecules such as chemical or medicinal compounds such as drugs whose MW <500, the 
locations of transition points are based on an arbitrary selection of the frequencies that are 
more pronounced for the compound being analysed as the functional groups present are few. 
Such an approach assumes that information about the structural changes leading to the phase 
transition is known a priori. However, for large molecules such as the proteins, biomolecular 
compounds, cells (and samples in this study), the conformational changes cannot be easily 
anticipated because the bands suitable for monitoring complex molecular processes cannot 
be chosen without any a priori assumption about the structure and its infrared intensity 
relationship. This is due to the fact that essential information on any dynamic process being 
analysed by FT-IR spectroscopy does not lie at any individual wavenumber, but across many 
wavenumbers, mostly correlated to each other. These contain many overlapping bands and 
so data interpretation cannot be made by simple visual inspection and therefore, to uncover 
the structure–infrared intensities relationship, unrestricted by any presumptions, suitable 
multivariate methods such as PCA and hierarchical cluster analysis (HCA) are used to look 
at differences and similarities between these spectra.  
 Visual comparisons of the general contours of the spectra were made with bands 
assignments according to peak wavenumber regions and the shape of the normalised spectra 
were compared with metabolic fingerprints of sera, urine and synovial fluids. While the 
spectral contours were similar in shape to all three, they shared spectral contours closer to 
those in synovial fluid.  As the spectral data illustrated the need to use multivariate statistical 
techniques in the analysis, PCA and PC-DFA were applied to discriminate between the data 
sets.  
 Metabolic differences were identified between DD fibroblasts and in control (internal 
and external) fibroblasts through variable passages from the different sites. Analyses of these 
profiles lead to identification of metabolic differences where a synchronous separation 
pattern in early passages was observed in Study 1A & 2A). PCA demonstrated clear 
separation of the three sites from early cell passage cultures (0, 1 & 2). Samples from Study 
2C also displayed this trend and showed separation of the respective sites from early cell 
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passage cultures (0, 1 & 2). The cord and control fibroblast clusters were in closer proximity 
in the scores plot of PC1 and PC2 across passages 0-3, while the nodules fibroblast were 
clearly separable in all PCA plots and were confirmed by Euclidean distances calculated in 
hierarchical cluster analysis using PyChem.  
However, in higher passage numbers (4-6) a random asynchronous pattern in the 
scores plot was observed across all samples. The analyses from both studies demonstrate that 
cultures of different tissue phenotypes from passage 3 show little separation across the cell 
types, (while not being too far apart), and from thereon, subsequent passage numbers 
demonstrated a random asynchronous pattern in metabolic profiles that appear the PCA 
scores plots.  
 The analyses of the PCA scores plots between the five sample types from DD subsets 
in Study 2B demonstrated overlapping between the clusters in samples across passages 0-3. 
In the early passages however, the clusters of nodules and SON were in close proximity to 
each other, while the clusters representing the fibroblasts of cords, fascias and fat were often 
closer than those of the nodule. While PCA showed some differences, an alternative MVA 
method could to be applied to discriminate between these individual cell types.  
 
3.3.2 Strengths and weaknesses of the study 
The FT-IR data together with PCA provide good classification of spectra of DD subsets in 
Study 1 and 2 and also distinguishes spectra from external controls in study 2C with PC-
DFA. Classification of FT-IR data may be explored further using first and second derivatives 
of spectra or by exploring alternative preprocessing methods.  However, the classification 
achieved so far is encouraging, as this technique not only separates DD nodule and cord 
fibroblasts from the two controls, but also between the two fibrotic elements i.e. nodules 
from cords. In addition the analyses across all passages suggest that early passage cultures 
are close representatives of the metabolic fingerprints of those in disease state in vivo and 
may be more appropriate for further DD studies. In addition data from the late passages 
support the hypothesis that the cell culture monolayer environment may alter the functional 
characteristics of the samples, possibly by selecting against a subpopulation of cells which 
survived the in vitro conditions. Differences in FT-IR spectral profiles in DD and in controls 
can be exploited further to test hypotheses with the use of formalin-fixed samples for 
discrimination of normal and diseased tissue. To discriminate between footprint spectral 
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data, supervised chemometrics analysis such as artificial neural networks and genetic 
algorithms may be applied. 
 In order to validate PCA and PC-DFA analyses independently, the data can be 
projected into the PCA or PC-DFA ordinate space. This involves each class within the data 
set being randomly split, and forming a test sample set and a training set. Generate PCA 
and/or PC-DFA models independently for the training set, and the test set then to be 
subsequently projected into the same ordinate space. A close alignment between training and 
test clusters would indicate the validity of the PCA and PC-DFA model. This is particularly 
necessary when the number of variables is considerably larger than the number of samples 
and when one wants to ensure that the hypotheses generated are robust [140]. 
 We have shown that FT-IR spectroscopy is a powerful fingerprinting tool when 
combined with multivariate analyses. It has enabled the detection and acquisition of several 
endogenous metabolic fingerprints from cultures derived from different tissue phenotypes. 
However, due to the complicated nutrient rich medium, this technique was not appropriate 
for detecting patterns of secreted (footprint) metabolites. Nevertheless, it has proven to 
rapidly and accurately identify and distinguished on the basis of separation of the unique 
fingerprints of intact fibroblast cells from diseased and non-diseased regions. Preliminary 
results obtained from Study 1 and validation with those of Study 2 has shown FT-IR to be 
powerful as a diagnostic tool.  
 While it has been recognised that FT-IR is not as specific and sensitive as some 
techniques such as GC-TOF-MS, the high throughput, rapidity and reproducibility of FT-IR 
is demonstrable through the large body of research published using this technology. FT-IR is 
recognised as a valuable tool for metabolic fingerprinting as is able to analyse cellular 
constituents composed of carbohydrates, fatty acids, amino acids, protein, nucleic acids, and 
polysaccharides rapidly and simultaneously with a minimum amount of sample preparation. 
 One of the potential limitations of FT-IR is that the absorption of water is very 
intense.  An attempt to overcome this problem was the dehydration of samples in 50
O
C 
incubator prior to loading onto the stage of the spectrometer. In future analysis, the water 
signal could be subtracted. Alternatively, a related vibrational technique, Raman 
spectroscopy may be used as a complementary tool to confirm the results of FT-IR , yet this 
would be more expensive, low through put, and require much longer analysis time. 
Chapter 3                          Metabolic Fingerprint Analysis of Passaged Dupuytren’s Disease Cultured Fibroblasts 
111 
 
 This study has enabled characterisation and classification of the various sites thought 
to be involved in DD. In addition, chemometrics has strongly facilitated pattern recognition 
of disease state when compared with normal palmar fascia from several cultures (early and 
late) allowing us make an informed choice of a suitable passage to perform subsequent 
studies in this project. Thus, the present study is not only taken up as a more complicated 
case to discriminate from macroscopical and genetic studies, but also to verify the feasibility 
of spectroscopic methods in predicting the DD tumour response to in vitro cultivation.  
 
3.3.3 Trypsin Effect 
The differences between metabolic profiles achieved from those of early and late passages 
determined by FT-IR and multivariate analyses are clear from the statistical analyses. The 
relation between the Fisher ratio and passage number showing a linearly decreasing value for 
ratio as the passage number increases is also suggestive of a decrease in the ratios due to cell 
subcultivation with the use of trypsin (passage increase). This correlates with findings from 
those of the PCA plots that show separation between DD disease phenotypes in the passage 
1 only (Study 1A) and little separation of samples in subsequent passage numbers. However, 
why this change occurs at such an early onset is not understood. One possible reason for this 
could be the treatment of trypsin to collect these anchorage-dependent cells that were 
cultivated on a solid culture substrate (polystyrene flasks). Trypsinisation of cells may have 
had detrimental effects such as the proteolysis of the cell membrane proteins. Furthermore 
subcultivation and collection of the cells performed in this way could have had detrimental 
effects on the cell number count as well as morphological and conformational changes of the 
cell. This type of methodology and its suitability to retrieve cells could be discussed with a 
cytogeneticist who would have a better perspective. The analysis to locate this change in cell 
cultures (or even cell line) is required early on in establishing a cell line. Little is published 
about the effects of trypsinisation and this method is considered as standard protocol to 
collect anchorage-dependent cells. It is also possible that no study has tried to see what 
changes are/could be taking place at this early stage and may put this down to cells 
undergoing an immortalisation transformation process. A few studies have raised concerns 
about trypsinisation [141, 142]. The synchrony seen between a decrease in the Fishers ratio 
and passage number could be due to a trypsin treatment effect as all passages were produced 
at a convenient point in time in connection to the cells approaching confluence, where many 
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cells had already experienced confluence. With the view that the trypsin had no effect, the 
'passage effect' on metabolite fingerprint is simply because the metabolites were grouped 
into the same culture media representing each passage. Or by contrast, if the process of the 
passage had no effect at all, it would be possible to measure (metabolite) flux as a function 
of passage as the flux would be a continuum. To solve this problem mechanically scraping 
cells (which although may break the intact cell) may avoid the problem of conformational 
changes during sub-cultivation using trypsin (this method is used for harvesting cells from 
cultures for subsequent studies). Additionally, the average concentration of metabolites over 
each passage could be measured. Close examination of the plot at each passage suggests 
there as though there is an inflection (in the plot) at each passage when in fact the process is 
one of gradual change which should be independent of trypsin. Furthermore, this could be 
also be investigated by frequent changes of media to increase the resolution of metabolite 
secretion (on the metabolic footprint).  
 
3.3.4 Conclusion 
The application of FT-IR spectroscopy conducted under carefully controlled conditions with 
appropriate chemometric techniques to differentiate between DD and control fibroblasts has 
been demonstrated to be a powerful tool for discriminating between these cell types in 
individual DD patients, as well as samples from controls. No study to date has attempted to 
demonstrate metabolic analytical differences of dupuytren fibroblast cultures derived from 
different DD tissue phenotypes in early (primary) cultures compared to late passages. This 
study implies that early passage numbers are suitable representatives for DD studies. In 
addition based on their separation, these data demonstrate a gradation in profiles of certain 
metabolites (obtained from their unique fingerprints) in fibroblasts of DD phenotypes 
compared with control. Metabolic fingerprinting is predictive not only of disease but also of 
disease phenotype. The technique has major advantages of speed, sensitivity, and the ability 
to analyse many hundreds of samples simultaneously.  
 
 
 
  
Chapter 4 
Metabolic profiling of Dupuytren’s disease 
fibroblasts under oxidative stress  
  
4.1 Introduction 
4.1.1 Metabolism and Warburg effect in DD 
At present, little is known regarding DD pathogenesis, and even less regarding its cellular 
functions, i.e. metabolic functions and regulation of intermediates involved in glycolysis, 
TCA cycle, pentose phosphate shunt and amino acid metabolism. Studies of genetic 
abnormalities and environmental factors have provided evidence for a multifactorial nature 
of DD. The disease progresses with the growth of abnormal fibroblasts and localised 
ischemia/hypoxia. It is speculated that microvessel narrowing preceding localised hypoxia 
may be one possible cause of DD, where fibroblast proliferation ensues during perivascular 
connective tissue damage.  
In this Chapter we test our hypothesis whether DD cells are under the Warburg 
effect. This was achieved by inducing a perturbation in healthy cells (fascial cells) cultured 
in pO2 = 158 mmHg corresponding to a concentration of 21% atmospheric oxygen and 
compare their metabolic profiles with healthy cells exposed to hypoxia i.e. in pO2 = 8 
mmHg corresponding to concentration of 1% oxygen. Then we examine the hypothesis that 
any such differences are akin the Warburg effects noted for tumour cells in the literature by 
comparing the extracts from intracellular (endo-) metabolomes acquired from DD nodule, 
cord and SON cultures against those acquired from healthy cells and under hypoxia-induced 
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fascia. The extracellular (exo-) metabolomes acquired from DD nodule and healthy fascia in 
normal and hypoxia-induced cultures. In addition, response to hypoxia is also examined in 
the intracellular metabolomes of disease cells; this may aid in biomarker identification by 
imposing stress on the disease cells. Furthermore the question is; if a Warburg effect exists, 
in which DD phenotype is this effect greatest? What are these key players (metabolites) and 
which pathways are these mapped onto? In addition, we test another hypothesis; whether 
changes occurring in abnormal fibroblasts are due to gene expression alone or dictated by 
metabolism or a combination of both? (see Chapter 5). The objectives were to investigate 1) 
perturbation effect on healthy fascia cells to investigate whether healthy cells in hypoxia 
mimic disease state scenario 2) progression of disease compared to healthy (nodule, cord and 
SON vs. fascia) 3) the effect of 1% oxygen tension on these samples (1% vs. 21%). The aim 
is to get a deeper understanding of the dynamics involved in the DD cellular system. Sample 
reproducibly of DD and control cells has been shown in Chapter 3. This study employed the 
use of GC-MS to determine metabolic profiles.  
 Metabolic differences between fibroblast cell samples (passage number 3) cultured in 
normoxic and hypoxic conditions have identified a number of significantly dysregulated 
metabolites involved in both amino acid metabolism and carbohydrate metabolism pathways 
in nodule, cord and SON pairwise analyses. The comparisons between disease and control 
fascia reveal that cysteine, aspartic acid and a sugar molecule were significantly down-
regulated in disease. The perturbation effect in control fascia resulted in the identification of 
a number of significant metabolites involved in carbohydrate metabolism and amino acid 
metabolism. While relatively fewer metabolites have been identified in disease when 
compared with control, the perturbations effects have revealed a relatively larger number of 
significant metabolites. It has been demonstrated that GC-MS is a highly sensitive and high 
throughput analytical technique for biomarker screening and identification in DD samples, 
able to discriminate between different oxygen tension and tissues types (cultures), also 
enabling detailed profiling of the induced perturbation of metabolome. This is the first time 
that GC-MS and metabolomics analysis methodology been applied to the characterisation of 
DD samples. 
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4.2 Results 
4.2.1 MVA on GC-MS data acquired from all samples in hypoxia and normoxia 
The intracellular distribution of metabolites and metabolic changes induced by these abiotic 
perturbations were investigated by metabolomics. GC-TOF-MS was employed, providing in 
this study the detection of 129 different metabolite peaks from the intracellular metabolome 
(in each of the 126 samples) and 79 from the exometabolome (36 samples). A typical total 
ion current (TIC) chromatogram from mammalian endometabolome is shown in Figure 23.  
 
 
 
Figure 23 Typical TIC for mammalian cells. 
 
To assess sample variability, GC-TOF-MS analysis was performed on 126 samples, 
constructed from 4 different tissue phenotypes (nodule, cord, skin overlying nodule and 
transverse palmar fascia – i.e. control) cultured in triplicates for each O2 tension. In this 
study there are three factors of interest; 1) progression of disease compared to healthy 
(nodule, cord and SON vs. fascia) 2) the effect of 1% oxygen tension on these samples (1% 
vs. 21%), 3) perturbation effect on healthy fascia cells to investigate whether healthy cells in 
hypoxia mimic disease state scenario. To identify the source of greatest variation within the 
combined and individual groups of data for all samples MVA was employed. The initial 
stage of the data analysis strategy was to use unsupervised exploratory data analysis; PCA 
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was employed to discover any natural groups within the data and also used for discovering 
any outliers before pre-processing. Other methods for outlier detection such as Winsorisation 
may not have provided suitable results as this was an unbalanced data set with respect to 
sample type (phenotypic differences e.g. nodule, n = 7, fascia n = 3). A number of known 
and unknown metabolites were identified. 69 of the 129 metabolites were known metabolites 
or indicatives of sugar. Table 5 shows the identified metabolites and the super families of 
pathways in which they contribute. The results of the PCA for all 8 samples types cultured in 
21% O2 and hypoxia 1% O2 showed separation in clusters from fascia cells to those from all 
skin samples in PC1. There was no obvious separation between these two samples types 
when compared with cords and nodule samples. There was overlap in these clusters in PC1 
and PC2. The results of the PCA are shown in Figure 24(a). Most N21 samples also 
clustered together and separated from N1 in PC1. No trends were clearly observed in cords. 
The 4 samples in Figure 24(b) cultured in 21% O2, plus F1 shows S21 samples separate in 
PC1 from fascia and cord (except patient 5) in PC1. This confirms that SON derived 
fibroblasts were a different sample type (from epidermis) compared with fibroblasts derived 
from nodule, cord and fascia (fascial cells beneath dermis and fat). 
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Figure 24 a) PCA score plot from GC-MS data acquired from 126 samples; nodule, cord, fascia and SON 
fibroblasts cultured in 1% and 21% oxygen. Red dot = N1, red triangle = N21, green dot = C1, green triangle = 
C21, blue dot = F1, blue triangle = F21, magenta dot = S1, magenta triangle = S21. b)  PCA scores plot from 
nodule, cord, fascia and SON fibroblasts cultured in 21% oxygen and fascia cultured in 1% oxygen. In each 
plot the numbers represent patients (each sample with three biological replicates. The numbers represent 
samples (each patient with three biological replicates. Red round dot = N21, green dot green dot = C21, blue 
dot = F21, magenta dot = S21, cyan dot = F1. 
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Table 5 List of 69 known detected metabolite features (peaks) and their involvement in corresponding pathways. „Yes‟ to 
Definitive ID = the metabolite in the sample has matched (by retention index and mass spectrum) to an authentic chemical 
standard present in MMD‟s EI-MS mass spectral library. „No‟ = the mass spectrum only matches to a metabolite in other 
mass spectral libraries (i.e. not the Manchester library). Definitive ID = Due to the nature of the analysis, not all metabolites 
detected can be accurately identified and some have similar chemical structure and were assigned by best possible match 
score.  
Metabolite No HMDB Accession ID Metabolite Identification Definitive Pathway
1 trimethylamine-N-oxide no
2 HMDB00883 valine yes
3 HMDB00192 cystine yes
4 HMDB00929 tryptophan yes
5 HMDB00687 leucine yes
6 HMDB00050 adenosine yes
7 HMDB00172 isoleucine yes
8 HMDB00687 leucine yes
9 HMDB00172 isoleucine yes
10 HMDB00123 glycine yes
11 HMDB00162 proline yes
12 HMDB00187 serine yes
13 HMDB00161 alanine yes
14 HMDB00167 threonine yes
15 HMDB00191 aspartic acid yes
16 HMDB00191 aspartic acid yes
17 HMDB00574 cysteine yes
18 HMDB00696 methionine yes
19 HMDB00574 cysteine yes
20 HMDB00696 methionine yes
21 HMDB00159 phenylalanine yes
22 HMDB00159 phenylalanine yes
23 HMDB00159 phenylalanine yes
24 HMDB00123 glycine yes
25 HMDB00182 lysine yes
26 HMDB00182 lysine yes
27 HMDB00182 lysine yes
28 HMDB11733 glycylglycine no
29 HMDB00158 tyrosine yes
30 HMDB00158 tyrosine yes
31 HMDB00883 valine yes
32 HMDB00167 threonine yes
33 HMDB00191 aspartic acid yes
34 HMDB00143 galactose yes
35 sugar no
36 inositol no
37 sugar no
38 sugar no
39 sugar no
40 sugar no
41 sugar no
42 sugar no
49 sugar no
43 HMDB00827 octadecanoic acid yes
44 HMDB10368 cholesterol yes
45 HMDB00482 octanoic acid yes
46 HMDB00220 hexadecanoic acid yes
47 HMDB00131 glycerol yes
48 HMDB00131 glycerol yes
50 HMDB00126 glycerol-3-phosphate yes
51 HMDB01401 glucose-6-phosphate yes
52 HMDB01401 glucose-6-phosphate yes
53 HMDB02730 nicotinamide yes
54 HMDB00210 Pantothenic acid yes
55 3-ureidopropionic acid and/or beta-alanine no
56 HMDB00641 glutamine yes
57 HMDB00641 glutamine yes
58 HMDB00641 glutamine yes
59 HMDB00300 uracil yes
60 HMDB00300 uracil yes
61 sucrose no
62 sucrose no
63 HMDB00254 succinic acid yes
64 HMDB00094 citric acid yes
65 HMDB00243 pyruvic acid yes
66 thiourea no
67 thiourea no
68 thiourea no
69 à-D-Galactopyranosiduronic acid no Uronic acid pathway
Amino Acid Metabolism
Carbohydrate Metabolism
Fatty Acid Metabolism
Glycerolipid Metabolism 
Glycolysis pathway
Metabolism of Cofactors and Vitamins
Metabolism of Other Amino Acids
Starch and sucrose metabolism
Tricarboxylic acid cycle
Urea cycle
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4.2.2 Effect of O2 tension in intracellular metabolomes of healthy cells  
(F1 vs. F21) 
 
The results from PCA for healthy fascial cells and those under hypoxic insult (F21 and F1) 
are shown in Figure 25(a).  The PCA scores plots show within patient‟s signature was 
stronger than between patients. To analyse the variance a semi-supervised method, ANOVA-
PCA was used which removes uninteresting sources of variance and the results are more 
interpretable. Most of the variance (TEV vs. # PCs) was captured in the first three 
components. The relationship between the data is very well elucidated in Figures 25(c) that 
display PC1 vs. PC2 scores plot. Analysis along the PC1 axis shows that this component 
divides the data into two groups (albeit broad clusters) i.e. F1 clusters and F21 clusters. To 
identify which chemical compounds might be responsible for such separation the 
corresponding loading plot (Figure 25(b)) was assessed. Because the separation between 
healthy and hypoxic fascia appeared in PC1, the variables that show a large diversity in PC1 
are more likely to be the chemicals that differentiate these classes. The numbers represent 
the unique metabolite ID given to the 129 variables, each number corresponds to one peak 
observed in chromatograms.  
From the loadings plot, the variable peaks on the extremes were mainly responsible 
for the separation exhibited in the scores plot whereas those close to the origin had little or 
no contribution to such separation. Examination of the loading plot revealed peaks with the 
highest variability. This was used to compare relative metabolite concentrations in samples 
and whether peaks (metabolite ID‟s) from loading plots correspond with those from 
univariate analysis. Many of these factors were induced by the hypoxic insult. The results 
were mapped onto pathways such as glycolysis, citric acid cycle, amino acid metabolism to 
see which metabolites were up/down regulated as a consequence of hypoxic insult. 
A number of known and unknown metabolites were identified. Variables identified 
from both loadings and univariate analysis (Wilcoxon - sign rank test [143]) in Table 6 and 7 
were considered as significant and box-whisker plots were drawn to display relative 
concentration distributions of metabolites with respect to sample and perturbation effect. 
Using an appropriate level of statistical significance (p ≤ 0.05) major differences in 23 
metabolites were identified (also from PCA) as significantly dysregulated in the 
endometabolomes. Of these 8 were known metabolites; pantothenic acid, a sugar and cystine 
elevated significantly while citric acid, cysteine (identified twice metabolite 40 and 44), 
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aspartic acid, and 3-ureidopropionic acid and/or beta-alanine levels decreased. A further 15 
metabolite features (peaks) were significant but remain unidentified. The metabolites ID 
(e.g. MET 100) are given in Table 7. 
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Figure 25 (a) PCA scores plot showing the separation between hypoxic fascia cells and healthy cells. The 
numbers represent patient the three patients that were entered into the study; patient 4, 7 & 8; each with three 
biological replicates Black denotes control F21 and blue is perturbed fascia; F1. (b) The corresponding PCA 
loadings plot from the first principal component illustrating which features are important for separation in PC1; 
the numbers correspond to the metabolite peaks. These data points were used for univariate analysis. Data 
points that lie close to origin (zero), have little or no contributions toward separations, whereas points that are 
further away from the origin (zero) have more significant contributions toward the separations. (c) PCA scores 
plot from ANOVA-PCA 
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4.2.3 Disease vs. hypoxia induced and healthy fascia 
PCA was then performed on the two disease fibroblasts, with F21 and F1, separately and in 
conjunction. DFA was applied on the PCs (from PCA) to compare more closely the 
clustering in C21 with hypoxia induced and healthy fascia and the same was done for N21. 
Figures 26(a) and (b) represent the PC-DFA scores plot. In Figure 26(a) DF1 separates C21 
from F21 & F1. In Figure 26(b) DF2 separates N21 from F21, while DF1 separates hypoxic 
F1 from normoxic; F21 & N21 clusters. Figure 27(a) shows the scores plot following 
ANOVA-PCA on N21, C21 and F21 and then including F1 respectively in Figure 27(b). It 
can be observed from both scores plots the separation between N21 & F21 appears in PC1 
while separation between C21 & F1 appears in PC2. In addition, PC2 also separates F1 from 
F21 and demonstrates these clusters to be closer to those in C21. As previously, loadings 
were plotted and the variables with data points further away from the origin (zero) that had 
more significant contributions toward the separations were examined.  
The results from Wilcoxon-rank test [143] are as follows. For nodule samples 
compared with normal fascia (N21 vs. F21), 11 metabolites were identified as significantly 
different. Of these 5 known metabolites; cysteine (identified twice - due to the nature of the 
analysis, not all metabolites detected can be accurately identified and some having similar 
chemical structure and were assigned by best possible match score hence all metabolites are 
assigned a Definitive ID), a sugar, phenylalanine, leucine and aspartic acid a decrease was 
observed in nodules. A further 6 metabolite features (peaks) were significant but remain 
unidentified (Table 7). For cords compared with normal fascia (C21 vs. F21), 9 metabolites 
were identified as significantly different. Of these 4 known metabolites; levels of glycerol-3-
phosphate increased while leucine, a sugar and pantothenic acid decreased. Some of these 
trends have been shown in the box-whisker plots in Figures 32(a-j). A further 5 unidentified 
metabolite features were also significant.  
The majority of known metabolites displayed disconcordant changes when disease 
(N21 & C21) and F1were compared with normal fascia F21. Sugar and pantothenic acid 
displayed this trend; up in F1 and down in C21. However, cysteine levels were 
downregulated in both N21 and F1.  
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Figure 26 3D DFA plot based on GC-MS analysis showing the relationship between the disease, healthy and 
hypoxia induced fascia cells (a) DD cords, hypoxia induced fascia cell and normal (healthy) subjects, (b) DD 
nodules, hypoxia induced fascia and healthy subjects. Each symbol represents an individual subject (green 
triangles = C21, red triangles = N21, blue triangles = F21, and cyan dots = F1.  
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Figure 27 a) ANOVA-PCA scores plot based on autocsaled GC-MS data showing the relationship between 
ANOVA-PCA scores plot based on autocsaled GC-MS data showing the relationship between two disease and 
control; N21,C21,F21. The numbers represent the patients. b) ANOVA-PCA scores plot based on autocsaled 
GC-MS data showing the relationship between the four samples; N21, C21, F21 and F1. The numbers represent 
three patients.  Each coloured dot/point represents a sample type. Number refers to Patients 4, 7 and 8. Letters 
refer to replicates.  
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Table 6 Metabolite peaks observed to be statistically different when comparing the intracellular extracts detected for O2 
tensions of 1 and 21%. The legend denotes super families of pathways corresponding to the metabolite detected. The red 
arrow denotes an increase in metabolite concentration. The green arrow denotes a decrease in metabolite concentration. 
No. Metabolite ID F1 vs F21 N1 vsN21 C1 vs  C21 S1 vs  S21 N21 vs  F21 C21 vs  F21 C21 vs  N21
p -value p -value p -value p -value p -value p -value p -value
1 leucine 0.3828 0.0526 ↑ 0.0011 ↑ 0.0098 ↑ 0.0313 ↓ 0.0078 ↓ 0.4887
2 sugar 0.0469 ↑ 0.2146 0.3981 0.5781 0.6250 0.0156 ↓ 0.4631
3 glycerol-3-phosphate 1.0000 0.0024 ↓ 0.7344 0.4961 0.2500 0.0156 ↑ 0.0391 ↑
4 Pantothenic acid 0.0078 ↑ 0.0218 ↑ 0.0080 ↑ 0.4961 0.6875 0.0547 ↓ 0.4887
5 glucose-6-phosphate 0.3828 0.1075 0.5755 0.0098 ↓ 0.6875 0.0781 0.4887
6 sucrose 0.9375 0.0413 ↓ 0.9479 0.1094 0.5625 0.0781 0.6257
7 isoleucine 0.2188 0.0040 ↑ 0.3259 0.7002 1.0000 0.1094 0.3394
8 glucose-6-phosphate 0.5469 0.0854 0.5503 0.0322 ↓ 1.0000 0.1094 0.4543
9 citric acid 0.0156 ↓ 0.0025 ↓ 0.0043 ↓ 0.0098 ↓ 0.3125 0.1484 0.4212
10 tyrosine 0.4609 0.9359 0.3317 0.0244 ↓ 0.3125 0.1484 0.0353 ↑
11 sugar 0.3125 0.1337 0.0152 ↑ 0.1309 0.3125 0.1953 0.8904
12 succinic acid 0.1953 0.0486 ↑ 0.0522 ↑ 0.7646 0.4375 0.1953 0.6387
13 sugar 0.1953 0.0176 ↑ 0.0169 ↑ 0.2324 0.4375 0.2500 0.3028
14 cystine 0.0469 ↑ 0.0029 ↑ 0.0353 ↑ 0.0313 ↑ 0.5000 0.2500 0.9375
15 sugar 0.4375 0.0067 ↑ 0.0586 0.4316 0.0313 ↓ 0.2500 0.2412
16 glutamine 0.3125 0.0353 ↓ 0.1627 0.2754 0.4375 0.2500 0.3804
17 valine 0.3125 0.0395 ↑ 0.0836 0.6875 0.8125 0.2969 0.1688
18 tryptophan 0.1953 0.0072 ↑ 0.0031 ↑ 0.0391 ↑ 0.0625 0.3125 0.2061
19 glycylglycine 0.1094 0.0023 ↑ 0.0771 0.1250 0.1250 0.3125 0.1484
20 glycerol 1.0000 0.0582 0.0005 ↑ 0.8457 0.8438 0.3828 0.5830
21 phenylalanine 0.8438 0.0141 ↑ 0.0304 ↑ 0.0244 ↑ 0.0313 ↓ 0.3828 0.0302 ↑
22 methionine 0.9453 0.0129 ↑ 0.0479 ↑ 0.1094 0.0625 0.3828 0.4263
23 lysine 0.5469 0.1119 0.2322 0.2783 0.2188 0.3828 0.0353 ↑
24 cholesterol 0.5469 0.9359 0.3703 0.0098 ↓ 0.5625 0.3828 0.1514
25 cysteine 0.0547 ↓ 0.0218 ↓ 0.2471 1.0000 0.0313 ↓ 0.4609 0.2524
26 glycine 0.3828 0.1365 0.2959 0.0244 ↓ 0.2188 0.4609 0.3591
27 uracil 0.2500 0.4997 0.0141 ↓ 0.2783 0.5625 0.5469 0.8904
28 lysine 0.3750 0.9359 0.0187 ↓ 0.3203 0.6875 0.5469 0.0353 ↑
29 nicotinamide 0.7422 0.6529 0.0366 ↑ 0.3594 0.8750 0.5469 0.2439
30 leucine 0.6406 0.0017 ↑ 0.1790 0.4131 0.8438 0.5469 0.4212
31
3-ureidopropionic acid 
and/or beta-alanine 0.0469 ↓ 0.2485 0.5862 0.0273 ↓ 1.0000 0.5469 1.0000
32 octadecanoic acid 0.4688 0.0148 ↓ 0.8789 0.0098 ↓ 0.3125 0.5469 0.2163
33 adenosine 0.6406 0.0055 ↑ 0.0910 0.5195 0.2188 0.5781 0.2293
34 sugar 0.3125 0.2311 0.0366 ↑ 0.4961 1.0000 0.6406 0.9341
35 aspartic acid 0.0391 ↓ 0.3547 0.5016 0.2402 0.0625 0.6406 0.5614
36 isoleucine 0.3125 0.0005 ↑ 0.0218 ↑ 0.0420 ↑ 0.0625 0.6875 0.1514
37 glycerol 0.6406 0.0168 ↑ 0.0206 ↑ 0.0840 0.6875 0.7422 0.9460
38 aspartic acid 0.9453 0.2273 0.1084 0.1934 0.0313 ↓ 0.8438 0.0637
39 methionine 0.8438 0.3271 0.3317 0.0420 ↑ 0.0625 0.8438 0.2676
40 valine 0.9453 0.0056 ↑ 0.3958 0.6377 0.0938 0.8438 0.2166
41 sucrose 0.8438 0.0386 ↓ 0.3981 0.8125 0.8125 0.8438 0.3054
42 cysteine 0.0156 ↓ 0.4445 0.2180 0.7002 0.0313 ↓ 0.9453 0.0637
43 octanoic acid 0.1094 0.0129 ↑ 0.2432 0.2324 1.0000 0.9453 0.8552
44 sugar 0.8438 0.0218 ↓ 0.8228 0.9658 0.0625 0.9453 0.0043 ↓
45 thiourea 0.1250 0.0078 ↓ 0.0039 ↓ 0.3750 0.5000 1.0000 0.8125
46 thiourea 0.1094 0.0049 ↓ 0.0161 ↓ 0.0156 ↓ 0.7500 1.0000 0.5703
47 lysine 0.0938 0.0026 ↑ 0.2273 0.4961 0.0625 1.0000 0.0023 ↑
48 serine 0.2500 0.0012 ↑ 0.6788 0.5703 0.1250 1.0000 0.1934   
Pathway Amino acid metabolism Carbohydrate metabolism Fatty acid metabolism Metabolism of Cofactors and Vitamins Urea cycle
Metabolite level ↑ up regulated ↓ down regulated  
Chapter 4                                          Metabolic profiling of Dupuytren’s disease fibroblasts under oxidative stress   
125 
 
 
Table 7 Metabolite peaks observed to be statistically different when comparing the intracellular extracts 
detected for O2 tensions of 1 and 20%. These metabolites are unknown and hence MET ID in order detected is 
given. The colours indicate the significant metabolites. 
No. Metabolite ID F1 vs F21 N1 vsN21 C1 vs  C21 S1 vs  S21 N21 vs  F21 C21 vs  F21 N21 vs  C21
p -value p -value p -value p -value p -value p -value p -value
1 MET 31 0.0078 0.0836 0.0304 0.2061 0.5625 0.0781 0.3591
2 MET 54 0.0078 0.0003 0.0080 0.0371 0.4375 1.0000 0.7197
3 MET 55 0.0078 0.0766 0.3760 0.1748 0.4375 0.0781 0.8904
4 MET 83 0.0078 0.0702 0.0442 0.6875 0.3125 0.4609 0.5416
5 MET 107 0.0078 0.0910 0.0620 0.0273 0.5625 0.3828 0.2293
6 MET 115 0.0078 0.0641 0.0569 0.0830 0.8438 0.1094 0.7615
7 MET 14 0.0156 0.0641 0.0930 0.1475 0.0938 0.2500 0.7615
8 MET 27 0.0156 0.1712 0.8107 0.3652 0.8438 0.5469 0.0580
9 MET 45 0.0234 0.4688 0.1454 0.2324 0.8438 0.3828 0.6387
10 MET 71 0.0234 0.6009 0.0479 0.5195 0.6875 0.0781 0.1876
11 MET 9 0.0313 1.0000 1.0000 0.5000 1.0000 1.0000 1.0000
12 MET 19 0.0313 0.0437 0.0002 0.1250 0.8750 0.2188 0.7002
13 MET 122 0.0313 1.0000 0.0005 1.0000 1.0000 1.0000 1.0000
14 MET 32 0.0391 0.0836 0.3317 0.1230 0.5625 0.0781 0.6788
15 MET 114 0.0391 0.0329 0.9405 0.8311 1.0000 0.3828 0.0554
16 MET 100 0.8438 0.0009 0.5862 0.0273 0.0313 0.4609 0.1272
17 MET 13 0.6875 0.0070 0.1221 0.7695 0.6250 0.2188 0.3910
18 MET 29 0.7422 0.0079 0.0400 0.0186 0.0313 0.3125 0.7615
19 MET 59 0.1094 0.0100 0.0072 0.7344 0.0625 0.2500 0.3303
20 MET 58 0.5469 0.0100 0.2790 0.3203 0.0313 0.2500 0.3894
21 MET 21 0.8438 0.0112 0.0364 0.0137 0.0313 0.4609 0.7148
22 MET 3 1.0000 0.0158 0.5257 0.5771 0.4375 0.3828 0.4212
23 MET 77 0.1875 0.0181 1.0000 0.0313 0.0625 0.0156 0.1475
24 MET 62 0.3828 0.0329 0.6813 0.7646 1.0000 0.6406 0.9780
25 MET 96 1.0000 0.0340 0.3271 0.8438 0.0313 0.6875 0.3894
26 MET 99 0.3125 0.0442 0.8228 0.7646 1.0000 0.8438 0.1688
27 MET 126 0.8438 0.0479 0.5228 0.7695 0.6250 0.3750 0.0186
28 MET 28 0.3828 0.0534 0.8721 0.1016 0.6875 0.9453 0.8904
29 MET 1 0.4375 0.9697 0.0002 0.4688 0.2500 1.0000 0.7344
30 MET 102 0.5000 1.0000 0.0020 1.0000 0.2500 0.3750 0.0039
31 MET 82 0.1484 0.2954 0.0022 0.2402 0.0938 0.3828 0.4543
32 MET 121 1.0000 1.0000 0.0078 1.0000 0.0625 0.0313 1.0000
33 MET 112 0.2500 0.0625 0.0117 0.5000 1.0000 0.3125 0.4375
34 MET 61 0.1094 0.3144 0.0152 0.0322 0.5625 0.0547 0.9780
35 MET 4 0.2500 0.0645 0.0156 0.3750 1.0000 0.2500 0.8125
36 MET 124 0.8750 0.7002 0.0156 0.7500 0.5000 0.2500 0.6875
37 MET 60 0.4609 0.7782 0.0169 0.1016 0.3125 0.0391 0.4212
38 MET 106 0.3125 0.0582 0.0171 1.0000 0.4375 0.8438 0.9658
39 MET 17 0.4609 0.3981 0.0401 0.9658 0.1563 0.3828 0.0256
40 MET 25 0.1484 0.0836 0.0522 0.1016 0.8438 0.2500 0.8904
41 MET 123 0.5469 0.7475 0.1560 0.0049 0.2188 0.1484 0.7615
42 MET 120 0.7422 0.9679 0.8519 0.0049 1.0000 0.6406 0.3894
43 MET 125 1.0000 0.1701 0.2180 0.0244 0.6875 0.1484 0.6788
44 MET 119 0.3828 0.1590 0.8228 0.0322 0.4375 0.2500 0.5614
45 MET 74 0.7422 0.8092 0.8789 0.8125 0.0313 0.9453 0.7609
46 MET 128 0.0547 0.4939 0.1169 0.2783 0.5625 0.0234 0.0730
47 MET 94 1.0000 0.1250 1.0000 1.0000 1.0000 0.1250 0.0010
48 MET 16 0.4609 0.2273 1.0000 0.3203 0.1563 0.8438 0.0084
49 MET 7 0.7422 0.8405 0.4209 0.3750 1.0000 1.0000 0.0215  
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4.2.4 Disease vs. Disease – Nodule vs. Cord 
MVA was also performed on the DD cords against DD nodules i.e. C21 vs. N21. Little could 
be depicted from the PCA scores plots (Figure 28). From the Wilcoxon-rank test [143], 5 
metabolites showed a significant increase in cords compared with nodules. These are 
glycerol-3-phosphate, tyrosine, phenylalanine and lysine (identified three times). A sugar 
was markedly down regulated in nodules. In addition 6 unknown metabolites were also 
shown to have significant differences (Table 7). 
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Figure 28 PCA scores plot comparing two disease samples. 
 
 
4.2.5 Nodule, Cord and Skin overlying nodule under hypoxic stress 
MVA was then performed on the DD nodule, cord and SON data to compare against those 
cultured in hypoxic stresses i.e. N1 vs. N21, C1 vs. C21 and S1 vs. S21. Figures 29 (a-c) 
shows the PCA scores plot following ANOVA-PCA in each case. It can be observed from 
all scores plots the separation between samples cultured in normoxic state compared with 
hypoxic conditions separate in PC1. This is clearer in the case of nodules and SON. The 
cords (C21) however show overlap in clusters across PC1 and in PC2, while the hypoxic 
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cords (C1) are mostly observed in PC2. The loadings plot and univariate analyses results are 
as follows.  
For nodules in hypoxia 1% compared with cultures in 21% (N1 vs. N21) 46 
metabolites were identified as significantly different. Of these 30 known metabolites; 20 
increased in hypoxic cultures: leucine (identified twice), pantothenic acid, isoleucine 
(identified twice), succinic acid, a sugar, cystine, another sugar, valine (twice), tryptophan, 
glycylglycine, phenylalanine, methionine, adenosine, glycerol, octanoic acid, lysine and 
serine. A decrease in the relative concentrations for the following 10 metabolites was 
observed: glycerol-3-phosphate, sucrose (twice), citric acid, glutamine, cysteine, 
octadecanoic acid, a sugar and thiourea (twice). The 16 unknown metabolites that displayed 
significant differences are listed in Table 7.  
For cords in hypoxia 1% compared with cultures in 21% (C1 vs. C21) 40 metabolites 
were identified as significantly different. Of these 19 known metabolites; 14 increased in 
their concentration in hypoxic cultures: leucine, pantothenic acid, sugars (three), succinic 
acid, cystine, tryptophan, glycerol (twice), phenylalanine, methionine, nicotinamide and 
isoleucine. A decrease in the relative concentrations for the following 5 metabolites was 
observed: citric acid, uracil, lysine and thiourea (twice). The 21 unknown metabolites that 
displayed significant differences are listed in Table 7.  
For SON in hypoxia 1% compared with cultures in 21% (S1 vs. S21) 26 metabolites 
were identified as significantly different. Of these 15 known metabolites; 6 increased in their 
concentration in hypoxic cultures: leucine, cystine, tryptophan, phenylalanine, isoleucine and 
methionine. A decrease in the relative concentrations for the following 9 metabolites was 
observed: glucose-6-phosphate (twice), citric acid, tyrosine, cholesterol, glycine, 3-
ureidopropionic acid and/or beta-alanine, octadecanoic acid and thiourea. The 11 unknown 
metabolites that displayed significant differences are listed in Table 7.  
The majority of metabolites displayed concordant changes when cord and nodules 
were perturbed in hypoxia (i.e.  increased in both or decreased in both). Citric acid was 
downregulated in hypoxic samples including F1. Pantothenic acid levels increased in both 
disease hypoxic cultures (N1, C1) and F1. Leucine is elevated in N1, C1 and S1 but 
decreases in N21 and C21 compared with controls F21. Figure 30 displays the general trend 
observed in DD nodules, cords and fascia from 3 patients cultured in two oxygen tensions. 
Hypoxia has an influence on disease and healthy cells. Figure 31 shows the separation 
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between DD nodules and fascia and their respective hypoxic counterparts in scores plot from 
PCA and ANOVA-PCA.  
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Figure 29 PCA scores plot demonstrating changes due to hypoxic effect in a) nodules, b) cords and c) skin 
overlying nodules. 
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Figure 30 PCA scores plot demonstrating changes due to hypoxic effect in nodules, cords and control samples 
from three patients. The ellipses do not have statistical significance and are for illustrative purpose only. 
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Figure 31 PCA and ANOVA-PCA scores plot demonstrating changes due to hypoxic effect in both nodules 
and fascia. 
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Figure 32 Box-whisker plots demonstrating altered expression of metabolites in intracellular metabolomes of 
nodules, cords and Fascia in 1% and 21%. a) cysteine, b)cysteine, c) leucine, d) phenylalanine, e) aspartic acid, 
f) pantothenic acid, g) cystine, h) citric acid, i) 3-ureidopropionic acid &/or beta-alanine and j) lysine. The red 
line in the box represents the median change in the peak value; the lower and upper boundaries of the box 
represent the 25th and 75th percentiles, respectively; the lower and upper whiskers represent the 5th and 95th 
percentiles, respectively; and crosses represent the outliers.**p ≤ 0.05 Wilcoxon sign rank test. 
 
 
4.2.6 Effect of O2 tension on the metabolic footprint (exometabolome) 
Two known (ornithine and leucine) and one unknown metabolites (um01) were identified as 
significantly different between samples in N21 vs. F21 (n = 3 nodule, n = 3 fascia; in 
triplicates). None of these metabolites were found to be significantly different between N1 
and N21. Um01 and ornithine were significantly elevated in samples from N21 compared to 
F21 (p = 0.007 and 0.03 respectively). Leucine levels were found to be significantly 
decreasing in samples from N21 (p = 0.03) and F1 (p = 0.05) compared to F21 (Figure 33(a-
c)). 
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4.2.7 Pathway analysis 
Analysis of all known metabolites in the dataset using KEGG database revealed that 
members of the amino acid metabolism pathway were significantly overrepresented in the 
list of metabolites that changed specifically in the setting of hypoxic ischemia. In the case of 
DD nodule and cord samples, the results indicate, that dysregulation in intermediates 
involved in carbohydrate and amino acid metabolism may attribute to DD formation. Table 6 
illustrates the directional change with red arrow (upregulated) and green arrow 
(downregulated). 
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Figure 33 Box and whisker plots demonstrating altered expression of metabolites in conditioned cultured 
medium in DD Footprints in response to different atmospheric O2 tensions. (a) UM01, (b) ornithine, (c) 
leucine, **p ≤ 0.05 Wilcoxon signed rank test. 
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4.3 Discussion 
4.3.1 Principal Findings 
Metabolomics has expanded rapidly into new scientific fields in recent years. Despite this 
expansion, there are no reports of metabolomic (metabolic fingerprint or footprint) 
investigations in DD or any studies of DD cells following exposure to altered oxygenation. 
Variations in the intracellular metabolomes represent biochemical reactions in cells and 
therefore can aid in hypothesis generation regarding the activities within DD compared to 
control cells. From these variations, the pathways affected can be deduced, and the mode of 
action of disease pathogenesis better understood.  
In these preliminary studies despite a small clinical cohort of patients the aim was to 
identify novel biomarkers and determine whether metabolomic strategies were appropriate 
for the investigation of DD, including the assessment of comparison of technical and 
biological variability. In Chapter 3, FT-IR spectroscopy was used to produce unique 
fingerprints of DD and control fibroblasts based on biological provenance of each sample. 
This method represents a novel approach for sample characterisation and has allowed for 
classification of disease samples based on their genotype-phenotype differences and 
identified a suitable passage representative allowing further investigation of this disease in a 
controlled manner through construction of a reproducible cell culture model. Although this 
method proved to be both effective and rapid, it did not yield specific metabolite 
information. To elucidate key metabolites (and their levels in terms of relative abundance), 
an untargeted metabolic profiling approach using GC-MS was applied on selected test 
subjects to identify groups of metabolites associated with a specific pathways thought to be 
involved in the pathogenesis of DD. A targeted approach could then be applied to focus on 
specific groups of metabolites (e.g. lipids, carbohydrates, amino acids). The results from 
metabolomics analyses combined with transcriptomic data are confronted with many 
systems biology tools that facilitate investigation in a more controlled manner in order to 
deduce key pathways thought to be involved in disease. This will be discussed in Chapter 6. 
Using GC-MS, the metabolic profiles of endogenous and secreted metabolites were 
acquired from (1) DD cords and nodules from the palm against the unaffected transverse 
palmar fascia (internal control), (2) DD the skin overlying the nodule and (3) those in (1) and 
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(2) were compared between their counterparts under hypoxic stresses. A total of 129 
metabolites were detected in the analysis of the intracellular metabolome and 79 metabolites 
detected from the footprint. While transport of metabolites between sub-cellular 
compartments may play a key role in regulation of metabolism, the current quenching, 
extraction and analytical approach provides only average metabolite levels throughout the 
full cellular volume. 
The first aim was to determine whether we could detect metabolites (endogenous) in 
healthy cells under hypoxic stress (F1) and compared these with the metabolic profiles 
acquired from healthy transverse palmar fascia (F21). Next, these metabolic profiles were 
compared with DD nodule, cord and SON. This was done to investigate whether DD tumour 
cells were akin to the tumours in which exists the Warburg effect. Furthermore, these 
metabolic profiles were compared with their counterparts under hypoxic stress to test the 
response to hypoxia in the metabolomes of nodules, cords and SON. The key players from 
this study were then used to investigate the cellular dynamics in the transcriptomes (Chapter 
5). For these samples differences between metabolic footprints in two different O2 tensions 
were also investigated. This advanced sensitivity in detecting changes in DD cultures.  
Multivariate analyses demonstrated within-class inter-patient/site variation was less 
than between-class inter-patient/site variation. This shows that there are greater differences 
between classes (between patients and their respective samples cultured in different O2 
tensions) than within classes (patients/samples cultured at the same O2 tension), which are 
necessary to deduce metabolic changes between the experimental classes. These results 
show that metabolomic methodologies are suitable for distinguishing metabolic variations in 
cultures of DD at different O2 tensions. They also indicate that when appropriate 
experimental design is applied, observed differences are likely to originate from true 
biological variation rather than technical inaccuracies. The groups of metabolites that were 
identified as significantly different in the endometabolomes were amino acids, sugars or 
intermediates in carbohydrate metabolism as explained below. 
Cysteine, decreased in N21, N1 and F1 compared to control samples. This sulfur-
containing amino acid is a building block to most proteins. It is unique among the twenty 
common amino acids because it contains a thiol group with can undergo oxidation of a pair 
of cysteine residues producing cystine, a disulfide-containing derivative. This reaction is 
reversible. The disulphide bonds of cystine are crucial to defining the structures of many 
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proteins. Cystine levels however notably increase in all hypoxic samples. This disulphide 
molecule is generally found in high concentrations in the cells of the immune system, 
skeletal and connective tissues and skin. Hair and skin are 10-14% cystine [49]. A decrease 
in sugars levels in disease cells and increase in hypoxic cells indicate altered glucose 
metabolism in fibroblasts in response to changes in O2 tension. Leucine decreases in N21 
and C21. By contrast it increases in N1, C1 and S1. This essential amino acid is a group of 
three amino acids known as branched-chain amino acids – BCAA (valine and isoleucine 
being the other two) whose carbon structure is marked by a branch point. These three amino 
acids are critical to human life and are particularly involved in stress, energy and muscle 
metabolism. Stress state e.g. surgery, trauma, cirrhosis, infections, fever and starvation 
require proportionately more BCAA than other amino acids and probably proportionately 
more leucine than either valine or isoleucine [49]. Phenylalanine, an essential amino acid is 
observed as downregulated in N21 but upregulated in C21 compared with N21. Previous 
literature reports some tumours use more phenylalanine, particularly in melanoma. One 
strategy suggested to deal with this is to exclude this amino acid from the diet,  the other is 
to increase phenylalanine's competing amino acids, i.e., tryptophan, valine, isoleucine and 
leucine, but not tyrosine [49]. Aspartic acid levels decrease in N21, This non-essential amino 
acid is synthesised from glutamic acid by enzymes using vitamin B6. The amino acid has 
important roles in the urea cycle and DNA metabolism. Aspartic acid is a major excitatory 
neurotransmitter which is sometimes found to be increased in epileptic and stroke patients. 
Pantothenic acid, also called vitamin B5, was elevated in all hypoxic samples. By contrast 
this water-soluble vitamin decreased in C21. Pantothenic acid is required to sustain life; is 
needed to form coenzyme-A (CoA), and is thus critical in the metabolism and synthesis of 
carbohydrates, proteins, and fats. It is found almost in all foods [49]. 
The final aim of the metabolomics experiments was to determine whether GC-MS 
could define differences in exometabolome of cells exposed to different atmospheric O2 
tensions. Using an appropriate level of statistical significance (p ≤ 0.05) only three 
metabolites were identified as significantly different in the exometabolomes; ornithine, 
leucine and the third is unknown. Ornithine; an amino acid not encoded by DNA, i.e. it is 
not involved directly in protein synthesis. In mammalian non-hepatic tissues, the main use of 
the urea cycle is in arginine biosynthesis, ornithine is an intermediate, in this metabolic 
process, and thus is quite important [144]. It is believed not to be a part of genetic code 
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because polypeptides containing unprotected ornithines undergo spontaneous lactamization. 
Overall, no major differences were demonstrated in the exometabolomes. This may suggest 
that cultures in O2 levels exceeding those estimated as physiological for term human cell 
cultures (6-7%) may not significantly alter the secreted metabolic content.  
 
4.3.2 Strengths and weaknesses of the study  
For mammalian cells in culture, characterisation of metabolic footprint and within the cells 
(intracellular metabolites; “fingerprinting”) both have validity for assessment of cellular 
function [145, 146]. Metabolic footprinting offers technical simplicity, high-throughput, and 
automation as samples are simply centrifuged to separate medium and cells prior to analysis 
and is an appropriate tool for screening of large sample libraries. None of the difficulties 
associated with sampling intracellular metabolomes, including cell leakage during 
quenching, are present. It provides a picture of metabolism over a period of time instead of a 
snapshot, as is the case for intracellular metabolism [145]. However, the intracellular 
metabolite profile most accurately defines the metabolic status of the cell, and one of the 
most crucial technical features for characterisation of intracellular metabolites is the 
quenching and extraction process. Many metabolites are extremely labile and, for example, 
ATP and glucose 6-phosphate have turnover rates of less than 1-2s and hence cellular 
metabolism must be stopped immediately (quenched) upon sampling of the cells to prevent / 
minimise metabolite turnover. Here a metabolomics approach within an integrated systems 
biology framework is applied to understand the metabolic and functional response to 
hypoxia in DD cells compared to DD and healthy cells. This high-throughput approach has 
facilitated the identification of several biomarkers (small molecules) thought to be involved 
in DD pathogenesis. In addition, simultaneous measurements of two factors in 126 samples 
i.e. difference in cell type and effect of hypoxia has been possible.  Oxidative stress has been 
linked to many diseases [147-149]. Increased levels of oxidative biomarkers can be detected 
in aging population; oxidants are produced by endogenous sources, such as mitochondrial 
respiration, which generates reactive oxygen species (ROS) as by products. Increased 
production of oxidants results from saturation of antioxidant defenses [150], such as 
inactivation of antioxidant enzymes and depletion of sulfhydryls due to nutritional 
imbalance or exposure to xenobiotics [151]. 
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In order to improve the statistical validity of the acquired data, and to facilitate 
epidemiological studies, it is highly desirable to employ data set sizes composed of hundreds 
if not thousands of samples. This requires reproducible analyses over time scales ranging 
from several months to years. The Human Serum Metabolome project [133, 152], conducted 
by the University of Manchester, AstraZeneca, and GlaxoSmithKline, is a study which 
presents this particular challenge. Raw and processed analytical data, together with clinical 
and physiological metadata for the subjects, is a highly useful resource. However, such 
sample collection regimes of many diseases such as DD are not always possible for 
metabolomics experiment, e.g. the fact that patient samples are not always available at the 
time that is optimal for the research project and so in this experiment a small clinical number  
n=8 was only possible. 
The findings from this experiment can now lead to a more targeted profiling 
approach using LC-MS/MS or NMR spectroscopy. The principal carbohydrate product of 
glycolysis is pyruvate, which was not measured as significant here. A key metabolite of 
pyruvate is alanine, which is produced via pyruvate transamination. Levels of alanine were 
also detected. It is clear that several amino acid, sugars and fatty acids altered in DD. This 
investigation provides evidence of this and future studies should be targeted at the amino 
acid utilisation patterns. 
An apparent issue with sample collection/preparation was observed in TIC by the 
high chromatogram baselines. This suggested a high concentration of phosphate and glucose 
in the intra-cellular extracts not due to high concentrations of these metabolites in the cell 
but the issue of all the footprint and wash step involved potentially leaving minute traces 
before the quenching solution was added. Rapid quenching following footprint collection 
was performed instantly to prevent changes in metabolism. This may have been the case in 
few samples due to the large volume of media being aspirated (35mL) and one wash (10mL) 
step which then was also aspirated quickly. The high phosphate concentration interfered in 
accurate determination of the internal standard (succinic acid-d4) as both elute close to each 
other. To overcome this problem all data was normalised according to total peak area for all 
detected peaks for a single sample, i.e. (peak area-metabolite/total peak area for all 
metabolites) x 100. 
Both the strength and weakness of PCA is that it is a non-parametric analysis. One 
only needs to make the assumptions outlined in Chapter 2.2.2 and then calculate the 
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corresponding answer. There are no parameters to tweak and no coefficients to adjust based 
on user experience - the answer is unique and independent of the user [153]. This same 
strength can also be viewed as a weakness. If one knows a priori some features of the 
structure of a system, then it makes sense to incorporate these assumptions into a parametric 
algorithm - or an algorithm with selected parameters. PCA showed little separation of 
different samples types in Figure 24(a-b), therefore, a supervised method, ANOVA-PCA 
was used. This method removed uninteresting sources of variance and the results were more 
interpretable than without ANOVA. This can be seen in Figures 27(a-b). PCA is most 
commonly used to gain an intuitive view of the multivariate data, however, when there are 2 
or more underlying influential factors PCA is not always the best method to reveal the 
influence of these factors. Methods such as PARAFAC [154] and PLS [94] may be more 
appropriate. Again, due to small sample number of patients and only 3 biological replicates 
such methods were not applicable here.  
 Supervised classification attempts to build a predictive model based on a subset of 
samples with known origin (training set). If there are sufficient chemical differences between 
the samples that are detected by GC-MS the model should be able to predict the class 
membership of unknown samples. The accuracy of such prediction can then be assessed by 
using an independent data set (test set) not used during the training stage. DFA was applied 
and the scores plots can be seen in Figures 26(a-b). Despite supervised learning methods, the 
variability between patients is observed in this analysis. This could be due to the patients 
recruited not displaying a similar proliferative disease stage (e.g. early vs. late stage, 
contracted vs. non-contracted hand) and could mostly be at interface or in transformation 
from one state to another. DD cords do however have the least significant no. of differences 
compared with normal fascia, while nodules show 6 significant defected metabolites.  
The study has potential limitations that should be considered. First, although 
sampling in patients who served as their own biological controls (1% and 21%) helped 
diminish interindividual variability and signal-to-noise problems, the study population was 
nevertheless small. Thus, it is important to note that changes in metabolites that failed to 
reach nominal significance in this study still may be scientifically important and should be 
further investigated. For this reason, biological pathway trend analysis offered increased 
advantage to detect subtle but significant differences. Further testing in larger cohorts will 
provide the opportunity for both confirmation and exploration of subgroups of interest, 
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including those based on varying proliferative stages, which this study was underpowered to 
do. Moreover, larger datasets will provide sufficient precision in the estimates of the utility 
of each marker to allow for appropriate relative weighting of each component. Another 
weakness is that independent measurements of lactate and ATP have not been made and 
therefore it cannot be confirmed whether the Warburg is being used or not. The study does 
highlight many trends and these shall be sought in the transcriptome profile in Chapter 5 and 
6. 
 
4.3.3 Conclusions 
Currently, metabolomics has been applied as a hypothesis generation strategy, as there is 
little known of expected metabolic differences in DD. This study is novel in that it also is 
testing for the first time analytical tools and various DD passaged cells. The difficulties 
faced and successfully overcoming challenges associated with primary cultures (e.g. high 
variability and low n number) should not be understated. Metabolic profiling is used to 
detect a wide range of metabolites covering a number of different metabolic classes to 
provide as large an overview of metabolism as achievable. The intracellular and selective 
extracellular metabolome have been studied, giving clues to metabolic pathways that may be 
utilised within the DD cell environment and the effects these cells may be having on their 
environment through released products. Furthermore this approach reveals the effect these 
cells may exert upon induction of a hypoxic insult to disease and healthy cells.  However, 
from Table 6 and 7, it can be observed that the metabolites found significantly dysregulated 
in F1 vs. F21 analysis were not akin the N21 vs. F21 metabolites. From this we may be 
tempted to falsify the first hypothesis that difference in disease and healthy cells maybe akin 
to the differences in healthy cells in normoxia and hypoxia as the number of identified 
metabolites do not coincide in the cases (except cysteine). Because such few dysregulated 
metabolites have been identified in disease it is more appropriate to test this hypothesis in 
the transcriptome for a more clear understanding as it is expected that changes occurring in 
the cells metabolome would also be observed at the transcript level.  
What can be concluded is that these data suggest that hypoxia possesses a role in DD 
investigations as a number of metabolites were significantly upregulated in disease upon 
perturbations which were identified previously as downregulated in disease. Two areas of 
metabolism were highlighted for systems biology and transcriptomics investigation; amino 
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acid (leucine cysteine) metabolism and carbohydrate metabolism. Fatty acid and metabolism 
of cofactors and vitamins should be investigated. These findings will be correlated with 
those in Chapter 5 as a better understanding of the mechanistic links between cellular 
metabolism and transcriptome profiles may ultimately lead to better treatments for DD and 
other disease.  
 
  
Chapter 5 
Dynamic changes in Dupuytren’s Disease 
and control transcriptome in hypoxia 
 
5.1 Introduction 
5.1.1 Exploring dynamical changes in DD and control transcriptome  
In Chapter 4 we investigate the dynamic changes occurring in DD phenotypes and healthy 
fascia in response to hypoxia. A number of key metabolites and pathways that may 
contribute to DD progression or have been invoked as a consequence of hypoxic stress are 
highlighted. Intermediates involved in amino acid and carbohydrate metabolism have shown 
significant differences from this analysis. In this Chapter we extend this approach to 
investigate this effect in their transcriptome. This study examines whether gene expression 
analysis of such cells could provide a more representative picture of the dynamics involved 
in DD. It is surmised these transcripts will produce a specific signature for DD 
complementing the metabolomics study and allow us to look for metabolic pathways and 
cell signaling pathways / targets in a controlled systematic manner. The emerging data will 
form the basis for selecting appropriate models for pathway studies.  
In this study, we test the experimental model of hypoxia induced in DD and healthy 
cells, the effect on its transcriptome profile and seek to understand factors that induce 
discriminating changes in both the metabolic and signaling pathways. The aim is to identify 
potential biomarkers of DD and characterise a possible altered biochemical profile of the DD 
cells compared to healthy fascia in patients with and to determine the metabolic impact of 
hypoxia in both. From results in Chapter 4, the nodule displays the maximum differential 
Chapter 5                           Dynamic changes in Dupuytren’s disease and control transcriptome in hypoxic stress 
143 
 
response (compared with cord and SON is a different cell type) compared with healthy 
fascia.  
In this study, we set out to (1) understand progression of disease compared to healthy 
(nodule vs. fascia) (2) profile DD nodules to investigate the effect of 1% oxygen tension on 
these samples (1% vs. 21%), and 3) investigate the perturbation effect on healthy fascia cells 
to examine whether healthy cells in hypoxia mimic disease state scenario. The study 
employed Affymetrix Human Genome U133 Plus 2.0 GeneChip oligonucleotide arrays [58] 
to determine transcript profiles of fibroblasts cultured in normoxic and hypoxic conditions.  
The study revealed a small number of DE transcripts that were common in N21 vs. 
F21 and F1 vs. F21 analysis. These transcripts were involved in the following pathways: - 
MAPK signaling pathway, ECM-receptor interaction, p53 signals pathway, tyrosine 
metabolism, nicotinate and nicotinamide metabolism, phenylalanine metabolism and vitamin 
B6 metabolism. 
Landmark genes previously identified to be associated with DD were also confirmed 
and key collagens, collagenases, metalloproteinases, and inhibitors, cell adhesion molecules 
and integrins were identified. Genes involved in focal adhesion, regulation of actin 
cytoskeleton, ECM-receptor interaction, vascular smooth muscle contraction pathways, 
cysteine and methionine metabolism were markedly dysregulated. From the perturbation 
effect in N1 vs. N21 fatty acid metabolism, toll-like receptor signaling pathway, biosynthesis 
of unsaturated fatty acids, PPAR signaling pathway, citrate cycle (TCA cycle), glycine, 
serine and threonine metabolism pathways were enriched. These results suggested 
correlation with the molecules dysregulated in the metabolomes. In addition strengthened 
our hypothesis that DD is a disease of networks, where molecules are interconnected and a 
number of amino acid metabolism molecules are actively DE in DD nodules and this 
perturbation effect is observed at both the transcriptome and metabolome levels within a 
cell. These results indicate a number of important candidate genes associated with DD 
formation, which may provide clues for molecular mechanisms involved in DD 
pathogenesis. 
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5.2 Results  
5.2.1 Gene expression Analysis  
Affymetrix microarray technology was adopted to address whether the metabolites found to 
be significantly differentially expressed in Chapter 4 between F1 vs. F21, N21 vs. F21 and 
N1 vs. N21 correlate with differences at the mRNA level. A total of 12 samples were 
analysed using three analysis methods (n = 3 transverse palmar ligaments from DD cases 
acting as control, n = 3 transverse palmar fascia cultured in hypoxia, n = 3 DD nodule 
samples and n = 3 DD nodules cultured in hypoxia). The boxplots shown in Figure 34 
illustrate the distribution for expression values created by each of the normalisation methods 
RMA, GC-RMA, and multi-mgMOS. The PCA scores plot from the multi-mgMOS 
normalised and GC-RMA normalised expression set are given in Figures 35(a) and 35(b) 
respectively.  
It can be seen from Figure 35(a) PC1 appears to be separating the arrays by patient, 
whereas PC2 appears to be separating the arrays by oxygen tension. The grouping of N1 & 
N21 clusters and F1 & F21 clusters is much tighter in pumaPCA using multi-mgMOS 
normalised data. Figure 35(b) using GC-RMA normalised data and standard PCA also 
shows a similar trend across PC1 where separation is observed with respect to patients and 
PC2 separates for disease or healthy cells. This is not the case with patient 60 because PC2 
separates the samples based on oxygen tension not disease. But separation can still be 
observed between disease and healthy samples (in all conditions) in patient 60. One reason 
the difference observed here between pumaPCA and standard PCA is because expression 
levels have been normalised using GC-RMA in Figure 3b; the quantile normalisation used in 
GC-RMA removes such differences. On the whole, both methods show similar observations 
– patients separated along PC1 and oxygen tension (1 always higher than 21 for the same 
patient/cell type) along PC2. Samples of same type from each patient are clustered but there 
is no strong systematic trend for the disease vs. healthy samples that can be seen in PC2.  
HCA using Euclidean distance (average linking) matrix was applied to GC-RMA 
normalised data following a Two-way ANOVA, cut off value p ≤ 0.05 and fold change > 2 
resulting in 461 significant genes. Genes were clustered by applying two-way clustering 
where on one axis (horizontal) array samples (F21 (control), F1, N21 and N1) and on the 
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other axis (vertical) are the genes. The heat map and clustering algorithms identified subsets 
of genes that were co-expressed similarly. An expanded region (cluster of genes) resulting 
from agglomerative HCA of all samples is shown in Figure 36. Presence of large contiguous 
patches of colour represent groups of genes that share similar expression patterns over 
multiple conditions. Branch lengths represent the degree of similarity between the genes. 
Co-regulated and functionally related genes were statistically grouped into clusters. Larger 
groups of clustered genes were examined where we observed a strong tendency for these 
genes to share common roles in cellular processes. Genes illustrated in Cluster A consist of 
co-expressed genes which appear to separate disease from fascia irrespective of oxygen 
concentration. Cluster B groups co-expressed genes impacted by oxygen tension.   
In order to identify genes unique to each of these conditions differential gene 
expression was analysed for F1 vs. F21, N21 vs. F21 and N1 vs. N21 for each of the three 
patients using 1) Limma that produced p-values and q-values (adjusted p values), and log10 
fold change in genes (up, down, or unchanged) between the conditions and these probesets 
were compared with 2) Puma that generated the probability of PPLR statistical scores for 
each probe set by two-way comparisons between pairs of these sample groups. PPLR values 
range from 0 to 1, with values closest to 0 representing the most significantly down-
regulated probe sets and values closest to 1, representing the most significantly up-regulated 
probe sets. Values of 0.5 represent no significant change.  
Probe sets ≥ 1.5 threshold value and with a PPLR value > 0.9 (significantly up-
regulated) and < 0.1 in at least one of the comparisons were compared for their presence 
across the statistically and biologically significant transcript lists retrieved from these 
individual analyses   (i.e., transcripts over- and under expressed in gene lists generated from 
pairwise analyses of F1 vs. F21 compared with those in N21 vs. F21. The same was done for 
other N1 vs. N21 gene lists. Statistical false-positives in this data have been minimized by 
using a high cut-off PPLR value for puma methods (0.9 and 0.1) and a FDR (Benjamini and 
Hochberg) for Limma p-values to locate more disease specific and hypoxia-responsive 
genes. A correction method for PPLR values does not exist at present and filtering in this 
way was deemed appropriate.  
Venn diagrams were generated to illustrate the distribution of the probe set for the 
Limma probe sets with FDR applied. Over representation analysis of probes falling in top 
1000 PPLRs values and weakest 1000 PPLR values was followed by ontological mapping to 
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investigate significant overrepresentations and associations between genes belonging to 
specific patterns and Gene Ontology categories. The same gene lists were also used for 
KEGG pathway analysis (refer to Tables 31-33 in Appendix D). To test whether the genes 
could be mapped onto the pathways detected by metabolomics and also show changes at 
mRNA level by any chance, a  less stringent selection criteria was applied by including 
PPLR values >0.8 and <0.2 counting for the genes showing 1.5-fold or more changes in two 
out of three independent experiments e.g. patient to patient comparison. Table 8-9 show 
significant DE genes identified from each of the pairwise analyses that were common across 
three patients from F1 vs. F21 analysis and N21 vs. F21 analysis. Figure 42 show GO 
analysis from top over expressed genes in N21 vs. F21. Table 10-12 show the top scoring 
pathways from the overlapping (common) DE genes identified from pairwise analyses in 
clusters from heatmaps (Figure 43-44, 48). Tables 13 and 14 show a section of DE from N1 
vs. N21 analysis. 
 
44Fascia 1% 
44Fascia 21% 
44Nodule 1%
44Nodule 21%
60Fascia 1% 
60Fascia 21% 
60Nodule 1%
60Nodule 21%
61Fascia 1% 
61Fascia 21% 
61Nodule 1%
61Nodule 21%
 
Figure 34 Boxplots to show distributions of expression values created by each of the summarisation methods. 
Data set processed by RMA, GCRMA and multi-mgMOS (global median scaling) respectively. 
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Figure 35 First two components after applying a) pumapca and b) prcomp to the 12 samples. 
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Figure 36 A section from the hierarchical clustered display of data from 
12 samples (average) F21, F1, N21 & N1 normalised using GC-RMA, 
followed by Two-way ANOVA. Genes were clustered by applying 2-
way clustering where on x-axis are the array samples and on the y-axis 
are the genes. Genes that are upregulated appear in red; those that are 
downregulated appear in green; black indicates approximately the same 
gene expression as the mean for that gene across all samples. Genes in 
cluster A consist of co-expressed genes which appear to separate disease 
from fascia. Cluster B groups co-expressed genes impacted by oxygen 
tension. 
 
 
A
B
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Probe sets with a probability of positive log-ratio (PPLR) value greater than 0.9 
(significantly up-regulated) in at least one of the comparisons generated a list of 669 probe 
sets. 47 probe sets are uniquely up-regulated when comparing the gene expression profile of 
F1 vs. F21 and N21 vs. F21. When comparing N21 vs. F21, 130 probe sets are uniquely 
upregulated, interestingly however, 4 probe sets are upregulated in all comparisons. The 
number of probe sets associated with a significantly down-regulated PPLR value (0.1) for 
N1 vs.N21was higher than the number for up-regulated probe sets. 256 probe sets alone were 
unique and significantly down regulated in N1 vs.N21 (Figure 37).  
B. PPLR ≤ 0.1A. PPLR ≥ 0.9
 
Figure 37 Distribution of probe sets with a PPLR value greater than 0.9 (A), PPLR less than 0.1 (B) in any one 
of the three comparisons (F1 vs. F21, N21 vs. F21 or N1 vs. N21 are shown in Venn diagrams. 
 
 
Combining probe sets that were either significantly upregulated (0.9) or significantly down-
regulated (0.1) in at least one of the comparisons (F1 vs. F21, N21 vs. F21 and N1 vs. N21) 
generated a list of 669 probe sets (Figure 38(a)). 141 of these probe sets were unique to F1 
vs. F21, 119 of these were unique to N21 vs. F21 and 113 unique to N1 vs. N21. A total of 
54 genes were significantly up-regulated or down-regulated and overlapping in F1 vs. F21 
and N21 vs. F21, 166 overlapped in F1 vs. F21 and N1 vs. N21). 34 genes were common in 
all three comparisons (F1 vs. F21, N21 vs. F21 and N1 vs. N21). By contrast GC-RMA 
normalisation followed by Limma models revealed only 30 probe sets unique to N21 vs. F21 
of which none overlapped with F1 vs. F21 combination, and relatively lower number of 
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probesets unique to F1 vs. F21 (30 probe sets), and unique to N1 vs. N21(31) can be seen in 
Figure 38(b). The 669 probe sets with a PPLR value greater than 0.9 or less than 0.1 in at 
least one of the comparisons (F1 vs. F21, N21 vs. F21 and N1 vs. N21) underwent clustering 
analysis. A number of distinct clusters were generated and probe sets from each cluster were 
subjected to expression analysis systematic explorer (EASE) online tool and DAVID [63]. 
For each cluster, overrepresented GO groups were identified. For each individually patient, 
significant DE was examined and Figure 39 shows the extent of patient variability. Patient 
61 demonstrated the maximum number of DE genes for N21 vs. F21 analysis and N1 vs. 
N21 (514 and 752 respectively). 
 
 
b) GC-RMA + Limma, p=<0.05, FC >1.5a) Multi-mgMOS + Puma, PPLR> 0.9 and <0.1
 
Figure 38 Analysis of microarray data of DD samples using a) mmgMOS and IPPLR for differential 
expression PPLR values were calculated for fascia in normal and hypoxia (F1 vs. F21), nodules in normal and 
hypoxia (N1 vs. N21) and nodules compared to healthy fascia (N21 vs. F21). Distribution of probe sets with a 
PPLR value greater than 0.9 and less than 0.1 in any one of the three comparisons (F1 vs. F21, N21 vs. F21 and 
N1 vs. N21) are shown in Venn diagram b) GC-RMA and Limma to identify differential expression, probe sets 
where p-value ≤ 0.05 and fold change > 1.5 are shown Venn diagram. 
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Patient 44,4 Patient 60,7
Patient 61,8  
Figure 39 Venn diagrams to show filtered probelists following PPLR thresholds applied to data sets from individual 
patients to determine extent of patient variability. Patient 44 (4 from metabolomics study), patient 60 (7 from 
metabolomics study) and patient 61(8 from metabolomics study). PPLR values were calculated for Fascia in normal 
and hypoxia (F1 vs. F21), nodules in normal and hypoxia (N1 vs. N21) and nodules compared to healthy fascia 
(N21 vs. F21). Distribution of probe sets with a PPLR value greater than 0.9 and less than 0.1 in any one of the three 
comparisons (F1 vs. F21, N21 vs. F21 and N1 vs. N21) are shown. 
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5.2.2 Effect of O2 tension in intracellular transcriptomes of healthy cells 
The Venn diagrams from puma analyses in Figure 39 show the number of transcripts that 
were significantly differentially expressed. In hypoxic conditions F1 cells show upregulation 
in a number of intermediates involved in glycolysis and carbohydrate metabolism. Some 
hypothetical proteins are present. This was observed using both methods (puma + limma). 
Figure 40 demonstrates the individual filtered probelists from each patient which allows 
determination of the variability between patients upon hypoxia. Patient 60 consists of 136 
uniquely significant DE genes in F1 vs. F21, while patient 44 demonstrates the smallest 
change with 62 differentially expressed genes. The 25 gene names relevant to the 36 probe 
IDs common across patients are given in Table 8. 
A number of transcripts are consistent across all patients; some showing 
greater/lower PPLR values, however the trends observed are mostly similar across the three 
patients with varying levels of significant expression. In patients 61, 70 probe sets from N1 
vs. N21 list are overlapping with many of the differentially expressed transcripts in F1 are 
also observed in the N1. While no transcripts were identified common from Limma analysis 
in this list for N21 vs. F21.     
 
Effect of Hypoxia in healthy cells across patients F1 vs. F21 
 
Figure 40 Venn diagram showing comparison across patient samples where healthy fascia was compared to 
perturbed fascia. 
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Table 8 The 25 genes (36 probes) significant common in all 3 samples where healthy fascia was induced with 
hypoxic environment. 
Affymetrix Probe ID Gene Name
202464_s_at 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3
204347_at adenylate kinase 3-like 2; adenylate kinase 3-like 1
207692_s_at aggrecan
227337_at ankyrin repeat domain 37
201623_s_at aspartyl-tRNA synthetase
201848_s_at BCL2/adenovirus E1B 19kDa interacting protein 3
222646_s_at ERO1-like (S. cerevisiae)
217967_s_at family with sequence similarity 129, member A
217871_s_at hypothetical protein LOC284889
201650_at junction plakoglobin
212689_s_at lysine (K)-specific demethylase 3A
200738_s_at phosphoglycerate kinase 1
202619_s_at procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2
207543_s_at prolyl 4-hydroxylase, alpha polypeptide I
1554997_a_at prostaglandin-endoperoxide synthase 2
226452_at pyruvate dehydrogenase kinase, isozyme 1
226682_at RAR-related orphan receptor A
219888_at sperm associated antigen 4
212353_at sulfatase 1
202796_at synaptopodin
228483_s_at TAF9B RNA polymerase II, TATA box binding protein (TBP)-associated factor, 31kDa
201010_s_at thioredoxin interacting protein
200822_x_at TPI1 pseudogene; triosephosphate isomerase 1
219410_at transmembrane protein 45A
218149_s_at zinc finger protein 395  
 
 
 
 
 
 
Chapter 5                           Dynamic changes in Dupuytren’s disease and control transcriptome in hypoxic stress 
154 
 
 
5.2.3 Disease vs. healthy fascia 
GO biological process and molecular function overrepresentations are illustrated in Figure 
42. The genes enriched in biological processes range from cellular processes involving 
biological regulation. More than half of 1000 gene lists are involved in binding or protein 
binding. Other molecular functions involve catalytic activity and regulator activities. 
From PPLR analyses, 119 transcripts were significantly differentially expressed 
unique to N21 vs. F21 analysis combining data from all patients. The GO 
overrepresentations from these gene lists show upregulation in a number of intermediates 
involved in oxidative phosphorylation, ribosomal subunits, albeit direct glycolysis and 
carbohydrate metabolism intermediates are not clear from this list. A large number of 
downregulated genes have been enriched in pathways associated in Focal cell adhesion 
pathway, ECM-receptor (Figure 46) and TGF beta pathway. A small number was also linked 
with pentose phosphate metabolism. The PPLR method generated a greater number of 
significantly expressed gene lists.  
The PPLR values compare N21 from F21 samples in individual patients which allow 
determination of variability between patients. 36 probe sets are consistent across all patients. 
The gene names associated with the 36 Probe IDs common across the three patients are 
shown in the Venn diagram (Figure 41) and the 25 corresponding genes are listed in Table 9. 
The trends observed are mostly similar across the three patients with varying level of 
significant expression. Many of the differentially expressed transcripts in N21 vs. F21 are 
also observed in N1 vs. N21 but these show an opposite 
effect (i.e. downregulation upon perturbation).  
Figure 41 Venn diagram showing 
comparison across patient samples where 
DD nodule was compared to healthy 
fascia. 
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Table 9 The 25 genes (36 probes from Venn diagram) significant common in all 3 samples where DD nodule 
was compare with fascia.  
 
Affymetrix Probe ID Gene Name
209555_s_at CD36 molecule (thrombospondin receptor)
225496_s_at synaptotagmin-like 2
219148_at PDZ binding kinase
1568618_a_at UDP-N-acetyl-alpha-D-galactosamine
209396_s_at chitinase 3-like 1 (cartilage glycoprotein-39)
203764_at discs, large (Drosophila) homolog-associated protein 5
219685_at transmembrane protein 35
209047_at aquaporin 1 (Colton blood group)
201843_s_at EGF-containing fibulin-like extracellular matrix protein 1
201291_s_at topoisomerase (DNA) II alpha 170kDa
228407_at signal peptide, CUB domain, EGF-like 3
209806_at histone cluster 1, H2bk
211959_at insulin-like growth factor binding protein 5
224941_at PAPPA antisense RNA (non-protein coding)
222608_s_at anillin, actin binding protein
201539_s_at four and a half LIM domains 1
221593_s_at ribosomal protein L31 pseudogene 49
225647_s_at cathepsin C
205923_at reelin
227345_at tumor necrosis factor receptor superfamily, member 10d, decoy with truncated death domain
209120_at nuclear receptor subfamily 2, group F, member 2
202503_s_at KIAA0101
208792_s_at clusterin
229400_at homeobox D10
218009_s_at protein regulator of cytokinesis 1  
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Figure 42 Pie charts showing gene ontology overrepresentations from 1000 up and 1000 downregulated genes 
illustrated as a percentage of the 2000 probesets involved in nodules 21 % compared with fascia 21%. 
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Figure 43 Probelist (119) unique to N21 vs. F21 where PPLR values ≥0.9 and ≤0.1 
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Table 10 KEGG pathways retrieved from 119 probe lists unique to N21 vs. F21. 
KEGG Pathway Gene Name
Cell adhesion molecule 1
Integrin, alpha 8
Neuroligin 4, X-linked
CD44 molecule
Collagen, type V, alpha 3
Integrin, alpha 8
Mitogen-activated protein kinase 13
Rho GDP dissociation inhibitor (GDI) beta
Aldehyde oxidase 1
Nicotinamide nucleotide adenylyltransferase 2
CD44 molecule 
Mitogen-activated protein kinase 13
Bladder cancer Death-associated protein kinase 1
Cysteine and methionine metabolism Methionine adenosyltransferase II, alpha
Ether lipid metabolism Lysophosphatidylcholine acyltransferase 2
Glycosphingolipid biosynthesis - ganglio series ST3 beta-galactoside alpha-2,3-sialyltransferase 5
Selenoamino acid metabolism Methionine adenosyltransferase II, alpha
Tryptophan metabolism Aldehyde oxidase 1
Tyrosine metabolism Aldehyde oxidase 1
Valine, leucine and isoleucine degradation Aldehyde oxidase 1
Vitamin B6 metabolism Aldehyde oxidase 1
Cell adhesion molecules (CAMs)
ECM-receptor interaction
Neurotrophin signaling pathway
Nicotinate and nicotinamide metabolism
Shigellosis
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Figure 44 Heatmap displaying expression ratios from 88 probelist overlapping from the pairwise analysis on 
N21 vs. F1 and F1 vs. F21. Few F1 and N21 genes are correlated.  
Chapter 5                           Dynamic changes in Dupuytren’s disease and control transcriptome in hypoxic stress 
160 
 
F1 F21 N21
 
Figure 45 Heatmap displaying expression ratios from the most significant transcripts overlapping from the 
pairwise analyses in N21 vs. F1 and F1 vs. F21. Red = upregulated and green = downregulated.  
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Table 11 KEGG pathways retrieved from 88 overlapping probe lists common to N21 vs. F21 and F1 vs. F21. 
KEGG Pathway Gene Name
Activating transcription factor 4 
Dual specificity phosphatase 1
Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 4
Platelet-derived growth factor receptor, alpha polypeptide
Activating transcription factor 4 
Cyclin-dependent kinase 2
Platelet-derived growth factor receptor, alpha polypeptide
CD44 molecule (Indian blood group)
Integrin, beta 8
Integrin, beta 8
Protein kinase, AMP-activated, alpha 2 catalytic subunit
Cyclin G2
Cyclin-dependent kinase 2
Aldehyde oxidase 1
Macrophage migration inhibitory factor (glycosylation-inhibiting factor)
Folate biosynthesis Gamma-glutamyl hydrolase 
Nicotinate and nicotinamide metabolism Aldehyde oxidase 1
Phenylalanine metabolism Macrophage migration inhibitory factor (glycosylation-inhibiting factor)
Primary bile acid biosynthesis Cholesterol 25-hydroxylase
Regulation of autophagy Protein kinase, AMP-activated, alpha 2 catalytic subunit
Vitamin B6 metabolism Aldehyde oxidase 1
MAPK signaling pathway
Prostate cancer
ECM-receptor interaction
Hypertrophic cardiomyopathy (HCM)
p53 signaling pathway
Tyrosine metabolism
 
 
 
Table 12 KEGG pathways retrieved from 113 problelists unique to N1 vs. N21. 
KEGG Pathway Gene Name
Lysosome Adaptor-related protein complex 1, sigma 2 subunit
Arylsulfatase G
Cathepsin K
Tripeptidyl peptidase I
Toll-like receptor signaling pathway Cathepsin K
Mitogen-activated protein kinase kinase 2
Toll-like receptor 1
Biosynthesis of unsaturated fatty acids Fatty acid desaturase 1
Stearoyl-CoA desaturase (delta-9-desaturase)
Fatty acid metabolism Acyl-CoA synthetase long-chain family member 3
Dodecenoyl-Coenzyme A delta isomerase 
Peroxisome Acyl-CoA synthetase long-chain family member 3
Isocitrate dehydrogenase 1 (NADP+), soluble
PPAR signaling pathway Acyl-CoA synthetase long-chain family member 3
Stearoyl-CoA desaturase (delta-9-desaturase)
Terpenoid backbone biosynthesis Farnesyl diphosphate synthase 
Isopentenyl-diphosphate delta isomerase 1
Citrate cycle (TCA cycle) Isocitrate dehydrogenase 1 (NADP+), soluble
Glycine, serine and threonine metabolism Serine racemase
Porphyrin and chlorophyll metabolism Biliverdin reductase A
RNA polymerase Polymerase (RNA) III (DNA directed) polypeptide B
Thyroid cancer Mitogen-activated protein kinase kinase 2  
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Figure 46 ECM-receptor interaction diagram schema obtained from KEGG database. These genes are 
significantly differentially expressed in N21 vs.F21. 
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5.2.4 Disease in hypoxic stress 
From PPLR analyses, 113 transcripts were significantly differentially expressed unique to 
N1 vs. N21 analysis combining data from all patients. The GO overrepresentations from 
these genelists show downregulation in a number of intermediates involved in oxidative 
phosphorylation, ribosomal subunits, glycolysis, citric acid cycle, carbohydrate metabolism 
and fatty acid metabolism intermediates. A large number of upregulated genes have been 
enriched in pathways associated in Focal cell adhesion pathway, ECM-receptor and TGF 
beta pathway. A small number was also linked with pentose phosphate metabolism. The 
PPLR method generated a greater number of significantly expressed gene lists. Table 13 and 
14 show a section of the clusters where inducing hypoxia in nodules has up regulating effect, 
particularly in patient 61 and down regulating effect from the three patients combined.  The 
Venn diagram in Figure 47 shows a comparison across patient where perturbed nodule was 
compared to unperturbed nodule (N1 vs. N21). Patient 61‟s nodules demonstrated the 
maximum number of DE genes. 
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Figure 48 Heatmap displaying 113 DE genes unique to N1 vs. N21. 
 
Figure 47 Venn diagram showing comparison across 
patient samples where perturbed nodules N1 was 
compared to unperturbed disease nodules N21. 
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Table 13 A cluster from the most significantly upregulated genes in nodules in 1% in descending order for 
patient 61. The PPLR values for each pairwise analysis and each patient is given. Coloured PPLRs values were 
filtered through applied thresholds >0.9 and <0.1 and cut off at 1.5 threshold calculated by variance /mean of 
standard error. Upregulated genes in nodule in 21% were downregulated upon hypoxic induction. Blue PPLR 
value = F1 vs.F21, red PPLR value = N21 vs.F21 and orange PPLR value = N1 vs. N21. 
Gene Title
44 60 61 44 60 61 44 60 61
0.718574 0.887815 0.637286 0.00822 0.9871 2.256E-07 0.709087 0.645745 1 anillin, actin binding protein
0.969455 0.99376 0.892637 0.99301 0.854193 0.0057309 0.321391 0.00579 1 cartilage oligomeric matrix protein
0.968656 0.99793 0.98547 0.06015 0.99202 0.54178045 0.99317 0.99851 0.99999 keratin 19
0.702811 0.538372 0.847788 0.827663 0.781848 0.0301109 0.504834 0.894362 0.99999 keratin associated protein 1-5
0.716923 0.861019 0.579127 0.114924 0.99327 2.589E-05 0.486039 0.603754 0.99997 ribonucleotide reductase M2
0.988427 0.99531 0.955704 0.476238 0.694773 0.17141395 0.97107 0.97624 0.99996 phosphoglycerate kinase 1
0.933711 0.97894 0.795848 0.544678 0.94342 0.0976347 0.804438 0.819971 0.99995 enolase 1, (alpha)
0.483066 0.97582 0.202194 0.829364 0.892457 0.21871269 0.544958 0.602791 0.99995 microtubule-associated protein 7
0.766935 0.98115 0.243967 0.600533 0.89107 0.19367931 0.790868 0.251839 0.99984 tenascin C
0.841894 0.99288 0.765051 0.875038 0.740007 0.0083822 0.762495 0.704613 0.99971 ADAM metallopeptidase with thrombospondin type 1 motif, 1
0.740832 0.93558 0.370647 0.03545 0.96865 0.0007852 0.586164 0.537268 0.99966 topoisomerase (DNA) II alpha 170kDa
0.735155 0.889697 0.447871 0.06701 0.97229 0.0014163 0.514132 0.528171 0.9993 protein regulator of cytokinesis 1
0.920004 0.86878 0.963535 0.826189 0.0153 0.22709253 0.854154 0.98938 0.99885 Hyaluronan synthase 2
0.961601 0.892888 0.221875 0.874232 0.22141 0.0037772 0.492348 0.55322 0.99875 TIMP metallopeptidase inhibitor 3
0.9797 0.98946 0.727395 0.676385 0.813496 0.12474992 0.85177 0.840167 0.99863 glucose-6-phosphate isomerase
0.998009 1 0.99986 0.89911 0.98869 0.67676494 0.96854 0.99255 0.99843 procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2
0.649619 0.582144 0.425659 0.06597 0.464525 0.54276319 0.799399 0.796252 0.99838 lymphocyte antigen 6 complex, locus K
0.634552 0.562206 0.815759 0.02089 0.95202 0.0001784 0.473758 0.588634 0.998 PDZ binding kinase
0.953371 0.99866 0.668381 0.97358 0.857032 0.0585368 0.514532 0.65614 0.99777 collagen, type V, alpha 1
0.93749 0.97806 0.235076 0.206388 0.93781 0.0471915 0.294236 0.456295 0.99698 follistatin
0.687632 0.894347 0.039551 0.828983 0.747221 0.0750765 0.435088 0.587703 0.9966 protein disulfide isomerase family A, member 6
0.734488 0.99987 0.084193 0.96719 0.99904 0.20530817 0.336546 0.117982 0.99644 collagen, type XII, alpha 1
0.873885 0.838389 0.127601 0.011 0.99767 0.0051529 0.866715 0.521115 0.99615 four and a half LIM domains 1
0.742307 0.97551 0.796964 0.861947 0.770534 0.18283947 0.522767 0.706115 0.99592 lysyl oxidase-like 2
0.71332 0.96421 0.90394 0.475086 0.87881 0.091007 0.676519 0.708455 0.99568 cysteine-rich, angiogenic inducer, 61
0.753956 0.93508 0.069555 0.595971 0.871871 0.17986166 0.50156 0.462219 0.99563 prolyl 4-hydroxylase, beta polypeptide
0.810472 0.96983 0.913577 0.572733 0.90831 0.11940655 0.636146 0.709332 0.99546 cysteine-rich, angiogenic inducer, 61
0.736274 0.97777 0.428559 0.9254 0.629151 0.0039913 0.487503 0.508989 0.9954 lysyl oxidase
0.996448 0.99519 0.995476 0.398058 0.489721 0.39197187 0.99765 0.99508 0.99515 pyruvate dehydrogenase kinase, isozyme 1
0.986508 0.94687 0.043057 0.99959 0.887674 0.0134854 0.809172 0.04709 0.99426 aggrecan
0.892211 0.91928 0.886742 0.511751 0.675846 0.26925903 0.808951 0.755733 0.99399 phosphofructokinase, platelet
0.983147 0.97257 0.974628 0.627699 0.67941 0.46854296 0.9077 0.96069 0.9927 triosephosphate isomerase 1
0.835124 0.96378 0.147373 0.700977 0.833064 0.16435574 0.579176 0.478601 0.9927 prolyl 4-hydroxylase, beta polypeptide
0.713036 0.479589 0.859703 0.133181 0.776016 0.0269158 0.485595 0.79558 0.9925 pituitary tumor-transforming 1
0.999576 0.99456 0.997872 0.97057 0.150293 0.10488757 0.93717 0.99418 0.99248 adenylate kinase 3-like 1
0.597714 0.836998 0.516529 0.54815 0.90954 0.0972981 0.289431 0.321367 0.99243 solute carrier family 7 
0.999333 0.99709 0.999809 0.419378 0.662824 0.7528722 0.99841 0.99941 0.9924 BCL2/adenovirus E1B 19kDa interacting protein 3
Fas 1- Fas 21 Nod 21 - Fas 21 Nod 1 - Nod 21
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Table 14 A cluster from the most significantly upregulated genes in nodules in 1% in descending order for 
patient 61. The PPLR values for each pairwise analysis and each patient is given. Coloured PPLRs values were 
filtered through applied thresholds >0.9 and <0.1 and cut off at 1.5 threshold calculated by variance /mean of 
standard error. Upregulated genes in nodule in 21% were downregulated upon hypoxic induction. Blue PPLR 
value for F1 vs. F21, red PPLR value for N21 vs.F21 and orange PPLR value N1 vs. N21. A cluster of 
differentially expressed genes. Blue PPLR value = F1 vs. F21, red PPLR value = N21 vs. F21 and orange PPLR 
value = N1 vs.N21. 
 
F1 v F21 N21 v F21 N1 v N21 Gene Title
0.214384 0.99999 8.1E-06 stonin 2
2.01E-05 0.99999 1.3E-11 chitinase 3-like 2
0.551767 0.99998 1.9E-07 lysophospholipase-like 1
0.500286 0.99997 0.115965 WNT1 inducible signaling pathway protein 2
0.948089 0.999948 6.7E-05 ribonuclease P RNA component H1
0.911325 0.99992 0.00015 ribosomal protein L31
0.924233 0.99983 2.7E-06 cytochrome c oxidase subunit VIIc
0.742703 0.99982 0.00108 cytochrome P450, family 24, subfamily A, polypeptide 1
0.017217 0.99981 0.00088 tumor necrosis factor, alpha-induced protein 6
0.086406 0.9998 0.01343 GTP binding protein overexpressed in skeletal muscle
0.587924 0.99969 7.3E-07 lymphocyte antigen 96
0.907669 0.99956 0.01174 microRNA 21
0.868802 0.99954 5E-05 prefoldin subunit 4
0.763007 0.99947 0.468237 runt-related transcription factor 2
0.585672 0.99947 0.00593 cystatin A (stefin A)
0.685392 0.99933 0.160908 neuritin 1
0.027009 0.99916 1E-06 interleukin 1 receptor, type II
0.643232 0.99913 0.00286 cartilage intermediate layer protein
0.411317 0.99892 0.00016 ATP-binding cassette, sub-family B (MDR/TAP), member 5
0.811695 0.99876 7.6E-05 hypothetical LOC388789
0.311654 0.9986 0.00315 basic helix-loop-helix family, member e22
0.619723 0.9985 0.401579 glucosaminyl (N-acetyl) transferase 1, core 2
0.527067 0.99842 0.0001 hypothetical protein MGC5566
0.093916 0.99834 0.07707 dipeptidyl-peptidase 4
0.724518 0.99813 0.00022 TatD DNase domain containing 1
0.462208 0.99802 0.0014 glycoprotein, alpha-galactosyltransferase 1 pseudogene
0.645576 0.99796 0.00041 alkB, alkylation repair homolog 7 (E. coli)
0.727138 0.99794 2.4E-05 growth arrest-specific 5 (non-protein coding)
0.626711 0.99752 0.00605 parathyroid hormone-like hormone
0.467238 0.99602 0.00671 chitinase 3-like 1 (cartilage glycoprotein-39)
0.965408 0.99589 0.00098 integrin beta 3 binding protein (beta3-endonexin)
0.013607 0.99563 4E-05 plexin domain containing 1
0.777867 0.99493 0.00041 methylmalonyl CoA epimerase
0.736525 0.99491 0.00175 synaptonemal complex central element protein 1-like
0.902797 0.99437 0.00055 LSM domain containing 1
0.847522 0.99423 0.01113 ribosomal L24 domain containing 1
0.000479 0.99413 0.101812 clusterin  
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5.3 Discussion 
5.3.1 Principal Findings 
Transcriptome profiling has enabled the investigation of the expression levels of thousands 
of genes associated with DD formation simultaneously. A quantitative comparison was made 
between 1) mRNA expression levels in normal oxygenated and hypoxic transverse palmar 
fascia in search for novel hypoxia-induced genes to investigate whether this change was 
mimicked in disease state scenario. 2) The transcriptional response to hypoxia was also 
investigated in nodules from the same patients. 3) mRNA expression levels in normal 
oxygenated disease with healthy fascia. The study and funds permitted for 12 Affymetrix 
microarrays, 4 samples cultured at two oxygen levels from 3 patients.  
Landmark genes identified in previous studies [9, 19, 155] to be involved in DD were 
also validated in this study. In addition, this study has made possible identification of genes 
not only displaying unique characteristics of disease cells compared with normal palmar 
fascia but also transcriptionally hypoxia-activated genes in both healthy and disease cells. 
Several common effects of hypoxia were seen in the DD nodules and fascia, such as an 
increase in glycolytic metabolism; however, the response to hypoxia varies greatly between 
the individual patients. We discuss these key findings below.  
A meta-analysis of top1000 genes with PPLR values > 0.8 and lowest 1000 genes 
with PPLR value < 0.2 for each pair in a given analysis were entered into KEGG pathway 
database to identify molecular pathways (metabolic and signaling) that were statistically 
significantly enriched (from uploaded gene lists). Significantly up regulated gene lists 
produced enrichment in 20 molecular pathways enriched for F1 vs. F21. Significantly down 
regulated gene lists produced enrichment in 33 molecular pathways enriched for F1 vs. F21 
(Appendix; Table J). Gene enrichment analysis was then performed using top 1000 and 
bottom 1000 genes significantly dysregulated in gene lists from pairwise comparison of N21 
vs. F21 and then repeated with gene lists for the combination pair N1 vs. N21. An attempt to 
connect the common pathways into a hypothetical common molecular network for each 
combination/pair and compare with pathways identified in Chapter 4 from metabolomics 
data is given Chapter 6 currently in progress.  
Differential alterations in gene expression in N21 (compared with F21) were 
observed in pathways associated with focal cell adhesion, apoptosis, and inflammation. 
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Among the dysregulated transcripts, marked enrichment was observed in those directly 
involved in developmental processes including cell growth, proliferation, differentiation, 
regulation of cell death, biological cell adhesion, localisation, extracellular matrix-receptor 
interaction, and cell communication. Neuritin and Amphiphysin were upregulated in N21. 
Neuritin is a growth-promoting protein and may be involved in tumorigenesis [156]. Cell 
adhesion molecules were up regulated in N21. Major down regulated groups of genes were 
involved in focal cell adhesion pathway.  Focal adhesions connect the ECM to actin 
filaments of the cell. This cell-to-ECM adhesion is regulated by specific cell surface cellular 
adhesion molecules (CAM) known as integrins. Integrins are cell surface proteins that bind 
cells to ECM structures, such as fibronectin and laminin, and also to integrin proteins on the 
surface of other cells [157]. Fibronectins bind to ECM macromolecules and facilitate their 
binding to transmembrane integrins. The attachment of fibronectin to the extracellular 
domain initiates intracellular signaling pathways as well as association with the cellular 
cytoskeleton via a set of adaptor molecules such as actin [157]. CD36 was significantly 
down regulated in N21. Collagen, type VI, alpha 6, was found upregulated in N21, but 
downregulated in N1. No change was observed in F1. Vascular cell adhesion molecule 1, 
collagen, type XII, alpha 1 and collagen, type XIV, alpha 1 were upregulated in disease but 
downregulated upon perturbation in N1.  
 However, from Table 11 and Figure 44(a) and 44(b), it can be observed that 
relatively few transcripts identified as significantly dysregulated in F1 vs. F21 analysis were 
present in N21 vs. F21 analysis. From these analyses it is tempting to falsify the first 
hypothesis that difference in disease and healthy cells maybe akin to the differences in 
healthy cells in normoxia and hypoxia as only a very small number of significant DE 
transcripts coincide in F1 and N21 candidate lists. In Chapter 6 these significant candidates 
(i.e. metabolites and transcripts) from Chapter 4 and 5 are integrated to visualize 
relationships using network analysis (e.g. candidate metabolites and transcripts in F1 vs.F21 
using IPA and these networks are mapped on the networks from significant molecules in 
N21 vs. F21 analysis.  
These results imply that DD is associated with a stimulation of collagen gene 
expression at the transcriptional and translational levels together with an increase in the rate 
of collagenolytic activity in up regulated inhibitors such as ADAM metallopeptidase 
domains (ADAM12 and ADAM19). A disintegrin-like and metalloproteinase with 
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thrombospondin type 1 motif, 2 (ADAMTS2) and TIMP were notably differentially 
expressed in DD nodule tissues compared with external controls only.  
 
A list of few DE genes unique to disease 
CD44 molecule, encodes a cell-surface glycoprotein involved in cell-cell interactions, cell 
adhesion and migration. It is a receptor for hyaluronic acid (HA) and can also interact with 
other ligands, such as osteopontin, collagens, and matrix metalloproteinases (MMPs) [158]. 
This protein participates in a wide variety of cellular functions including lymphocyte 
activation, recirculation and homing, hematopoiesis, and tumour metastasis. Alternative 
splicing is the basis for the structural and functional diversity of this protein, and may be 
related to tumour metastasis. Collagen, type V, alpha 3, encodes an alpha chain for one of 
the low abundance fibrillar collagens. Fibrillar collagen molecules are trimers that can be 
composed of one or more types of alpha chains. Type V collagen is found in tissues 
containing type I collagen and appears to regulate the assembly of heterotypic fibers 
composed of both type I and type V collagen [159]. This gene product is closely related to 
type XI collagen and it is possible that the collagen chains of types V and XI constitute a 
single collagen type with tissue-specific chain combinations. Mutations in this gene are 
thought to be responsible for the symptoms of a subset of patients with Ehlers-Danlos 
syndrome type III [160]. 
Mitogen-activated protein kinase 13; encodes proteins which are members of the 
MAP kinase family. MAP kinases act as an integration point for multiple biochemical 
signals, and are involved in a wide variety of cellular processes such as proliferation, 
differentiation, transcription regulation and development [161]. This kinase is closely related 
to p38 MAP kinase, both of which can be activated by proinflammatory cytokines and 
cellular stress. MAP kinases 3, and 6 can phosphorylate and activate this kinase. 
Nicotinamide nucleotide adenylyltransferase 2; this gene product belongs to the 
nicotinamide mononucleotide adenylyltransferase (NMNAT) enzyme family, members of 
which catalyse an essential step in NAD (NADP) biosynthetic pathway. Ganglioside GM3 is 
known to participate in the induction of cell differentiation, modulation of cell proliferation, 
maintenance of fibroblast morphology, signal transduction, and integrin-mediated cell 
adhesion. Aldehyde oxidase produces hydrogen peroxide and, under certain conditions, can 
Chapter 5                           Dynamic changes in Dupuytren’s disease and control transcriptome in hypoxic stress 
170 
 
catalyze the formation of superoxide. Aldehyde oxidase is a candidate gene for amyotrophic 
lateral sclerosis. 
 
Some DE genes common to N21 and F1 albeit not always in the same direction. 
Activating transcription factor 4; The protein encoded by this gene belongs to a family of 
DNA-binding proteins that includes the AP-1 family of transcription factors, cAMP-
response element binding proteins (CREBs) and CREB-like proteins. These transcription 
factors share a leucine zipper region that is involved in protein-protein interactions, located 
C-terminal to a stretch of basic amino acids that functions as a DNA binding domain. Dual 
specificity phosphatase 1, The expression of DUSP1 gene is induced in human skin 
fibroblasts by oxidative/heat stress and growth factors. It specifies a protein with structural 
features similar to members of the non-receptor-type protein-tyrosine phosphatase family, 
and which has significant amino-acid sequence similarity to a Tyr/Ser-protein phosphatase. 
DUSP1 may play an important role in the human cellular response to environmental stress as 
well as in the negative regulation of cellular proliferation.  
Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 4; the product 
of this gene is a member of the nuclear factors of activated T cells DNA-binding 
transcription complex. The product of this gene plays a role in the inducible expression of 
cytokine genes in T cells, especially in the induction of the IL-2 and IL-4. Cyclin-dependent 
kinase 2; the protein encoded by this gene is a member of the Ser/Thr protein kinase family. 
It is a catalytic subunit of the cyclin-dependent protein kinase complex, whose activity is 
restricted to the G1-S phase, and essential for cell cycle G1/S phase transition. This protein 
associates with and regulated by the regulatory subunits of the complex including cyclin A 
or E, CDK inhibitor p21Cip1 (CDKN1A) and p27Kip1 (CDKN1B). Integrin, beta 8; in 
general, integrin complexes mediate cell-cell and cell-extracellular matrix interactions and 
this complex plays a role in human airway epithelial proliferation. Protein kinase, AMP-
activated, alpha 2 catalytic subunit; encodes a protein that is a catalytic subunit of the AMP-
activated protein kinase (AMPK). AMPK is an important energy-sensing enzyme that 
monitors cellular energy status. In response to cellular metabolic stresses, AMPK is 
activated, and thus phosphorylates and inactivates acetyl-CoA carboxylase (ACC) and beta-
hydroxy beta-methylglutaryl-CoA reductase (HMGCR), key enzymes involved in regulating 
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de novo biosynthesis of fatty acid and cholesterol. Cholesterol 25-hydroxylase; an intronless 
gene that is involved in cholesterol and lipid metabolism.  
 
Some DE genes unique to N1 list 
Arylsulfatase G; Sulfatases, such as ARSG, hydrolyze sulfate esters from sulfated steroids, 
carbohydrates, proteoglycans, and glycolipids. They are involved in hormone biosynthesis, 
modulation of cell signaling, and degradation of macromolecules. Cathepsin K; The protein 
encoded by this gene is a lysosomal cysteine proteinase involved in bone remodeling and 
resorption. Toll-like receptor 1; This family of protein plays a fundamental role in pathogen 
recognition and activation of innate immunity. TLRs are highly conserved from Drosophila 
to humans and share structural and functional similarities. They recognize pathogen-
associated molecular patterns (PAMPs) that are expressed on infectious agents, and mediate 
the production of cytokines necessary for the development of effective immunity.  Stearoyl-
CoA desaturase (delta-9-desaturase); an iron-containing enzyme that catalyzes a rate-
limiting step in the synthesis of unsaturated fatty acids. The principal product of SCD is 
oleic acid, which is formed by desaturation of stearic acid. The ratio of stearic acid to oleic 
acid has been implicated in the regulation of cell growth and differentiation through effects 
on cell membrane fluidity and signal transduction. 
 Within our candidate gene lists across the multiple comparisons a group of hypoxia-
responsive genes have been identified. Hypoxia affected the expression of multiple genes in 
F21, and N21 which were either induced or repressed under these conditions. Some of these 
lists are novel candidates for hypoxia-driven angiogenesis including vascular endothelial 
growth factor (VEGF) and matrix metalloproteinases MMPs [162]. The KEGG pathways 
enriched by these genes include glycolysis and gluconeogenesis, hypertrophy model, wnt 
signaling pathway, smooth muscle contraction and pentose phosphate pathway. 
Interestingly a cluster of these genes were also dysregulated in N1. Tables 10, 11 and 
12 display several concordant differentially expressed genes in these two samples i.e. up in 
fascia 1% and up in nodule 1% following the perturbation effect. In addition to the KEGG 
pathways identified by genelists F1, gene enrichment was observed in the following 
pathways:  eicosanoid synthesis, prostaglandin synthesis regulation, fatty acid degradation, 
glycogen metabolism, blood clotting cascade, GPCRDB class A rhodopsin-like pathway. 
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VEGFA was upregulated in N21 and also in F1. VEGF has been reported to be a 
major contributor to angiogenesis, increasing the number of capillaries in a given network 
[163]. Previous in vitro studies clearly demonstrate that VEGF is a potent stimulator of 
angiogenesis because, in the presence of this growth factor, plated endothelial cells will 
proliferate and migrate, eventually forming tube structures resembling capillaries. 
Up-regulated genes included those for glycolysis, the tricarboxylic acid (TCA) cycle. 
Ethanol and lactate production was not observed under hypoxic conditions  indicating that 
glucose was not fermented to these compounds via the glycolytic pathway. Hypoxia down-
regulated some genes involved in transcription initiation by RNA polymerase II, and also 
some hypothetical protein coding genes that were previously upregulated in N21.  
 
5.3.2 Strengths and weakness of study 
For any system under study, we need to understand
 
the magnitude and diversity of gene 
expression in the unperturbed
 
state and normal state. It is accepted
 
that, for any particular 
parameter, physiological "normalcy"
 
is not a strict value but is rather a range of values 
presented
 
by healthy individuals. It is perhaps due to this reason "normal" fascia gene 
expression displays similar variability, while this not the case for disease samples. This 
study has used microarray technology to simultaneously profile healthy cells in normal and 
perturbed state to understand the gene expression profiles of these healthy cells prior to 
comparison with disease. Additionally, perturbation effects in disease cultures have 
implicated several genes to be downregulated which were previously found to be 
upregulated.  The profiling of healthy palmar fascia and in perturbed conditions is a key 
strength of this study. A key strength of this study is that samples were obtained from 
previous optimised methods using FT-IR in order to confirm reproducibility. Optimised 
modeling cell culture system and sample harvesting methodology from same population of 
cells allowed for comparison with the intracellular metabolome.  
Another key strength of this study was the use of Affymetrix oligonucleotide arrays 
that allows the examination of 47,000 transcripts simultaneously. Previous studies report the 
use of microarrays with a significantly lower number and we used a chip with 22,500 
previously. This same strength can be considered as a weakness as increase in chip probe 
size also increases noise in the data generated and this may result in an increase in false 
discoveries as well as true discoveries in subsequent data analysis. For this reason, robust 
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data analysis methods using 3 independent methods with three normalisation methods have 
been employed to infer unique discoveries.  The method also allowed comparisons across 
fascia and nodule within and across individual patients by generating a range of contrasts 
matrices from the p-data uploaded (readaffy files). Also contrasts between individual probe 
sets of uncertainty using PPLR methods were used. The limma methods accounted for false 
discoveries, while puma methods accounted for probe level uncertainties and yielded a much 
greater number of DE genes. Regardless of the different methods employed, high noise to 
signal ratio is still a significant factor in the data set. FDR removed all such noise and false 
genes resulting in only handful i.e. 20 genes. Occasional occurrence where the adjusted p-
values are equal to 1 suggests this is not an error situation but rather an indication that there 
is no evidence of DE in the data after adjusting for multiple testing. To make objective 
judgments about the most promising candidates for follow-up studies, a trading off of both 
p-values and log odd values could be a good criteria but selection of genes solely on multiple 
correction or one method would a be a criteria too stringent. 
While an attempt to profile normal here has been made, n = 3 is an insufficient 
number and only acceptable for a pilot study. To formulate new hypotheses, as previously 
stated this sample number must increase as the variability within these 3 patients, (different 
growth stage of disease, individual patient signature, and other traits) may have a significant 
impact on results generated from this study. Such variability
 
between individuals emphasises 
the need to pool samples, and
 
to perform additional biological and analytical replicates. The 
current study could not afford replicates, as the cost for 12 arrays was already £6000 alone. 
Three patients too small a sample number, large noise to signal ratio within the dataset and 
high patient to patient variation is evident from PCA. The individual patient signature was 
greater in some case. e.g. collagen V was up regulated in patients 44 and 60 but not in 61. 
This biased analysis does not give rise to correct pathways prediction. 
The statistical analysis of microarray data represents a significant challenge as the 
aim is to apply standard statistical approaches to determine
 
gene expression and gene 
expression alteration significance,
 
thus enabling the extraction of significant biological 
information
 
from a morass of noise and variability. However, present data analysis 
methodologies
 
do not adequately deal well with the number of possible combinations. 
Statisticians
 
are experienced with handling data involving a limited number
 
of variables, but 
a large number of samples (e.g., the average
 
weight of persons in UK is a problem of a single 
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variable
 
and 62 million samples). Microarrays turn this problem on its
 
head, producing 
thousands of variables from a small number of
 
samples; the number of samples is 
significantly less compare to the number of observation (e.g. 1:10000). Hence the reason a 
number of different methods are employed in this study. In particular the puma method 
employs the multi-chip modified gamma Model Of Signal and noise-propagation in 
principal component analysis (NPPCA) method [164] which propagates the expression level 
uncertainty to improve the results of  PCA. Puma-PCA scores plot show clarity in 
observations than standard PCA due to the scale difference and the purity and compactness 
of the clusters observed. The large scale on PCA plots generally implies incorrect or 
unsuitable data preprocessing (large scale does not reveal differences within the data set as 
high intensity variables could be dominating low intensity variables). 
Because of the statistical issues raised by microarray technology,
 
it is necessary that 
findings be confirmed using independent
 
methodological criteria, preferably with samples 
from same RNA used to derive the original targets and a larger cohort followed.
  
A limitation 
of this study is that these alterations have not been confirmed or validated due to time 
constraints. An ideal, rapid, high through-put, method for confirmation
 
of microarray data 
would be quantitative (real time) RT-PCR using
 
the TaqMan 
 
LightCycler (Roche 
Diagnostics).
 
Alternatively, Northern blots may provide the benefit of direct quantification. 
This is
 
important, as significant gene expression changes detected on
 
a microarray may be 
related to a small fraction of the cells.
  
Because a microarray experiment may reveal putative changes
 
in the expression of 
hundreds of genes, it is practically
 
impossible to confirm all of the data. However, it is 
important to evaluate a reasonable number of genes.
 
That said, confirmational studies may 
raise other issues such that although
 
microarray experiments might indicate an increase or 
decrease
 
in the expression of a gene, an independent method might reveal
 
a greater or a 
lesser change which could then lead to further new plausible questions about the validity of 
the microarray
 
data.
 
The hypothesis behind using an exploratory tool of this kind is that clustered genes
 
may be coregulated and therefore may be involved in similar
 
functions. To make
 
sense of 
these data, and depict gene function the hypotheses that emerge from analysis
 
of systemic 
expression information must be tested empirically.
 
This requires integration of 
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transcriptomic knowledge with
 
metabolomics and other omics to test hypotheses within the
 
physiological integrity of the DD cell.  
 
5.3.3 Conclusion 
This study is the first to show that hypoxia elicits systematic transcriptional responses in DD 
and healthy palmar fascia cells. Global transcriptome profiling of the cellular response to 
hypoxia has revealed a multitude of novel mechanisms and functions which may be affected 
by hypoxia in DD and merit further study. The study has demonstrated a unique approach to 
the analysis of DD.  
 
 
  
Chapter 6 
Inferring the metabolic and transcriptional 
networks specific to Dupuytren’s disease 
tumours 
 
6.1 Introduction 
 
6.1.1 Metabolic Pathway analysis and Integration with transcriptomics data to 
aid biomarker discovery in Dupuytren’s Disease 
 
In Chapters 4 and 5 systematic studies investigating the changes the in metabolomes and 
transcriptomes of DD phenotypes and healthy fascia have been performed. Methods utilising 
cluster analyses or correlation of gene-expression profiles are common approaches to predict 
function based on the assumption that genes with similar functions are likely to be co-
expressed. This however cannot advance our understanding of the more complex system, 
consisting of many yet to be identified (unravel) network relationships between these 
molecules which in turn shall lead to better understanding the functionality of these cells and 
monitor situations to predict  DD progression. For this reason it is important to study the 
disease as a system and the many interacting components at the global level and also at the 
subcellular organisational levels. 
A full understanding of metabolic networks requires quantitative data about 
transcript levels, protein levels or enzyme activities, and metabolite levels. This information 
will then allow construction of probabilistic and mechanistic models to investigate effects of 
perturbations imposed on the system. For example,  investigating any changes in metabolite 
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levels that would contribute to the regulation of gene expression and any change in the levels 
of transcripts would then have an impact upon the levels of the encoded enzymes and the 
levels of subsequent metabolites and most likely on the DD metabolic phenotype. The 
proportion of metabolite-transcript correlations identified from the transcript-metabolic 
profiling of DD and control fibroblast will provide clues and give possible direction in 
understanding whether these correlations (between metabolites and transcripts) are due to 
regulation of gene expression by metabolites, or the metabolites being changed as a 
consequence of a change in gene expression.  
Because our metabolic and transcript profile data originates from the same biological 
samples in steady state growth rates and these data have been normalised and statistically 
analysed using stringent methods to select for statistically significant DE transcripts and 
dysregulated metabolites, it is anticipated that now a realistic determination of the 
congruence between the levels of certain metabolites, gene transcripts and their cognate 
protein product(s) can be inferred. However, as noted from the previous chapter the 
abundance of significantly DE genes alone (and now in combination with metabolites) 
makes their study a formidable yet challenging task. There is a clear need for methods that 
would allow sorting these molecules and their families and selecting the most important 
ones, i.e. prioritising the targets for experimental studies.  
In this study, we utilise the statistically significant filtered data sets generated from 
studies in Chapters 4 and 5 from DD and healthy cells in normal and perturbed conditions to 
construct 1) metabolic networks i.e. metabolic pathways based on topological analysis using 
MetPA 2) metabolic and transcriptional networks employing IPA to integrate molecules and 
construct networks from the focus molecules (network eligible molecules in Ingenuity 
knowledge base). Construction of networks in MetPA enabled identification of metabolic 
pathways from overrepresentation analysis, The construction of networks in IPA from the 
most statistically significant molecules facilitated data visualisation and identified key 
interactions between the molecules e.g. direct or indirect binding between the molecules 
residing in the cell including subcelluar locations i.e. nucleus, cytoplasm, plasma membrane 
and extracellular space (confirmed from literature; PubMed). Any molecules not specific to a 
subcelluar location for example, some endogenous chemicals (metabolites) were assigned to 
an unknown location.   
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Inferences are made from constructed networks where transcriptomics data has been 
superimposed on metabolite networks as well as mapping of perturbed state onto disease 
specific networks; e.g. trends of transcription factor binding site enrichment in the promoters 
of these gene groups led to the identification of regulatory metabolic and signaling pathways 
that implicate discrete metabolic-transcriptional networks associated with specific molecular 
subtypes of DD (i.e. nodule).  
This analysis indicates that approaches of this type can provide unique insights into 
the differential regulatory molecular studies associated with DD and connective tissue 
disorders and will aid in discovery / identification of specific transcriptional networks and 
pathways as potential targets for tumour subtype-specific therapeutic intervention. The 
detailed analysis of metabolomic and transcriptomic data using integrative pathway analysis 
in this study has identified a number of candidate metabolites and pathways that may be of 
potential importance in the pathophysiology of DD and with further studies may prove to be 
important as biomarkers of DD. The mapping of perturbed networks (from F1 vs. F21 
analysis) upon unperturbed networks (from N21 vs. F21 analysis) is suggestive that 
molecules (found from this study) under hypoxic stresses in transverse palmar fascia do not 
correlated with the statistically significant molecules in disease. Some correlation is present, 
but not prominent. A major observation from mapping perturbed networks (from N1 vs. N21 
analysis) upon disease networks (N21 vs. F21) was that upon hypoxic perturbation most if 
not all disease molecules under hypoxia became downregulated. The integration of 
metabolomics and transcriptomics data in the current study via integrative pathway analysis 
has also facilitated the contextualization of probable biomarkers related to DD. Future 
validation work is needed to assess the utility of potential novel biomarkers of DD and to 
determine their ability to characterise this disease.  
 
6.2 Results 
6.2.1 Metabolic Pathway enrichment and topological analysis using MetPA  
Pathway analyses in MetPA were conducted to construct metabolic pathways based on 
topological analysis for each of the candidate metabolite lists from the pairwise analyses 
generated in Table 6 in Chapter 4. The analyses were conducted through two routes: 1) 
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pathway enrichment analysis supporting both over-representation analysis as well as gene-
set enrichment analysis based approaches. The Fishers‟ exact test was applied to generate a 
list of significant matched pathways arranged by p-values from pathway enrichment 
analysis. 2) Pathway topological analysis was performed based on the centrality measures of 
a metabolite in a given metabolic network. Centrality is a local quantitative measure of the 
position of a node relative to the other nodes, and is used in analysis to estimate a node‟s 
relative importance or role in network organisation [139]. Since metabolic networks are 
directed graphs, relative betweenness centrality measures were selected to calculate 
compound importance. The pathway impact is calculated here as the sum of the importance 
measures of the matched metabolites normalised by the sum of the importance measures of 
all metabolites in each pathway.   
The results from pathway analysis are presented graphically as well as in a detailed 
table. The graphical output contains three levels of information to view; metabolome view 
(Figure 49), pathway view (Figure 50), and compound view. The first two were employed in 
this study, the latter is not as the analyses for this dataset have been performed and shown in 
Chapters 2 and 4. The metabolome view contains all the matched pathways (the 
metabolome) arranged by p-values (from pathway enrichment analysis) on y-axis, and 
pathway impact values (from pathway topology analysis) on x-axis. The node color is based 
on its p-value and the node radius is determined based on their pathway impact values. The 
pathway name is given in the table. From these nodes the metabolic pathway corresponding 
to the node on the metabolome view is selected. This pathway is essentially a simplified 
KEGG pathway map showing only chemical compounds. The default node color within the 
reference metabolome is light blue. The matched nodes display varied heat map colors based 
on their p-values. The common compound names (KEGG IDs) can be obtained from any 
node which reveals more detailed information as well as links to curated database. The 
results are presented below. Selected figures are only provided here. 
 For each analysis, a table containing detailed results from the pathway analysis was 
generated. The list of matched compounds from the F1 vs. F21 is given below. Since 
multiple pathways are tested at the same time, the statistical p-values from enrichment 
analysis are further adjusted for multiple testings. In particular, the Total is the total number 
of compounds in the pathway; the Hits is the actually matched number from the user 
uploaded data; the Raw p is the original p value calculated from the enrichment analysis; the 
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Holm p is the p-value adjusted by Holm-Bonferroni method; the FDR p is the p-value 
adjusted using False Discovery Rate; the Impact is the pathway impact value calculated 
from pathway topology analysis.  
Table 15 lists the significant pathways derived from the metabolome pathways 
summary for F1 vs. F21 analysis in Figure 48 where each node represents a pathway. 
Pantothenate and CoA biosynthesis and beta-Alanine metabolism are the top two pathways 
identified from the pathway topological analysis (impact 0.29 and 0.30 respectively) and are 
also significant in the pathway enrichment analysis (4.52E-3 after adjustment of multiple 
testing). Further checking of the metabolite concentrations by plotting the boxplot and 
investigating any significant downstream effect on metabolites/compounds in the pathways 
was explored. In the pathways below (Figure 49) the enriched endogenous compounds are 
Pantothenic acid (KEGG ID: C00864), Ureidopropionic acid (KEGG ID: C02642 1) and 
Beta-Alanine (KEGG ID: C00099).  
Table 16 lists the significant pathways derived from N1 vs. N21 analysis. Alanine, 
aspartate and glutamate metabolism, glycerolipid metabolism and pantothenate and CoA 
biosynthesis are the top three pathways from the pathway topological analysis (impact 0.21, 
0.20 and 0.18 respectively). Although the pathway enrichment analysis p-values after 
adjustment for multiple testing are not small, these are more likely to be significant than the 
Aminoacyl-tRNA biosynthesis pathway which has a relatively small p-value after multiple 
testing, but lower impact (0.11).  
Pantothenate and CoA biosynthesis was the only significant pathway derived from 
C1 vs. C21 analysis with impact 0.18 and FDR corrected p-value = 2.63E-01. For the S1 vs. 
S21 analysis beta-Alanine metabolism (impact 0.30, FDR p-value = 1.62E-01) and Glycine, 
serine and threonine metabolism pathways (impact 0.20, FDR p-value =  2.85E-01) were 
significant. For disease N21 vs. F21 analysis relatively fewer metabolites were identified and 
so the phenylalanine metabolism pathways was identified with a relatively low impact (0.12) 
but p-value = 1.07E-01. Aminoacyl-tRNA biosynthesis pathway had a raw p-value = 1.32E-
02 and 0 impact. For the C21 vs. F21 analysis Pantothenate and CoA biosynthesis impact 
0.18 and raw p-value = 4.41E-02 and FDR 7.59E-01. 
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Table 15 Result from Pathway Analysis with MetPA for F1 vs. F21 matched list of identifiers. 
 
 
 
 
Figure 49 Summary of Pathway Analysis from F1 vs. F21 metabolite list with MetPA. Topological pathway 
analysis in metabolome view. 
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Figure 50 Pathway view of the top two highest scoring pathways (Pantothenate and CoA biosynthesis and 
beta-Alanine metabolism).  
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Table 16 Result from Pathway Analysis with MetPA for N1 vs. N21 matched list of identifiers. 
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6.2.2 Metabolic and Signaling pathway analysis using IPA  
Integration of transcript and metabolite candidates 
„Core‟ and „Metabolomics Analyses‟ were performed in the IPA system using candidate 
gene and metabolites lists produced from data analyses from the pairwise analyses (F1 vs. 
F21, N21 vs. F21 and N1 vs. N21) in Chapters 4 and 5. Initial analysis using integrative 
pathway mapping (metabolite with transcript data) has shown several observed markers in 
DD (nodules) involved in key networks, biological functions and signaling and metabolic 
pathways are involved in amino acid metabolism and metabolism of cofactors and vitamins. 
The most significant biological functions and canonical pathways across multiple 
datasets (i.e. comparing results between gene/compound list from all three pairwise analyses; 
F1 vs. F21, N21 vs. F21 and N1 vs. N21), are shown in (Figures 51-54). The canonical 
pathways are displayed as bar charts across one axis. The other axis displays the ratio which 
is calculated as follows: the number of genes in a given pathway that meet cut-off criteria, 
divided by total number of genes that make up that pathway. Taller bars have more genes 
associated with the canonical pathway than shorter bars. For the single analysis (e.g. 
gene/compound list from the N21 vs. F21 analysis), a graph displaying the various pathways 
is presented from largest ratio to smallest ratio. For comparison analyses (i.e. 
gene/compound list from all three pairwise analyses F1 vs. F21, N21 vs. F21 and N1 vs. 
N21), various pathways are presented from largest ratio to smallest ratio according to the 
first experimental group. Canonical pathways that are associated with a particular network 
can be superimposed on molecules within the respective network. 
Based on Fishers exact test for top canonical pathways associated in disease (N21) 
resulted in nicotinate and nicotinamide metabolism (p-value = 7.98E-03), p38 MAPK 
signaling (p-value = 1.03E-02), ATM signaling (p-value = 2.88E-02), antiproliferative role 
of TOB in T cell signaling (p-value = 4.64E-02) and ERK5 signaling (p-value = 4.95E-02). 
The top molecules identified from this analysis include upregulated: amphiphysin (AMPH), 
ankyrin-3 (ANK3), ankyrin repeat domain 28 (ANKRD28), adaptor-related protein complex 
1, sigma 2 subunit (AP1S2), aryl hydrocarbon receptor nuclear translocator 2 (ARNT2), 
arylsulfatase D (ARSD), arsenite methyltransferase (AS3MT), activating transcription factor 
4 (ATF4), autism susceptibility candidate 2 (AUTS2), cell adhesion molecule 1 (CADM1) 
and downregulated:  zinc finger protein 423 (ZNF423), zinc finger protein 124 (ZNF124), 
wingless-type MMTV integration site family member 2 (WNT2), WNK lysine deficient 
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protein kinase 4 (WNK4), transient receptor potential cation channel, subfamily C, member 
6 (TRPC6), tissue factor pathway inhibitor 2 (TFPI2), tissue factor pathway inhibitor (TFPI),  
sulfotransferase family, cytosolic, 1C, member 4 (SULT1C4), solute carrier family 6 
(neurotransmitter transporter, taurine), member 6 (SLC6A6), and sema domain, 
immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3E (SEMA3E). 
 The top canonical pathways associated perturbation in healthy fascia (F1) analysis 
resulted in inositol metabolism (p-value = 7.41E-05), fructose and mannose metabolism (p-
value = 1.85E-04), glycolysis/gluconeogenesis (p-value = 2.48E-04), AMPK signaling (p-
value = 3.7E-03) and pentose phosphate pathway (p-value = 3.88E-03). The top molecules 
identified from this analysis include upregulated: ATP-binding cassette, sub-family B 
(MDR/TAP), member 10 (ABCB10), abl-interactor 2 (ABI2), A disintegrin and 
metalloproteinase with thrombospondin motifs 6 (ADAMTS6), adenylosuccinate synthase 
like 1 (ADSSL1), 1-acylglycerol-3-phosphate O-acyltransferase 5 (AGPAT5), adenylate 
kinase 2 (AK2), adenylate kinase 4 (AK4), v-akt murine thymoma viral oncogene homolog 3 
(AKT3), aldolase A, fructose-bisphosphate (ALDOA), aldolase C, fructose-bisphosphate 
(ALDOC) and downregulated: zinc finger protein 124 (ZNF124), WD repeat domain 78 
(WDR78), tRNA splicing endonuclease 2 homolog (TSEN2), tumor protein D52-like 1 
(TPD52L1), tumor necrosis factor receptor superfamily, member 21 (TNFRSF21) 
transmembrane protein 97 (TMEM97), toll-like receptor 3 (TLR3), sulfotransferase family, 
cytosolic, 1C, member 4 (SULT1C4), spermatid perinuclear RNA binding protein (STRBP), 
sulfide quinone reductase-like (SQRDL).  
The top canonical pathways associated with perturbation in disease (N1) analysis 
identified were glycolysis/gluconeogenesis (p-value = 1.99E-06), inositol metabolism (p-
value = 5.18E-05), pentose phosphate pathway (p-value = 2.52E-03), PI3K/AKT signaling 
(p-value = 4.5E-03) and fructose and mannose metabolism (p-value = 6.65E-03). The top 
biofunctions associated were cell death, carbohydrate metabolism, small molecule 
biochemistry, cell morphology and cellular development with top molecules identified 
upregulated: aldolase C, fructose-bisphosphate (ALDOC), apelin (APLN), BCL2/adenovirus 
E1B 19kDa interacting protein 3 (BNIP3), aspartyl-tRNA synthetase  (DARS), egl nine 
homolog 1 (EGLN1), F-box protein (FBXO16), fibroblast growth factor 1 (FGF11), gamma-
glutamyl hydrolase (GGH), macrophage migration inhibitory factor (MIF), prolyl 4-
hydroxylase, alpha polypeptide I (P4HA1) and downregulated: zinc finger protein 654 
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(ZNF654), zinc finger protein 593 (ZNF593), Wilms tumor 1 associated protein (WTAP), 
WD repeat domain, phosphoinositide interacting 1 (WIPI1), WD repeat domain 78 
(WDR78), vascular endothelial growth factor A (VEGFA), tripeptidyl peptidase I (TPP1), 
triosephosphate isomerase 1 (TPI1), tumor protein D52-like 1 (TPD52L1) and thioredoxin-
related transmembrane protein 4 (TMX4). 
Figures 51 and 52 display the comparison analyses for the top canonical pathways. It 
can be seen that the perturbation effect has revealed other pathways than those identified for 
disease. The perturbation effect has many molecules associated with the glycolysis pathway 
or sugar metabolism, DE molecules in F1 score highest in cancer associated pathways, while 
top disease molecules (from N21) score the highest in pathways involved in vitamin B5 and 
signaling ways. 
 
 
Figure 51 A summary of the distribution of metabolite markers across top scoring pathways from N21 vs. F21 
analysis. This indicates that metabolite markers reflect CoA enzyme metabolism, key signaling pathways 
nicotinate and nicotinamide metabolism, p38 MAPK Signaling, antiproliferative Role of TOB in T Cell 
Signaling, ERK5 Signaling. 
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Figure 52 A summary of the distribution of metabolite markers across top scoring pathways from F1 vs. F21 
analysis. 
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Figure 53 A comparison analysis of top scoring pathways displaying a summary of the distribution of 
metabolite markers across top scoring pathways.  
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Figure 54 A comparison analysis across the top scoring biological functions in the three pairwise analyses.  
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Network analysis integrating candidate transcripts with candidate metabolites 
Following transcript analysis a list of networks were generated de novo based on the input 
data. These networks do not have directionality and contain molecules involved in several 
pathways. Table 17 shows the two most significant networks resulting from each analysis. 
Molecules of interest which interacted with other molecules in the Ingenuity Knowledge 
Base were identified as Network Eligible Molecules which served as "seeds" for generating 
networks. More details on The  Network Generation Algorithm can be found in [165]. All of 
the molecules that compose each network are listed. Network eligible molecules appear in 
bold, other molecules are in regular font. An asterisk appears next to any gene for which the 
input file contained more than one identifier. A score based on a p-value calculation is 
determined. This calculates the likelihood that the Network Eligible Molecules that are part 
of a network are found therein by random chance alone. Mathematically, the score is simply 
the negative exponent of the right-tailed Fisher's exact test result. For example, if the score is 
3, then there is a 1 in 1000 chance that the Network Eligible Molecules found in that 
network appeared there just by chance. The score is a measure of the number of Network 
Eligible Molecules in a network; the greater the number of Network Eligible Molecules in a 
network, the higher the score (lower the p-value) will be. The number of focus molecules 
indicates the number of Network Eligible Molecules per network. The maximum number of 
molecules per network is currently limited to 35.  The three most significant functions for 
each network are listed under the column Top Functions. Further analysis into the high-level 
functional categories for individual networks was performed. For the analysis N21 vs. F21, 
Network 1 revealed the three functions with 24 molecules associated with immunological 
disorder, 21 molecules associated with autoimmune disease and 15 molecules associated 
with rheumatoid arthritis. 
Network Explorer tool in IPA was used to visualise molecular relationships 
representing inter-relationships between molecules. Genes, proteins, and metabolites 
(endogenous chemicals) were displayed as various shapes. The shapes are indicative of the 
molecular class (protein family, or metabolite). Colouring is based on the expression values 
that were uploaded with the dataset. Red indicates up-regulation (positive values), green 
indicates down-regulation (negative values), gray indicates the molecule was part of the 
dataset but did not meet the specified cut-off value, and white indicates the molecule was 
added from the Ingenuity Knowledge Base. Lines connecting molecules indicate molecular 
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relationships. Dashed lines indicate indirect interactions; solid lines indicate direct 
interactions. The style of the arrow indicates specific molecular relationships and the 
directionality of the interaction (A acts on B). A legend is provided in Figure 55. Canonical 
Pathways that are associated with a particular network were then overlaid highlighting 
individual molecules that are involved in a specific canonical pathway. As visualising these 
networks becomes increasingly difficult, the list of canonical pathways most significant for 
disease (N21 vs. F21 analysis) is shown only; Figure 62. 
The networks generated displayed relevant relationships as specified by the filters 
applied. This may have excluded some of the relationships for every network eligible 
molecule. Also because some interactions present in the Ingenuity Knowledge Base were not 
used in the network generation process the molecules of interest and their relationships were 
reinserted as could be biologically important. For this reason the full complement of direct 
and indirect interactions for a molecule within the network are highlighted. Each network 
illustrates the molecules within their subcellular compartments i.e. nucleus, cytoplasm, 
plasma membrane and extracellular space. For molecules where no subcellular localisation 
information was currently available in the IPA knowledge database were categorized into an 
„unknown space.‟ 
Figures 56-60 illustrate the networks listed in Table 17. These are the top networks 
resulting from the combined candidate gene/metabolite identifiers. Table 18 displays an 
enhanced view of the top function and molecules from Network 1 that are generated from 
DD nodule candidate list of metabolites/transcripts. 
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Table 17 Top scoring networks from Core analysis (significant transcriptomic and metabolite data 
sets). 
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Table 18 Enhanced view of function and molecules from Network 1 generated from disease (N21 vs. F21 
analysis) candidate list of metabolites/transcripts. 
 
Function Annotation Molecules # Molecules
immunological disorder
ADK, AMPH, ANK3, ANKRD28, AR, ARHGDIB, ARNT2, 
AUTS2 (includes EG:26053), CADM1, CAMK1D, CD44, 
CDK2, CHRM3, DAPK1, DCHS1, DPF3, DUSP1, EIF1, 
ELL2, ERP29, ESD, FCHO2, FRMD3, FTH1
24
autoimmune disease
ADK, AMPH, ANK3, ANKRD28, ARHGDIB, AUTS2 
(includes EG:26053), CADM1, CAMK1D, CD44, CDK2, 
CHRM3, DAPK1, DCHS1, DPF3, DUSP1, ELL2, ERP29, 
ESD, FCHO2, FRMD3, FTH1
21
rheumatoid arthritis
ADK, AMPH, ANKRD28, ARHGDIB, AUTS2 (includes 
EG:26053), CADM1, CAMK1D, CD44, DAPK1, DCHS1, 
DUSP1, ESD, FCHO2, FRMD3, FTH1
15
 
 
 
 
Figure 55 a) Key for all networks. b) Relationship legend. 
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Network 1 – Effect of hypoxia on healthy fascia  
 
Figure 56 Top scoring Network 1 based on the significant differentially expression transcripts and metabolites 
from F1 vs. F21 gene/metabolite lists. Colour coding of the nodes corresponds to the direction of responses 
(up-regulation shown in red and down-regulation shown in green). Lines that connect two molecules represent 
relationships. Any two molecules that bind, act upon one another are orange.  
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Network 2 - F1 vs. F21 analysis 
 
Figure 57 Top scoring Network 2 based on the significant differentially expression transcripts and metabolites 
from F1 vs. F21 gene/metabolite lists. Color coding of the nodes corresponds to the direction of responses (up-
regulation shown in red and down-regulation shown in green. Any two molecules that bind, act upon one 
another, are shown in orange. 
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Network 1 – Top molecules highlighted from DD Nodules vs. healthy fascia analysis 
 
Figure 58 Top scoring network based on the significant differentially expression transcripts and metabolites 
From N21 vs. F21 gene/metabolite lists. Color coding of the nodes corresponds to the direction of responses 
(up-regulation shown in red and down-regulation shown in green). Lines that connect two molecules represent 
relationships. Any two molecules that bind, act upon one another, or that are involved with each other in any 
other manner would be considered to possess a relationship between them (orange). Each relationship between 
molecules is created using scientific information contained in the Ingenuity Knowledge Base. 
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Network 1 from N1 vs. N21 analysis 
 
Figure 59 Top scoring network based on the significant differentially expression transcripts and metabolites  
From N1 vs. N21 gene/metabolite lists. Colour coding of the nodes corresponds to the direction of responses 
(up-regulation shown in red and down-regulation shown in green). Lines that connect two molecules represent 
relationships. Any two molecules that bind, act upon one another are orange. 
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Network 2 from N1 vs. N21 analysis 
 
Figure 60 Top scoring Network 2 based on the significant differentially expression transcripts and metabolites 
From N1 vs. N21 gene/metabolite lists. Colour coding of the nodes corresponds to the direction of responses 
(up-regulation shown in red and down-regulation shown in green). Lines that connect two molecules represent 
relationships. Any two molecules that bind, act upon one another are shown in orange. Dashed lines are 
indicative of indirect binding and/or relationships with confirmed literature references. 
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6.2.3 Metabolite and gene mapping 
One of the aims of the DD metabolomics work was to provide putative biomarkers of 
disease phenotype that can be monitored to determine the effect of hypoxia and discover 
novel metabolite entities and possibly translate a metabolic network for in vitro studies. To 
gain additional confidence that these metabolite changes are associated with transcriptional 
changes, rather than just a product of altered phenotype based upon induced perturbation 
transcriptomics data were overlaid on the metabolite-centric networks and pathways. Table 
19 shows the two most significant networks resulting from metabolomics analysis. Top 
transcriptomics information from Network 1 was overlaid on the metabolic network shown  
in Figures 61 - 65 to illustrate the analysis of disease (N21) and for effect of hypoxia on 
networks molecules upon perturbation in disease cells (N1). This now provides smaller 
networks from which key molecules can be used to depict our components which may be 
used for modeling; in silico studies for further experimentation and validation. The networks 
were then overlaid with the most significant canonical pathways specific for molecules with 
individual network (e.g. Figure 62). Figures 66 and 67 mapped the top scoring molecules 
from F1 and N1 upon N21 Network 1. A notable switching in direction (up or 
downregulated) of some molecules is observed.   
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Table 19 Top scoring networks from metabolomics analysis (significant metabolite data sets). 
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Transcript data superimposed on metabolite Network 1 - N21 (disease molecules) 
 
Figure 61 Transcriptomics data superimposed on the metabolite network 1 generated from molecules in the 
analysis of N21 vs. F21. 
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Figure 62 Transcriptomics data superimposed on the metabolite network (1) generated with analysis of N21 v 
F21 with top scoring canonical pathways overlaid. These are: role of cytokines in mediating communication 
between immune cells, glucocorticoid receptor signaling, role of macrophages, fibroblasts and endothelial cells 
in rheumatoid arthritis and signaling and production in macrophages.  
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Transcript data superimposed on metabolite Network 2 - N21 vs. F21 
 
Figure 63 Transcriptomics data superimposed on the metabolite network (2) generated from molecules in the 
analysis of N21 vs. F21. 
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Transcript data superimposed on metabolite-centric Network 1 - N1 vs. N21  
 
Figure 64 Transcriptomics data superimposed on the metabolite network (1) generated from molecules in N1 
vs. N21 analysis. 
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Transcript data superimposed on metabolite-centric Network 2 - N1 vs. N21   
 
Figure 65 Transcriptomics data superimposed on the metabolite network (2) generated from molecules in N1 
vs. N21 analysis. 
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F1 molecules mapped onto N21 network (superimposed on Figure 58) 
 
Figure 66 Molecules from F1 transcript-metabolite network superimposed on the N21 network (1).  
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N1 molecules mapped onto N21 (superimposed on Figure 58) 
 
Figure 67 Molecules from N1 transcript-metabolite network superimposed on the N21 network (1).  
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6.3 Discussion 
6.3.1 Principal Findings 
In this study we analysed the transcriptome and metabolome profiles representing specific 
signatures of DD that have been shown in studies Chapter 4 and 5. The analysis identified 
several transcriptional pathways and implicated multiple regulatory networks that 
characterise and classify the different molecular subtypes. 
Among the networks identified for the disease vs. healthy analysis (N21 vs. F21), two 
notable ones were found to be associated with molecular subtypes of autoimmune disease, 
connective tissue disorder and rheumatic disease. Network 1 revealed the three biological 
functions with 24 molecules associated with immunological disorder, 21 molecules 
associated with autoimmune disease and 15 molecules associated with rheumatoid arthritis. 
The first network, characterised by the SATB1, TNF, CSF2, TGFβ2, MMP1, TGFβ2 and 
molecules dominated by molecular signaling and possible cross-talking interactions (direct 
and indirect relationships) between transcriptional pathways. Landmark genes identified in 
previous studies associated or thought to be involved in DD and were also validated in this 
study (Table 20). In addition, other genes not previously described in the study following 
perturbation in disease are reported in Table 21.  
The first goal of this study was to determine key metabolic pathways based on 
topological pathway analysis. The result from this analysis is a list of canonical pathways 
and gene sets relevant to progression in DD. In addition, the analysis indicates in which 
stage of progression a pathway is relevant: i.e. cord development pathways, response to 
hypoxia, and nodule development and also its response to hypoxia and pathways that are 
activated when normal cells are induced with hypoxia. 
Mapping of the molecules associated with perturbation effect in healthy fascia (F1) 
and disease (N1) on to the network constructed for N21 vs. F21 analysis (disease) have 
highlighted some key switching  patterns i.e. changes in molecules. Notably, upon 
perturbation of disease, key molecules that were identified as upregulated were either down 
regulated or no change in those molecules was observed.  These opposing trends suggest 
(perhaps an ambitious statement) that careful and effective decrease of oxygen in nodules, 
may be indicative that some of these molecule can be restored to normal activity. Mapping 
of transcript data on metabolite networks has shown some good correlation at the two 
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subcelluar levels depicting a change in transcriptome has a downstream effect on 
metabolome networks (and perhaps vice versa too). 
 
Table 20 18 key molecules identified in this study previously confirmed in literature to affect connective tissue 
disorders including rheumatic disease. 
 
 
Function Annotation Molecules in disease (N21) networks # Molecules
affects connective tissue disorder (18/18)
ADK, AMPH, ANKRD28, ARHGDIB, AUTS2 
(includes EG:26053), CADM1, CAMK1D, CD44, 
CDK2, COL12A1, COL5A3, DAPK1, DCHS1, 
DUSP1, ESD, FCHO2, FRMD3, FTH1
18
affects rheumatic disease (16/16)
ADK, AMPH, ANKRD28, ARHGDIB, AUTS2 
(includes EG:26053), CADM1, CAMK1D, CD44, 
CDK2, DAPK1, DCHS1, DUSP1, ESD, FCHO2, 
FRMD3, FTH1
16
 
 
 
 
 
Table 21 Previously reported functions of molecules highlighted to be of significantly DE upon perturbation in 
nodule. 
 
Function Annotation Molecules perturbed in disease  network - N1 # 
Molecules
affects apoptosis of 
connective tissue 
cells (18/31)
BCL2, CASP3, CASP8, CDKN1A, CEBPB, DDIT3, 
DUSP1, FASLG, FN1, GAB1, JUN, MAPK14, MMP9, 
NSMAF, RAF1, RELA, TGFB1, TNF
18
decreases apoptosis 
of connective tissue 
cells (15/31)
BCL2, CD44, DUSP1, EP300, FN1, IL13, IL1A, IL1B, 
INS, RELA, SAA1, TGFB1, TGFB2, TIMP1, TNF
15
increases apoptosis 
of connective tissue 
cells (12/31)
CD44, CD40LG, EP300, FASLG, IFNG, JUN, LGALS8, 
MMP9, RAF1, TGFB1, TNF, VEGFA
12
 
 
 
6.3.2 Strengths and weaknesses of the study  
The metabolites are interconnected through metabolic reactions, generally grouped into 
metabolic pathways [166]. Classical metabolic maps provide a relational context to interpret 
metabolomics experiments and a wide range of tools have been developed to locate 
metabolites within metabolic pathways. However, the representation of metabolites within 
separate disconnected pathways overlooks most of the connectivity of the metabolome 
[166]. By definition, the reference pathways cannot integrate novel pathways nor show 
relationships between metabolites that may be linked by common neighbors without being 
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considered as joint members of a classical biochemical pathway [166]. The IPA is a proof of 
knowledge based comprehensive software of data analysis that can help researchers model, 
analyse, and understand the complex biological and chemical systems at the core of life 
science research [67]. By metabolomics analysis in the IPA, the phenotypic data of the 
metabolites can be validated and correlated with the targeted metabolites with the potential 
metabolic pathways, and related to biochemical functions. 
An importantly successful application for metabolomics has been in diagnosing 
drugs-induced toxicities in kidney, liver and heart. Here we demonstrated the use of 
metabolomics screening combined with transcriptomics and IPA analysis as a novel usable 
strategy to characterise the biochemical perturbation induced by hypoxia, revealing several 
biomarkers resulting from this perturbation effect that could be suggestive of the potential 
metabolic pathways that can be targeted for future studies in higher, more complex systems 
i.e. primary cells from human samples with high biodiversity. This strategy confirms and 
strengthens the applicability of metabolomics analysis methodology to investigate the 
perturbation effect in DD phenotypes and it highlights the strong potential of the network 
analysis made possible by IPA.   
The strength of being able to visualise possible interactions between molecules at the 
cellular level can be seen as a step closer to building constraint based models, or kinetic 
models or even abstract models to generate novel yet directed hypotheses. Once assembled, 
the model provides a means to organise the data about the DD system, to rapidly and 
inexpensively test hypotheses through in silico experimentation and to generate new 
hypotheses which can be tested in the laboratory. Not only can this kind of modeling 
approach transform raw data into actionable insights, but it can be an invaluable addition to 
an experimental program, that will allow researchers to ask more pertinent questions and to 
plan and design more focused experiments that have a much higher chance of discovering 
meaningful knowledge adding to existing knowledge and may translate into directed 
research; a step closer to understanding and targeting mechanisms in DD. The ultimate goal 
would be to integrate and process all these measurements to formulate mathematical models 
that recapitulate all previous observations and predict new behaviour together with 
environmental perturbations. Unfortunately time constraints have prevented the 
implementation of this. 
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Chapters 2, 4 and 5 utilised numerous computational methods to identify trends and 
patterns of gene expression and small endogenous and exogenous chemicals (from 
metabolome) specific to different DD cells, and healthy cells. These have led to the 
discovery of several genetic patterns or molecular signatures that aid in distinguishing 
biologically relevant aspects of tumour behaviour, their identity and some functional 
knowledge. It should be stressed that data integration from different data sources imposes 
major tasks such as including careful assembly of similar and complementary information 
from heterogeneous data sources and deletion of duplicated data. Such requirements demand 
considerable hand coded programming efforts, as different data formats have to be combined 
into a common schema.  
 
6.3.3 Conclusions 
In a systems approach, the various cellular networks are perturbed by changing 
environmental conditions of disease and healthy cells. The impact of the perturbation is 
assessed in by constructing key networks from the most significantly dysregulated molecules 
to evaluate any changes as measured and the consequences of these changes as they present 
themselves throughout the cellular networks. Key molecules in DD nodules network have 
been identified. However, the data still requires the development and assistance of new 
software tools and algorithms that can extract meaningful biological insights which yield in 
systems level understanding of cellular responses. Furthermore, models (e.g. kinetic models) 
from these data should be initiated. The application of high-throughput gene expression and 
metabolic profiling to the study of DD will now broaden our thinking about the biology of 
this quasi–neoplasia by providing deeper insights into the mechanisms underlying tumour 
promotion and progression. 
 
  
Chapter 7 
Conclusion and outlook 
7.1 Thesis Summary 
The sequencing of multiple genomes and the concomitant parallel development of 
computational SB tools start to realise the promise of functional genomics has created an 
opportunity for investigating DD in a way that was hardly imaginable 10 years ago. Today 
SB studies together with advances in molecular biological techniques and instrumentation 
allow for a directed, systematic effort aimed at producing a complete catalogue of 
biochemical activities, biological functions and their interactions, at least for simple 
unicellular life forms (e.g. bacteria and yeast). 
In this thesis a major advancement to the application of functional genomics and 
metabolomics methodologies has been made to investigate human disease and this study for 
a higher organism is highly challenging, novel and original. The aim of this research thesis 
was to develop and test the hypothesis that DD is a network disease.  This hypothesis was 
tested in two parts with the following questions in mind: 
(i) The DD and corresponding healthy tissue differ in function through 
differences between their molecular and intercellular networks, rather than differences in a 
single molecule, or in a plethora of unrelated molecular species.    
(ii) DD can be caused by any of a variety of perturbations in the regulatory 
networks that lead to the network differences. 
With this in mind systematic studies were conducted employing a SB approach 
which involved making use of metabolomics and transcriptomics methodologies to enable 
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the profiling and characterisation of signatures from DD phenotypes. The major innovation 
presented in this thesis is the use of metabolites and gene (transcript) sets in a data-centric 
mechanistic modeling approach for the construction of potential networks that may be 
associated or involved in tumour progression rather than single genes. Previous research in 
the field of DD where single genes were studied have provided a wealth of important 
information and these molecules may now be regarded as markers of certain stages of 
disease progression. While it is important to identify these individual genes as biomarker 
landmarks, a broader understanding of the functional biological processes occurring during 
disease progression has been missing. 
 Before we can interpret any data related to physiological and pathological transitions 
in DD, a question one should answer is, “What is normal?” as for any system under study, 
there exists a requirement to understand the magnitude and diversity of its typical activity 
whether in metabolism, gene expression or influence of its environment in the unperturbed 
state. Recent research in DD progression has taken a step closer to gaining insight into 
biologically related gene sets from the transverse palmar fascia, but none to date have 
explored the profound detrimental effects of subcultivation on their unique molecular 
(biochemical) signatures.  
In Chapter 1 an introduction to this thesis is given presenting the approach and 
hypotheses tested in this study. Section 1.2; Appendix A reviews scientific literature 
available on DD and discusses the rationale to undertake a SB approach to investigate DD as 
it proposes it to be a disease of networks. The techniques, instruments and algorithms used 
to test these hypotheses are given in Chapter 2.   
As it is important for SB to be employed on defined and reproducible experimental 
(and computational) systems, Chapter 3 examined how DD and healthy cells changed 
following excision and cultured over a period of time. This highlighted the optimal 
conditions to further investigating the DD system, as a compromise between retaining in situ 
DD character and having sufficient cell numbers for analysis; the concept of a systems 
signature defined through FT-IR spectroscopy was applied. Using this procedure, the 
reproducibility in vitro of DD subsets (i.e. nodule, cord, fat & SON) was compared with 
internal control (transverse palmar fascia) and external controls (carpal ligamentous fascia) 
based on their unique biochemical signatures. The results indicated that different DD 
phenotypes exhibit marked variability in the overall pattern of metabolic fingerprints 
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(nodule, cord, skin and fat). The results from the metabolic fingerprinting based on PCA of 
DD nodule, cord and fascia has implied an early passage number (0-3) would faithfully 
represent the test subject as its phenotype would be closest to the in vivo state. Due to 
uneven sample size (and cellular content), certain supervised methods such as ANN could 
not be applied to the model to assess validity of the model, but PCA and PC-DFA indicated 
good clustering and separation between different sample types (from disease and healthy and 
also between samples from highly biodiverse individuals i.e. patients). The application of 
FT-IR spectroscopy conducted under carefully controlled conditions with appropriate 
chemometric techniques to differentiate phenotype between DD and control fibroblasts has 
been demonstrated to be a powerful tool for the rapid screening and discrimination between 
the anatomical cell types within individual DD patients as well as samples from controls. 
This study highlights early passage cultures are close representatives of the metabolic 
fingerprints of those in disease phenotype state in vivo and are more appropriate for further 
DD studies. However, PCA of FT-IR footprint spectra did not yield any statistically 
significant results. This may be because the culture medium in which secreted metabolites 
were collected was nutrient rich and contained undefined reagents including FBS. The study 
supports the hypothesis that the cell culture monolayer environment may alter the functional 
characteristics of the DD samples, possibly by abiotically selecting against a subpopulation 
of cells which survived the in vitro conditions, and result in degradation of the sample‟s 
phenotypic identity. 3D cultures may improve over cell monolayer culturing and should be 
considered in future studies. 
The classification achieved is encouraging, as FT-IR spectroscopy not only 
discriminates DD phenotypes from the two controls, but also between the two fibrotic 
elements i.e. nodules from cords, fat and SON. Despite high biodiversity in patients, this 
trend could be observed in most patients when examined alone, if not altogether in the PCA 
scores plots when combined. In addition this technique demonstrates internal fascia is an 
appropriate control and can be distinguished from diseased fibroblasts using chemometrics 
techniques. The use of internal transverse palmar fascia as the control will attribute to the 
homogeneity and consistency in future studies. 
One problem with the current implementation of the PCA model is its unsuitability to 
assess multiple influential trends (too many variables - as this could lead to poor 
generalisation performance of the model due to under fitting). Given the clinical nature of 
Chapter 7                                                                                                                            Conclusion and Outlook 
215 
 
this project, samples sets are often too few. Any experimental error reducing the already few 
numbers interferes with the chosen models applied and cluster analyses, making this a biased 
data set depicting an unbalanced sample number and experimental design. Alternatively, it 
may be necessary to apply other supervised methods that complement the existing in silico 
model if it is to be used on larger data sets. This may involve a slightly different optimisation 
technique.  
 Future studies should consider the following to improve and optimise the current cell 
culture methodology: culture and harvest a greater total amount and full sets of DD samples 
e.g. n = 20 nodules, n = 20 cords, n = 20 transverse palmar fascia. Initial confirmation of 
phenotypic identity, morphological assessment and fibroblast purity, should be obtained 
using immunocytochemistry and/or immunohistochemistry. Furthermore, alternative sample 
processing and extraction methods may be compared for future metabolomics studies e.g. 
snap freeze biopsies in methanol or subject samples to FT-IR spectroscopy immediately 
from culture flask and not thaw from frozen (but this would not be valid for different time 
points (days) as technical variation could be introduced) to make a comparison of current 
methods using chemical information from formalin fixed tissues. 
  To validate the current results, that a „passage effect‟ is one possible effect on the 
fibroblast cultures, an independent validation of the trypsin and passage effect should be 
applied where cells should be isolated from the test tissue from a minimum of three patients 
and passaged a total of six times (Passage 0 to Passage 6). Using qRT-PCR, expression of all 
genes of interest (approx 10-12 initially) selected from bioinformatics and text mining 
analysis should be quantitatively assessed (e.g. (collagen type I ligament/tendon‟s main 
matrix constituent), collagen type III, fibronectin, metalloprotease-13 [MMP-13], and tissue 
inhibitor of metallopreotease-1[TIMP-1]). An alternative approach could be to determine the 
passage effect by simultaneous growth of fibroblasts from two sets of biopsies cut in half 
arriving on the same day and grown in different sized culture flasks and passaged upon 
confluence. For example (one piece of nodule tissue, cut into two and processed for 
fibroblast cell culture. one pellet transferred into a T25cm
2
 flask and the other into a T75cm
2
.  
Here the use of natural language processing (NLP), text mining and machine learning 
methodologies would be of considerable utility if one could train these to represent more 
quantitative, effective and efficient ways to capture data generated from SB experiments. 
Due to advances in high-throughput -omics technologies, e.g. gene expression data from 
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microarray experiments and protein interaction databases, together with large volume of 
digital textural documents such as PubMed, an unprecedented opportunity is created to apply 
computational techniques for a comprehensive study of the structure and dynamics of the 
systems components, and thus provide a robust foundation to systems biologists. It must not 
be understated that despite the high quality obtained through manual curation, NLP and 
machine learning methodologies represent a more effective and efficient way to capture and 
curate large data sets resulting from iterative SB experiments. Though efficiencies can be 
built in to the manual curation systems, it cannot be compared to the speeds achieved by 
NLP tools. Automated extraction of data using NLP technologies is fast but the accuracy of 
the data captured and the data points that are omitted comprise major areas that need to be 
improved. In principle, the requirement is the discovery of new knowledge from hidden texts 
that will help with recognition of extracted relations from entities that are shown to be truly 
interesting and not merely erroneous trends that could occur from the processed data.  
In Appendix E2(3), a novel method (application) under construction which may later 
be incorporated into an existing text mining tool (FACTA) [167] is proposed. This addition 
to the existing tool would play a crucial role in SB research and should allow the end user to 
make decisions and perform text processing and clustering of selected categories of interest. 
Various discussions with Dr Philip J Day arising from this study, have led to the initial 
design and set-up of an application which may facilitate in quantitative and qualitative 
selection of candidate genes (following reproducibility study in Chapter 3) to validate from 
the literature. The project involves chunking/parsing/zoning of data sets from DD specific 
methodologies from which entities (proteins, genes, and chemicals) are retracted. The 
strategy involved retrieval of these entities from the literature based on an ordered ranking 
system that would specifically identify the technique (e.g. genes discovered through a 
microarray study or immunohistochemistry) from which the molecule was discovered. 
Furthermore, which group (authors, laboratories) report these findings and to gain a deeper 
understanding the sub sections in a given article e.g. abstract, method or results section of an 
article would enable the users to select and filter a sub group of entities based on their 
individual experimental predictions/queries as identification of entities from irrelevant 
sections in a article could be avoided e.g., molecules identified in the results section of a 
peer-reviewed journal than found by chance say in the methods which could lead to 
ambiguity in novel findings.  
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The workflow is briefly shown in Appendix E3 where I started to build the reference 
collections (libraries) from existing and known information retrieval sources such as 
PubMed, Scopus, Science direct etc. This consists of full articles on 1) DD scientific and 
literature, and 2) entities (i.e. techniques from which these proteins, genes, metabolites were 
discovered to obtain information directly from domain experts or from biological annotation 
databases. Here one of the challenges was to determine the optimal queries for selecting all 
relevant annotations from various biological resources, to cope with the different 
granularities of heterogeneous information types and the incompleteness of manually curated 
information. The idea is once the entities in sentences were parsed/chunked/curated etc the 
completed „mini tool‟ would then be connected with the larger tool, FACTA, to enable 
prediction and inference of entities relevant to DD biology, gene expression and specific 
techniques the genes were inferred from using this test model (in this case the idea was 
selection of candidate genes from text mining to validate results from Chapter 3).  
In Chapter 4 the above two hypotheses were tested with DD and corresponding 
healthy and normal metabolomes. One hypothesis was, whether the difference in disease cell 
types (nodule, cord and SON) and control cell type is the same as the difference in control 
fibroblasts (transverse palmer fascia) cultured in normoxia and hypoxia. Secondly, in which 
specific disease cell type (i.e. nodule or cord) is the difference with normal cells in 
intracellular metabolome the largest?  Thirdly, the Warburg effect was tested by inducing 
hypoxia in the disease cell types. The study employed GC-MS for metabolic profiling and 
identification revealed a few yet important metabolites that were significantly dysregulated 
in disease compared with fascia. Supervised analysis methodologies such as DFA and 
ANOVA-PCA were employed in addition to unsupervised methods (PCA) to make 
inferences from the mass spectral data. Metabolites involved in amino acid metabolism were 
significantly down-regulated in nodules including leucine, phenylalanine, cysteine, aspartic 
acid and a sugar. Leucine and a sugar were also significantly down-regulated in cords, in 
addition to these, metabolites from carbohydrate metabolism, cofactors and vitamin 
metabolism pathways i.e. glycerol-3-phosphate (up-regulated) and pantothenic acid (down-
regulated) respectively were identified.   
The question whether the metabolites dysregulated in fascia upon perturbation are the 
same as those dysregulated in nodule and cord is difficult to address from this analysis alone, 
as only cysteine and aspartic acid (both down-regulated) were common to both. Whether this 
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was a true correlation or by chance alone has been investigated in the transcriptomes of these 
subjects addressed in Chapter 5. Furthermore from Table 6, the perturbation effect caused by 
inducing hypoxia to disease cells revealed a large numbers of metabolites that were 
significantly up/down-regulated. These were mostly involved in amino acid metabolism and 
also carbohydrate metabolism. Whether this correlation could also be observed at the 
transcriptome level was then further investigated in Chapter 5.  Total RNA from DD nodules 
and fascia from 1% and 21% (from three patients) were used as the maximum difference in 
metabolites numbers was observed in nodules than cords. Since the SON samples were a 
different cell type from all others (fascia vs. epidermis in PCA analysis), it was excluded 
from the transcriptome analysis.  
One of the major strength of this study was the novel approach to harvest, extract 
both metabolites and RNA without affecting the RNA integrity. This method was previously 
attempted in neuroblastoma cells lines [132] but an improved method had been implemented 
here. The extraction steps were in total three (not four as previously described) at 4
o
C and 
the RNA quality was preserved. The co-extraction of transcripts and metabolites is believed 
to be important because the amount and integrity of both mRNA and metabolites are 
unaffected from the dual analyte extraction procedure.  
In Chapter 5 the DD nodules were compared with normal and perturbed fascia, to 
investigate the Warburg effect in the DD transcriptome. The study employed Affymetrix 
Human Genome U133 Plus 2.0 GeneChip oligonucleotide arrays to determine transcript 
profiles of fibroblasts cultured in normoxic and hypoxic conditions. The study revealed a 
small number of DE transcripts that were common in N21 vs. F21 and F1 vs. F21 analysis. 
These transcripts were involved in the following pathways: - MAPK signaling pathway, 
ECM-receptor interaction, p53 signals pathway, tyrosine metabolism, nicotinate and 
nicotinamide metabolism, phenylalanine metabolism and vitamin B6 metabolism. Since so 
many DE transcripts were identified from microarray analysis it is difficult to assess whether 
these correlations were true or by chance. This was further explored through network 
analysis using IPA in Chapter 6. The common DE genes can be seen in Figure 44b. 
The perturbation effect in DD nodules caused by hypoxia was also examined to 
address whether the dysregulated metabolites also can be measured by this study to correlate 
at the transcriptome level. Further we would like to address which of the identified candidate 
DE transcripts/genes and metabolites from Chapter 4 show congruence across the various 
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levels of systemic description in the context of pathways i.e. the DD metabolome and 
transcriptome. Integration of these complex data sets has been a key challenge and is the 
objective of Chapter 6, which involved mapping molecules from one analysis onto disease 
networks of known genome wide pathway maps. Several methods for microarray data 
analysis and metabolite datasets were explored. As the vast number of results from the 
microarray study resulted in an abundance of DE transcripts, three normalization methods 
complemented by two Bayesian methods; limma and puma were used to make statistically 
significant inferences from the data. The limma method was found too stringent while the 
puma algorithm allowed for maximal inference from the data. Based on the puma method, 
little synchrony in DE transcripts were observed from N21 vs. F21 and F1 vs. F21 analysis 
gene lists. From the unique 119 DE probe lists identified in N21 vs. F21 analysis, the 
following pathways were highlighted:- cell adhesion molecules, ECM-receptor interaction, 
neurotrophin signaling pathway, nicotinate and nicotinamide metabolism, cysteine and 
methionine metabolism, ether lipid metabolism, selenoamino acid metabolism, tryptophan 
metabolism, tyrosine metabolism, valine, leucine and isoleucine degradation and vitamin B6 
metabolism. A number of these pathways are amino acid metabolism pathways, and so we 
can confirm there is a strong correlation in DD at both the transcriptome and downstream in 
the intracellular metabolome. From the perturbation effect in N1 vs. N21 fatty acid 
metabolism, toll-like receptor signaling pathway, biosynthesis of unsaturated fatty acids, 
PPAR signaling pathway, citrate cycle (TCA cycle), glycine, serine and threonine 
metabolism pathways were enriched. Again this strengthened our hypothesis that DD is a 
disease of networks, where molecules are interconnected and a number of amino acid 
metabolism molecules are actively DE in DD nodules and this perturbation effect is 
observed at both the transcriptome and metabolome levels within a cell. 
 The same analysis methods were not applicable to metabolomic data sets as by 
contrast the variables (metabolites) are far fewer and appropriate chemometrics approaches 
were employed. If both „omic data sets could be normalized using the same methods then 
statistical significance and congruence between the identified transcript and metabolites 
would be more powerful to facilitate interpretation in terms biological relationships. At 
present the two „omics studies must be analysed separately using different yet most suitable 
methods. 
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New data analysis methods need to be derived to integrate these heterogeneous data 
sets. A correlation between protein and metabolites is being made [168]; these molecules can 
be identified through mass spectrometry. This is not possible for transcripts. To enable data 
integration Ingenuity Systems now allow incorporation of small molecules (HMDB ID‟s and 
CAS registry numbers) in addition to gene/transcript/enzyme data for network analysis of 
network eligible molecules present in the Ingenuity Pathways Knowledge Base. In Chapter 6 
we first integrate the candidate metabolite with the candidate transcripts for each pairwise 
analysis, and then map these networks onto networks generated for N21 vs. F21 analysis.  
 Using the currently available technologies, we have intended to address the overlap 
between transcripts, and metabolic activity altered by oxidative stress using DD fibroblasts 
as an experimental system. As environmental factors are considered to play a role in the 
development of DD, data from proteome and epigenomes should also be studied within a SB 
framework.  
 A major conclusion from this correlation analysis is that (from Tables 6,7, 11 and 
Figures 44, 58, 66 and 67), it relatively few metabolites/transcripts identified as significantly 
dysregulated in F1 vs. F21 analysis were present in N21 vs. F21 analysis. From these 
systematic analyses it is now appropriate to challenge the first hypothesis that difference in 
disease and healthy cells maybe akin to the differences in healthy cells in normoxia and 
hypoxia. As only a very small number of significant molecules coincide in F1 and N21 
candidate lists. In Chapter 6 these significant candidates (i.e. metabolites and transcripts) 
from Chapters 4 and 5 were integrated to visualize relationships using network analysis (e.g. 
candidate metabolites and candidate (prominent) transcripts in F1 vs. F21 using IPA and 
these networks are mapped on the networks from significant molecules in N21 vs. F21 
analysis. From Figures 66 (F1 candidates) and 67 (N1 candidates) superimposed onto Figure 
58 (N21 vs. F21 candidate molecules), this can be observed and that hypoxia has an opposite 
effect, few molecules were in common and SATB1 being one of them, was upregulated in 
F1 as well as N21. 
 It should be emphasized, here that the above conclusion is based on a correlation 
analysis only and not considering the biological relationships between transcripts, proteins 
and their downstream metabolites. In depth knowledge of cell biology would greatly 
facilitate further examination of these molecules in the respective networks and also 
knowledge of which metabolites are related to certain proteins.  
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 In this study we have also validated the hypothesis that changes of metabolite levels 
upon perturbation would reveal changes at the transcript levels (or perhaps vice versa). This 
has been observed both in healthy and disease phenotypes. Large and quantitative transcript 
and metabolite data was acquired from techniques currently allowed. However until the 
relevant biology is uncovered there are concerns regarding the interpretation expressed 
above. Following-up with future experimental work will ratify these conclusions/hypotheses. 
Through this thesis some of the technical challenges associated with working with 
complex organisms (i.e. human cells) using a SB approach are addressed. These successfully 
addressed aspects are:- (i) system wide component identification and quantification (“omics” 
data) at the level of mRNA, and small molecular weight metabolites; (ii) experimental 
identification of physical component interactions, for information processing networks; (iii) 
and integration of heterogeneous data sets. The next major challenges are to address which 
computational inferences ought to be made from the structure, type, and quantity of 
component interactions from these data. This step is essentially required to achieve a 
holistic, quantitative, and predictive understanding through mathematical models that will 
enable an iterative cycle between prediction and experiments, the hallmark of systems 
biology. In addition a major challenge is to understand heterogeneity both at the biological 
and cellular levels (e.g. patient, technical, biological variability).   
 
Finally future work that could be pursued from this thesis would involve the following as 
illustrated in Figure 68 (i.e. the next steps from page 42):- 
1. Reconstruct integrated cellular networks into an in silico model. 
2. Reconcile the experimentally observed responses with those predicted by the model. 
3. Design and perform new perturbation experiments to distinguish between competing 
model hypotheses. 
Chapter 7                                                                                                                            Conclusion and Outlook 
222 
 
Experimental data
Experimental data
Modeling Prediction
Determine fluxes 
through metabolic 
networks
Determine fluxes 
through signaling and 
regulatory networks
Identification of 
components
Identification of 
interactions
Quantification of 
interactions
 
Figure 68 Future outlook for a DD systems roadmap. The comprehensive component concentrations identified 
in this thesis through omics studies provide input data for inferring component interactions using computational 
methods. The challenge is for computational modeling methods yet to be developed to enable prediction of the 
functional network state from the concentrations and to infer the information processing network that controls 
the functional state. 
 
In conclusion, it should be recognised that increasing sample replications is not always 
possible, particularly for clinical samples where patients are under treatment and any new 
diagnostic test is a secondary goal. Therefore, there needs to be greater emphasis on more 
robust experimental design. For example, to avoid sample bias, adequate matching of 
patients with disease to those who are healthy, in terms of gender, age, BMI, and ethnicity, 
as well as other extrinsic factors such as metabolic rates, pharmaceutical use and diet. In 
addition, if future studies include females or patients with pre-existing medical history of 
other disease e.g. diabetics then additional factors such as diurnal effects should be 
considered. All of these factors will significantly influence the subject‟s physiological 
profile, and these need to be carefully considered when generating a robust experimental 
design.  
This novel study has demonstrated a major advancement in understanding DD. 
Systematic hypothesis driven studies have been performed to investigate the DD state 
dynamics. A number of dysregulated metabolites and transcripts involved in amino acid 
metabolism, carbohydrate metabolism and also metabolism of cofactors and vitamins have 
been identified from these integrative analyses. Upon perturbation several of these 
transcripts and metabolites involved in the mentioned pathways were significantly 
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dysregulated. For the first time, early passage numbers are shown to provide representative 
metabolic and transcript fingerprinting for investigating DD. A parallel analysis of transcript 
and metabolic profiles of DD fibroblasts is performed and the parameters are correlated 
across the various levels of systemic description. This will now enable us to examine the 
extent to which systems biology helps investigate pathological mechanisms in DD other 
related connective tissue disorders. This thesis should provide a fundamental change in DD 
research.
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Abstract 
 
Dupuytren‟s disease (DD) is an ill-defined fibroproliferative disorder affecting the palms of 
the hands of some Northern Europeans.  Cellular components and processes associated with 
DD pathogenesis include cytokines, growth factors, adhesion molecules, and extracellular 
matrix components. Free radicals and localised ischemia may trigger the proliferation of DD 
tissue.   Histology has confirmed the presence of collagens, myofibroblast and myoglobin 
proteins in DD, but at widely varying abundances.   Several genes are over- or under- 
expressed in DD tissue.  Although the existing data sets contain potentially valuable (though 
largely un-interpreted) information, the precise aetiology of DD remains unknown.  We 
question whether seeking further information about DD in ways that assume the disease to 
be due to a single faulty gene, is likely to lead to a breakthrough.  Thus we propose that DD 
is in fact a disease of several networks rather than of a single molecule per se, and show that 
this accounts for the experimental observations.  We outline how DD may be investigated 
more effectively by employing systems biology which considers the disease process as a 
whole rather than focusing on specific molecules.   
 
Key words 
Dupuytren‟s disease/contracture, systems biology, transcriptomics, gene expression 
profiling, metabolomics, proteomics, modelling, free radicals, myofibroblast, multifactorial 
disease. 
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Introduction 
 
Although Dupuytren‟s disease (DD) is commonplace in General Practice and despite 
decades of both experimental and clinical investigations into the disease, its precise 
aetiology remains unclear.   DD resides within the poorly understood, yet important category 
of superficial quasi-neoplastic proliferative fibromatoses [1].  Phenotypically, it is a nodular 
palmar fibromatosis.  It often causes permanent flexion contracture of the 
metacarpophalangeal (MCP) and proximal interphalangeal joints (PIPJ) of the digits [2] 
(Figure 1) leading to loss of function, discomfort and deformity of the hand.  Ultimately, this 
then leads to a permanent contracture of the involved digits [2-6].  
DD is a non malignant disease as it does not metastasize [7]:  it may invade locally 
within the palmar aponeurosis of the hand (sparingly supplied with blood vessels as 
compared to other parts of the body) but it does not disseminate to other tissues.  DD 
behaves as a benign neoplastic disorder:   DD is progressive and irreversible with a high rate 
of recurrence after its main treatment, i.e. surgical excision [8].   The increasing severity and 
recurrence can lead to amputation of the affected digit [9-11].  A thorough understanding of 
the diagnostic, prognostic and theragnostic indicators affecting the disease is therefore 
important.    
The three stages of DD growth (proliferative, involutional, and residual) involve 
myofibroblasts [12-15].   DD is associated with abundance of collagen, fibronectin, 
integrins, cytokines and many other growth factors [2, 9, 16-18].  Differential gene 
expression microarray studies and biomarker identification strategies found the expression of 
several genes correlate with DD [19-28].  Nevertheless, none of these studies has established 
the molecular mechanism of DD formation and hence the molecular basis of its diagnosis 
and therapy is not in sight.  This is unlike diseases such as cancer, where at least the 
oncogenes have been identified, albeit not as single causes [29]. 
Systems biology is one of the most widely discussed fields among the emerging post-
genomic disciplines [30].  Its bottom-up variant combines mechanistic modelling with 
quantitative experimentation in studies of genetic networks, signal transduction pathways, 
metabolic networks and their integrations [30-37].  It aims at understanding how the 
interaction of multiple components within a cell, tissue, organ or indeed individual leads to 
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much of the biological function.   The mathematics and the quantitative experimentation are 
not aims in themselves but merely serve to address the full complexity and emergence of 
biological phenomena at all functional levels within the system being studied (from cell to 
ecosystem) [30].  
  Systems-level approaches are beginning to make some pace towards scientific 
comprehension of pathway control, regulation, and function [38-41].  This has improved the 
understanding of some diseases [42], and has provided new rationales for drug discovery 
[43-45]. More than 1800 publications on DD have appeared since the original publication by 
Guillaume Dupuytren in 1831. The field of Systems Biology is growing exponentially with 
more than 8500 papers to date. Many characteristics and the complex biological behaviour 
of DD fibroblasts may constitute an invitation to a systems level approach to DD at both the 
cellular and the molecular level.  In this review, we outline such an approach.    
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Review criteria 
PubMed and Scopus searches were conducted to identify all relevant scientific literature 
evaluating the pathogenesis of DD, published in English to in or before June 2010 (with the 
addition of early literature in French).  Studies were confined to cytogenetic studies, 
histological findings, genomic approaches and biomarker-related discoveries of 
biomolecular components involved in the pathogenesis of DD.  The keywords used in 
various combinations included (* used as wildcard truncation): Dupuytren* disease, 
contracture, gene expression, microarray*, chromosome, cytogenetic*, *array, treat*, 
therap*, manag*, surg*, excis* fibroblast*, tissue* biopsie*, cel* plus character searches for 
animal or in vitro studies and studies evaluating prophylactic treatment.   Review articles 
were used as additional sources for primary papers by cross-checking the reference sections 
with the master list of compiled articles.  Full text articles were retrieved for those studies in 
which subsequent findings had been reported from the same research group.  The 
methodological quality of each paper was examined (for example, whether statistical data 
analysis was sufficiently detailed to allow for reproducibility).   Each study was assessed in 
terms of the direction of the conclusions vis-à-vis the phenomenon investigated, whether 
positive, negative or inconclusive.   
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Dupuytren’s disease and its many faces  
Connective tissue fibrosis  
Human skin exhibits a remarkable diversity in structure and function across anatomic sites 
[46].  Fibroblasts are the principal cells of this stromal tissue.  They are responsible for 
extracellular matrix (ECM) synthesis in connective tissues and thereby play a vital role in 
tissue repair and wound healing [7, 47].   In the various connective tissues where they occur, 
they constitute a heterogeneous population of cells [47-49].   Many diseases are associated 
with fibroblasts, either through fibroblasts being implicated in their aetiology or because of 
the fibrosis consequent to damage to other cell types.  Fibrosis is a consequence of excessive 
synthesis and deposition of collagen by abnormal fibroblasts [27].  The ensuing excessive 
ECM accumulation is a common feature of many connective tissue diseases.  Fibrosis can 
affect not only the skin but also internal organs such as lungs and kidneys, leading to organ 
dysfunction and failure.   Clinical examples include renal interstitial fibrosis [50], 
scleroderma, sarcoidosis [51], idiopathic pulmonary fibrosis [52], retroperitoneal fibrosis 
[53] and DD [54].  A complex network of intercellular interactions involving a diverse range 
of molecules, including growth factors, cytokines, chemokines and endothelin may drive the 
pathological events that ultimately lead to uncontrolled connective tissue fibrosis.  
 
Pathophysiology 
The pathophysiology of DD is thought to arise either from a defect in the wound repair 
process or from an abnormal response to wounding.  These hypotheses are based upon 
biochemical characterisation of affected tissues showing increased deposition of collagen III 
relative to collagen I and increased levels of collagen hydroxylation and glycosylation [55].  
We note that these hypotheses are non-molecular and may associate the disease with effects, 
rather than with a single cause. The following sections will reflect upon the current 
understanding of DD pathophysiology. 
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The myofibroblast  
An early attempt at a functional interpretation of the histopathological changes observed in 
DD settled on the assumption that the cellularity (quantified as the cellular density) of the 
DD nodules (see below) was indicative of the activity of the disease [6].  Later, the disease 
was classified into three stages: proliferative, involutional and residual.  The diseased tissue 
was further subdivided into the essentially fibrous nodules, reactive tissue, and residual 
tissue.   
Normal palmar skin is similar to the skin of the sole, and differs from skin covering 
the rest of the body.  Essential to the dermis are the fibroblasts with spindle-shaped cell 
bodies and nuclei that produce fibres, which can be seen by light microscopy.  Collagen is 
the most abundant constituent of these filamentous components.  Further investigations into 
the ultrastructure of DD tissue revealed the presence of myofibroblasts at various 
abundances. These specialised mesenchymal cells express smooth muscle α-actin, in which 
an acquisition of a smooth muscle like function may explain the contractility observed in DD 
[13].  
 
Cell heterogeneity 
Fibroblasts are identified by their spindle-shaped morphology.  They possess the ability to 
adhere to plastic culture vessels, and are thus identifiable upon the absence of markers for 
other cell lineages.  The presence and role of myofibroblasts in DD have been studied by 
many independent authors, mostly revolving to similar conclusions, which are summarized 
below. 
Ultrastructural studies confirm that DD tissues can be classified into several stages 
according to their cellularity  [6].  These different stages may co-exist in the same specimen, 
with different cell populations at maximum density in each stage.  DD contains two 
structurally distinct fibrotic elements; the nodule and the cord.  The nodule is described as a 
highly vascularised tissue containing a large number of fibroblasts, with a high percentage 
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being recognised as myofibroblasts due to their expression of the α-smooth muscle actin.  
The cord is relatively avascular and acellular; collagen-rich with few myofibroblasts.  The 
haematoxylin and eosin stained DD sections shown in Figures 2(A) and 2(B) demonstrate 
large numbers of relatively cellular (nodules) and relatively a-cellular, tendon-like regions 
(cords).  There are different opinions regarding the origin and development of this aspect of 
the DD phenotype, viewing either the nodule as developing into the cord as the disease 
progresses over time or, the two structures representing independent stages of the disease.     
The presence of myofibroblasts in DD has inspired the histopathological literature 
[56-58]:  Their morphologic characteristics of being both a fibroblast and a smooth muscle 
cell might be related to the contraction involved in DD.   In terms of their ultrastructure, DD 
myofibroblasts resemble myofibroblasts of granulation tissue thought to be responsible for 
contraction during wound healing.  The Dupuytren myofibroblast synthesizes fibronectin, an 
extracellular glycoprotein that connects myofibroblasts and connects them to the 
extracellular stromal matrix through an integrin.  In a study of 43 cases of DD tissue, 
histopathological changes suggested that certain growth factors may induce proliferation of 
such genetically abnormal myofibroblasts [15].   
Not all palmodigital aponeurotic structures are affected by DD.  The areas that are affected 
macroscopically, do so at an irregular depth and distribution, with the more superficial layers 
and ulnar side of the palm being affected most.  Macroscopically, neither the deep 
retinacular tissue that includes the transverse palmar ligament or fascia also known as 
“Skoog‟s fibres” nor the fibrous flexor tendon sheaths, appear to be involved in DD.   
Recent advances in microarray technology and bioinformatics have revealed an 
appreciable cell-to-cell heterogeneity:  According to genome-wide gene expression profiles, 
fibroblasts come in various subtypes [48].   In one study, fibroblast samples were clustered 
on the basis of the expression levels, using the Partitioning Around Medoids algorithm [59].  
This identified diverse sets of genes being expressed in the different subtypes.  The authors 
proposed that different anatomic sites have characteristic, distinct phenotypes, which 
persisted in vitro even when fibroblasts were isolated from the influence of other cell types.  
They termed this phenomenon „topographic differentiation‟.  We note that expression 
differences at the level of mRNA need not necessarily lead to functional differences, as 
control and regulation of cell function also involves other levels of cellular organisation such 
as translation and posttranslational modification [40].  Further substantiation that the 
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differences in mRNA expression correlate with differences at the proteomics, metabolomics, 
or morphological level should be welcome [60].  Chang et al. [48] did not find such 
differences when they evaluated cultured fibroblasts from diverse DD sites but all with the 
morphology of elongated, spindle-shaped cells.  Immunofluorescence microscopy showed 
that the fibroblast cultures were uniformly positive for a mesenchymal marker, but negative 
for markers of epithelial, smooth muscle, endothelial, perineural, and histiocytic cells.  The 
study revealed that the different passages of the same fibroblast culture clustered with each 
other, indicating that their in vitro phenotypes were stable.  One aspect of the topographic 
genomic program in fibroblasts may be the coordinate regulation and synthesis of the ECM 
proteins in a site-specific manner.  Taken together, the information suggests that fibroblasts 
with the morphology of elongated, spindle-shaped cells may themselves be more 
homogeneous and that the heterogeneity observed by Kaufman et al. [59] concerned 
fibroblasts differentiated to morphologically different subtypes. 
 
Growth factors  
Table 1 lists the components that have been implicated as modulators of the DD fibroblast 
transdifferentiation into myofibroblasts. Possible roles of these growth factors in DD 
pathogenesis  have been discussed in previous reviews [61] and we summarise just a few 
[62-70].  Among the cytokines, TGF-β is thought to be a significant inducer of 
myofibroblast transdifferentiation because of its  ability to up-regulate α-smooth muscle 
actin and collagen in fibroblasts, both in vivo and in vitro [66].   
 
Linkage analysis 
A study performed in a five generation Swedish family suggested that DD was inherited in 
an autosomal dominant pattern [71].  Mitochondrial and X-linked inheritance of this 
dominant factor in this family were ruled-out because of the male to female and male to 
male transmissions of DD.  Linkage analysis implicated a single region of approximately 
30cM on chromosome 16 bounded by microsatellite markers D16S3131 and D16S514, and 
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produced a logarithm of the odds (LOD) score >1.5.  Genotyping of individuals made up of 
four siblings affected by the disease but from another branch of the family together with the 
use of additional microsatellite markers supported linkage to that region and produced a 
maximal LOD score of 3.2 for D16S415, with four other markers producing LODs of >1.5.  
Linkage was further restricted to a single 6cM region between markers D16S419 and 
D16S3032 on chromosome 16.  
 When a disease is dominant, it is likely to be caused by a single allele of a single 
gene, and by the molecule it encodes.  From this perspective, the above findings would 
suggest that DD is a single gene disease.  However, to date, the linkage to a single gene has 
not been reported up to an LOD that is much more significant than the marginal value of 3 in 
this Swedish study and the penetrance in this study was incomplete.  In addition, the disease 
develops at an advanced age, there are many more sporadic cases of DD, and there are few 
such families for which the genetic analysis has been performed.  
 Other studies have shown assocation of the disease with other loci, including a 
positive association with HLA-DRB1*15 on chromosome 6 in Caucasians [72].   A study of 
20 British DD patients with a maternally transmitted inheritance pattern demonstrated a 
mutation within the mitochondrial genome (mitochondrial 16 S ribosomal RNA region) in 
90% of patients [73].  The defective mitochondria generated abnormally high levels of free 
radicals and induced defects in apoptotic mechanisms, and might hence directly participate 
in the pathogenesis of the disease.    
 
Free radicals  
Oxygen free radical production has been proposed to be one of the many factors contributing 
to tissue damage in DD [74].  A relation between localised ischaemia, superoxide free 
radicals, hydrogen peroxide, hydroxyl radicals and DD was projected from this study in 
which palmar fascia from 10 individuals who had DD were subjected to 0-60 minutes of 
tourniquet ischaemia.  Palmar fascia obtained from 10 suitable control patients (having 
carpal tunnel decompression) were subjected to the same insult.  The concentration of 
hypoxanthine was 6-fold higher in Dupuytren's palmar fascia as compared to the control 
palmar fascia.  The suggestion was that before the ischaemia and in DD patient tissue more 
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than in non-DD patient tissue, xanthine oxidase present in the endothelial cells around the 
small vessels was converting hypoxanthine into xanthine and perhaps further into uric acid, 
and this implies that measuring metabolites directly in tissue could be an important step to 
understanding the network of events involved in DD.  Both these steps are catalyzed by 
xanthine oxidase, with super oxide free radicals and hydrogen peroxide as by-products.  This 
mechanism is illustrated in Figure 3.  These free radicals would damage the perivascular 
connective tissue, with fibroblasts attempting to repair the damage.  The free radicals might 
directly stimulate proliferation of fibroblasts, as upon addition of free radicals to fibroblast 
cultures from DD palmar fascia, higher concentrations of free radicals led to toxicity, but 
lower concentrations stimulated fibroblast proliferation.  This group also suggested that the 
observed increase in collagen type III might be a result of fibroblast proliferation [74].   
Hypoxanthine was more abundant in nodular areas than in the tight fibrous cords.  
Based on these studies it is speculated that microvessel narrowing, leading to localised 
hypoxic conditions may be one cause of DD, secondary to age, smoking and other 
environmental factors.  Although this is a crisp hypothesis, most of the extensive histologic 
and biochemical studies on DD continue to be controversial.  Examples include studies on 
the types of collagen present in DD cell or tissue, the presence of the myofibroblast and 
factors such as vascularity including microvascular and macrovascular contributions.   
 
Animal models 
No animal model exists for the study of DD fibromatoses.  Yet, results of animal studies of 
possibly related diseases may be informative.  An attempt to explore the level of basic 
fibroblast growth factor (bFGF), a known angiogenic factor in dermal fibrosarcoma in 
transgenic mice, has revealed three stages of that disease, i.e. mild fibromatosis, aggressive 
fibromatosis, and fibrosarcoma.  The latter two stages were highly vascularised when 
compared with both the normal dermis and the initial mild lesion.  Analysis of cell cultures 
derived from biopsies of these lesions, revealed that bFGF synthesis occurred in all three 
stages as well as in normal dermal fibroblasts derived from the same mice.  However, the 
location of bFGF changed from its normal cell-associated state in the fibromatotic to 
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extracellular in the subsequent two stages.  In this multistep tumorigenesis pathway a 
discrete switch to the angiogenic phenotype may correlate with bFGF export [75]. 
Another study discussed the effects of electrical stimulation on joint contracture in 
rats [76, 77], while others have monitored loss of motion with time as well as myofibroblast 
numbers in a rabbit knee model of post-traumatic joint contractures [78].  The latter study 
revealed that myofibroblasts in the posterior joint capsules were elevated 4-5 times in the 
knees with contractures when compared with the contralateral knees.  The initial decrease in 
severity was followed by stabilisation of motion loss.  The association of motion loss with 
myofibroblast abundance mimics the human scenario of permanent post-traumatic joint 
contractures [78].   
 As a substitute for animal models for DD, in silico models using an integrated 
systems approach could ultimately investigate the effects caused by amplification or 
modification of various factors, such as determining change upon tensile force application.  
The creation of a virtual hand using in-silico modeling [79] would be of interest and may 
elucidate functional outcomes/behaviours of the proliferation of diseased cells.  Hereto it 
should be useful to map expression patterns onto such an anatomical model and to hook it up 
to in silico models of metabolism and gene expression [80].  The changes in diseased palmar 
fascia could be compared to the normal fascial state in the hand and allow detection of 
abnormal fibroblasts early on.  Such an approach could overcome the ethical issues in animal 
research studies [45].   
Hunting for the candidate gene by transcriptomics 
DNA microarray studies allow differential analysis of the expression of multiple genes [81].  
This should permit correlating gene-expression variations with DD.  Of course both effects 
and causes of DD would show up.  However, such microarray studies would test the 
proposal that (see above) DD is nothing more complictated than an (autosomal, dominant) 
single-gene disease.  In the simplest case, the DNA micro arrays should then show a strong 
correlation with a single such gene, which should moreover localize to a single 6cM region 
between markers D16S419 and D16S3032.  The genes localised on chromosome 16 listed in 
our previous study [21] are hemoglobin, alpha 2, cadherin 11, type 2, OB-cadherin 
(osteoblast), matrix metallopeptidase 2, hemoglobin, alpha 1, periplakin, tryptase alpha/beta 
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1, tryptase beta 2. However, the issue of bulk measurement caused by sample heterogeneity 
serves to raise the baseline signal of all transcripts and reduce the contribution of signal from 
the specifically targeted cells.  
Alterations of gene expression in Dupuytren‟s nodules [28], Peyronie‟s plaques [82], 
and cultured fibroblasts have been reported.  Subsequently, we optimized on unbiased 
experimental design, sample size, and on data sets to be large enough to elucidate the 
mechanisms underlying the disease process. The macroscopically distinct, fibrotic elements 
of the DD tissue, i.e. the nodule and the cord, were considered as two separate entities, as if 
arisen from separate precursor cells.  Gene-expression profiles were compared between 
diseased Dupuytren tissue biopsies (both nodules and cords) and corresponding healthy 
tissue (the transverse palmar fascia adjacent to the diseased site) from the same patients.  We 
also compared these gene-expression profiles with those from the palmar fascia of 
individuals not affected by DD [21].  This study confirmed the DD specific expression of 
many genes, some of which had been documented as such previously [16, 61].  Using a 
pathway orientated approach, several additional genes were found to be of statistical 
significance for DD.  The genes established as deregulated in DD belonged to a wide variety 
of categories, including immune response, angiogenesis, apoptosis, cell adhesion and cell-
matrix adhesion, cell cycle and proliferation, cell differentiation, transcription, development, 
signaling and signal transduction, protein synthesis and folding, oxygen transport, and 
carbohydrate metabolism (Figure 4). 
More recently, a study compared the gene expression profiles of fibroblasts isolated 
from Dupuytren patients and controls.  Here, the authors used two microarray platforms 
(Illumina™ and GE CodeLink™ Bioarray Systems) initiating a quantitative and comparable 
approach [83].  They again found tens of genes to be altered in mRNA expression level, 
which differed between the two platforms.  They confirmed the down regulation of three of 
the genes by QPCR, which included those encoding a proteoglycan, a fibulin and type XV 
collagen alpha 1 chain [83].  Again using PCR, Ulrich and colleagues found that DD tissue 
amplified mRNA encoding one metalloprotease and two tissue inhibitors of metalloproteases 
[84]. 
 The results are not particularly supportive of the hypothesis that altered expression of 
a single autosomal gene is solely responsible for DD.  Many more genes seem to correlate 
with the disease.  The possibility remains however that all these genes are downstream a 
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single key gene, the expression of which might have changed significantly but currently 
unnoticeably.   The observation that genes with fairly obvious functional connotations to 
DD, such as metalloproteases, proteoglycans and collagen components, have altered 
expression, brings home the message however that even if the disease were to have a single-
gene origin, its aetiology is likely to involve multiple regulatory pathways and genes 
downstream of such a key gene, the diversity of which in the human population would then 
cause appreciable dispersion in its pathology.  Up to now the hunt for the single DD gene 
has not only failed but also weakened its own motivation; there may be many genes 
involved.  The more definitive evidence of the effect of targeted knock outs or anti sense 
RNA is still lacking, in part because of the absence of a clear hypothesis on which gene 
would cause the disease, and the lack of animal models. 
 
Hunting for the candidate protein by proteomics 
Proteomics is the systematic, genome-wide analysis of protein identity, quantity, and 
function.  Proteins are closer to function than transcripts are, therefore proteomics has been 
thought to have more potential than genomics and transcriptomics for deriving clinically 
useful applications, in diagnostics, prognostics and therapeutics.  The DD proteome analysis 
venture began in 2006 with the study of protein expression profiles in an attempt to identify 
potential disease protein biomarkers [85, 86].  In one study, 2-D gel electrophoresis was 
performed to extract proteins from diseased tissue (nodule and cord), the Skoogs fibres, and 
normal control tissues.  MALDI-TOF-MS (matrix-assisted laser desorption ionization time-
of-flight mass spectrometry) was used to generate a peptide mass fingerprint that was used to 
search protein databases.  However, the authors did not report names of identified proteomic 
changes in their abstract. 
Another study employed Surface Enhanced Laser Desorption/Ionization Time-of-
Flight Mass Spectrometry (SELDI-TOF-MS) to analyse normal and disease palmar fascia 
from DD patients using Ciphergen's SELDI-TOF-MS Protein Biological System II (PBSII) 
ProteinChip reader [86].  The study revealed several differentially expressed low molecular 
weight (<20 kDa) tissue proteins and identified three disease-associated protein features 
(4600.8 Da, 10254.5 Da, and 11405.1 Da) that were elevated (5, 12, and 4-fold respectively).  
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Three potential low molecular weight protein markers (p4.6DC, p1ODC, p11.7DC) for DD 
were identified.   However, there has been some debate as to the reproducibility of SELDI-
TOF-MS [87], and this and perhaps the lack of overall coverage of the proteome means that 
the two studies are not comparable. 
More recently, a study using an integrative proteomic-interactomic approach [88] 
proposed several molecular processes (see below) to be involved in DD progression.  It 
coupled 2-D gel electrophoresis with MS and compared the proteomic profile of DD tissue 
with that of unaffected patient-matched palmar fasciae tissue.  Several proteins correlated 
with DD.  The findings were used to create a protein-protein interaction network 
(interactome) map on the basis of the proposed interactions in the Human Interactome Map 
(HiMAP) [89] and the Search Tool for the Retrieval of Interacting Proteins (STRING) [90]:  
Because it was not possible to design a complete interactome from the experimental data, 
several proteins were added to the experimental set to fill gaps so as to yield a complete 
network.  This integrated approach suggested several different pathways to be involved such 
as extra- and intra-cellular signalling, oxidative stress, cytoskeletal changes, and alterations 
in cellular metabolism.  In particular, ERBB-2 and IGF-1R receptors and Akt signalling 
pathway emerged as novel components of pro-survival signalling in Dupuytren‟s fibroblasts.  
One should exercise care however not to over-interpret these results, as they are partly based 
more on inference involving other protein interaction data obtained in different contexts.  In 
addition, increased activity of pathways need not involve increased protein levels [91] and 
increased pathway expression may be a homeostatic rather than a primary aetiological event. 
  
The dilemma: more or less data; less or more understanding 
With every paper about the genomics of DD, the enigma of the disease seems to increase.    
As more and more aspects associating with DD are spotted, we see less and less 
understanding of the disease for its many molecules [92].  The hypothesis that in DD a 
single gene is at fault, is likely to be false.  Even if the disease were set in motion by a single 
genetic factor, then it encounters so many diverse processes during its aetiology, that it will 
be co-determined by the many factors that regulate those processes.  Indeed, it is more likely 
that the networks governing differentiation of normal fibrocytes of the palm of the hand are 
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perturbed irreversibly such that they differentiate into muscle tissue without the proper 
controllers of contraction and relaxation.   It is also more likely then that there are a number 
of different sets of genetic perturbations that could cause the same type of perturbation that 
then leads to DD.  Here DD is much like cancer [42]. 
The dilemma is that although we now avail of an unprecedented set of methodologies 
for the identification and analysis of all the molecules in living cells, that methodology alone 
is not enough.  We need something substantially more to understand how all those molecules 
interact to create functional networks.  Seeing more molecules may not help our 
understanding.  Seeing the connections between them and more mechanism might.   
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Dupuytren’s disease and Systems Biology 
Where Systems Biology might come in 
Abnormal development of tissue such as in DD and cancer, stresses the surrounding tissue.  
Hence an association of these diseases with normal tissue repair processes should be 
expected.  Such an assocation does not imply that repair processes are causally involved in 
the development of disease.  The same is true for other homeostatic processes.  Because 
persistence of the disease may depend on the success of the homeostatic response of the 
surrounding tissue, it is difficult to distinguish between the genes involved causally in the 
development of such a disease and the genes involved in the homeostatic response.   
In addition, a characteristic of tissue repair processes mediated by growth factors is 
that once the original tissue state has been re-achieved, the autocrine and/or paracrine 
mechanisms return to normal; the repair process tends to be transient and experiments with 
insufficient temporal resolution may miss it.  A classic example is wound healing [17].  In 
the temporarily differentiated state, some genes are active and others are repressed.  
Identification of mechanisms of differentiation then requires the identification of the 
temporal patterns of gene activity that are causally involved rather than just consequences 
without causal significance.  These patterns may depend on DNA and chromatin 
modification [93], as well as on the activity of multiple regulatory proteins [94].  In turn 
these modifications and activities are functions of the state of the cells and of their growth-
factor enriched environment [95].   Their regulation may occur at different levels (Table 1) 
and thus, cell lineage and cell types such as fat, skin, epidermal, dermal fibroblasts and the 
roles played by them in, for instance, differentiation, should be another aspect of the 
exploration of genes involved in DD pathogenesis.   
More generally, there may be no process in any living organism that stands alone 
[96].  Processes are linked extensively, if not through metabolic or gene expression 
networks, then through RNAs (sense, anti-sense or micro [97]), or though dynamic 
ultrastructure [93, 98, 99].  To understand how living cells function, one needs to have a way 
to look at the operation and integration of several simultaneous processes, as a function of 
time.  Since the sum of a negative and a positive effect is important, yet uncertain in the 
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absence of precise assessment of magnitudes, the required approach needs to be precise 
experimentally and quantitative in the analysis.  Since virtually all molecules of a living cell 
are connected, the approach needs to relate to molecular biology as well as functional 
genomics [30]. It is in appreciating these concertations of the various levels of cell 
functioning, that systems biology might come to the rescue. 
This systems biology activity should differ from the traditional molecular biological 
approach, where reductionist strategies assist in the characterization of the molecular 
components of the much larger cellular system [100].  In molecular biology a „favourite‟ 
candidate gene or gene product may be investigated on its own (e.g.  by 
immunohistochemistry) using some pre-existing knowledge of its function but without 
simultaneously looking at the pathway in which it is active.  Whilst this approach is useful 
when detailing the molecular mechanism of action, it does not automatically lead to 
understanding of how the protein or gene acts responsively so as to make the whole cell and 
ultimately the whole organism, function.  Organisms depend on many more than a single 
gene function [101, 102].  Unless one gene or its product were the single rate limiting step 
for the organism or cell function (e.g. survival, proliferation rate) of interest, more than one 
gene product must be considered. 
 The attractive and thereby rather persistent concept of „the‟ rate limiting step in a 
network process has been invalidated for metabolic pathways [103], for gene expression 
circuits [104-106], and for signal transduction [107, 108].  Already in Escherichia coli gene 
expression is under tight and subtle homeostatic control, involving gene-expression and 
metabolic regulation through topoisomerase I, DNA gyrase, the supercoiling state of the 
DNA itself, and ATP simultaneously [104].  For signal transduction pathways the subtleties 
in control are not much less [107, 109-111].  Much the same applies to regulation [40, 112].  
Accordingly, the default way of examining how the functioning and malfunctioning of 
network processes is controlled and regulated in DD should reckon with the likelihood that 
many more than one molecular process is involved.  The systems biology developed and 
tested in simpler organisms and systems offers various methodologies to do so [41, 98, 100]. 
 An immense number of studies have been conducted at the genome and 
transcriptome (set of all mRNA molecules, or „transcripts‟, produced in a cell or a tissue) 
levels.  More are now following at the levels of the proteome, (set of entire complement of 
proteins expressed by a genome, cell, tissue or organism), interactome (interactions between 
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all molecules within a cell), and metabolome (complete set of small-molecule metabolites).  
A priori this functional genomics may have seemed a promising approach.  It should show 
most if not all the factors involved in a disease such as DD.  However, it has not yet 
delivered on its promises, neither in any disease, nor (yet) in DD (see the above discussion).  
This might be attributed to the sheer number of molecules involved, but then bioinformatics 
should know how to deal with those numbers.   
 What is the key issue here?   Why might the direct accumulation of knowledge of 
ultimately all components of a living organism, or of a disease, without much further 
processing, not lead to understanding of function or malfunction, of physiology and 
pathology? The reason may be:  most functions depend on the concerted action of a number 
of processes the rates and efficiencies of which influence each other.  For instance the 
synthesis of a given protein (e.g. myosin) will depend on the synthesis of 20 aminoacyl 
tRNAs which again depends on the synthesis of the corresponding amino acids.  A stark 
example is that of the molecule cyclin D which is involved in the mechanism of the cell 
cycle by oscillating in terms of its activity [113].  Alone in a test tube, cyclin D activity 
would not oscillate and it is only because of its dynamic interaction with a dynamic network 
of other proteins that cyclin D cycles and the cell with it [114]. Moreover these oscillations 
are generally found at the single cell level and as such analyses should be aimed at these 
entities rather than averages of the population [115]. 
 Systems Biology specializes in understanding the roles such interactions play in 
bringing about biological function [116].  It thereby aims to complete the large part of the 
job molecular biology and genomics fail to accomplish, i.e. the job of understanding 
physiology and pathology.  This is more easily said than done however.  It is the activities of 
all the components of living systems and their relationships to each other that multiply or 
integrate rather than add up to the living organism.  In recognition of this complexity, 
systems biology attempts to harness the power of mathematics, engineering, and computer 
science to analyse and integrate data from all the „omics‟ [35], ultimately through the 
construction of experiment-based, in silico models [117]. 
Molecular biological components and the systems in which they function (e.g.  
substrates, enzymes, metabolites, genes in a cell, tissue or organism) and pathways 
mediating their functional outcome, are many times more complex than networks and 
circuits such as the London Underground.  Yet, the London Underground is already 
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complex: making sure that one particular station functions efficiently such that each minute 
one train could depart, does not guarantee that indeed one train will depart per minute.  
Mostly likely, many fewer trains will depart because further down the tube there are other 
stations that are less efficient, or because at some stations up the tube excessive numbers of 
people wish to board or leave the train, or because the train driver overslept.    Network 
studies reside at the crossroads of disciplines, from mathematics (graph theory, 
combinatorics, probability theory) to physics (statistical thermodynamics, macromolecular 
crowding), and from computer science (network generating algorithms, combinatorial 
optimisation) to the life sciences (metabolic and regulatory networks between proteins and 
nucleic acids).  The impact of network theory on understanding is strong in all natural 
sciences [118], especially in systems biology with gene networks [119], metabolic networks 
[41, 120, 121], plant systems biology [122], and even food webs [123].  Yet, biological 
systems will not be understood by existing network theory alone.  Their properties are much 
more complex than the properties of standard networks, for instance in that their networks 
adapt and change temporary [124], are hierarchical in terms of space, time and organization 
[98], and have been optimized through evolution for multiple properties that we do not yet 
understand [41, 100, 125].   New network theories are needed and will have to be more 
targeted towards understanding biological systems functionally [126].  These will have to 
integrate strongly with genomics and molecular data, because different biological networks 
may need somewhat different theories, if only because their objective (evolutionary purpose) 
is different.  The Flux Balance Analysis objective function of maximum growth yield for 
instance [127], is irrelevant for the human erythrocyte and muscle cell, which do not grow 
[100].  For the former, the objective functions of oxygen carrying capacity plus binding 
capacity in the lungs and delivery capacity in the tissues, without consuming the oxygen 
needed by those tissues, will make more sense; for the latter, performance independent of 
oxygen supply will do.  It remains to be seen whether in the development of DD the flux 
pattern adjusts to a new criterion of optimality, such as in some cases of tumorigenesis 
[128]. 
 
System diseases versus molecular diseases  
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Noting that molecular biology and genomics do not suffice for understanding living systems 
is one thing, but actually making a difference by applying systems approaches, may be quite 
another.  We shall here sketch how a systems approach to DD might make a difference.  The 
first role systems biology may have is that of clarifying that DD is a type of disease that, 
although common, is not engrailed in scientific tradition, and should not be approached by 
traditional methodologies alone. For this we first need to clarify what the difference is 
between a systems-biology disease and a single-molecule disease.    Figure 5  illustrates this 
difference.  A single-gene disease depends in principle on a single gene only, or at least that 
is how it is often approached.  But of course, a disease cannot depend on a gene (if defined 
as the corresponding DNA sequence) alone:  it will depend on its gene product (F in Figure 
5(A)), and in fact on the molecular function of the latter.  For instance a muscular dystrophy 
could result from a mutation in the gene encoding myosin, the molecular function of which 
is muscle contraction.  If that muscular dystrophy would only be found when the myosin 
gene has been mutated and if the severity of the disease would not be influenced by other 
factors, then that muscular dystrophy would be a single-gene disease.  In actuality there are 
many different genetic lesions that lead to similar muscular dystrophies, including lesions in 
mitochondrially encoded genes [129].   
A better candidate for a mono-gene disease may be phenylketonuria, an inherited 
(autosomal recessive) metabolic disease that is largely due to mutations in the phenylalanine 
hydroxylase (PAH) gene [130].  However, its therapy (dietary restriction) shows that the 
disease can be influenced by external factors.  Moreover, mutations in genes involved in the 
synthesis of a cofactor of the phenylalanine hydroxylation reaction also lead to the disease, 
and there are multiple alleles of the PAH gene with different implications for the severity of 
the disease.  Hence even this disease exhibits characteristics of systems biology diseases, and 
therapy could well benefit from a corresponding approach. 
The dubious concept that diseases are essentially due to the perturbation of a single 
gene is pervasive, be it mostly in an implicit sense.  The concept is recognized in the gene 
hunt approaches to diseases where a transcriptome analysis is aimed at the identification of a 
so-called „candidate gene‟, where the word „candidate‟ refers to the implicit expectation that 
a single molecular culprit may be found for a disease or other phenotypic feature.  The early 
molecular biology of cancer was an example, with a hunt for the oncogene and before that, 
for the single molecular processes (membrane fluidity for instance) that could be held 
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responsible for the disease.  Of course for cancer this concept has long faded, thanks to the 
demonstration that cancer development requires cooperativity between at least three 
oncogenes [29, 131].  Indeed, many more than 70 oncogenes and tumor suppressor genes 
have been identified, which are not all involved in all cancers [29].   
 Figure 5(A) may be judged a caricature of single-gene diseases then, as most diseases 
have multiple genes associated with them.  However, such diseases could be considered to 
be a group of single-molecule diseases; i.e. many diseases each caused by a different single 
gene lesion, but all with similar phenotypes [132].  This would explain the association of 
multiple genes with the disease and still essentially reduce it to single-gene diseases (Figure 
5(A)).    The difference between a disease being a group of single-gene diseases and being a 
systems biology disease is that the former should still only depend on the single molecule 
that is faulty.  In the case of a group of single gene diseases, there should be no other faulty 
molecules important for that individual disease and there should be no influences on the 
disease severity of other gene changes (e.g. polymorphisms) or conditions (e.g. diet) on that 
disease.  Notably, a single patient‟s transcriptome should then show only changes in the 
single molecular culprit and not in many factors controlling the network leading to the 
disease.  And in the transcriptomes of different patients suffering from the same disease 
group, that single molecular culprit should be different.    
The suspicion that single-gene diseases may be rare, mirrors the point made above 
that there are few completely rate-limiting steps in cell biology.  Indeed, dominance should 
be common and loss of function in heterozygous deletions rare:   The very fact that most 
pathways consist of many steps, strongly reduces the average effect a heterozygous deletion 
should have on their flux [133, 134].  The phenomenon of parallel pathways further reduces 
the effect of deletions [135].  Single gene perturbations would thereby rarely lead to disease.  
For disease to occur multiple genetic lesions are likely to be required. 
What then is a systems biology disease?  As illustrated by Figure 5(B), in a systems 
biology disease the function that is compromised depends cooperatively on a number of 
pathways, the functioning of each of which again depends on many cooperating molecular 
factors.  In systems biology diseases one would typically find multiple changes in the 
transcriptome of each patient, differing between individual patients but such that all have a 
very similar disabling effect on network function.   
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It might seem that the identification of the variety of transcriptome changes that lead 
to the same network change and hence to the same effect on function could be achieved by 
top-down systems biology, i.e. by measuring variations of transcriptomes and function and 
by then designing the linear combination of transcriptome changes that would 
computationally lead to the most extreme effect on function and malfunction [136].  
However, functional dependencies are frequently nonlinear in biological systems and 
therefore more mechanism, kinetics and topology of the network needs to be known to make 
this strategy effective.  Ultimately a dynamic model that is true-to-reality should be able to 
do this job, but that of course requires an enormous experimental effort before such a model 
would be reliable enough [137, 138].  Until that time, it would seem that an experimental 
diagnosis to see whether the observed changes in gene expression do cause the changes in 
function that are essential for the disease to occur, remains an essential components of 
systems biology. 
Identifying a disease as a systems biology disease does not dispel molecules from its 
pathology:  molecules are always involved.  The issue is whether the change in networking 
of the molecules is crucial for the disease, i.e. whether the disease is more a consequence of 
faulty networking than of malfunctioning of individual molecules.  If the disease is due to 
molecules defaulting at their own molecular function only because of changes inherent to 
those molecules (such as through mutations), it should perhaps be called a molecular disease.  
For every disease it may be useful to decide whether it is more molecular or more systems 
biological in the above sense. 
 Once a disease has been recognized as a systems biology disease, then what 
difference should this make for research, diagnosis and therapy?  The answer is 
straightforward:  When dealing with a network disease, one should deal with the network; 
when dealing with a molecular disease one should concentrate on the molecule.  For systems 
biology diseases, transcriptome patterns should be mapped onto the known cellular 
pathways.  One should not try to establish correlations between individual mRNAs and 
disease, but rather between the effects of mRNA changes on a pathway and the disease.  The 
concept „candidate pathway‟ or even „candidate network‟ should be substituted for 
„candidate gene‟.  In addition, cell function is only partly controlled and only partly 
regulated at the level of transcription [98]. Hence one should also involve the levels of the 
proteome, of the metabolome, and of function, and not each independently but all together; 
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then, one should ensure that the changes observed make collective sense.  For if some factors 
in a pathway change up and others down, this may not enhance function; the changes should 
be related to pathway kinetics or control and it should be checked whether together they 
affect the function or the malfunction that is of interest for the disease.  Figure 6 shows that 
the issue may be complicated further because a disease may readily involve more than one 
function.  Persistent malignant cancer for instance may involve proliferation, lack of 
apoptosis, metastasis and multiple drug resistance. 
 
Is DD a molecular or a systems biological disease? 
After defining the differences between molecular and systems diseases, we should now 
establish which of the two DD is.  One aspect comes to mind immediately:  DD has been 
identified as a disease inherited in an autosomal dominant pattern [71].  It was linked to a 
single 6cM region on chromosome 16.  This would suggest that all DD patients should have 
a mutation in this part of their genome, and that transcriptomes of DD patients should be 
altered in terms of the level of the transcripts encoded by this part of the genome, or in terms 
of the coding sequence of one of those transcripts.  However, the dominance was incomplete 
and has only been observed in a single Swedish family.  This suggests that the genes on 
chromosome 16 are only dominant when other genes in the genome are of certain allelic 
forms (i.e. the ones that happen to dominate in that particular Swedish family).  Moreover, in 
many other cases many other mRNAs were changed in expression levels, although it 
remains to be analyzed whether in those papers there was always a change in an mRNAs 
from the 6 cM region on chromosome 16. In our own studies, the DD-nodule transcriptomes 
of individual patients all exhibited multiple changes in mRNA levels and these changes 
overlapped, but were not identical between individuals. The proteome did not point at a 
single protein either.  The functional studies pointed at myofibroblast enrichment, but not 
clearly as the sole cause and neither was a causal relationship between a gene on 
chromosome 16 in the 6 cM region and differentiation of myofibroblasts established. This all 
shows that DD is not a single-gene disease and suggests that it is not just a group of pure 
single-gene diseases either. 
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 For further understanding of DD then, a hypothesis-driven systems biology approach 
should allow for selection of candidate pathways.  This could be based on a priori 
observations in human in vitro or in vivo (linkage and expression studies, for example), or on 
the basis of knowledge in related diseases (such as plantar fibromatosis, peyronies, musculo-
aponeurotic fibromatosis and even keloid disease).  Inter-relationships may be sought 
between hypothesized underlying mechanisms governing these fibrotic disorders and 
physiological changes predicted for changes in molecular and environmental changes 
impacting on those mechanisms.  This could then be extended to understand inter- vs. intra-
individual variability.   Such analysis should lead to hypotheses about mechanisms by which 
network changes would cause the DD phenotype.  By bringing about those network changes 
by multiple molecular interventions in a tissue culture model system for DD, the hypotheses 
could then be tested.  Such an approach should also help put into perspective existing 
inconclusive discoveries.  It would thereby maximize the utilization of data obtained in 
molecular approaches from molecular biology, which provide an extensive database.  Then 
systems biology would reduce this to a smaller but more implicative knowledge base, 
perhaps in the sense of a live model repository [117]. 
 
Systems Biology advances  
Already, systems-level approaches are making a pace towards scientific understanding and 
biotechnological applications [30].  Recently, the National Heart, Lung and Blood Institute 
(NHLBI) of the US‟ NIH initiated the Program for Genomic Application (PGA) of 
advancing functional genomic research.  One such PGA is known as CardioGenomics in 
which the primary aim is to study how the transcriptional network of the cardiovascular 
system responds to genetic and environmental stresses and how the network is altered in 
disease conditions.  Research in CardioGenomics focuses on transcriptional profiling of 
murine models of cardiomyopathy, on the diseased versus normal human myocardium, and 
on identification of the gene mutations that cause familial hypertrophic cardiomyopathy and 
left-heart obstructive lesions.  Meanwhile studies using a CardioChip (a custom built cDNA 
microarray), have identified differentially expressed genes in diseased conditions as 
compared to the normal heart [139].  With this approach the limitations of molecular, genetic 
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and functional genomics research in gaining a complete understanding of a complex disease 
such as heart failure are again being highlighted. Many recent articles illustrate the use of 
proteomics technology to investigate the disease-state proteome using a multitude of 
experimental techniques and elucidate biomarkers that may be indicative of pathological 
network states [140, 141], and the same process is happening within the area of 
metabolomics [142]. However, the subject is in urgent need of a systems biology approach.  
There is an extensive and successful systems biology activity that focuses on the heart [143].  
The focus of that activity has however been on the electrophysiology and the relationships of 
its models with metabolism and gene expression is still in the making, e.g. in an important 
project, the virtual physiological human [144, 145].  
Cancer cannot be considered as a single molecule disease as so many oncogenes have 
been identified.  Because there is no cancer that is caused by a single mutation (even 
retinoblastoma is focal, i.e. does not occur in all cells of the individual with the responsible 
mutation), cancer is not just a collection of single-gene diseases either [29, 131]:  Complex 
networks of relationships between genes, gene products and/or proteins govern neoplastic 
processes [29, 42].  Cancer requires the simultaneous deregulation of a set of genes [29, 
131], which act in a cooperative mode.  In other words, cancer requires the deregulation of a 
network of genes or even of various networks of genes.  It is a systems biology disease 
therefore [42], or even a collection of systems biology diseases [132]. Whole-genome 
association scans and mutational screens of cancer genomes  identify gene interactions that 
associate with cancer [146].  It is now time to project these discoveries onto cancer 
pathways, or onto normal pathways that are essential for tumors to develop into malignancy 
[147]. 
Systems Biology as integrator of heterogeneous ¬omic datasets  
The ¬omics experiments generate heterogeneous data and meta data torrents.  Not only 
should this data be put to best use when studying the complex system of interest through 
systems biology, the modelling by systems biology would serve as a way to organize the 
data rationally.  These heterogeneous datasets are normally deposited in a broad spectrum of 
public and commercial databases and for them to be put into context it is important that both 
their own format and their annotation are standardized.   Emerging standard languages such 
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as the systems biology Markup Language (SBML) [148], Cell Markup Language (CellML) 
[149], Cell System Markup Language (CSML) [150],  Biological Pathway Exchange 
(BioPAX) [151] and Systems Biology Graphical Notation (SBGN) [152], and modelling 
tools such as COmplex PAthway SImulator (COPASI) [153], Cytoscape [154] and Pathway 
databases (e.g.  Ingenuity pathway analysis software) facilitate data representation and inter-
operability from leading multidisciplinary research groups [155].  Important also is the Java 
Web Simulation (JWS) facility which quality controls kinetic models and puts them into a 
live repository, enabling through-web experimentation in silico for scientists naive with 
respect to modeling but experiment prone [156].  BioModels is a parallel model repository 
not built for in silico experimentation but focusing on annotation [157]. 
Systems biology is gaining increasing support from a wide variety of sources.  To 
name but a few, UK‟s BBSRC and EPSRC have funded six Systems Biology research 
centres and three doctoral training centres dedicated to Systems Biology, the Wellcome 
Trust supports the Heart Physiome Project and the Integrative Animal and Human 
Physiology Initiative [158, 159].  Evidence from medical research charities [160] such as the 
Arthritis Research Campaign, British Heart Foundation and Cancer Research UK is 
indicative of systems biology becoming an increasingly important component of their 
research programmes.  The FP7 Marie Curie Training Network NucSys presents a 
nutrigenomic approach to aging-related diseases vis-a-vis the systems biology of nuclear 
receptors [161].  German BMBF‟s HepatoSys is focusing on quantitative understanding of 
complex and dynamic cellular processes in detoxification, endocytosis, iron regulation and 
regeneration in mammalian hepatocytes [162].  Switzerland and Luxembourg are the most 
active countries pro capita.  Other emerging Systems Biology includes the development of 
personalised medicine [163] and of the systems biology of ageing [164, 165] as well as 
integrative pharmacogenomics, biomarker discovery for disease prognoses, and therapy 
monitoring [166-171].  The field applies quantitative, mechanistic approaches to understand 
disease, cell, tissue or organism holistically from bottom up, top down and/or middle out 
[172] approaches.  There is great interest in biomarker discovery, and as many diseases are a 
result of genetic and/or metabolic disorders [173], it makes a great deal of sense to measure 
gene expression (transcriptome) and metabolites (metabolome) directly [142] at these 
functional levels with systems biology enabling  correct interpretation and prediction of 
functional outcomes [174]. 
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Imaging  
Finally, it would be incomplete to mention systems biology in medicine and not mention the 
advantages technological imaging has given us to capture disease [175].  Perhaps the biggest 
growth area in imaging technologies is fluorescence imaging, with various technologies 
being adapted for in vivo analysis; although recent advances in label-free methods such as 
Raman microspectrometry are also showing promise [176].  The development of imaging 
techniques, will allow researchers to address some of the questions in molecular oncology 
such as how the components of intracellular signalling pathways interact in real time (e.g. 
[177, 178]).  The current and developing instrument-based technological platforms 
(computed tomography (CT), magnetic resonance imaging (MRI), positron emission 
tomography (PET), confocal microscopy, and Raman microspectroscopy) already provide a 
platform for initiating a knowledgebase relationship between the clinician, patient and 
scientist.  However, a systematic analysis would fill missing gaps in this knowledge base, as 
illustrated in Figure 7.  Integration of the observation platform with dynamic-spatial models 
[79] has not yet been achieved much but should now raise the utility of the imaging 
approaches to new levels.  For DD the potential is to image the metabolic state of the various 
cells in the nodule and the cord as a function of contractile activity, in order to examine how 
that activity could be modulated.  At the cellular level the de- and re-differentiation of 
fibroblasts and myofibroblasts might be monitored and modelled. 
 
Discussion  
DD research has so far implicated a re-differentiation of fibroblasts into myofibroblasts.  
Functional genomics studies have highlighted multiple mRNAs of which the expression 
level differs between diseased and healthy tissue.  Extracellular matrix enzymes are involved 
in the disease.  High throughput and candidate-gene association studies have suggested 
multiple biomarkers for the disease, but these would require invasive sampling.   Association 
of the disease with a single gene has been inconclusive.  Thus in the absence of radically 
new findings, the present mainstream research paradigm is unlikely to lead to a full 
Appendix                                    
254 
 
understanding of the disease.  Progress is impressive in terms of collecting more data, but 
less so in terms of understanding these data and hence the disease. 
What is known about DD suggests that DD is neither a discrete single-gene disease 
nor a group of single-gene diseases.  The experimental data are much more consistent with 
DD being a systems biology disease.  Such diseases are determined much more by the 
malfunctioning of the network of the macromolecules rather than by the malfunctioning of 
the individual macromolecules themselves.  At present this is a suggestion only, because the 
data are inconclusive.  However, we have indicated how a progressive systems approach 
could test this hypothesis.  It would identify the network states that correlate with DD and 
then bring about changes in these network states with predicted outcomes in terms of disease 
progression, aggressiveness and the ability to reoccur after therapeutic intervention.  
Comparison with actual outcomes would serve as the test of the suggestion.  Experimentally 
the approach would not be much different from approaches that are being developed 
anyway, but the experimental design would be different, involving systems biology, multiple 
modulations and monitoring of time dependence.  
 If indeed DD turns out to be a systems biology disease, we propose that the approach 
to the disease should change drastically:  analysis, diagnosis and therapy should target 
pathways rather than genes or their products.  The concept of a „candidate gene‟ should be 
replaced with that of „candidate pathway(s)‟.  Studies should be aimed at elucidating cause-
effect chains, rather than correlating and thereby not being able to distinguish consequences 
of the diseased state from its causes.   To be more concrete, from the experimental data, 
alterations in pathways should be inferred.  Using transgenic and antisense approaches in 
cell lines, these pathway alterations should then be induced and the predicted development 
into a DD cellular phenotype tested.   The pathways are expected to be integrals of gene 
expression, signalling and metabolic networks and so should be the approach and data 
analysis.  At present DD research is not conducted in the required integrative manner.  
Consequently, what we propose has substantial ramifications for the organization of DD 
research.   
If we are right, the rewards would be substantial:  No longer will the data collected in 
this field disappear into the diasporas of the experimental literature; they will be analyzed in 
terms of network models and when informative connected to them with proper data 
annotation [179].  Once the network hypotheses turn out to be successful, they will underpin 
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the development of new rational biomarkers strategies, and become starting points for 
therapeutic intervention and prophylaxis.   
We suggest that adopting a systems biology approach to analyze DD has the 
potential to improve the knowledge gained in both in vivo and in vitro DD research.  This 
may be in the form of hypotheses generation in a carefully controlled experiment, or in the 
form of making experimental data address issues that limit DD understanding.   
Even though myofibroblasts obtained from different stages of DD may exhibit 
features that could trigger contraction and uncontrollable growth, neither the diversity of 
these cells nor the extent or nature of local specificity in situ in their differentiation has been 
examined systematically.  Remodeling of vascular connective tissue should be of 
fundamental importance as DD progresses over time and the ability of that tissue to be 
remodelled could be a gratuitous factor in the development of the disease.  Matrix 
remodeling and matrix turnover is controlled by a complex network of cell-cell and cell-
matrix interactions [180].  Mathematical modelling in a systems biology approach could 
help deduce the net outcome where the product would be a robust balance between 
proliferative and degradative processes.  This could extend the work from previous findings 
where the expressions of the family of enzymes and inhibitors are directly associated with 
matrix turnover (the matrix metalloproteinases (MMPs) and their natural inhibitors (TIMPs) 
[23]).  Furthermore, the constraints imposed by non-functional protein–protein interactions 
on gene expression and proteome size could be studied. 
Metabolomics alone can help identify metabolite markers and has many exciting 
clinical applications [163, 173, 181].  As well as genomics, transcriptomics and proteomics, 
the fluxomics, lipidomics, interactomics, glycomics and secretomics studies of biofluids 
within the Dupuytren‟s system together have the potential to improve our understanding 
immeasurably, especially if they are integrated, and full integration is only plausible through 
systems approaches.  Investigating this deforming complex fibromatosis as part of a systems 
biology approach (Figure 8) will benefit not only the understanding of the diseased sites, but 
will also address the effects on the ECM surroundings and excreted by-products, and could 
offer suggestions for early diagnosis.  This could then be extended to explore relations 
between DD, bone formation and mineralization, as many deregulated genes that co-exist 
may lead to further complications.  A novel systems approach along with existing 
knowledge will give a comprehensive view of the network of gene interactions played in 
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gene regulation and their functional properties involved in patterning DD from normal state.  
Systems biology approaches may provide clues for new diagnostic and prognostic markers 
for DD and as well as design of innovative novel therapeutic tools. 
Conclusions  
DD is likely to be a systems biology disease.  The corresponding mechanistic strategy 
offered by systems biology may lead to important new insights into DD tumorigenesis, 
based on the analysis of molecular interactions that become deregulated in the DD tumour 
phenotypes (nodule, cord).  This approach will not only extend but also integrate and 
complement existing methods and information.  The existing genomic data will serve as 
metadata for a systems oriented knowledgebase, partly in the form of experimentally tested 
mathematical models, which then lead to breakthroughs in prophylactic and therapeutic 
measures in DD.   
List of abbreviations  
bFGF: basic fibroblast growth factor; 
BioPAX: Biological Pathway Exchange;  
CellML: Cell Markup Language;   
COPASI: COmplex PAthway SImulator;  
CSML: Cell System Markup Language;  
CT: computed tomography;  
DD: Dupuytren's disease; 
ECM: extracellular matrix ECM; 
HiMAP: Human Interactome Map; 
HLA-DRB1: major histocompatibility complex, class II, DR beta 1; 
JWS: Java Web Simulation;  
LOD: logarithm of the odds; 
MCP: metacarpophalangeal;  
MMPs: matrix metalloproteinases; 
MRI: magnetic resonance imaging;  
NHLBI: National Heart, Lung and Blood Institute;  
PAH: phenylalanine hydroxylase; 
PBSII: Protein Biological System II;  
Appendix                                    
257 
 
PET: positron emission tomography; 
PGA: Program for Genomic Application; 
PIPJ: proximal interphalangeal joints;  
QPCR: Quantitative polymerase chain reaction; 
SBGN: Systems Biology Graphical Notation;  
SBML: systems biology Markup Language;  
SELDI-TOF-MS: Surface Enhanced Laser Desorption/Ionization Time-of-Flight  Mass 
Spectrometry; 
STRING: Search Tool for the Retrieval of Interacting Proteins; 
TGF-β: Transforming growth factor-beta; 
Competing interests 
The author(s) declare that they have no competing interests. 
 
Acknowledgements and Funding 
SR thanks BBSRC and EPSRC for her studentship via the Doctoral Training Centre, at The 
Manchester Centre for Integrative Systems Biology, UK. HW and RG thank various funders 
[http://www.systembiology.net/support/] but in particular the EPSRC and BBSRC for their 
support of the above two centres.                       
Appendix                                    
258 
 
 
References   for  Appendix A; Section 1.2  
1. McFarlane RM MD, Flint MH, editors: Dupuytren’s disease: biology and treatment. New York: 
Churchill Livingstone; 1990. 
2. Rayan GM: Dupuytren Disease: Anatomy, Pathology, Presentation, and Treatment. J Bone Joint 
Surg Am 2007, 89:189-198. 
3. Horner RL, Bralliar F: Dupuytren's contracture. Analysis of 100 consecutive surgical cases. Rocky 
Mountain medical journal 1971, 68:49-52. 
4. Schroter G: The recognition of Dupuytren's contracture as an occupational disease. Beitr Orthop 
Traumatol 1971, 18:78-80. 
5. Tubiana R: Dupuytren's disease. Present status of the treatment. Cah Med 1971, 12:1305-1309. 
6. Meyerding HW BJ, Broders AC: The Etiology and Pathology of Dupuytren's Contracture. Surgery, 
Gynecology and Obstetrics 1941. 
7. Seemayer TA LR, Schürch W, Thelmo WL: The myofibroblast: biologic, pathologic, and theoretical 
considerations. Pathology Annual 1980, 15 (Pt 1):443-470. 
8. Bayat A, McGrouther DA: Management of Dupuytren's disease - Clear advice for an elusive 
condition. Ann R Coll Surg Engl 2006, 88:3-8. 
9. Shaw RB, Chong AKS, Zhang A, Hentz VR, Chang J: Dupuytren's disease: History, diagnosis, and 
treatment. Plast Reconstr Surg 2007, 120. 
10. Hindocha S, Stanley JK, Watson S, Bayat A: Dupuytren's Diathesis Revisited: Evaluation of 
Prognostic Indicators for Risk of Disease Recurrence. J Hand Surg Am 2006, 31:1626-1634. 
11. Hayton MJ, Gray ICM: Dupuytren's contracture: A review. Current Orthopaedics 2003, 17:1-7. 
12. Tse R, Howard J, Wu Y, Gan B: Enhanced Dupuytren's disease fibroblast populated collagen lattice 
contraction is independent of endogenous active TGF-beta2. BMC Musculoskelet Disord 2004, 5:41. 
13. Drake MJ, Hedlund P, Andersson KE, Brading AF, Hussain I, Fowler C, Landon DN: Morphology, 
phenotype and ultrastructure of fibroblastic cells from normal and neuropathic human detrusor: 
Absence of myofibroblast characteristics. J Urol 2003, 169:1573-1576. 
14. Moyer KE, Banducci DR, Graham WP, Ehrlich HP: Dupuytren's disease: physiologic changes in 
nodule and cord fibroblasts through aging in vitro. Plast Reconstr Surg 2002, 110:187 - 193. 
15. Iwasaki H MH, Stutte HJ, Brennscheidt V: Palmar fibromatosis (Dupuytren’s contracture). 
Ultrastructural and enzyme histochemical studies of 43 cases. Virchows Arch A [pathol Anat] 
Histopathol 1984, 405:41-53. 
16. Lubahn JD, Pollard M, Cooney T: Immunohistochemical Evidence of Nerve Growth Factor in 
Dupuytren's Diseased Palmar Fascia. J Hand Surg Am 2007, 32:337-342. 
17. Clozel M SH: Role of endothelin in fibrosis and antifibrotic potential of bosentan. Ann Med 2005, 
37:2-12. 
18. Cordova A, Tripoli M, Corradino B, Napoli P, Moschella F: Dupuytren's contracture: An update of 
biomolecular aspects and therapeutic perspectives. J Hand Surg Br 2005, 30:557-562. 
19. Hnanicek J, Cimburova M, Putova I, Svoboda S, Stritesky J, Kratka K, Sosna B, Horak J: Lack of 
association of iron metabolism and Dupuytren's disease. J Eur Acad Dermatol Venereol 2008, 
22:476-480. 
20. Kaur S, Forsman M, Ryhänen J, Knuutila S, Larramendy ML: No gene copy number changes in 
Dupuytren's contracture by array comparative genomic hybridization. Cancer Genet Cytogenet 
2008, 183:6-8. 
21. Rehman S, Salway F, Stanley JK, Ollier WER, Day P, Bayat A: Molecular Phenotypic Descriptors of 
Dupuytren's Disease Defined Using Informatics Analysis of the Transcriptome. J Hand Surg Am 
2008, 33:359-372. 
22. Forsman M, Paakkonen V, Tjaderhane L, Vuoristo J, Kallioinen L, Salo T, Kallioinen M, Ryhanen J: The 
Expression of Myoglobin and ROR2 Protein in Dupuytren's Disease. J Surg Res 2008, 146:271-275. 
23. Johnston P, Chojnowski AJ, Davidson RK, Riley GP, Donell ST, Clark IM: A Complete Expression Profile 
of Matrix-Degrading Metalloproteinases in Dupuytren's Disease. J Hand Surg Am 2007, 32:343-351. 
Appendix                                    
259 
 
24. Lee LC, Zhang AY, Chong AK, Pham H, Longaker MT, Chang J: Expression of a Novel Gene, MafB, in 
Dupuytren's Disease. J Hand Surg Am 2006, 31:211-218. 
25. O'Gorman D, Wu Y, Seney S, Zhu R, Gan B: Wnt expression is not correlated with beta-catenin 
dysregulation in Dupuytren's Disease. J Negat Results Biomed 2006, 5:13. 
26. Samuel CS, Hewitson TD: Relaxin in cardiovascular and renal disease. Kidney Int 2006, 69:1498-
1502. 
27. Maureen DM: Endothelin and endothelin receptor antagonists in systemic rheumatic disease. 
Arthritis Rheum 2003, 48:1190-1199. 
28. Pan D, Watson HK, Swigart C, Thomson JG, Honig SC, D N: Microarray gene analysis and expression 
profiles of Dupuytren's contracture. Ann Plast Surg 2003, 50:618-622. 
29. Hanahan D, Weinberg RA: The Hallmarks of Cancer. Cell 2000, 100:57-70. 
30. Westerhoff HV, Palsson BO: The evolution of molecular biology into systems biology. Nat 
Biotechnol 2004, 22:1249-1252. 
31. Kholodenko BN, Kiyatkin A, Bruggeman FJ, Sontag E, Westerhoff HV, Hoek JB: Untangling the wires: 
A strategy to trace functional interactions in signaling and gene networks. Proc Natl Acad Sci 2002, 
99:12841-12846. 
32. An G, Hunt CA, Clermont G, Neugebauer E, Vodovotz Y: Challenges and rewards on the road to 
translational systems biology in acute illness: four case reports from interdisciplinary teams. J Crit 
Care 2007, 22:169-175. 
33. Ahn AC, Tewari M, Poon C-S, Phillips RS: The Limits of Reductionism in Medicine: Could Systems 
Biology Offer an Alternative? PLoS Medicine 2006, 3:e208. 
34. Katagiri F: Attacking Complex Problems with the Power of Systems Biology. Plant Physiol 2003, 
132:417-419. 
35. Spivey A: Systems Biology: The Big Picture. Environ Health Perspect 2004, 112: A938–A943. 
36. Jensen PR, Gugten AAvd, Bier M, Heeswijk WCv, Rohwer JM, Molenaar D, Workum Mv, Richard P, 
Teusink B, Bakker BM, et al: Hierarchies in control. Journal of Biological Systems 1995, 3:139-144. 
37. Kahn D, Westerhoff HV: Control theory of regulatory cascades. J Theor Biol 1991, 153:255-285. 
38. Steven Wiley H, Shvartsman SY, Lauffenburger DA: Computational modeling of the EGF-receptor 
system: a paradigm for systems biology. Trends Cell Biol 2003, 13:43-50. 
39. Schoeberl B, Gaudet S, Albeck JG, Janes K, Sorger PK, DA. L: The apoptotic decision process in TNF 
alpha-stimulated HT-29 cells: a combined computational and experimental approach. Mol Biol Cell 
2002, 13:11A-A. 
40. Daran-Lapujade P, Rossell S, van Gulik WM, Luttik MAH, de Groot MJL, Slijper M, Heck AJR, Daran J-
M, de Winde JH, Westerhoff HV, et al: The fluxes through glycolytic enzymes in Saccharomyces 
cerevisiae are predominantly regulated at posttranscriptional levels. Proc Natl Acad Sci 2007, 
104:15753-15758. 
41. Westerhoff HV: Signalling control strength. J Theor Biol 2008, 252:555-567. 
42. Hornberg JJ, Bruggeman FJ, Westerhoff HV, Lankelma J: Cancer: A Systems Biology disease. 
Biosystems 2006, 83:81-90. 
43. Boshoff HI, Barry CE, Hornberg J, Bruggeman F, Bakker B, Westerhoff H: Metabolic control analysis 
to identify optimal drug targets. In Systems Biological Approaches in Infectious Diseases. Volume 64: 
Birkhäuser Basel; 2007: 171-189: Progress in Drug Research]. 
44. Bakker BM, Assmus HE, Bruggeman F, Haanstra JR, Klipp E, Westerhoff H: Network-Based Selectivity 
of Antiparasitic Inhibitors. Mol Biol Rep 2002, 29:1-5. 
45. Westerhoff HV, Mosekilde E, Noe CR, Clemensen AM: Integrating systems approaches into 
pharmaceutical sciences Eur J Pharm Sci 2008, 35:1-4. 
46. Rinn JL, Wang JK, Liu H, Montgomery K, van de Rijn M, Chang HY: A Systems Biology Approach to 
Anatomic Diversity of Skin. J Invest Dermatol 2008, 128:776-782. 
47. Hinz B: Formation and Function of the Myofibroblast during Tissue Repair. J Invest Dermatol 2007, 
127:526-537. 
48. Chang HY, Chi JT, Dudoit S, Bondre C, Van De Rijn M, Botstein D, Brown PO: Diversity, topographic 
differentiation, and positional memory in human fibroblasts. Proc Natl Acad Sci 2002, 99:12877-
12882. 
Appendix                                    
260 
 
49. Darby IA, Hewitson TD, Kwang WJ: Fibroblast Differentiation in Wound Healing and Fibrosis. In Int 
Rev Cytol. Volume Volume 257: Academic Press; 2007: 143-179 
50. Eddy A: Interstitial macrophages as mediators of renal fibrosis. Exp Nephrol 1995:76-79. 
51. Hunninghake G: Sarcoidosis: linking inflammation and fibrosis. Am J Med Sci 1995:124-133. 
52. Selman M, eacute, Pardo A, Kaminski N: Idiopathic Pulmonary Fibrosis: Aberrant Recapitulation of 
Developmental Programs? PLoS Medicine 2008, 5:e62. 
53. Vaglio A, Salvarani C, Buzio C: Retroperitoneal fibrosis. The Lancet 2006, 367:241-251. 
54. Hindocha S, John S, Stanley JK, Watson SJ, Bayat A: The heritability of Dupuytren's disease: Familial 
aggregation and its clinical significance. J Hand Surg Am 2006, 31:204-210. 
55. Fitzgerald AMP, Kirkpatrick JJR, Naylor IL: Dupuytren's disease - the way forward? J Hand Surg Br 
1999, 24:395-399. 
56. Gabbiani G, Majno G: Dupuytren's contracture: fibroblast contraction? An ultrastructural study. Am 
J Pathol 1972, 66:131-146. 
57. Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, RA B: Myofibroblasts and mechano-regulation of 
connective tissue remodelling. Nat Rev Mol Cell Biol 2002:349-363. 
58. Tomasek JJ, Vaughan MB, CJ H: Cellular structure and biology of Dupuytren's disease. Hand Clin 
1999:21-34. 
59. Kaufman L, Rousseeuw P: Finding Groups in Data: An Introduction to Cluster Analysis (Wiley Series in 
Probability and Statistics). Wiley-Interscience; 2005. 
60. Goodacre R, Vaidyanathan S, Dunn WB, Harrigan GG, Kell DB: Metabolomics by numbers: acquiring 
and understanding global metabolite data. Trends Biotechnol 2004, 22:245-252. 
61. Kloen P: New insights in the development of Dupuytren's contracture: a review. British Journal of 
Plastic Surgery 1999, 52:629-635. 
62. Alioto RJ, Rosier RN, Burton RI, Edward Puzas J: Comparative effects of growth factors on fibroblasts 
of Dupuytren's tissue and normal palmar fascia. J Hand Surg Am 1994, 19:442-452. 
63. Badalamente MA, Hurst LC, Grandia SK, Sampson SP: Platelet-derived growth factor in Dupuytren's 
disease. J Hand Surg Am 1992, 17:317-323. 
64. Badalamente MA, Sampson SP, Hurst LC, Dowd A, Miyasaka K: The role of transforming growth 
factor beta in Dupuytren's disease. The Journal of Hand Surgery 1996, 21:210-215. 
65. Bayat A, Alansar A, Hajeer AH, Shah M, Watson JS, Stanley JK, Ferguson MWJ, Ollier WER: Genetic 
susceptibility in Dupuytren's disease: lack of association of a novel transforming growth factor 
beta(2) polymorphism in Dupuytren's disease. J Hand Surg Br 2002, 27 B:47-49. 
66. Vaughan MB, Howard EW, Tomasek JJ: Transforming Growth Factor-[beta]1 Promotes the 
Morphological and Functional Differentiation of the Myofibroblast. Experimental Cell Research 
2000, 257:180-189. 
67. Berndt A, Kosmehl H, Mandel U, Gabler U, Luo X, Celeda D, Zardi L, Katenkamp D: TGF? and bFGF 
synthesis and localization in Dupuytren's disease (nodular palmar fibromatosis) relative to cellular 
activity, myofibroblast phenotype and oncofetal variants of fibronectin. Histochemical Journal 
1995, 27:1014-1020. 
68. Lappi DA, Martineau D, Maher PA, Florkiewicz RZ, Buscaglia M, Gonzalez AM, Farris J, Hamer M, Fox 
R, Baird A: Basic fibroblast growth factor in cells derived from Dupuytren's contracture: Synthesis, 
presence, and implications for treatment of the disease. J Hand Surg Am 1992, 17:324-332. 
69. Gonzalez AM, Buscaglia M, Fox R, Isacchi A, Sarmientos P, Farris J, Ong M, Martineau D, Lappi DA, 
Baird A: Basic fibroblast growth factor in Dupuytren's contracture. Am J Pathol 1992, 141:661-671. 
70. Serini G, Gabbiani G: Mechanisms of Myofibroblast Activity and Phenotypic Modulation. 
Experimental Cell Research 1999, 250:273-283. 
71. Hu FZ, Nystrom A, Ahmed A, Palmquist M, Dopico R, Mossberg I, Gladitz J, Rayner M, Post JC, Ehrlich 
GD, Preston RA: Mapping of an autosomal dominant gene for Dupuytren's contracture to 
chromosome 16q in a Swedish family. Clinical Genetics 2005, 68:424-429. 
72. Brown JJ, Ollier W, Thomson W, Bayat A: Positive association of HLA-DRB1*15 with Dupuytren's 
disease in Caucasians. Tissue Antigens 2008, 72:166-170. 
73. Bayat A, Walter J, Lambe H, Watson JS, Stanley JK, Marino M, Ferguson MWJ, Ollier WER: 
Identification of a novel mitochondrial mutation in Dupuytren's disease using multiplex DHPLC. 
Plastic and Reconstructive Surgery 2005, 115:134-141. 
Appendix                                    
261 
 
74. Murrell GA FM, Bromley L: Free radicals and Dupuytren's contracture. Br Med J (Clin Res Ed) 1987, 
28:1373-1375. 
75. Kandel J, Bossy-Wetzel E, Radvanyi F, Klagsbrun M, Folkman J, Hanahan D: Neovascularization is 
associated with a switch to the export of bFGF in the multistep development of fibrosarcoma.  Cell 
1991, 66:1095-1104. 
76. Akai M SY, Tateishi T.: Electrical stimulation on joint contracture: an experiment in rat model with 
direct current. Arch Phys Med Rehabil 1997 Apr;78(4):405-9. 
77. Tart RP, Dahners LE: Effects of electrical stimulation on joint contracture in a rat model. J Orthop 
Res 1989, 7:538-542. 
78. Hildebrand KA, Sutherland C, M. Z: Rabbit knee model of post-traumatic joint contractures: the 
long-term natural history of motion loss and myofibroblasts. J Orthop Res 2004 Mar;22(2):313-20. 
79. Soh J, Turinsky AL, Trinh QM, Chang J, Sabhaney A, Dong X, Gordon PM, Janzen RP, Hau D, Xia J, et al: 
Spatiotemporal integration of molecular and anatomical data in virtual reality using semantic 
mapping. Int J Nanomedicine 2009, 4:79-89. 
80. Westerhoff HV: The Silicon Cell, Not Dead but Live! Metabolic Engineering 2001, 3:207-210. 
81. Forster T, Roy D, Ghazal P: Experiments using microarray technology: limitations and standard 
operating procedures. J Endocrinol 2003, 178:195-204. 
82. Qian A, Meals RA, Rajfer J, Gonzalez-Cadavid NF: Comparison of gene expression profiles between 
Peyronie's disease and Dupuytren's contracture. Urology 2004, 64:399-404. 
83. Satish L, Laframboise WA, O'Gorman DB: Identification of differentially expressed genes in 
fibroblasts derived from patients with Dupuytren's Contracture. BMC Med Genomics 2008, 1:1-10. 
84. Ulrich D, Ulrich F, Piatkowski A, Pallua N: Expression of matrix metalloproteinases and their 
inhibitors in cords and nodules of patients with Dupuytren’s disease. Arch Orthop Trauma Surg 
2009, 129:1453-1459. 
85. Bayat A, Winder C, Stanley J, Day P, Goodacre R: Proteome analysis of dupuytren's disease 
differentiating between disease tissue phenotypes (nodule, cord and transverse palmar fascia) and 
control palmar fascia. J Hand Surg 2006, 31:5. 
86. O'Gorman D, Howard JC, Varallo VM, Cadieux P, Bowley E, McLean K, Pak BJ, Gan BS: Identification 
of protein biomarkers in Dupuytren's contracture using Surface Enhanced Laser Desorption 
Ionization Time-of-Flight Mass Spectrometry (SELDI-TOF-MS). Clin Invest Med 2006, 29:136-145. 
87. Baggerly KA, Morris JS, Coombes KR: Reproducibility of SELDI-TOF protein patterns in serum: 
comparing datasets from different experiments. Bioinformatics 2004, 20:777-785. 
88. Kraljevic Pavelic S, Sedic M, Hock K, Vucinic S, Jurisic D, Gehrig P, Scott M, Schlapbach R, Cacev T, 
Kapitanovic S, Pavelic K: An integrated proteomics approach for studying the molecular 
pathogenesis of Dupuytren's disease. J Pathol 2009, 217:524-533. 
89. Rhodes DR, Tomlins SA, Varambally S, Mahavisno V, Barrette T, Kalyana-Sundaram S, Ghosh D, 
Pandey A, AM C: Probabilistic model of the human protein-protein interaction network. Nat 
Biotechnol 2005, 23:951 - 959  
90. von Mering C, Jensen LJ, Kuhn M, Chaffron S, Doerks T, Krüger B, Snel B, P B: STRING 7 — recent 
developments in the integration and prediction of protein interactions. Nucleic Acids 2007, 
35:D358–D362. 
91. ter Kuile BH, Westerhoff HV: Transcriptome meets metabolome: hierarchical and metabolic 
regulation of the glycolytic pathway. FEBS Lett 2001, 500:169-171. 
92. Lazebnik Y: Can a biologist fix a radio?Or, what I learned while studying apoptosis. Cancer Cell 
2002, 2:179-182. 
93. van Driel R, Fransz PF, Verschure PJ: The eukaryotic genome: a system regulated at different 
hierarchical levels. J Cell Sci 2003, 116:4067-4075. 
94. de-Leon SB-T, H. E: Gene Regulation: Gene Control Network in Development. Annu Rev Biophys 
Biomol Struct 2007, 36:191-212. 
95. Westerhoff HV, Koster JG, van Workum M, Rudd KE: On the control of gene expression. . In Control 
of metabolic processes. Edited by Cornish-Bowden A C, M.L., editor. New York: Plenum Press; 1989: 
399-413 
96. Wagner A, Fell D: The small world inside large metabolic networks. Proc Biol Sci 2001 7:1803–1810. 
Appendix                                    
262 
 
97. Hendrickson DG, Hogan DJ, McCullough HL, Myers JW, Herschlag D, Ferrell JE, Brown PO: Concordant 
Regulation of Translation and mRNA Abundance for Hundreds of Targets of a Human microRNA. 
PLoS Biol 2009, 7:e1000238. 
98. Westerhoff H, Kolodkin A, Conradie R, Wilkinson S, Bruggeman F, Krab K, van Schuppen J, Hardin H, 
Bakker B, Moné M, et al: Systems biology towards life in silico: mathematics of the control of living 
cells. J Math Biol 2009, 58:7-34. 
99. Westerhoff HV, Aon MA, Vandam K, Cortassa S, Kahn D, M. V: Dynamic and hierarchical coupling 
Biochim Biophys Acta 1990, 1018:142-146. 
100. Westerhoff HV, Winder C, Messiha H, Simeonidis E, Adamczyk M, Verma M, Bruggeman FJ, Dunn W: 
Systems Biology: The elements and principles of Life. FEBS Lett 2009, 583:3882-3890. 
101. Glass JI, Assad-Garcia N, Alperovich N, Yooseph S, Lewis MR, Maruf M, Hutchison CA, Smith HO, 
Venter JC: Essential genes of a minimal bacterium. Proc Natl Acad Sci 2006, 103:425-430. 
102. Fraser CM, Gocayne JD, White O, Adams MD, Clayton RA, Fleischmann RD, Bult CJ, Kerlavage AR, 
Sutton G, Kelley JM, et al: The minimal gene complement of Mycoplasma genitalium. Science 1995, 
270:397-394. 
103. Groen AK, Wanders RJA, Westerhoff HV, Vandermeer R, JM. T: Quantification of the contribution of 
various steps to the control of mitochondrial respiration. J Biol Chem 1982, 257:2754-2757. 
104. Stuger R, Woldringh CL, van der Weijden CC, Vischer NOE, Bakker BM, van Spanning RJM, Snoep JL, 
Weterhoff HV: DNA Supercoiling by Gyrase is Linked to Nucleoid Compaction. Mol Biol Rep 2002, 
29:79-82. 
105. Koster JG, Destrée OHJ, Westerhoff HV: Kinetics of histone gene expression during early 
development of Xenopus laevis. J Theor Biol 1988, 135:139-167. 
106. Snoep JL, Van Der Weijden CC, Andersen HW, Westerhoff HV, Jensen PR: DNA supercoiling in 
Escherichia coli is under tight and subtle homeostatic control, involving gene-expression and 
metabolic regulation of both topoisomerase I and DNA gyrase. Eur J Biochem 2002, 269:1662-1669. 
107. Hornberg JJ, Bruggeman FJ, Binder B, Geest CR, De Vaate AJMB, Lankelma J, Heinrich R, Westerhoff 
HV: Principles behind the multifarious control of signal transduction. FEBS J 2005, 272:244-258. 
108. Hornberg JJ, Binder B, Bruggeman FJ, Schoeberl B, Heinrich R, Westerhoff HV: Control of MAPK 
signalling: from complexity to what really matters. Oncogene 2005, 24:5533-5542. 
109. Heinrich R, Neel BG, TA. R: Mathematical models of protein kinase signal transduction. Mol Cell 
2002, 9:957-970. 
110. Kholodenko BN: Cell-signalling dynamics in time and space. Nat Rev Mol Cell Biol 2006, 7:165-176. 
111. Bastiaens P: Systems biology: When it is time to die. Nature 2009, 459:334-335. 
112. Rossell S, van der Weijden CC, Lindenbergh A, van Tuijl A, Francke C, Bakker BM, Westerhoff HV: 
Unraveling the complexity of flux regulation: A new method demonstrated for nutrient starvation 
in Saccharomyces cerevisiae. Proc Natl Acad Sci 2006, 103:2166-2171. 
113. Gardner TS, Dolnik M, Collins JJ: A theory for controlling cell cycle dynamics using a reversibly 
binding inhibitor. Proc Natl Acad Sci 1998, 95:14190-14195. 
114. Alberghina L, Westerhoff HV, Novák B, Chen K, Tyson J: Systems biology of the yeast cell cycle 
engine. In Systems Biology. Volume 13: Springer Berlin / Heidelberg; 2005: 305-324: Topics in Current 
Genetics]. 
115. Nelson DE, Ihekwaba AEC, Elliott M, Johnson JR, Gibney CA, Foreman BE, Nelson G, See V, Horton CA, 
Spiller DG, et al: Oscillations in NF-{kappa}B Signaling Control the Dynamics of Gene Expression. 
Science 2004, 306:704-708. 
116. Alberghina L, HV. W: Systems Biology: Definitions and Perspectives (Topics in Current Genetics). . 
Springer-Verlag Berlin and Heidelberg GmbH & Co. K; 2005. 
117. Snoep JL, Bruggeman F, Olivier BG, Westerhoff HV: Towards building the silicon cell: A modular 
approach. Biosystems 2006, 83:207-216. 
118. Barab, aacute, si A-L, aacute, szl, oacute, Albert R, eacute, ka: Emergence of Scaling in Random 
Networks. Science 1999, 286:509-512. 
119. Alon U: Network motifs: theory and experimental approaches. Nat Rev Genet 2007, 8:450-461. 
120. Schuster S, Hilgetag C, Woods JH, Fell DA: Reaction routes in biochemical reaction systems: 
Algebraic properties, validated calculation procedure and example from nucleotide metabolism. J 
Math Biol 2002, 45:153-181. 
Appendix                                    
263 
 
121. Reed J, Palsson B: Genome-scale in silico models of E. coli have multiple equivalent phenotypic 
states: assessment of correlated reaction subsets that comprise network states. Genome Res 2004, 
14:1797-1805. 
122. Marshall A, Gollapudi S, de Silva J, Hodgman C: A systems biology approach to modelling tea 
(Camellia sinensis). BMC Syst Biol 2007, 1:P13. 
123. Getz WM, Westerhoff HV, Hofmeyr J-HS, Snoep JL: Control analysis of trophic chains. Ecological 
Modelling 2003, 168:153-171. 
124. Reijenga KA, Bakker BM, Van Der Weijden CC, Westerhoff HV: Training of yeast cell dynamics. FEBS J 
2005, 272:1616-1624. 
125. Schuetz R, Kuepfer L, Sauer U: Systematic evaluation of objective functions for predicting 
intracellular fluxes in Escherichia coli. Mol Syst Biol 2007, 3. 
126. Molenaar D, van Berlo R, de Ridder D, Teusink B: Shifts in growth strategies reflect tradeoffs in 
cellular economics. Mol Syst Biol 2009, 5. 
127. Edwards JS, Covert M, Palsson B: Metabolic modelling of microbes: the flux-balance approach. 
Environmental Microbiology 2002, 4:133-140. 
128. Rodríguez-Enríquez S, Marín-Hernández A, Gallardo-Pérez JC, Carreño-Fuentes L, Moreno-Sánchez R: 
Targeting of cancer energy metabolism. Mol Nutr Food Res 2009, 53:29-48. 
129. Emery AE: The muscular dystrophies. The Lancet 2002, 359:687-695. 
130. Williams R, Mamotte C, Burnett J: Phenylketonuria: an inborn error of 1413 phenylalanine 
metabolism. Clin Biochem Rev 2008, 29:31-41. 
131. Robert A: The genetic origins of human cancer. Cancer 1988, 61:1963-1968. 
132. Weigelt B, Reis-Filho JS: Histological and molecular types of breast cancer: is there a unifying 
taxonomy? Nat Rev Clin Oncol 2009, 6:718-730. 
133. Kacser H, Burns J: The molecular basis of dominance. Genetics 1981, 97:639-666. 
134. Kacser H: Dominance not inevitable but very likely J Theor Biol 1987, 126:505-506. 
135. Price ND, Papin JA, Palsson BO: Determination of redundancy and systems properties of the 
metabolic network of Helicobacter pylori using genome-scale extreme pathway analysis. Genome 
Res 2002, 12:760-769. 
136. Janes KA, Albeck JG, Gaudet S, Sorger PK, Lauffenburger DA, Yaffe MB: A Systems Model of Signaling 
Identifies a Molecular Basis Set for Cytokine-Induced Apoptosis. Science 2005, 310:1646-1653. 
137. Bakker BM, Michels PAM, Opperdoes FR, Westerhoff HV: Glycolysis in Bloodstream Form 
Trypanosoma brucei Can Be Understood in Terms of the Kinetics of the Glycolytic Enzymes. J Biol 
Chem 1997, 272:3207-3215. 
138. Teusink B, Passarge J, Reijenga CA, Esgalhado E, Van Der Weijden CC, Schepper M, Walsh MC, Bakker 
BM, Van Dam K, Westerhoff HV, Snoep JL: Can yeast glycolysis be understood in terms of in vitro 
kinetics of the constituent enzymes? Testing biochemistry. Eur J Biochem 2000, 267:5313-5329. 
139. Sihag S, Cresci S, Li AY, Sucharov CC, Lehman JJ: PGC-1[alpha] and ERR[alpha] target gene 
downregulation is a signature of the failing human heart. J Mol Cell Cardiol 2009, 46:201-212. 
140. McGregor E, Dunn MJ: Proteomics of the Heart: Unraveling Disease. Circ Res 2006, 98:309-321. 
141. Mayr M, Yusuf S, Weir G, Chung Y-L, Mayr U, Yin X, Ladroue C, Madhu B, Roberts N, De Souza A, et al: 
Combined Metabolomic and Proteomic Analysis of Human Atrial Fibrillation. J Am Coll Cardiol 
2008, 51:585-594. 
142. Dunn WB, Broadhurst DI, Atherton HJ, Goodacre R, Griffin JL: Systems level studies of mammalian 
metabolomes: the roles of mass spectrometry and nuclear magnetic resonance spectroscopy. 
Chem Soc Rev 2010. DOI: 10.1039/B906712B  
143. Noble D: Computational models of the heart and their use in assessing the actions of drugs. J 
Pharmacol Sci 2008, 107:107-117. 
144. Kohl P, Noble D: Systems biology and the virtual physiological human. Mol Syst Biol 2009, 5. 
145. Turinsky AL, Fanea E, Trinh Q, Wat S, Hallgrímsson B, Dong X, Shu X, Stromer JN, Hill JW, Edwards C, 
et al: CAVEman: Standardized anatomical context for biomedical data mapping. Anat Sci Educ 2008, 
1:10-18. 
146. Maxwell C, Moreno V, Sole X, Gomez L, Hernandez P, Urruticoechea A, Pujana M: Genetic 
interactions: the missing links for a better understanding of cancer susceptibility, progression and 
treatment. Molecular Cancer 2008, 7:4. 
Appendix                                    
264 
 
147. Franovic A, Holterman CE, Payette J, Lee S: Human cancers converge at the HIF-2Î± oncogenic axis. 
Proc Natl Acad Sci 2009, 106:21306-21311. 
148. Hucka M, Finney A, Sauro HM, Bolouri H, Doyle JC, Kitano H, and the rest of the SF, Arkin AP, 
Bornstein BJ, Bray D, et al: The systems biology markup language (SBML): a medium for 
representation and exchange of biochemical network models. Bioinformatics 2003, 19:524-531. 
149. Cuellar AA, Lloyd CM, Nielsen PF, Bullivant DP, Nickerson DP, Hunter PJ: An Overview of CellML 1.1, 
a Biological Model Description Language. Simulation 2003, 79:740-747. 
150. Jeong E, Nagasaki M, Saito A, Miyano S: Cell System Ontology: Representation for Modeling, 
Visualizing, and Simulating Biological Pathways. In Silico Biol 2007, 7:623-638. 
151. Demir E, Cary MP, Paley S, Fukuda K, Lemer C, Vastrik I, Wu G, D'Eustachio P, Schaefer C, Luciano J, et 
al: The BioPAX community standard for pathway data sharing. Nat Biotechnol, 28:935-942. 
152. Le Novère N, Hucka M, Mi H, Moodie S, Schreiber F, Sorokin A, Demir E WK, Aladjem MI, 
Wimalaratne SM, Bergman FT, Gauges R, Ghazal P, Kawaji H, Li L, Matsuoka Y, Villéger A, Boyd SE, 
Calzone L, Courtot M, Dogrusoz U, Freeman TC, Funahashi A, Ghosh S, Jouraku A, Kim S, Kolpakov F, 
Luna A, Sahle S, Schmidt E, Watterson S, Wu G, Goryanin I, Kell DB, Sander C, Sauro H, Snoep JL, Kohn 
K, Kitano H: The Systems Biology Graphical Notation. Nat Biotechnol 2009, 27:735-741. 
153. Hoops S, Sahle S, Gauges R, Lee C, Pahle Jr, Simus N, Singhal M, Xu L, Mendes P, Kummer U: COPASI - 
a COmplex PAthway SImulator. Bioinformatics 2006, 22:3067-3074. 
154. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T: 
Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction Networks. 
Genome Res 2003, 13:2498-2504. 
155. Calvano SE, Xiao W, Richards DR, Felciano RM, Baker HV, Cho RJ, Chen RO, Brownstein BH, Cobb JP, 
Tschoeke SK, et al: A network-based analysis of systemic inflammation in humans. Nature 2005, 
437:1032-1037. 
156. Olivier BG, Snoep JL: Web-based kinetic modelling using JWS Online Bioinformatics 2004, 20:2143-
2144. 
157. Le Novere N, Bornstein B, Broicher A, Courtot Ml, Donizelli M, Dharuri H, Li L, Sauro H, Schilstra M, 
Shapiro B, et al: BioModels Database: a free, centralized database of curated, published, 
quantitative kinetic models of biochemical and cellular systems. Nucl Acids Res 2005, 34:D689-
D691. 
158. Trew ML, Smaill BH, Bullivant DP, Hunter PJ, Pullan AJ: A generalized finite difference method for 
modeling cardiac electrical activation on arbitrary, irregular computational meshes. Math Biosci 
2005, 198:169-189. 
159. [http://www.physiome.ox.ac.uk] 
160. [http://www.mrc.ac.uk] 
161. http://www.uku.fi/nucsys. 
162. [http://www.systembiologie.de] 
163. van der Greef J, Hankemeier T, McBurney RN: Metabolomics-based systems biology and 
personalized medicine: moving towards n = 1 clinical trials? Pharmacogenomics 2006, 7:1087-1094. 
164. Kirkwood TBL: A systematic look at an old problem. Nature 2008, 451:644-647. 
165. João F. Passos, Zglinicki TV, Kirkwood TBL: Mitochondria and ageing: winning and losing in the 
numbers game. Bioessays 2007, 29:908-917. 
166. Shreenivasaiah PK, Rho S-H, Kim T, Kim DH: An overview of cardiac systems biology. J Mol Cell 
Cardiol 2008, 44:460-469. 
167. Lemberger T: Systems biology in human health and disease. Mol Syst Biol 2007, 3. 
168. Bader S, Kühner S, Gavin A-C: Interaction networks for systems biology. FEBS Lett 2008, 582:1220-
1224. 
169. Mani KM, Lefebvre C, Wang K, Lim WK, Basso K, Dalla-Favera R, Califano A: A systems biology 
approach to prediction of oncogenes and molecular perturbation targets in B-cell lymphomas. Mol 
Syst Biol 2008, 4. 
170. Miller JA, Oldham MC, Geschwind DH: A Systems Level Analysis of Transcriptional Changes in 
Alzheimer's Disease and Normal Aging. J Neurosci 2008, 28:1410-1420. 
171. Krishna R, Schaefer HG, Bjerrum OJ: Effective integration of systems biology, biomarkers, 
biosimulation and modelling in streamlining drug development. Eur J Pharm Sci 2007, 31:62-67. 
Appendix                                    
265 
 
172. Noble D: The Music of Life: biology beyond genes. Oxford Oxford University Press; 2006. 
173. Hollywood K, Brison DR, Goodacre R: Metabolomics: Current technologies and future trends. 
Proteomics 2006, 6:4716-4723. 
174. Heazell AEP, Brown M, Dunn WB, Worton SA, Crocker IP, Baker PN, Kell DB: Analysis of the 
Metabolic Footprint and Tissue Metabolome of Placental Villous Explants Cultured at Different 
Oxygen Tensions Reveals Novel Redox Biomarkers. Placenta 2008, 29:691-698. 
175. Megason SG, Fraser SE: Imaging in Systems Biology. Cell 2007, 130:784-795. 
176. Ellis DI, Goodacre R: Metabolic fingerprinting in disease diagnosis: biomedical applications of 
infrared and Raman spectroscopy. Analyst 2006, 131:875-885. 
177. Maeder CI, Hink MA, Kinkhabwala A, Mayr R, Bastiaens PIH, Knop M: Spatial regulation of Fus3 MAP 
kinase activity through a reaction-diffusion mechanism in yeast pheromone signalling. Nat Cell Biol 
2007, 9:1319-1326. 
178. Chen Y-CM, Kappel C, Beaudouin J, Eils R, Spector DL: Live Cell Dynamics of Promyelocytic Leukemia 
Nuclear Bodies upon Entry into and Exit from Mitosis. Mol Biol Cell 2008, 19:3147-3162. 
179. Novere NL, Finney A, Hucka M, Bhalla US, Campagne F, Collado-Vides J, Crampin EJ, Halstead M, 
Klipp E, Mendes P, et al: Minimum information requested in the annotation of biochemical models 
(MIRIAM). Nat Biotechnol 2005, 23:1509-1515. 
180. Humphries M, Reynolds A: Cell-to-cell contact and extracellular matrix. Curr Opin Cell Biol 2009, 
21:613-615. 
181. Kim YS, Maruvada P, Milner JA: Metabolomics in biomarker discovery: future uses for cancer 
prevention. Future Oncology 2008, 4:93-102. 
 
 
 
Figure Legends 
 
Figure 1: Different stages of disease progression.  Stage A generally starts as a small lump 
in the palm of the hand often just under the digit on the palmar crease.  In Stage B the 
disease spreads up the fascia and into the fingers leading to the development of a cord.  
Following this, Stage C demonstrates that as the disease spreads up the fingers eventually 
creating a tight cord, the fingers are forced to progressively bend, and are unable to 
straighten, effecting an irreversible contracture. 
Figure 2: Haematoxylin and Eosin staining of DD tissue from (A) the nodule and (B) cord.  
The nodule is a focus of proliferating young fibroblasts having no particular orientation and 
associated with minimal collagen deposition.  Nodules slowly disappear leaving a dense 
contracted fibrous cord which becomes increasingly acellular and tendon-like. 
Figure 3: Hypoxia-induced mechanisms leading to production of reactive oxygen species 
triggering tissue damage at the cellular level.  A mechanistic drawing illustrating free radical 
production leading to tissue damage.  Reproduced from reference 73. 
Figure 4: The cellular components, molecular functions and biological processes derived 
from genes in expression studies using Gene Ontology.   
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Figure 5:  Molecular (A) versus Systems Biological (B) disease.  A: In the molecular, or 
single-gene disease, a mutation in or around a piece of DNA causes a change in function of 
the gene product F.  F is solely responsible (or the rate limiting step) for the physiological 
function that is impaired in the disease, or for the pathology itself.  B: In the Systems 
Biological or network disease, the biological function that is impaired in the disease, or the 
new pathological function, depends on many factors (called Z here) at the same time.  
Factors Z themselves depend on many other factors, on genes and environmental (e.g. 
nutritional, hormonal, age) factors, and ultimately even on the development of the pathology 
itself.   In terms of transcriptomics, changes in any factors shown could correlate somewhat 
with the disease, in either type of disease.  In the molecular disease (A) however, the 
correlation between the disease and changes in the single causative disease gene should be 
100 %.   When, as in Systems Biology the cause-effect relationships are investigated, the 
correlations should be time and perturbation dependent as consistent with the network drawn 
(e.g. a deletion of Y might not affect the disease totally, but should destroy the causal 
correlation between gene 2 and disease).   The Systems Biology paradigm is not soft 
however, as in that case the correlation between disease and network state should be 100 %.  
Figure 6:  The complex reality of most diseases, as proposed here for DD.  DD depends of 
the simultaneous occurrence of a number of malfunctions, each of which is controlled by a 
network of internal and environmental factors.  These networks also have other effects (Z) 
than DD.   In this case of a systems biology disease, only a careful dissection of the network 
changes on the basis of accurate experiments that involve (i) different points in 
time/progression of the disease and different genetic and environmental backgrounds, (ii) 
quantitative experimentation at the transcriptomic, proteomic, metabolomic and functional 
level, and (iii) computation assisted analysis and experimental design, can lead to 
understanding of the disease and rational and optimally effective therapies.  
Figure 7: A proposed information flow of DD research versus normal fibroblast biology 
research.  In the top-down branch of the systems biology effort, data maps generated by 
large scale experiments first need to be annotated and subjected to statistical analysis in 
order to extract biologically relevant information.  That information should then generate 
hypotheses concerning patterns of molecular behaviour or dynamic parameters of the 
networks.  Phenomenological or partly mechanistic mathematical modelling can already help 
here to weed the impossible from the possible and to enable one to put multiple complex 
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interactions into single testable hypotheses.  Then, predictions can be made and tested.   This 
may spiral through iterations of top-down systems biology into an ever improving set of 
hypotheses which may become more and more mechanistic.  A bottom-up Systems Biology 
branch of the research may begin with proposed mechanisms (such as stimulation of 
fibroblast growth because of enhanced ROS production) and make mathematical models of 
this in order to assist with experimental design.  By a spiral of testing and adjusting the 
hypothesis this will ultimately lead to a hypothesis that is better and better tested and 
involves more and more of the network.  At each step, data will be churned or sublimed into 
information with a reduction in the amount of unnecessary bits but an increase in accuracy, 
quality and usefulness to improve and generate stronger models of the DD cell.  A metabolic 
or signaling network can then be represented in silico and its properties studied using 
computer-simulated perturbations.  For instance, the flux balance model could be applied to 
predict the behaviour of metabolic networks upon perturbation of the optimised metabolites 
within a metabolic pathway. 
Figure 8: A Systems Biology approach to understanding DD.  An overview of the proposed 
integrative network-based analysis characterising DD tumorigenic versus  oncogenic and 
normal mechanisms and guiding therapeutic interventions.  Biological organisation has a 
nested, hierarchical structure.  Each hierarchy, however, is bounded to some epistemological 
degree due to the principles of biocomplexity.  Systems Biology takes an integrative 
approach and tries to synthesize the biological knowledge to understand how the molecules 
act together within the network of interaction that makes up Life (e.g.  the living cell).  
Classical systems biology approaches will focus on the characterisation and description of 
mechanisms of cellular control with an emphasis on genetic regulation and intracellular 
signaling through inferred information from omics experiments.  Translational systems 
biology attempts to extrapolate the knowledge generated at the subcellular level to the type 
of systemic behavior seen in the clinical setting e.g.  imaging and histopathology. Exploding 
amounts of unravelled biological data cannot be understood by simply drawing lines 
between interacting molecules, but requires a more organic approach where model building 
and simulations advance the understanding of DD.     
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Table Legends 
Table 1 Components implicated as modulators of the DD fibroblast transdifferentiation into myofibroblasts. 
Table 1. Components implicated as modulators of the 
DD fibroblast transdifferentiation into myofibroblasts
Adhesion molecules
Basic fibroblast growth factor 
Chemokines
Cytokines
Endothelin
Extracellular matrix components 
Granulocyte-macrophage colony stimulating factor
Growth factors
Interferons
Interleukin-1
Platelet-derived growth factor
Transforming growth factor beta (TGF-β) 
Tumor necrosis factor
 
Table 2 Multiple levels of regulation in the biocomplexed cellular system. 
Regulation may occur at different levels
Gene transcription level
Regulation of transcription of genes into RNA.
RNA processing level
Regulation of the transport of the RNA into the cytoplasm.
mRNA translation level
Regulation of the efficiency of translation of the mRNA into proteins.
Protein level
Modification of the translation product - Some proteins will loose their function.
Metabolic level
Intrinsic regulation - the metabolic pathway self-regulates to respond to changes in the 
levels of substrates or products. Extrinsic regulation - e.g. glucose metabolism by the 
hormone insulin.
Regulation of an enzyme in a pathway  and/or the control exerted by this enzyme affects 
changes in its activity have on the overall rate of the pathway (the flux through the 
pathway).
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Figure 3 
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Appendix B 
Table 22 Molecular bonds and their corresponding vibrational modes when molecular orbitals absorb photons 
certain infrared wavelengths. 
Group Mode Peak  (nm) 
O - H stretch 2800 
N - H stretch 3000 
C - H stretch 3400 
C = O stretch 5800 
C = C stretch 6100 
N - H rotation 6500 
C - H rotation 7300 
H - C - H scissors 6800 
 
 Table 23 Typical vibrational bonds and their wavenumbers. 
Bond Wavenumber/cm
-1 
C-H 2840 - 3095
C-C 1610 - 1680
C=O 1680 - 1750
C-O 1000 - 1300
C-Cl 700 - 800
3233 - 3550
2500 - 3300
N-H 3100 – 3500
C=C 2000 - 3000 
O-H
 
 
Figure 69 Four important regions of the IR spectrum. 
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Table 25 
Study ID Age Sex
DD8 77 M Nodule Cord Fascia
DD9 58 M Nodule Cord Fascia
DD10 76 M Nodule Cord Fascia
DD11 67 M Nodule Cord Fascia
DD12 52 M Nodule Cord Fascia
DD13 74 F Nodule Cord Fascia
STUDY 1A
Site
 
 
Table 26 
Study ID Age Sex
DD9 58 M Nodule Cord Fascia Fat Skin
DD11 67 M Nodule Cord Fascia Fat Skin
DD12 52 M Nodule Cord Fascia Fat Skin
DD13 74 F Nodule Cord Fascia Fat Skin
Site
STUDY 1B
 
Table 27 
Study ID Age Sex
DD16 46 M Cord Fascia
DD17 67 M Nodule Cord Fascia
DD2-R Nodule Cord Fascia
DD18 68 M Nodule Cord
Site
STUDY 2A
 
Table 28 
Study ID Age Sex
DD16 46 M Cord Fascia
DD17 67 M Nodule Cord Fascia Fat Skin
DD2-R Nodule Cord Fascia Fat Skin
DD18 68 M Nodule Cord Fat
Site
STUDY 2B
 
Figure 70 Left (I) cultured fibroblasts from nodules. Right (II) cultured fibroblasts from cord. 
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Table 29 
Study ID Age Sex Site
DD16 46 M Cord Fascia
DD17 67 M Nodule Cord Fascia
DD2-R Nodule Cord Fascia
DD18 68 M Nodule Cord
CT4 67 M Fascia*
CT5 78 M Fascia*
CT6 62 F Fascia*
CT7 50 F Fascia*
CT8 28 M Fascia*
*from CTD patient, external control
STUDY 2C
 
Table 30 
Study ID Age Sex
CT4 67 M Fascia* Fat* Skin*
CT5 78 M Fascia* Fat* Skin*
CT6 62 F Fascia* Fat* Skin*
CT7 50 F Fascia* Fat* Skin*
CT8 28 M Fascia* Fat* Skin*
*from CTD patient, external control
Site
STUDY 2D
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Appendix C 
FIGURES 71 (I)-(V) H&E Stains of DD tissue phenotypes.  
Figure 71 H&E Stains of DD tissue phenotypes and controls 
 
(i) Nodule from DD17           (ii) Cord from DD2       (iii) Palmar fascia from DD17-internal control 
          
(iv) Fat from DD17          (v) Skin over nodule from DD17 
     
 
 
FIGURE 71 (VI-VIII) H&E Stains of control tissue. 
(vi) Fascia from CT7- 
external control                       (vii) Fat from CT7                    (viii) Skin from CT6 
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Figure 72 EMSC processed spectra of the secreted metabolites (footprint). 
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Figure 73 PCA Plot of the FT-IR spectra of metabolic footprint from fibroblasts derived from the DD 
phenotypes onto the plane defined by PC1 and PC2. 
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Appendix D 
Date harvested Patient ID DD Tissue DOB Age DD History Gender Ethnicity Smoking
Jan 22 2010 DD60 Nodule, cord & transverse palmar fascia 21/09/1943 67 Primary Male White English 15 pack years
Jan 22 2010 DD61 Nodule, cord & transverse palmar fascia 19/09/1933 77 Recurrent Male White English NO
Nov 19 2009 DD55 Nodule, cord 15/05/1947 63 Recurrent Male White English NO
Nov 19 2009 DD56 Nodule 11/09/1953 57 Primary Male White English NO
Feb 19 2009 DD41 Nodule, cord, skin over nodule Aug-35 75 Primary Male White English NO
Feb 19 2009 DD42 Cord, skin over nodule Aug-49 61 Primary Male White English NO
Feb 19 2009 DD43 Nodule, cord, skin over nodule Oct-37 73 Primary Male White English NO
Feb 19 2009 DD44 Nodule, cord, skin over nodule & transverse palmar fascia Dec-46 64 Primary Male White English NO  
Table 31 KEGG pathways enriched with highest and lowest PPLR values in F1 vs. F21. 
Highest 1000 PPLR values Gene Lowest 1000 PPLR values Gene
Ribosome 26 Metabolic pathways 94
Huntington's disease 20 Lysosome 34
Oxidative phosphorylation 20 Vibrio cholerae infection 16
Alzheimer's disease 17 Aminoacyl-tRNA biosynthesis 12
Parkinson's disease 17 ECM-receptor interaction 12
Spliceosome 13 Epithelial cell signaling 11
Glycolysis / Gluconeogenesis 12 N-Glycan biosynthesis 9
Cardiac muscle contraction 10 Fatty acid metabolism 8
TGF-beta signaling pathway 10 Amino sugar and nucleotide sugar metabolism 7
ECM-receptor interaction 8 Citrate cycle (TCA cycle) 7
Melanoma 8 Collecting duct acid secretion 7
p53 signaling pathway 8 Proteasome 7
Colorectal cancer 7 Valine, leucine and isoleucine degradation 7
Fructose and mannose metabolism 7 Pyruvate metabolism 6
Neuroactive ligand-receptor interaction 7 Sphingolipid metabolism 6
RNA degradation 7 Tryptophan metabolism 6
Bladder cancer 5 beta-Alanine metabolism 5
Pentose phosphate pathway 5 Biosynthesis of unsaturated fatty acids 5
Folate biosynthesis 2 Porphyrin and chlorophyll metabolism 5
Jak-STAT signaling pathway 2 Propanoate metabolism 5
Protein export 5
Fatty acid elongation in mitochondria 4
Glycosaminoglycan degradation 4
Glycosphingolipid biosynthesis - ganglio series 4
Glycosphingolipid biosynthesis - globo series 4
Limonene and pinene degradation 4
Neuroactive ligand-receptor interaction 4
Proximal tubule bicarbonate reclamation 4
Natural killer cell mediated cytotoxicity 3
Other glycan degradation 3
Valine, leucine and isoleucine biosynthesis 3
Insulin signaling pathway 2
Vitamin B6 metabolism 2
KEGG Pathway analysis for differentially expressed genes in 1000 highest and 1000 lowest PPLR values 
F1 vs F21
Pathway Pathway
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Table 32 KEGG pathways enriched with highest and lowest PPLR values in N21 vs. F21 
Highest 1000 PPLR values Gene Lowest 1000 PPLR values Gene
Ribosome 39 Focal adhesion 37
Oxidative phosphorylation 32 Pathways in cancer 34
Alzheimer's disease 26 Regulation of actin cytoskeleton 23
Huntington's disease 26 ECM-receptor interaction 19
Parkinson's disease 25 Cell cycle 15
Cardiac muscle contraction 13 Oocyte meiosis 14
Lysosome 12 Vascular smooth muscle contraction 14
Spliceosome 11 Gap junction 13
Proteasome 6 p53 signaling pathway 13
Regulation of actin cytoskeleton 3 Pancreatic cancer 11
Thiamine metabolism 2 Small cell lung cancer 11
Lipoic acid metabolism 1 Adherens junction 10
Arrhythmogenic right ventricular cardiomyopathy (ARVC)10
Dilated cardiomyopathy 10
Pathogenic Escherichia coli infection 10
Progesterone-mediated oocyte maturation 10
Viral myocarditis 10
Bacterial invasion of epithelial cells 9
Glioma 9
Melanoma 9
Colorectal cancer 8
Aminoacyl-tRNA biosynthesis 7
Bladder cancer 7
Non-small cell lung cancer 7
Shigellosis 7
Malaria 6
Dorso-ventral axis formation 4
Pentose phosphate pathway 4
Thyroid cancer 4
Huntington's disease 3
Neuroactive ligand-receptor interaction 3
One carbon pool by folate 3
Valine, leucine and isoleucine biosynthesis 3
Vitamin B6 metabolism 2
Oxidative phosphorylation 1
KEGG Pathway analysis for differentially expressed genes in 1000 highest and 1000 lowest PPLR values 
in N21 vs F21
Pathway Pathway
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Table 33 KEGG pathways enriched with highest and lowest PPLR values in N1 vs. N21 
Highest 1000 PPLR values Gene Lowest 1000 PPLR values Gene
Focal adhesion 34 Metabolic pathways 75
Regulation of actin cytoskeleton 25 Oxidative phosphorylation 33
Cell cycle 16 Ribosome 33
ECM-receptor interaction 16 Huntington's disease 27
Oocyte meiosis 16 Alzheimer's disease 25
Gap junction 14 Parkinson's disease 25
Adherens junction 13 Lysosome 16
Glycolysis / Gluconeogenesis 13 Spliceosome 12
Neurotrophin signaling pathway 13 Cardiac muscle contraction 11
p53 signaling pathway 13 Pathways in cancer 10
Progesterone-mediated oocyte maturation13 PPAR signaling pathway 10
Leukocyte transendothelial migration 12 Proteasome 9
Melanoma 12 Neuroactive ligand-receptor interaction 5
Pancreatic cancer 12 Chemokine signaling pathway 4
Pathogenic Escherichia coli infection 12 Regulation of actin cytoskeleton 4
Dilated cardiomyopathy 11 Thiamine metabolism 3
Fc gamma R-mediated phagocytosis 10 Jak-STAT signaling pathway 2
Hypertrophic cardiomyopathy (HCM) 10 Natural killer cell mediated cytotoxicity 2
Prostate cancer 10 Lipoic acid metabolism 1
TGF-beta signaling pathway 10
VEGF signaling pathway 10
Arrhythmogenic right ventricular cardiomyopathy (ARVC)9
Bacterial invasion of epithelial cells 9
Bladder cancer 9
Colorectal cancer 9
Glioma 9
Renal cell carcinoma 9
Non-small cell lung cancer 7
Aminoacyl-tRNA biosynthesis 6
Neuroactive ligand-receptor interaction 5
Pentose phosphate pathway 5
Starch and sucrose metabolism 5
Huntington's disease 3
Valine, leucine and isoleucine biosynthesis 3
Vitamin B6 metabolism 3
KEGG Pathway analysis for differentially expressed genes in 1000 highest and 1000 lowest PPLR values 
N1 vsN21
Pathway Pathway
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1. “Inferring the metabolic and transcriptional networks specific to Dupuytren‟s disease 
tumours with omics”, Joint FEBS/SystemsX 4th Advanced Lecture Course on 
Systems Biology; FEBS-SystemsX-SysBio2011: From Molecules to Function, 
Innsbruck, Austria, Feb 2011. 
 
2. “Parallel analysis of transcript and metabolic profiles of Dupuytren‟s Disease 
fibroblasts in response to altered O2 tension”, Systems Biology of Stem Cells 
Symposium, UC, Irvine, USA, May 2010.  
 
3.  “Systems Biology approaches for identifying cultured Dupuytren's Disease samples 
for analysis”, The 10th International Conference on Systems Biology, ICSB, 
Stanford, USA, Aug 2009.  
 
4. “Metabolic Fingerprint Analysis of Fibroblasts Derived from Differential 
Dupuytren's Disease Tissue Phenotypes”, Research & Innovation Exhibition, Central 
Manchester and Manchester Children's University Hospitals, NHS Trust, UK, Nov 
2008. 
 
5. “Computability in Biology: Metabolic Networks”, FEBS-SysBio2007 From 
Molecules to Life: March 2007, 2
nd
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1.  Rehman S, Salway F, Stanley JK, et al. Molecular Phenotypic Descriptors of 
Dupuytren's Disease Defined Using Informatics Analysis of the Transcriptome. J 
Hand Surg Am. 2008;33:359-372. 
 
2. Bevilacqua A, Wilkinson SJ, Dimelow R, Murabito E, Rehman S, Nardelli M, van 
Eunen K, Rossell S, Bruggeman FJ, Blüthgen N, De Vos D, Bouwman J, Bakker 
BM, Westerhoff HV. SEB Exp Biol Ser. 2008; 61:65-91.Vertical systems biology: 
from DNA to flux and back. 
 
3.  Li K, Zhu W, Zeng K, Zhang Z, Ye J, Ou W, Rehman S, Heuer B, Chen S. 
Proteome characterization of cassava (Manihot esculenta Crantz) somatic embryos, 
plantlets and tuberous roots. Proteome Sci. 2010 Feb 27;8(1):10. 
 
 
E3 Submissions for Publication 
1. Rehman S, Goodacre R, Day PJ, Bayat A, Westerhoff HV. Dupuytren's - A Systems 
Biology Disease? - review paper submitted to Arthritis Research & Therapy Mar 
2011.  
 
2. Rehman S, Day PJ. Dupuytren's Depicting accurate relationships in bio-networks 
from natural language processing approaches –In preparation. See abstract and text 
mining workflow below. 
 
3. Rehman S, Day PJ, Xu. Y, Dunn WB, Westerhoff HV. Goodacre R, Bayat A, 
Metabolic Fingerprint Analysis of Fibroblasts Derived from Differential Dupuytren's 
Disease Tissue Phenotypes, In preparation. 
 
4. Rehman S, Day PJ, Xu. Y, Dunn WB. Goodacre R, Bayat A, Westerhoff HV – The 
effect of Hypoxia in DD metabolomes and transcriptomes investigated through a 
Systems Approach, In preparation. 
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E3(2)  
Abstract 
Effective use of published scientific literature plays a crucial role in all stages of research. 
High-throughput experimental techniques used in „omics and integrative systems biology are 
generating exponential yet unraveled complex data sets. One of the goals of systems biology 
is to obtain overall quantitative description of dynamic cellular systems. This is currently not 
achievable as the number of components and interactions involved in these systems is quite 
large resulting in a very large parameter space, thus the generation of quantitative data sets. 
The important role of accurate and crucial literature analysis would improve and direct a 
large number of experimental studies that are initiated by mechanistic and hypothesis driven 
approaches. Natural Language Processing techniques combined with text mining have been 
propose as potential new elements for knowledge discovery as part of an application to 
biological investigation. Nevertheless, current text mining tools do not provide correlations 
within scientific entities (e.g. gene1-gene2) on the basis of biological relevance but are due 
to statistical recognition only. Text mining should now play a crucial role not only retrieving 
commonalities across entities on the basis of co-occurrence but also during a research study 
itself where the aim would be to validate, annotate and interpret the discovery results 
generated from analysing the experimentally generated data. In this article we describe our 
efforts in developing literature analysis and text mining solutions for extracting and 
documenting known entity-entity (e.g. gene-tissue) interactions by keywords searches based 
on the experimental methods they are discovered through with respect to the study.  We 
describe an abstract algorithm/pipeline and show how it can be mapped upon our existing 
workflow FACTA, a concrete service-based text mining workflow using a mix of text 
processing and data mining components. 
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